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CHAPTER 1 
General Introduction 
Introduction 
The nature of interactions between molecules has received considerable attention in the past1• 
Not in the least because those interactions form the basis for the existence of living organisms. 
The selectivity of an enzyme is e.g. being governed by the recognition of a particular substrate. 
On the one hand this has led to drug research, in which one tries to find compounds (ligands) 
that regulate a biological target (receptor). On the other, supramolecular chemistry has evolved, 
which studies the properties of structures that result from non-covalent interactions. In these 
mainly artificial non-biological systems, one molecule (host) is capable of interacting with 
another (guest). The insights obtained in either research area are relevant to each other and offer 
fundamental views on the interplay between molecules. 
Since peptides are important determinants in many biological processes, for example by acting 
as a ligand for a specific target, they are interesting starting points for the development of new 
drugs2• They can act e.g. as neurotransmitters, hormones, inhibitors and regulators in the 
immune system. However, therapeutic use of peptides is hampered by a couple of unfavorable 
properties. First, peptides usually suffer from a poor bioavailability. Their high solubility in 
water makes it difficult for them to pass natural barriers such as a cell membrane. Second, 
peptides are easily degraded by proteases, which leads to a short half-life. Furthermore, in 
peptides a large number of conformations is generally accessible which lowers their affinity for 
a receptor and makes prediction of the biologically active conformation difficult. Efforts in 
order to obtain molecules with the same or improved biological activity as peptides, without the 
above mentioned drawbacks, has led to the development of peptidomimetics3. 
Peptidomimetics 
Peptidomimetics3 can be defined as compounds which imitate the action of a peptide by 
displaying structural and functional features that mimic those of the native peptide leading to 
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certain (improved) biological properties of these mimetics. In the recent past, several categories 
of peptidomimetics have been developed. From these mimics, peptide bond isosteres, in which 
the peptide bond has been replaced with another functional group, can be considered as a first 
step from a biologically active peptide to a structure with improved properties. A number of 
these replacements have been reported, leading to e.g. peptoids4, alkenes5, urea6, carbamates7, 
sulfones8, phosphodiesters9 (figure 1). Sulfonamides10, however, have received relatively little 
attention as a moiety in peptidomimetics. 
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Figure 1. A peptide and examples of peptidomimetics containing peptide bond replacements. 
Peptidosulfonamides 
Sulfonamides have been used in the development of matrix metalloproteinase inhibitors10a MSH 
release inhibitors 10\ HIV-protease inhibitors IOc,d, catalytic antibodies i0e or penicillin analogs ior. 
In addition to being merely a peptide bond replacement, leading to altered properties e.g. 
polarity, stability and flexibility, of this mimic, sulfonamides can also be considered as 
transition-state analogs 11 of the hydrolysis of an amide bond. Transition-state analogs mimic 
the geometry and electronic structure of a transition-state of a reaction. Their resemblance to the 
transition-state allows them to act as enzyme inhibitors. Pauling has postulated that an enzyme 
contains an (active) site complementary to the transition-state of a reaction which it catalyzes12• 
This should give rise to a higher affinity of the enzyme for structures mimicking this transition-
state than e.g. for the substrate. Since these analogs cannot be processed by the enzyme they 
might act as inhibitors competing with the substrate. 
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Scheme 1. Fragmentation of a-aminomethane sulfonamides and their stable a- and {3-
substituted {3-aminoethane sulfonamides analogs as peptide bond replacements. 
Direct substitution of an amide bond by a sulfonamide yields an a-aminomethane sulfonamide. 
However, it has been reported that these compounds suffer from instability 13, caused by the 
availability of a facile fragmentation pathway (scheme I, top). This fragmentation can be 
completely avoided by using ~-aminoethane (peptido )sulfonamides, with an additional carbon 
atom between the sulfur and the nitrogen atom and for which we have developed 14 syntheses in 
our group. 
Synthesis of peptidosulfonamides 
Using amino acids as starting materials not only a-substituted aminoethane sulfonamides 
became accessible but also the ~-substituted derivatives (scheme I, bottom). The syntheses of 
these aminoethane sulfonamides have been extensively studied in our group 14. Key 
intermediate in these routes is a sulfinylchloride derived from a thioacetate. Such a thioacetate 
can be prepared from an aminoalcohol, which in tum can be obtained from an amino acid 
(scheme 2). Although several amino acids were used as starting materials in these syntheses, 
amino acids that contained a functional group in the side chain had not been used as such. At 
the start of the research described in this thesis, to our knowledge, a synthesis of functionalized 
peptidosulfonamides had not been described. Synthesis of such compounds would open up a 
whole range of new compounds that display a diversity similar to the amino acids from which 
they are derived. 
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Scheme 2. Syntheses of a- and {3-substituted aminoethane sulfonamides starting from amino 
acids. 
It should be noted that both a- and ~-substituted aminoethane sulfonamides lead to a shift of 
functional groups at either the N- or C-terminus of the sulfonamide containing mimics with 
respect to the side chain of the native peptide (figure 2). Therefore, it would be wise to 
investigate both a- and ~-substituted derivatives when considering ~-aminoethane 
sulfonamides as a peptide bond replacement in the preparation of potential biologically active 
compounds. 
a peptide containing 
one a-substituted 
aminoethane sulfonamide 
residue 
peptide 
a peptide containing 
one ~-substituted 
aminoethane sulfonamide 
residue 
Figure 2. A shift of functional groups, due to the introduction of a- or {3-substituted 
aminoethane sulfonamide. 
Surprisingly, earlier attempts to employ ~-aminoethane sulfonamides as transition-state analog 
containing HIV-protease inhibitors failed14a and therefore it would be interesting to further 
explore their possibilities as inhibitors for other types of enzymes. An interesting category of 
enzymes for this purpose seems to be the class comprising serine proteases, which participate 
in many biological processes and which operate through a different mechanism of action in 
comparison with the aspartate proteases. A pharmaceutically interesting enzyme in this category 
is thrombin. 
12 
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Thrombin 
Thrombin plays a central role in the blood coagulation cascade 15. Its major function is cleavage 
of four arginine-glycine peptide bonds in a fibrinogen molecule ultimately leading to a fibrin 
network16 (figure 3), which arrests bleeding. As many diseases are caused by thrombosis, a lot 
of attention has been paid to the regulation of this process. Thrombin has been considered as an 
attractive target for this purpose because of its key position in the blood coagulation cascade17 . 
Compounds able to modulate the activity of the enzyme might lead to therapeutic agents. In 
view of this, many inhibitors have been developed in the past18 • The limitations of these 
compounds with respect to stability, specifi6ty or oral bioavailability keep the search for new 
anti-thrombotics alive19• 
fibrinogen 
Arg Gly 
Scissile 
bond 
fibrin 
Figure 3. Cleavage of fibrinogen catalyzed by thrombin. 
First, homology of the structure of thrombin with e.g. chymotrypsin20 and later the 
determination of its crystal structure21 have led to a detailed view of the three dimensional 
structure related to its function22 . Thrombin consists of an A-chain and B-chain consisting of 
36 and 259 amino acid residues, respectively. Held together by a disulfide bridge they form a 
single contiguous body. In 1989, Bode and coworkers21 a published the X-ray structure of 
thrombin cocrystallized with PPACK23 (H-D-Phe-Pro-Arg chloromethylketone) followed not 
much later by several x-rays of other investigators22b·f. These crystal structures revealed 
thrombin having fold similar to other serine like proteases. Furthermore, the active site, buried 
in a cleft residing across the protease, contains a catalytic triad24 consisting of Ser-195, His-57 
and Asp-10225 . An oxyanion hole26, at the S 1-S 1' si te27 , is believed to stabilize the negative 
charge that is built up in the transition state of the hydrolysis of the peptide bond. Furthermore, 
several subsites can be distinguished, which are all partly responsible for the substrate 
specificity. The S3 and S2 sites are capable of accommodating hydrophobic residues (D-Phe 
13 
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Substrate Binding Mode Inhibitor Binding Mode Second Inhibitor Binding Mode 
Figure 4. Three different binding modes of thrombin28• 
and Pro in PPACK). A rigid insertion loop21 a (the TyrProProTrp loop) considerably restricts 
the size of amino acids that can enter this hydrophobic pocket. The S1 site is highly specific for 
arginine and, therefore, referred to as the specificity pocket. Asp-189 at the bottom of this 
pocket contributes substantially to binding of a basic residue, especially the guanidine function 
of arginine. Several binding modes can be distinguished for ligands28 (figure 4). In addition to 
a substrate binding mode based on the mode of binding of substrates, two types of inhibitor 
binding modes have been found which have in common that the oxyanion hole is not occupied 
in contrast to the substrate-like binding mode in which the carbonyl group of the basic amino 
acid is placed in the anion hole. Figure 5 gives a schematic representation of the interactions 
that are involved in the binding of PPACK to thrombin, generated by Ligplot29 • 
Finally, in a cleft approximately 20 A from Ser-195 an anion binding exosite can be found30 • 
The term fibrinogen recognizing exosite is considered to be more appropriate, as the former 
designation might lead to confusion with the heparin binding site. At this exosite, a negatively 
charged region of fibrinogen is bound, hence its name. Also e.g. the C-terminal region of 
hirudin31 and the derived hirulogs32 are capable of binding this anion binding exosite. 
Combinatorial supramolecular chemistry 
As was mentioned earlier in the introduction, from the interest in interactions between 
molecules the field of supramolecular chemistry has emerged33 . Many host-guest complexes 
have been prepared to study the principles of molecular recognition34. Insight in the mechanism 
of recognition of molecules might be used in the design of new compounds which are able to 
specifically bind to an (artificial) receptor molecule. If translated to the medicinal chemistry area 
14 
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Figure 5. Schematic representation of interactions in the complex of PPACK and thrombin29• 
this means that one is looking for a ligand ( e.g. inhibitor) which will bind selectively to a 
biological target (e.g. enzyme). However, in supramolecular chemistry it has been proven to be 
difficult to design and synthesize a host molecule which is able to bind selectively a particular 
guest. Furthermore, it is desirable to easily obtain insight into the binding properties once a 
host molecule has been prepared. A new area of research, denoted as combinatorial 
supramolecular chemistry35 seems to emerge that may be able to address this point. 
Combinatorial chemistry has provided the tools to synthesize large sets of compounds, denoted 
as (chemical) libraries36• This method of combining chemical constituents to obtain a diversity 
of structures was initially developed to identify new biologically active compounds. 
Combinatorial supramolecular chemistry, now, utilizes the diversity of a chemical library by 
probing a certain guest molecule for its binding properties with this library. In addition, a great 
number of possible host molecules may be easily prepared in order to find an appropriate 
receptor with desired properties towards a particular guest. This idea is being extended in the 
search for e.g. new catalysts37 or materials38• Feedback from such studies might lead to new 
insights which will give us the constraints to look within in the search for certain properties. 
A simple but successful concept in order to obtain synthetic receptor molecules has been the 
preparation of tweezer-like structures35• 39 • The idea is that two or more arms, attached to a 
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scaffold, can bind and recognize a ligand by multiple interactions as e.g. hydrogen bonds, 
hydrophobic interactions or salt bridges (figure 6). At first, individual tweezers were designed 
to recognize a specific guest molecule. However, with the appearance of combinatorial 
techniques it became possible to assay their affinity towards thousands of compounds, thus 
affording a much more refined view of the selectivity of the receptors40• More recently, libraries 
of receptor molecules have been constructed, in order to obtain a synthetic receptor molecule 
with optimal properties37'38 • 
() 
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l B(OH), a 
,,,.OH 
0 f 
YN-Cbz 
.-... . N H ( '(H 
'-./·,,NH H 
0
~N-cbz 
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Figure 6. Examples of tweezer-like receptor molecules. 
Encoded chemical libraries 
A limitation and therefore, also a challenge in these developments has been the determination of 
the chemical structure of the library member which has the desired properties, because the 
quantity of material available, e.g. on a single solid-phase bead, from a complex library is 
frequently insufficient for analysis. Several solutions which address this problem have been 
described41 •42 • The strategy of using tags42 is an elegant solution to identify the structures of 
compounds on a solid-phase bead. In this approach (tag)molecules are attached to the solid-
phase resin in addition to the compounds of interest. These tags provide a record of the 
chemical history of the solid support and thus reveal the identity of the library member they 
code for (figure 7). This method of encoded combinatorial synthesis may be applied to the 
construction of any collection of compounds, provided that the tag-chemistry does not interfere 
with the synthesis of the library and with the screening of the library for a particular property. 
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Figure 7. Schematic representation of the synthesis of an encoded library. The large circles 
represent resin beads; A, B, ... = reagent/building block; T = tag molecule 
The aim and outline of the thesis 
The aim of this thesis is to investigate the use of ~-aminoethane sulfonamides in the 
construction of a ligand for a biological target viz. thrombin on the one hand, and as a building 
block for the construction of artificial (tweezer-like) receptor molecules capable of selective 
binding on the other. From these studies it was expected that a more thorough understanding 
could be obtained of the sulfonamide functional group and peptidosulfonamides interacting 
with peptides in particular. Therefore, the thesis consists of two parts. 
In the first part of this thesis the synthesis of ~-aminoethane sulfonamide arginine analogs is 
described. The sulfonamides are proposed as transition-state analogs of the hydrolysis of the 
arginine-glycine peptide bond that is present in fibrinogen, the primary substrate of thrombin 
(figure 8). These transition-state analogs should mimic the geometry and electronic structure of 
the transition-state of this reaction and because of their resemblance to this transition-state act as 
enzyme inhibitors. 
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Figure 8. {3-aminoethane sulfonamides derived from fibrinogen as potential thrombin inhibitors. 
Chapter 2 deals with the synthesis of ~-substituted aminoethane sulfonamide containing 
arginine analogs, as potential thrombin inhibitors. Structures of existing thrombin inhibitors 
were used in the design of the corresponding aminoethane sulfonamide containing analogs. In 
addition to two types of active site directed low molecular weight inhibitors which were 
synthesized, a peptidosulfonamide arginine analog was incorporated into a 20-residue peptide. 
In order to be able to introduce this arginine analog into this peptide, a new building block had 
to be synthesized that was compatible with the Fmoc-solid phase strategy which was 
employed. In chapter 3 several approaches to the corresponding a-substituted analogs are 
described. The first two approaches, in order to obtain a-substituted arginine analogs, are 
based on routes towards a-substituted peptidosulfonamides which were developed previously 
in our group14c. The third approach uses an alkene as a starting material and although only 
peptidosulfonamide arginine analogs have been synthesized, this method might easily be 
extended to sulfonamide analogs of other amino acids. In chapter 4 the possibility is explored 
of the synthesis of conformationally restricted analogs of the a- and ~-substituted arginine 
sulfonamide derivatives, starting from hydroxyproline. The presence of functional groups in 
18 
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hydroxyproline is exploited in such a way that two types of conformationally restricted 
peptidosulfonamide analogs are accessible. The inhibitory activity towards thrombin of these 
compounds is evaluated in chapter 5, and it is attempted to rationalize the results using 
molecular modelling. A crystal structure of thrombin containing an inhibitor will be used as a 
starting point for this purpose. 
In the second part of this thesis, the synthesis and characterization is described of receptor 
molecules containing a sulfonamide functionality. These structures were studied as a first step 
in obtaining a more detailed view of peptidosulfonamides interacting with peptides. In chapter 6 
the synthesis of a tweezer-like molecule is described. This synthetic receptor consists of three 
parts (figure 9): 1) a dye molecule for visualization in a binding assay, 2) two arms, consisting 
of aminoethane sulfonamides and 3) a hinge part, i.e. a scaffold to which the arms and the dye 
are attached. The binding properties are evaluated using a -25,000 member resin bound 
tripeptide library. Although the synthetic receptor described in chapter 6 showed a remarkable 
binding selectivity, the binding affinity with ligands, in view of possible applications, had to be 
increased. Therefore, in chapter 7 the incorporation and consequences on both the affinity and 
selectivity of using less flexible "hinges" in tweezer-like synthetic receptors are described. In 
addition to the hinge described in chapter 6, five new hinges are synthesized, in which the 
rigidity and distance between the two receptor arms is varied. For the synthesis of the receptor 
molecules sulfonylchloride building blocks were used instead of sulfinylchlorides building 
blocks, resulting in better yields. Finally, in chapter 8 a preliminary study is described on the 
synthesis and characterization of a small biased library of carboxylic acid binding receptor 
molecules. A previously described receptor molecule, capable of binding the tetrabutyl 
ammonium salt of acetic acid, is used as a starting point for this library. 
Tweezer 
~ 
~--ff 
---:i~~~~ 
Arm 
Figure 9. The concept of a tweezer-like receptor molecule binding tripeptides. 
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CHAPTER2 
Synthesis of B ... substituted aminoethane sulfonamide 
Arg-Gly isosteres 
Introduction 
Peptide bond replacements have been important in the development of peptidomimetics, as they 
are often a first step from a biologically active peptide to analogs having improved properties 1• 
In the recent past, numerous replacements of peptide bonds have been reported2• This has led, 
among others, to the development of transition-state isosteres3• Compounds containing these 
moieties are interesting, because they may be useful in the design of enzyme inhibitors4 • 
Although a wide variety of transition-state isosteres has been described until now, relatively 
little attention has been paid to the sulfonamide isostere5• In order to further investigate the 
possibilities of these sulfonamides as transition-state analogs, it was decided to incorporate 
them in the design of potential inhibitors of thrombin. Thrombin has received much attention 
because of its important role in the blood coagulation cascade6• It cleaves fibrinogen at an 
arginine-glycine peptide bond7, which results in the formation of fibrin and eventually to blood 
clots. Many thrombin inhibitors have already been described8•9, which might give clues of the 
preference of the enzyme for certain ligands. In addition, a number of X-ray structures have 
been reported10, that could be used in structure based design of new thrombin inhibitors11 • 
Since thrombin cleaves the amide bond between an arginine and a glycine residue, transition-
state based inhibitors should mimic the transition-state of the hydrolysis of this amide bond. In 
0 0 
1 \\// 
R,NJS'R2 He 
NH 
HN~NH2 
Figure 1. a- and /3-substituted aminoethane sulfonamide analogs of arginine. 
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view of our interest in aminoethane sulfonamides, two possibilities arose of sulfonamide 
analogs of the dipeptide arginine-glycine sequence: an a- and a ~-substituted aminoethane 
sulfonamide12• The difference between the two is the site of attachment of the side chain of the 
corresponding amino acid, i.e. arginine, as is depicted in figure 1. In this chapter the synthesis 
of ~-substituted aminoethane sulfonamide analogs, mimicking the transition-state of the 
hydrolysis of an arginine-glycine bond, will be described. Chapter 3 will deal with the 
preparation of the a-substituted aminoethane sulfonamides. 
As was mentioned above, many inhibitors of thrombin have been described. Two categories of 
these inhibitors inspired us in the design of sulfonamide based analogs: the D-Phe-Pro-Arg and 
the phenylsulfonyl-Arg analogs9, a few representative examples of which are shown in figure 
2. The D-Phe-Pro-Arg inhibitors (figure 2, top) led to the idea to prepare a ~-substituted 
aminoethane sulfonamide analog of arginine, with H-D-Phe-Pro at the N-terminus (R1) and 
Gly-OH at the C-terminus (R2), as shown in figure 1 (right). In addition, retro mimetics13 
seemed to be interesting targets. Two stereoisomers of these analogs have been considered: R 1 
= H-Gly and R2 = Pro-D-Phe-OH and R1 = H-Gly and R2 = D-Pro-Phe-OH (figure 1, right). 
It should be noted that, due to the presence of two carbon atoms between the amino and the 
sulfonamide functional group, the position of the functional groups of the C-terminal residues 
has been shifted, relative to the position of the side chain of arginine in the original peptide 
(figure 3). This enticed us to leave out a C-terminal residue altogether and to replace it simply 
with an amide (R1 = H-D-Phe-Pro and R2 = NH2, figure 1, right) . 
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Ki Reference 
181 nM 9a 
37 nM 9b 
7.5nM 9c 
< 0.004 nM 9d 
106 nM 9e 
103 nM 9f 
19 nM 9g 
Figure 2. Examples of peptide derived thrombin inhibitors. 
/3-substituted aminoethane sulfonamides 
peptide 
peptide containing 
one ~-substituted 
arninoethane sulfonamide 
R1 H O R3 H O Rs 
·y,ry~-yf ~~0~~ 
H : 0 R2 : H : 0 R4 H 0 
I I I \ \ \ 
I : I \ \ \ 
I I I \ \ \ 
R1 H 6 R3 0 0 R4 H () ~ ~ -~0 ~t ~ .N~ 
~, 0 :: ~ ~ ~r O : 
H O R2 H H O Rs 
Figure 3. C-terminal shift of functional groups upon introduction of one /3-substituted 
aminoethane sulfonamide in a peptide chain. 
Second, the structure of the phenylsulfonyl type of inhibitors (figure 2, bottom) suggested to 
replace the D-Phe-Pro moiety with a dansyl group (R1 = Dansyl and R2 = NH2). These 
inhibitors have shown to possess a slightly different mode of binding to thrombin14 compared 
to the earlier mentioned D-Phe-Pro-Arg-type inhibitors, which might accommodate the 
sulfonamide moiety better. In addition to the low molecular weight compounds, it was 
attempted to incorporate the arginine-glycine isostere into a longer peptide. The peptide of 
choice was a hirutonin15 (figure 4), which belongs to a class of bifunctional thrombin inhibitors 
containing three moieties: 1) a D-Phe-Pro-Arg analog9a-d, as an active-site directed moiety (A); 
2) a carboxy terminal peptide capable of binding to thrombin's fibrinogen-recognition 
exosite16 , corresponding to residues 53-64 of hirudin, a natural inhibitor of thrombin (C); and 
3) a linker between these two fragments, Gly5 in this case (B). Another feature of hirutonins is 
that they have undergone an amide bond replacement at the P 1-P i' scissile bond 17 , in 
comparison with another class of bifunctional thrombin inhibitors, viz. the hirulogs18, which 
consist entirely of a-amino acids. The hirutonin that was investigated contained a ~-
hornoarginine at the P1 site and had a dissociation constant of 7.4 nM for thrornbin 15b. To 
investigate the consequence of the substitution of an amide with an sulfonamide bond on the 
binding affinity, the ~-homoarginine residue in the hirutonin was replaced with a ~-substituted 
aminoethane sulfonamide arginine derivative. 
A B C 
--------- - --------------------
H 
,,N~ H-D-Phe-Pro i X-(Gly)5-Asn-Gly-Asp-Phe-Glu-Glu-lle-Pro-Glu-Glu-Tyr-Leu-OH 
C 
X = II Ki= 7.4 nM 
0 
s 
or X = IN,. 
0 0 
Figure 4. A hirutonin and its sulfonamide analog. A) Active site directed moiety. B) Linker. 
C) Peptide capable of binding to the fibrinogen-recognition exosite. 
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The synthesis of the arginine-glycine sulfonamide isosteres is analogous to the synthesis, 
which has been developed earlier in our group12•19 for other P-substituted aminoethane 
sulfonamides. The key synthon of this route is a P-substituted aminoethane thioacetate 2 
(scheme 1). Reaction of this thioacetate with sulfurylchloride and acetic anhydride gives the 
corresponding sulfinylchloride 3. Coupling of the sulfinylchloride to an appropriate amine 
gives a sulfinamide 4, which can be oxidized to the desired sulfonamide 5. 
-
-
R Ac20 R 0 
' SAc - ' 
11 
BocHN~ S02Cl2 BocHN~8 'c1 
2 3 
R'NH2 
-
R 0 f II 
BocHN~8 'NHR' 
NaI04 R o"!-.p 
-- ~'/ s .... RuCl3 BocHN NHR' 
4 5 
Scheme 1. General representation of a synthesis of /3-substituted aminoethane sulfonamides. 
It was decided to start with the synthesis of an omithine-glycine sulfonamide isostere, for two 
reasons. First, in addition to arginine-glycine isosteres, ornithine-glycine sulfonamides would 
be obtained as an interesting class of compounds and this strategy will then be applicable to the 
synthesis of lysine sulfonamide analogs. Second, it was synthetically more attractive to start 
with omithine than with arginine, in view of anticipated problems in finding suitable protective 
groups for the guanidine moiety of arginine. Moreover, a number of convenient methods have 
been described in literature20 for transformation of an omithine into an arginine residue. 
A drawback of the synthesis of sulfonamides via a sulfinylchloride is that an oxidative step is 
always needed to obtain a sulfonamide. This oxidation step is not compatible with every 
functionality that might be present in a molecule21 • Additionally, the oxidation of sulfinamides 
on a solid phase turned out to be troublesome22 • For this reason another method for the 
preparation of peptidosulfonamides has been developed, which features the use of a 
sulfonylchloride. In order to show that the latter strategy could be employed for the synthesis 
of arginine sulfonamide analogs, an attempt was made to synthesize on the solid phase an 
arginine-glycine sulfonamide isostere, incorporated into a peptide. Thus, the required hirutonin 
analog in which exactly one amide bond was replaced by a sulfonamide (figure 4), was 
synthesized by this method. 
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Results and discussion 
The synthesis started with omithine derivative 6 of which the a and the 8-amino group were 
protected with a Boe and a Cbz group, respectively (scheme 2). Conversion of this omithine 
derivative 6 to aminoalcohol 7 was achieved in 83% yield by reduction of the in situ prepared 
mixed anhydride of 623 . Alcohol 7 was then transformed into its mesylate 8 with 
mesylchloride in the presence of triethylamine in 79% yield. The resulting mesylate was 
displaced in a substitution reaction using cesium thioacetate24, to afford key thioacetate 9 in 
69%. After preparation of the corresponding sulfinylchloride 10 by treatment of synthon 9 
with sulfurylchloride and acetic anhydride, a coupling reaction with an amine was carried out to 
obtain the desired sulfinamide, which was oxidized to the corresponding sulfonamide. For the 
coupling reaction four amines were selected: 1) H-Gly-OEt leading to omithine-glycine 
sulfonamide derivative 11; 2) H-Pro-D-Phe-0Me25 and its enantiomer 3) H-D-Pro-Phe-0Me25 
to give two of the four possible diastereoisomers, 12 and 13 of the retro13 
peptidosulfonamides; and 4) ammonia to obtain primary sulfonamide 14, in which, compared 
to analog 11, the glycine residue was replaced with an amide. In all four cases the used amine 
also acted as a base, to bind the liberated HCl. In this way, higher yields were obtained than by 
using e.g. triethylamine or N-methylmorpholine as a base26 • The thus obtained sulfinamides 
NHCbz 
1) ECF/Et3N C ...-. ~Cbz 
BocHN COOH 2) NaBH4 BocHN~OH 
7 6 
NHCbz 
CsSAc S02Cl2/ Ac20 
1) H-R 
SAc 
BocHN 
9 
NHC~:,O 
s" 
BocHN 'R 
11 R = Gly-OEt 
12 R = Pro-D-Phe-OMe 
13 R = D-Pro-Phe-OMe 
14 R = NH2 
1) H2/Pd/C 
2)[\ 
N 15 
CbzN)_. NHCbz 
CNHCbz 
,,~OMs BocHN 
CbzHNYNCbz 
NH 
CLo 
s" 
BocHN 'R 
16 R = Gly-OEt 
17 R = Pro-D-Phe-OMe 
18 R = D-Pro-Phe-OMe 
19 R = NH2 
8 
Scheme 2. Synthesis of fully protected sulfonamide arginine analogs. 
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were oxidized with Nal04 and RuC13 as a catalyst, to produce the ornithine analogs 11-14 in 
overall yields varying from 49% to 62%. Subsequent hydrogenolysis of the Cbz side chain 
protective group and reaction with pyrazole 1520e.f gave the protected arginine-glycine 
sulfonamide analogs 16-19 in 59% to 73% yield. It turned out that the guanidine Cbz groups 
were unstable under basic conditions, necessary for hydrolysis of the ethylester in 16, as a 
first step towards C-terminal chain extension. Therefore, a fragment coupling with the C-
terminal H-Pro-Phe-OMe dipeptide was carried out, prior to introduction of the guanidino 
group, to give 17 and 18 respectively. In contrast, the Boe group of the protected arginine 
analogs 16-19 could be removed with 25% TFA in DCM without any cleavage of the Cbz 
groups. Therefore, the D-Phe-Pro dipeptide moiety was introduced to sulfonamides 16 and 
19, in two steps after cleavage of the Boe group to afford peptidosulfonamides 22 and 23 in 
overall yields of 77% and 62% respectively (scheme 3). In the same way Boc-Gly-OH was 
introduced to peptidosulfonamides 17 and 18 to yield derivatives 24 and 25, both in 86% 
yield. After removal of the Boe group in 19 , the reaction with dansylchloride failed to afford 
27, however. 
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19 R = NH2 
1) TFA 
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CbzHNYNCbz 
f fll~NH q,,o BocHN ~ s:R N ·· N 
Al O H 22 R = GlyOEt 
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Scheme 3. Elongation at the N-terminus of the sulfonamide arginine analogs. 
/3-substituted aminoethane sulfonamides 
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Scheme 4. Introduction of a dansyl group on the sulfonamide arginine analog. 
Fortunately, it was possible to attach the dansyl group to sulfonamide 14, giving omithine 
sulfonamide derivative 26 in 68% yield (scheme 4). Now, it was possible to introduce the 
guanidine group by subsequent hydrogenolysis of the Cbz group and reaction with pyrazole 
15. The dansylated sulfonamide 27 was thus obtained in an overall yield of 61 %. 
Having prepared all desired ligands in their protected form, deprotection of the guanidine 
function was carried out to afford the corresponding HCI salts 28-32 (figure 5) in 66-92% 
Compound RI R2 
28 B oc-D-Phe-Pro Gly-OEt 
29 Boc-D-Phe-Pro NH2 
30 Boc-Gly Pro-D-Phe-OMe 
31 Boc-Gly D-Pro-Phe-OMe 
32 Dansyl NH2 
33 HCIH-D-Phe-Pro Gly-OEt 
34 HClH-D-Phe-Pro Gly-OH 
35 HCI'H-D-Phe-Pro NH2 
36 HClH-Gly Pro-D-Phe-OMe 
37 HClH-Gly D-Pro-Phe-OMe 
38 HClH-Gly Pro-D-Phe-OH 
39 HClH-Gly D-Pro-Phe-OH 
Figure 5. Arginine-glycine analogs that were tested for their thrombin inhibition. 
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yield, by removal of the Cbz groups from the guanidine function by hydrogenolysis. These 
compounds 28-32 might serve also as ligands for thrombin and therefore they were tested on 
their ability to inhibit this protease. Removal of the Boe group with either HCI in ether or IM 
HCl in water gave analogs 33-39 (figure 5) in quantitative yields, which were also tested. The 
results of the assay on thrombin inhibition will be discussed in chapter 5. 
As was mentioned above the sulfinylchloride based strategy cannot be applied to a solid phase 
synthesis22• Therefore, experiments were carried out towards the preparation of a 
sulfonylchloride analog of arginine. A route to a few aminoethane sulfonylchlorides has been 
already described in literature27 (scheme 5). However, a bottleneck in this synthesis was the 
preparation and especially the purification of the intermediate sulfonic acid obtained from the 
corresponding mesylate. In order to circumvent this, a slightly different and shorter route was 
desired, which might also be useful in the synthesis of other sulfonic acid derivatives (scheme 
6). The key step in this approach was the oxidation of a thioacetate to a sulfonic acid. The acid 
conditions of this reaction called for a relatively stable protective group for the arginine side 
chain and the acid labile 4-methoxy-2, 3, 5-trimethylphenylsulfonyl (Mtr) group28 proved to be 
suitable for this purpose. 
R 1) ECF/Et3N R MsCl/Et3N ~R ~ I OH OMs 
BocHN COOH 2) NaBH4 BocHN~ BocHN 
HCI 
Fmoc-Cl triphosgene 
Scheme 5. Synthesis of /3-substituted aminoethane sulfonylchlorides according to de Bont et 
al. 27a 
Therefore, the synthesis started with Mtr-protected arginine derivative 40 (scheme 6). The a-
amino group in 40 was protected with a Fmoc group for use in a solid phase Fmoc-strategy. 
After conversion to amino alcohol 41 in 78% yield by reduction of the in situ prepared mixed 
anhydride of Fmoc amino acid 4029 , a Mitsunobu reaction, using two equivalents Ph3P, DEAD 
and thiolacetic acid30, afforded thioacetate 42 in 70%. Subsequently, the sodium salt 43 of the 
sulfonic acid was obtained after oxidation by a mixture of hydrogen peroxide and acetic acid24 
followed by ion-exchange using DOWEX-Na+ resin. Finally, conversion of the sulfonic acid to 
the corresponding sulfonylchloride, by triphosgene and a catalytic amount of both 
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tetrabutylammonium chloride and DMF27, afforded 44 in an overall yield of 38% starting from 
thioacetate 42. Having prepared the arginine sulfonylchloride analog 44, it was used as a 
building block in the solid phase synthesis of a peptide containing a peptidosulfonamide. 
MtrHN'f NH MtrHNYN H 
NH NH 
l)ECF/Et3N ~ 
2) NaBH4 
OH 
FmocHN COO H FmocHN 
MtrHN'fNH 
NH 
Ph3P/DEAD ~ 
HSAc 
FmocHN SAc 
41 
triphosgene 
MtrHN'fNH 
NH 
~S02CI FmocHN 
44 
42 
Scheme 6. Synthesis of a /3-substituted aminoethane sulfonylchloride analog of arginine. 
The solid phase synthesis of this peptide commenced by loading a TentaGel-PHB31 resin with 
the first amino acid, Fmoc-Leu-OH, using a Sieber coupling32 • The next 16 amino acid 
residues were attached using standard protocols on an automated peptide synthesizer. After 
removal of the terminal Fmoc group by addition of 20% piperidine in NMP, 5 mol equivalents 
of sulfonylchloride 44 and NMM were added. Since a Kaiser-test indicated that the reaction 
was not complete even after 16 hours, the unreacted amines were capped with acetic anhydride 
in the presence of triethylamine. The last two amino acid residues were attached by a similar 
protocol as was used in the introduction of the other amino acids. Cleavage of the peptide from 
the resin was achieved with TFA, using water and ethanedithiol as scavengers33 • Purification 
by preparative HPLC afforded the desired peptide, albeit in a very low yield ( <5% ). Due to 
lack of time, no further experiments were carried out to optimize this result and the thus 
obtained analog was tested for its ability to inhibit thrombin. 
Conclusion 
In this chapter the preparation of ~-substituted aminoethane sulfonamide arginine-glycine 
isosteres was described. The followed approach featured a sulfinylchloride and was analogous 
to that described earlier by our group12 for e.g. phenylalanine-proline isosteres. It was decided 
to synthesize the ornithine-glycine isostere first, followed by conversion to the arginine analog 
in a later stage. This route afforded twelve ~-substituted aminoethane sulfonamides, which can 
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H~ 
(Tentagel PHB) 
2,6-dichloro-
benzoy !chloride 
Fmoc-Leu-OH 
Fmoc-Leu-~ 
j 16 times: 1) piperidine 2) Fmoc-Xxx-OH HBTU/HOBt/DIPEA 
Fmoc-(Gly)5-Asn-Gly-Asp-Phe-Glu-Glu-lle-Pro-Glu-Glu-Tyr-Leu-
l I I I I I I Trt OtBu OtBu OtBu 
H N._,,__"'-../NHMtr OtBu OtBu tBu 
l j 1) piperidine 
NH 2)44/NMM c·... 3) Ac20/Et3N 
"'~S02-{Gly)5-Asn-Gly-Asp-Phe-Glu-Glu-lle-Pro-Glu-Glu-Tyr-Leu-o-O 
Fmoc-HN I I I I I I I Trt OtBu OtBu OtBu 
OtBu OtBu tBu 
HN....._~NHMtr 
1 j 1) piperidine 
N H 2) Fmoc-Pro-OH/BOP/DIPEA 
3) piperidine 
4) Boc-D-Phe-OH/BOP/DIPEA 
S02-(G ly)5-Asn-G ly-Asp-Phe-G lu-G lu-1 le-Pro-G lu-G lu-Tyr-Leu-0 Boc-0-Phe-Pro-HN I I I I I I I 
Trt OtBu OtBu OtBu 
OtBu OtBu tBu 
HN....._ . ............ NH2 
l 1 TFA 
(N H S02-(Gly)5-Asn-Gly-A~:::lu-Glu-lle-Pro-Glu-Glu-Tyr-Leu-OH H-0-Phe-Pro-H~ 
45 
Scheme 7. Synthesis of hirutonin sulfonamide analog 45. 
be considered as being derived from two known classes of thrombin inhibitors, and were 
therefore tested as potential thrombin inhibitors. In addition, a novel method was developed for 
the synthesis of a ~-substituted aminoethane sulfonylchloride arginine derived building block 
that could be used in the solid phase synthesis of a peptide containing a sulfonamide isostere of 
arginine-glycine. Although overall yields were not very high, the results were promising and 
optimization should definitely lead to improvement of the yields. This novel method may also 
be used as a complementary method to existing procedures for the synthesis of other Fmoc-
protected sulfonylchloride building blocks. 
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Experimental 
General methods. 
DCM and DMF were dried on molecular sieves ( 4A). Triethylamine and DIPEA were distilled 
subsequently from ninhydrin and KOH. THF was distilled from LiAIH4• All other chemicals were 
used as purchased. Tentagel S PHB resin (130 µm) was purchased from Rapp Polymere, 
Tiibingen, Germany. Reactions were carried out at ambient temperature unless stated otherwise. 
TLC analysis was performed on Merck pre-coated silicagel 60 F-254 (0.25 mm) plates. Spots 
were visualized with UV light, ninhydrin or Cl2-TDM34 • Solvents were evaporated under reduced 
pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 ( 40-63 µm) 
and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 from Pharmacia 
was used for gel permeation chromatography. 
1H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 MHz) and chemical 
shift values are given in ppm relative to TMS. 13C-NMR spectra were recorded on a VARIAN 
G300-spectrometer (75.5 MHz) and chemical shift values are given in ppm relative to CDC13 
(77.0 ppm) or DMSO-d6 (39.7 ppm). 13C spectra were recorded using the attached proton test 
(APT) sequence. Fast atom bombardment (FAB) mass spectrometry was carried out using a Jeol 
JMS SX/SX 102A four-sector mass spectrometer, coupled with a HP-9000 data system. All 
compounds tested for thrombin inhibition were analyzed by HPLC and found to be over 95 % 
pure. HPLC analysis was carried out on a Gilson automated HPLC system 205 with a 233XL 
autosampler and a 119 UV-Vis detector. 
a-t-butyloxycarbonyl-E-benzyloxycarbonyl omithinol 7. 
To a solution of 4.0 g of protected omithine 6 (10.9 mmol) and 1.52 mL triethylamine (1 0.9 
mmol) in 60 mL THF was added dropwise 1.04 mL ethyl chloroformate (10.9 mmol) at -10° C. 
The resulting mixture was stirred for 15 minutes at 0° C. Then 1.24 g of NaBH4 (32.8 mmol) and 
100 mL MeOH were added at 0° C. Before the solvent was evaporated, stirring was continued for 
30 minutes at room temperature. Subsequently water was added and the aqueous solution was 
extracted three times with EtOAc. The combined organic layers were washed with IM KHS04, 5% 
NaHC03, brine and dried on Na2S04 • Evaporation of the solvent afforded 3.17 g of alcohol 7 
(83%). Rr 0.25 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDCI3) <> 1.43 (s, 9H, C(CH3) 3), 1.50-1.65 (m, 4H, C!!2C!!2CH2N), 2.57 (bs, IH, OH), 
3.20 (q, 2H, CH2N), 3.50-3.70 (m, 3H, C!!C!!iO), 4.75, 4.95 (two bs, 2H, NH), 5.10 (s, 2H, 
OCH2Ph), 7.35 (m, SH, ArH). 
13C-NMR (CDC13) o 26.5 (£H2CH2CH2N), 28.3 (C(£H3) 3), 28.5 (£H2CH2N), 40.7 (CH2N), 52.2 
(CHN), 65.2 (CH20), 66.6 (OCH2Ph), 79.5 (£(CH3) 3), 128.0, 128.4, 136.5 (CA'), 156.3, 156 .5 
(C=O) . 
Mesylate 8. 
6.78 g of alcohol 7 (19.2 mmol) was dissolved in 100 mL DCM. To this solution 2.95 mL 
triethylamine (21.12 mmol) and 1.56 mL mesyl chloride (20.16 mmol) were added at 0° C. The 
mixture was stirred for 90 minutes at room temperature, after which the solvent was evaporated 
and the residue dissolved in EtOAc. The solution was washed with 5% NaHC03, brine and dried 
on Na2S04 • Evaporation to dryness and crystallization of the residue from EtOAc/hexanes gave 
6.6 g of mesylate 8 (79%). Rr 0.31 (eluent: EtOAc/hexanes 1:1, v/v). 
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1H-NMR (CDC13) 8 1.44 (s, 9H, C(CH3) 3), 1.50-1.65 (m, 4H, C!!2C!1CH2N), 3.02 (s, 3H, CH3SOz), 
3.23 (q, 2H, CH2N), 3.83 (bs, lH, C!!CH20), 4.20 (m, 2H, CHC!:10), 4.70, 4.90 (two bs, 2H, NH), 
5.10 (s, 2H, OCH2Ph), 7.37 (m, 5H, ArH). 
13C-NMR (CDC13) 8 26.4 (fH2CH2CH2N), 28.3 (C(fH3) 3), 28.4 (~H2CH2N), 37.4 (CH3S02), 40.6 
(CH2N), 49.5 (CHN), 66.7 (OCH2Ph), 70.9 (CH20), 80.0 (~(CH3) 3), 128.07, 128.10, 128.5, 136.6 
(CAr), 155.3, 156.5 (C=O), 
Thioacetate 9. 
To a suspension of 2.72 g Cs2CQ3 (8.35 mmol) in 100 mL DMF, 1.29 mL of thiolacetic acid 
(16.7 mmol) was added at 0° C under an argon cushion. After stirring for 15 minutes, 6.53 g of 
mesylate 8 (15.2 mmol) was added and the resulting solution was stirred overnight. The mixture 
was poured into ice water, and extracted with EtOAc three times. The combined organic layers 
were washed with water, 5% NaHC03, brine and dried on Na2S04• Evaporation of the solvent, 
column chromatography (eluent: ether/hexanes 1:1) and recrystallization from ether/hexanes 
gave 4.32 g (69%) of thioacetate 9. Rf 0.24 (eluent: ether/hexanes 2:1, v/v). 
1H-NMR (CDC13) 8 1.43 (s, 9H, C(CH3) 3), 1.40-1.65 (m, 4H, CfiiC!1CH2N), 2.34 (s, 3H, CH3CO), 
3.00 (m, 2H, CHCfiiS), 3.20 (q, 2H, CH2N), 3.70 (bs, lH, Q!CH2S), 4.57, 4.95 (two bs, 2H, NH), 
5.09 (s, 2H, OCH2Ph), 7.37 (m, 5H, ArH). 
13C-NMR (CDC13) b 26.4 (fH2CH2CH2N), 28.3 (C~H3\), 30.4 (fH3C(O)), 31.4 (fH2CH2N), 33.8 
(CHfH2S), 40.6 (CH2N), 50.2 (CHN), 66.5 (OCH2Ph), 79.3 (~(CH3\), 128.0, 128.4, 136.6 (C~, 
155.4, 156.4 (C(O)NH), 195.5 (C(O)S). 
Sulfinylchloride 10. 
1.23 g thioacetate 9 (3.0 mmol) was dissolved in 10 mL DCM and placed under an argon 
cushion. After cooling to -20° C, 283 µL Ac20 (3.0 mmol) and 486 µL sulfuryl chloride (6.0 
mmol) were added. The solution was stirred for 1 hour at -5° C before the solvent was evaporated, 
followed by drying of the residue in vacuo. The crude sulfinylchloride, kept under argon, was 
used immediately for the preparation of a sulfinamide. 
Boc-Orn(Cbz)-'J'[CH2S02]-Gly-0Et 11. 
3.0 mmol of sulfinylchloride 10 was dissolved in 10 mL DCM, placed under argon and cooled to 
0° C. Then a suspension of 837 mg HCl.H-Gly-OEt (6.0 mmol) and 836 µL triethylamine (6.0 
mmol) in 20 mL DCM was added. The mixture was stirred overnight followed by evaporation of 
the solvent. Flash chromatography of the residue (eluent: EtOAc) yielded 1.13 g of sulfinamide 
(77%). Rr 0.26 (eluent: EtOAc). 
For oxidation, the sulfinamide (2.33 mmol) was dissolved in 5 mL DCM, 5 mL acetonitrile and 8 
mL water. At 0° C, 646 mg NaI04 (3.0 mmol) and a catalytic amount of RuCl3'H20 were added to 
the vigorously stirred solution. After stirring for 45 minutes at room temperature, 25 mL DCM 
was added and the aqueous layer was extracted three times with DCM. The combined organic 
layers were dried on MgS04• After removal of the solvent in vacuo, the product was purified by 
flash chromatography (eluent: EtOAc/hexanes 55:45, v/v) yielding 850 mg of sulfonamide 11 
(73%). The overall yield was 57%. Rr 0.68 (eluent: EtOAc). 
1H-NMR (CDC13) 8 1.20 (t, 3H, C~CH20), 1.43 (s, 9H, C(CH3) 3), 1.50-1.70 (m, 4H, 
C!!2C!!2CH2N), 3.10-3.35 (m, 4H, CHCfiiS, CH2CfiiN), 3.95 (two dd, Gly-C2H2), 4.15 (q, 2H, 
CH3Cfii0), 4.43 (bs, lH, CHN), 4.85 (d, lH, NHBoc), 5.08 (s, 2H, OCH2Ph), 5.38 (bs, lH, 
NHCbz), 6.10 (bs, lH, Gly-NH), 7.37 (m, 5H, ArH). 
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13C-NMR (CDC13) 6 13.9 (£H3CH20), 25.7 (£H2CH2CH2N), 28.3 (C(£H3) 3), 31.2 (£H2CH2N), 39.8 
(CH2£H2N), 44.3 (Gly-C2), 46.4 (CHN), 57.6 (CH2S02), 61.7 (CH3£H20), 66.5 (OCH2Ph), 80.1 
(g(CH3) 3), 128.0, 128.4, 136.6 (C'), 156.4, 156.5 (C(O)NH), 170.4 (Gly-C1). 
Boc-Orn(Cbz)-wJCH2S02]-Pro-D-Phe-OMe 12. 
2.0 mmol 10 was dissolved in 5 mL DCM, placed under argon and cooled to 0° C. Then a 
solution of 797 mg HCI.H-Pro-D-Phe-OMe (4.0 mmol) and 558 µL triethylamine (4.0 mmol) in 
10 mL DCM were added. The mixture was stirred overnight and evaporated. Purification by flash 
chromatography (eluent: 6% MeOH in DCM, v/v) yielded 793 mg of sulfinamide (60%). The 
sulfinamide was oxidized as described for 11. Flash chromatography (eluent: 5% MeOH in DCM, 
v/v) afforded 664 mg sulfonamide 12 (81 %). The overall yield was 49%. Rr 0.20 (eluent: 5% 
MeOH in DCM, v/v). 
1H-NMR (CDC13) <> 1.43 (s, 9H, C(CH3) 3), 1.45-1.75 (m, 4H, C!!2C!!2CH2N), 1.87 (qu, 2H, Pro-
C4H2), 2.08 (m, 2H, Pro-C3H2), 2.96-3.35 (m, 6H, CHC!!2S, CH2C!:b,N, Phe-C3H2), 3.38 (t, 2H, Pro-
C5H2), 3.68 (s, 3H, OCH3), 3.99 (m, lH, C!!CH2S), 4.25 (dd, lH, Pro-C2H), 4.80 (q, lH, Phe-c2H), 
5.08 (s, 2H, OCH2Ph), 5.23 (bs, 2H, NHCbz, NHBoc), 7.05-7.20 (m, llH, ArH, Phe-NH). 
13C-NMR (CDC13) 8 24.7 (Pro-C4), 26.1 (gH2CH2CH2N), 28.3 (C(gH3) 3), 30.7 (Pro-C3), 31.2 
(gH2CH2N), 37.4 (Phe-C3), 40.2 (CH~H2NH), 46.9 (CHN), 49.0 (Pro-C5), 52.2, 53.0 (Pro-C2, 
Phe-C2), 53.3 (CH2S02), 61.5 (OCH3), 66.5 (OCH2Ph), 79.7 (£(CH3) 3), 127.1, 127.9, 128.4, 128.6, 
129.2, 135.7, 136.6 (CA'), 155.3, 156.4 (C(O)NH), 171.1, 171.7 (Pro-C1, Phe-C1). 
Boc-Orn(Cbz)-w[CH2S02]-D-Pro-Phe-OMe 13. 
2.0 mmol 10 was dissolved in 5 mL DCM under argon and cooled to 0° C. Then a solution of 
797 mg HCI.D-H-Pro-Phe-OMe (4.0 mmol) and 558 µL triethylamine (4.0 mmol) in 10 mL 
DCM was added. The mixture was stirred overnight and evaporated. Purification by flash 
chromatography (eluent: 4.5% MeOH in DCM) yielded 870 mg of sulfinamide (66%) . Rr 0.33, 
0.42 (eluent: EtOAc) . 
The sulfinamide was oxidized as described for 11 and flash chromatography (eluent: 3% MeOH 
in DCM, v/v) gave 680 mg sulfonamide 13 (76%). The overall yield was 50%. Rr 0.60 (EtOAc). 
1H-NMR (CDC13) 8 1.43 (s, 9H, C(CH3) 3), 1.45-1.73 (m, 4H, C!:b,C!!2CH2N), 1.87 (qu, 2H, Pro-
c4H2), 2.05 (m, 2H, Pro-C3H2), 3.03-3.28 (m, 6H, CHC!!2S, CH2C!!zN, Phe-C3H2), 3.38 (t, 2H, Pro-
C5H2), 3.68 (s, 3H, OCH3), 3.99 (m, lH, C!!CH2S), 4.28 (dd, lH, Pro-C2H), 4.81 (q, lH, Phe-c2H), 
5.08 (s, 2H, OCH2Ph), 5.15, 5.77 (bs, 2H, NHCbz, NHBoc), 7.02 (d, lH, Phe-NH) 7.10-7.35 (m, 
lOH, ArH). 
13C-NMR (CDC13) 8 24.7 (Pro-C4), 26.1 (gH2CH2CH2N), 28.3 (C(gH3) 3), 30.9 (Pro-C3), 31.2 
(gH2CH2N), 37.5 (Phe-C3), 40.2 (CH2gH2NH), 46.5 (Pro-C2), 49.0 (Pro-C5), 52.2, 53.2 (CHN, 
Phe-C2), 53.3 (CH2S02), 61.6 (OCH3), 66.5 (OCH2Ph), 79.7 (£(CH3) 3) , 127.1, 127.9, 128.4, 128.6, 
129.2, 135.6, 136.7 (CA'), 155.3, 156.4 (C(O)NH), 171.1, 171.7 (Pro-C1, Phe-C 1). 
Boc-Orn(Cbz)-w[CH,SO,]-NH, 14. 
2.0 mmol 10 was dissolved in 10 mL DCM under argon and cooled to -10° C. Then NH3 was 
bubbled through the solution for 15 minutes. The mixture was stirred overnight and the solvent 
evaporated. Flash chromatography (eluent: 8% MeOH in DCM) afforded 586 mg of sulfinamide 
(73%). Rr 0.43 (eluent: 10% MeOH in DCM, v/v). 
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The sulfinamide was oxidized as described for 11 and column chromatography (eluent: 10% 
MeOH in DCM) yielded 520 mg sulfonamide 14 (85%). The overall yield was 62%. Rf 0.59 
(eluent: 10% MeOH in DCM, v/v). 
'H-NMR (CDC13) o 1.43 (s, 9H, C(CH3)3), 1.45-1.70 (m, 4H, C!!2C!!2CH2N), 2.85 (s, 2H, NH2), 
3.05-3.25 (m, 4H, CHC!!2S, CH2C!!zN), 4.02 (bs, lH, CHN), 5.03 (s, 2H, OCH2Ph), 5.50, 5.90 (m 
and bs, 2H, NHCbz, NHBoc), 7.30 (m, 5H, ArH). 
13C-NMR (CDClJ o 26.1 (fH2CH2CH2N), 28.3 (C(£H3) 3), 31.3 (£H2CH2N), 40.1 (CH2fH2N), 47.1 
(CHN), 59.0 (CH2S02), 66.6 (OCH2Ph), 80.2 ~(CH3) 3), 127.96, 128.02, 128.4, 136.5 (CA'), 156.3, 
156.7 (C(O)NH). 
N, N'-bis-Cbz-1-guanylpyrazole 15. 
This compound was prepared as described by Wu et al. zoe,f Starting from 1.4 7 g 1-H-pyrazole-1-
carboxamidine hydrochloride (10 mmol) afforded 2.0 g of the monoprotected intermediate 
(81 % ), which was crystallized from EtOH. The following reaction with this intermediate and Cbz-
OSu gave 2.1 g of bis-protected 15 (66%; pyrazole 15 was purified by column chromatography 
(eluent: EtOAc/hexanes 1:2, v/v) before it was crystallized from ether/hexanes). 
Boc-Arg(Cbz2)-'J'[CH7S07]-Gly-0Et 16. 
471 mg sulfonamide 11 (0.94 mmol) was dissolved in 8 mL EtOH. A catalytic amount of 10% 
Pd/C was added and the mixture was stirred for 4 hours under a hydrogen atmosphere. The 
catalyst was removed by filtration and the solvent evaporated. The residue was dissolved in 5 mL 
THF and 356 mg of pyrazole compound 15 (0.94 mmol) was added. The mixture was stirred 
overnight before 57 µL 2-aminoethanol (0.94 mmol) was added. After stirring for 10 minutes the 
solvent was evaporated and the residue dissolved in EtOAc. The solution was washed with 1 M 
KHS04, 5% NaHC03, water, brine and dried on Na2S04 • Evaporation of the solvent and flash 
chromatography (eluent: eluent: EtOAc/hexanes 4:6) afforded 466 mg of sulfonamide 16 (73%). 
Rr 0.43 (eluent: EtOAc/hexanes 1: 1, v/v). 
1H-NMR (CDC13) o 1.25 (t, 3H, C!!3CH20) 1.43 (s, 9H, C(CH3) 3), 1.50-1.75 (m, 4H, C!!2C!!2CH2N) 
3.20 (m, 2H, CHC!!zS) 3.47 (q, 2H, CH2C!!zN) 3.95 (two dd, Gly-C2H2) 4.19 (q, 2H, CH3C!!20) 
4.42 (bs, lH, CHN) 4.95 (d, lH, NHBoc) 5.12, 5.17 (twos, 4H, OCH2Ph) 6.00 (bs, lH, Gly-NH) 
7.37 (m, lOH, ArH) 8.36 (t, lH, CH2CH2CH2N!!) 11.74 (s, lH, NHCbz). 
13C-NMR (CDC13) o 14.0 (£H3CH20) 25.4 (£H2CH2CH2N) 28.3 (C(£H3)3), 31.7 (fH2CH2N) 40.4 
(CH2fH2N) 44.4 (Gly-C2) 46.8 (CHN) 57.6 (CH2S02) 61.6 (CH3fH 20) 67.0, 68.1 (OCH2Ph) 80.1 
(£(CH3)3), 127.8, 128.0, 128.3, 128.6, 128.7, 134.5, 136.7 (CA') 153.8, 156.0 (NC(O)O) 163.6 
(C=N) 170.2 (Gly-c1). 
Boc-Arg(Cbz2)-'J'[CH2S02]-Pro-D-Phe-0Me 17. 
To a solution of 470 mg sulfonamide 12 (0.70 mmol) in 20 mL t-butanol/water (4:1, v/v), 100 
mg Pd/C (10%) was added and the resulting mixture shaken under a 3 Bar hydrogen atmosphere 
in a Parr apparatus overnight. The catalyst was removed by filtration and the solvent evaporated. 
The residue was coevaporated three times with benzene and then dissolved in 4 mL THF. 265 mg 
of pyrazole compound 15 (0. 70 mmol) was added and the solution was stirred overnight. 
Evaporation of the solvent and flash chromatography (eluent: 2.5% MeOH in DCM, v/v) gave 
435 mg of peptidosulfonamide 17 (73%). Rr 0.30 (eluent: 3% MeOH in DCM, v/v). 
1H-NMR (CDC13) o 1.43 (s, 9H, C(CH3) 3), 1.50-2.20 (m, 8H, C!!2C!!2CH2N, Pro-C4H2, Pro-C3H2), 
2.96-3.38 (m, 6H, CHC!!2S, CH2C!!zN, Phe-C3H2), 3.42 (q, 2H, Pro-C5H2), 3.68 (s, 3H, OCH3), 3.99 
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(m, lH, C!!CH2S), 4.25 (dd, lH, Pro-C2H), 4.80 (q, lH, Phe-C2H), 5.10, 5.15 (s, 4H, OCH2Ph), 
5.37 (d, lH, NHBoc), 7.05 (d, lH, Phe-NH), 7.15-7.42 (m, 15H, ArH), 8.38 (t, lH, 
CH2CH2CHl~!!), 11. 75 (s, lH, NHCbz). 
13C-NMR (CDC13) 6 24.6 (Pro-c4), 25.6 (fH2CH2CH2N), 28.2 (C(fH3) 3), 30.5 (Pro-C3), 31.2 
(fH2CH2N), 37.4 (Phe-C3), 40.4 (CH2fH2NH), 47.1 (Pro-C2), 49.0 (Pro-C5), 52.1, 53.0 (CHN, 
Phe-C2), 53.3 (CH2S02), 61.5 (OCH3), 67.0, 68.0 (OCH2Ph), 79.7 (f(CH3) 3), 127.0, 127.7, 127.9, 
128.2, 128.32, 128.5, 128.6, 129.1, 134.5, 135.6, 136.7 (CAr), 153.7, 155.2, 155.9 (C(O)NH), 
163.5 (C=N), 170.9, 171.6 (Pro-C1, Phe-C1). 
B0c-Arg(Cbz2)-\j1[CH7S07]-D-Pro-Phe-0Me 18. 
Peptidosulfonamide 18 was prepared starting from 408 mg sulfonamide 13 (0.61 mmol) 
according to the procedure used to obtain 17. Flash chromatography (eluent: 2.5% MeOH in 
DCM, v/v) afforded 350 mg of peptidosulfonamide 18 (59%). Rr 0.78 (eluent: 10% MeOH in 
DCM, v/v). 
1H-NMR (CDC13) 6 1.43 (s, 9H, C(CH3) 3), 1.55-2.10 (m, 8H, C!!2C!!2CH2N, Pro-c4H2, Pro-C3H2), 
3.00-3.50 (m, 8H, CHCfliS, CH2CfliN, Phe-C3H2, Pro-C5H2), 3.68 (s, 3H, OCH3), 4.02 (m, lH, 
C!!CH2S), 4.28 (t, lH, Pro-C2H), 4.81 (q, lH, Phe-C2H), 5.08, 5.15 (s, 4H, OCH2Ph), 5.75 (bs, 2H, 
NHBoc), 6.93 (bs, lH, Phe-NH) 7.15-7.42 (m, 15H, ArH), 8.35 (t, lH, CH2CH2CH2Ng), 11.75 (s, 
lH, NHCbz). 
13C-NMR (CDC13) 6 24.7 (Pro-c4), 25.5 (fH2CH2CH2N), 28.3 (C(fH3) 3), 30.9 (Pro-C3), 31.2 
(fH2CH2N), 37.5 (Phe-C3), 40.5 (CH2£H2NH), 47.2 (Pro-C2), 49.0 (Pro-C5), 52.2, 53.2 (CHN, 
Phe-C2), 52.9 (CH2S02), 61.7 (OCH3), 67.0, 68.1 (OCH2Ph), 79.7 (£(CH3) 3), 127.1, 127.8, 128.0, 
128.29, 128.32, 128.6, 128.7, 129.2, 134.6, 135.5, 136.8 (CA'), 153.8, 155.2, 156.0 (C(O)NH), 
163.6 (C=N), 171.2, 171.6 (Pro-c1, Phe-C1). 
B0c-Arg(Cbz7H11[CH7S07]-NH7 19. 
Sulfonamide 19 was prepared from 274 mg sulfonamide 14 (0.66 mmol) according to the 
procedure described for 16 and the product was purified by flash chromatography (eluent: 2.5% 
MeOH in DCM, v/v) to give 323 mg of sulfonamide 19 (59%). Rr 0.30 (eluent: 5% MeOH in 
DCM, v/v). 
1H-NMR (CDC13) 6 1.43 (s, 9H, C(CH3) 3), 1.50-1.70 (q, 4H, CfliCfliCH2N), 3.18 (m, 2H, 
CH2Cg2N), 3.30-3 .60 (m, 2H, CHC!!2S), 4.22 (m, lH, CHN), 5.07 (m, lH, NHBoc), 5.11, 5.15, 
5.17 (d ands, 4H, OCH2Ph), 5.43 (bs, 2H, NH2), 7.30 (m, lOH, ArH), 8.38 (t, lH, CH2CH2CH2Ng), 
11.73 (s, lH, NHCbz). 
13C-NMR (CDC13) <> 25.6 (fH2CH2CH2N), 28.3 (C(fH3)3), 31.4 (fH2CH2N), 39.9 (CH2fH2N), 47 .0 
(CHN), 59.9 (CH2S02), 67.1, 68.2 (OCH2Ph), 79.7 (f(CH3)3), 128.0, 128.2, 128.38, 128.43, 
128.6, 128.7, 134.5, 136.5 (CA'), 153.8, 156.3, 156.5 (C(O)N) 163.5 (C=N). 
B0c-Pro-Arg(Cbz2)-\lf[CH2SOz]-Gly-OEt 20. 
To a solution of 466 mg sulfonamide 16 (0.688 mmol) in 7 mL DCM, 2.35 mL TFA was added. 
The mixture stirred for 30 minutes and subsequently evaporated to dryness. The residue was 
coevaporated with THF three times and dissolved in 5 mL DCM. To this solution 148 mg Boc-
Pro-OH (0.688 mmol), 304 mg BOP (0.688 mmol) and 360 µL DIPEA (2.06 mmol) were added. 
The reaction mixture was stirred overnight and the solvent evaporated followed by redissolving 
the residue in EtOAc and washing the resulting solution with lM KHS04, 5% NaHC03, brine and 
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drying on Na2S04 • Evaporation of the solvent and flash chromatography (eluent: EtOAc/hexanes 
3:2, v/v) gave 460 mg of peptidosulfonamide 20 (86%). Rr 0.14 (eluent: EtOAc/hexanes 3:2, v/v). 
'H-NMR (CDC1/CD30D) o 1.21 (t, 3H, C!bCHP), 1.36 (s, 9H, C(CH3) 3), 1.50-2.10 (m, 8H, 
C!:,!iC!!zCH2N, Pro-C3H2, Pro-C4H2), 3.18-3.43 (m, 6H, CHC!!2S, CH2CH2C!!2N, Pro-C5H2), 3.87 (d, 
Gly-C2H2), 4.14 (q, 2H, CH3C!!20, Pro-C2H2), 4.45 (bs, lH, CHN), 4.95 (d, lH, NHBoc), 5.06, 5.13 
(twos, 4H, OCH2Ph), 6.44 (bs, lH, S02CH2CHNH), 7.31 (m, lOH, ArH), 7.44(bs, lH, Gly-NH), 
8.36 (t, lH, CH2CH2CH2N!!), 11.64 (s, lH, NHCbz). 
13C-NMR (CDCl/CDPD) o 13.8 (£H3CHP), 24.0 (Pro-C4), 25.2 (£H2CH2CH2N), 28.1 (C(fH3)3), 
29.5 (Pro-C3), 31.0 (fH2CH2N), 40.1 (CH2CH2£H2N), 44.0 (Gly-C2), 45.3 (Pro-C5), 47.1 
(S02CH2fHN), 56.4 (Pro-c2), 60.6 (CH2S02), 61.7 (CH3fH20), 67.1, 68.1 (OCH2Ph), 80.6 
(£(CH3)3), 127.8, 128.0, 128.3, 128.5, 128.6, 134.5, 136.4 (CA'), 153.5, 155.8 (NC(O)O), 163.3 
(C=N), 170.5 (Gly-C'), 173.5 (Pro-C'). 
B0c-Pro-Arg(Cbz2)-y[CH,SO,]-NH7 21. 
Peptidosulfonamide 21 was prepared from 77 mg sulfonamide 19 (0.13 mmol) and 28 mg Boc-
Pro-OH (0.13 mmol) according to the procedure described for 20. The product was purified by 
flash chromatography (eluent: EtOAc/hexanes 4:1, v/v) yielding 81 mg of peptidosulfonamide 21 
(91 %). Rr 0.28 (eluent: EtOAc/hexanes 3:1, v/v). 
'H-NMR (CDC13) o 1.43 (s, 9H, C(CHJ3), 1.50-1.20 (m, 8H, C!!iC!!2CH2N), 3.20-3.50 (m, 2H, 
CH2Cg2N, CHC!!2S, Pro-C5H2), 4.19 (dd, lH, Pro-C2H), 4.40 (bs, lH, CHN), 5.11, 5.13, 5.17 (d 
ands, 4H, OCH2Ph), 5.63 (bs, 2H, NH2), 7.17 (m, lH, NHCHCH2S), 7.30 (m, lOH, ArH), 8.38 (t, 
lH, CH2CH2CH2N!!), 11.70 (s, lH, NHCbz). 
B0c-D-Phe-Pro-Arg(Cbz2)-w(CH2S02]-G1y-OEt 22. 
Peptidosulfonamide 22 was prepared from 456 mg sulfonamide 20 (0.588 mmol) and 156 mg 
Boc-D-Phe-OH (0.588 mmol) according to the procedure described for 20. The product was 
purified by flash chromatography (eluent: EtOAc/hexanes 3:1, v/v) yielding 488 mg of 
peptidosulfonamide 22 (90%). Rr 0.34 (eluent: EtOAc/hexanes 3:1, v/v). 
'H-NMR_ (CDC13) o 1.23 (t, 3H, C!bCH20), 1.36 (s, 9H, C(CH3) 3), 1.50-2.05 (m, 8H, C!!zC!!iCH2N, 
Pro-C3H2, Pro-c4H2), 2.63 (m, lH, Pro-C5H•), 2.91 (d, 2H, Phe-C3H2), 3.15 (d, 2H, CHC!!zS02), 
3.41 (bs, 2H, CH2CH2Cg2N), 3.52 (m, lH, Pro-C5Hb), 3.89 (q, Gly-C2H2), 4.16 (q, 2H, CH3C!!z0), 
4.24 (m, lH, C!!CH2S02), 4.45 (m, 2H, Phe-C2H, Pro-C2H), 5.09, 5.15 (twos, 4H, OCH2Ph), 7.14-
7.45 (m, 15H, ArH), 7.44(bs, lH, Gly-NH), 8.39 (t, lH, CH2CH2CH2N!!), 11.70 (s, lH, NHCbz). 
13C-NMR (CDC13) o 13.9 (fH3CH20), 24.1 (Pro-c4), 25.3 (£H2CH2CH2N), 28.2 (C(£H3)3), 28.9 
(Pro-C3), 30.9 (£H2CH2N), 38.7 (Phe-C3), 40.1, 40.2 (CH2CH2£H2N), 44.1, 44.2 (Gly-C2), 45.4 
(Pro-C5), 47.1 (S02CH2fHN), 54.0 (Phe-C2), 56.6 (Pro-C2), 60.9 (CH2S02), 61.8 (CH3CH20), 67 .1, 
68.1 (OCH2Ph), 80.2 (C(CH3)3), 127.1, 127.9, 128.0, 128.29, 128.32, 128.5, 128.6, 128.7, 129.3, 
134.5, 135.9, 136.6 (CA'), 153.6, 155.6, 155.9, 156.0 (NC(O)O), 163.4 (C=N), 170.3 (Gly-C'), 
171.3, 171.7 (Phe-C 1), 172.4, 172.5 (Pro-C'). 
B0c-D-Phe-Pro-Arg(Cbz2)-w(CH2S02]-NH2 23. 
Peptidosulfonamide 23 was prepared from 81 mg sulfonamide 21 (0.12 mmol) and 31 mg Boc-
D-Phe-OH (0.12 mmol) according to the procedure described for 20. The product was purified 
by flash chromatography (eluent: EtOAc/hexanes 4:1, v/v) yielding 68 mg of peptidosulfonamide 
23 (68%). Rr 0. 16 (eluent: EtOAc/hexanes 4:1 , v/v) . 
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1H-NMR (CDC13) cS 1.40 (s, 9H, C(CH3) 3), 1.45-1.90 (m, 7H, C!;!2C!LCH2N, Pro-C3H", Pro-c4H2) , 
2.05 (m, lH, Pro-C3Hb), 2.60 (m, lH, Pro-C5Ha), 2.95 (m, 2H, Phe-C3H2), 3.20 (m, 2H, CH2S02), 
3.45 (m, 2H, CH2C!LN), 3.57 (m, lH, Pro-C5Hb) 4.28 (dd, lH, Pro-C2H), 4.42 (m, 2H, CHN, Phe-
c2H), 5.11, 5.13, 5.17 (d ands, 4H, OCH2Ph), 5.37 (d, lH, NHBoc), 5.47 (bs, 2H, NH2), 7.07 (m, 
lH, NHCHCH2S), 7.30 (m, 15H, ArH), 8.38 (t, lH, CH2CH2CH2N!:!), 11.75 (s, lH, NHCbz). 
13C-NMR (CDC13) cS 24.3 (Pro-c4), 25.8 (£H2CH2CH2N), 28.4 (C(fH3) 3), 28.7 (Pro-C3) , 31.2 
(£H2CH2N), 38.7 (Phe-C3), 40.1 (CH2£H2N), 46.0 (NH£HCH2S) 47.2 (Pro-C5), 54.2 (Phe-C2), 
58.7 (CH2S02), 60.9 (Pro-C2), 67.1, 68.2 (OCH2Ph), 80.3 (C(CH3) 3), 127.2, 128.0, 128.2, 128.6, 
128.7, 128.8, 129.3, 134.5, 135.8, 136.6 (CA'), 153.8, 155.6, 156.3 (C(O)N) 163.6 (C=N), 171.5, 
172.1 (Pro-C1, Phe-C1). 
Boc-Gly-Arg(Cbz2)-'!l[CH2S02)-Pro-D-Phe-OMe 24. 
Peptidosulfonamide 24 was prepared from 213 mg sulfonamide 17 (0.25 mmol) and 44 mg Boc-
Gly-OH (0.25 mmol) according to the procedure described for 20. The product was purified by 
column chromatography (eluent: 4% MeOH in DCM, v/v) yielding 194 mg of 
peptidosulfonamide 24 (86%). Rr 0.38 (eluent: 5% MeOH in DCM, v/v). 
Boc-Gly-Arg(Cbz2)-'!f[CH1S01J-D-Pro-Phe-0Me 25. 
Peptidosulfonamide 25 was prepared from 350 mg sulfonamide 18 (0.41 mmol) and 72 mg Boc-
Gly-OH (0.41 mmol) according to the procedure described for 20. The product was purified by 
flash column chromatography (eluent: 4% MeOH in DCM, v/v) affording 319 mg of 
peptidosulfonamide 25 (86%). Rr 0.62 (eluent: 10% MeOH in DCM, v/v) . 
1H-NMR (CDC13) cS 1.43 (s, 9H, C(CH3) 3), 1.55-2.10 (m, 8H, C!:!2C!;!2CH2N, Pro-C4H2, Pro-C3H2), 
3.03-3.80 (m, 8H, CHC!;!iS, CH2C!;!2N, Phe-C3H2, Pro-c5H2), 3.70 (s, 3H, OCH3) , 4.29 (m, 2H, 
C!;!CH2S, Pro-C2H), 4.82 (q, lH, Phe-C2H), 5.11, 5.17 (s, 4H, OCH2Ph), 5.30 (t, lH, NHBoc), 6.99 
(d, lH, Phe-NH) 7.15-7.42 (m, 15H, ArH), 7.73 (d, lH, Gly-NH) 8.38 (t, lH, CH2CH2CH2Ng), 
11.73 (s, lH, NHCbz). 
13C-NMR (CDC13) cS 24.9 (Pro-C4), 25.9 (£H2CH2CH2N), 28.3 (C(£H3) 3), 30.0 (Pro-C3), 30.9 
(£H2CH2N), 37.5 (Phe-C3), 40.4 (CH2£H2NH), 46.1 (CHN), 47.4 (Gly-c2), 49.1 (Pro-C5), 52.3, 
53.2 (Pro-c2, Phe-C2), 53.3 (CH2S02), 61.7 (OCH3), 67.1, 68.2 (OCH2Ph), 79.7 (£(CH3) 3), 127.1, 
127.9, 128.1, 128.3, 128.4, 128.6, 128.7, 129.2, 134.6, 135.6, 136.6 (CA'), 153.7, 156.2 
(C(O)NH), 163.5 (C=N), 169.4, 171.4, 171.7 (Gly-c1, Pro-C1, Phe-C1). 
Dansyl-Orn(Cbz)-'!1[CH7S02J-NH2 26. 
207 mg sulfonamide 14 (0.50 mmol) was dissolved in 3 mL DCM. At 0° C 1 mL TFA was added 
and the mixture was stirred for 30 minutes at room temperature. Then the solvent was evaporated 
and the residue coevaporated with THF three times. The residue was dissolved in 2 mL DCM and 
135 mg dansyl chloride (0.50 mmol) and 140 µL triethylamine (1.0 mmol) were added. After 
stirring overnight the solvent was evaporated. Flash chromatography (eluent: 5% MeOH in DCM, 
v/v) afforded 186 mg of sulfonamide 26 (68%). Rr 0.46 (eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDC13) <5 0.96 (m, 2H, CH2C!LCH2N), 1.33, 1.53 (two m, 2H, C!LCH2CH2N), 2.46, 2.58 
(two m, 2H, CH2C!;!2N), 2.82 (s, 6H, NCH3) , 3.28, 3.44 (two dd, CHC!;!2S), 3.72 (m, lH, CHN), 
4.58 (t, lH, NHCbz), 4.99 (two s, 42H, OCH2Ph), 5.59 (bs, 2H, NH2), 6.18 (d, lH, NHS02), 7 .10 
(d, lH, ArH), 7.28 (m, SH, ArH), 7.50 (m, 2H, ArH), 8.30 (d, 2H, ArH), 8.51 (d, lH, ArH). 
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13C-NMR (CDC13) 8 25.1 (£H2CH2CH2N), 30.6 (£H2CH2N), 39.2 (CH2£H2N), 45.3 (NCH3), 49.9 
(CHN), 59.4 (CH2S02), 66.6 (OCH2Ph), 115.3, 118.8, 123.3, 127.96, 127.99, 128.4, 128.7, 129.4, 
129.7 130.0, 130.9, 134.6, 136.5, 152.0 (CA'), 156.6 (C(O)NH). 
Dansyl-Arg(Cbz2)-w[CH7S07]-NH7 27. 
Sulfonamide 27 was prepared from 186 mg sulfonamide 26 (0.34 mmol) according to the 
procedure described for 17. The product was purified by subsequent flash chromatography 
(eluent: 3% MeOH in DCM) and gel permeation chromatography (LH-20, DCM/MeOH 1:1, v/v), 
yielding 150 mg of sulfonamide 27 (61 %). Rr 0.51 (eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDC13) 8 1.21 (m, 2H, CH2C!!iCH2N), 1.49 (q, 2H, C!!2CH2CH2N), 2.86 (s, 2H, NCH3), 
2.96 (m, 4H, CH2C!!2N), 3.10, 3.26 (two dd, CHC!!2S), 3.79 (m, lH, CHN), 4.66 (s, 2H, NH2), 
5.11, 5.17 (twos, 4H, OCH2Ph), 6.06 (d, lH, NHS02), 7.14 (d, lH, ArH), 7.31-7.55 (m, 12H, 
ArH), 8.14 (t, lH, CH2CH2CH2NH), 8.27 (m, 2H, ArH), 8.52 (d, lH, ArH), 11.63 (s, lH, NHCbz). 
13C-NMR (CDC13) 8 24.7 (£H2CH2CH2N), 30.7 (£H2CH2N), 39.6 (CH2£H2N), 45.3 (NCH3), 50.4 
(CHN), 59.0 (CH2S02), 67.1 , 68.2 (OCH2Ph), 107.9, 115.2, 118.7, 123.2, 128.0, 128.2, 128.40, 
128.44, 128.6, 128.7, 129.4, 129.6, 129.8, 130.9, 134.6, 134.7, 136.6, 152.0 (CA'), 153.6, 155.9 
(C(O)NH) 163.4 (C=N). 
Boc-D-Phe-Pro-Argw[CH7S02]-Gly-0EtHC128. 
To a solution of 194 mg sulfonamide 22 (0.22 mmol) in 1 mL EtOH, 20 µL acetic acid and 20 
mg Pd.IC (10%) were added and the mixture was stirred overnight under a hydrogen atmosphere. 
The catalyst was then removed by filtration and the solvent evaporated. The acetic acid salt was 
first purified on Sephadex LH-20 and then converted to the hydrochloric acid salt 26 on a 
DOWEX er column. Lyophilization gave 96 mg of the peptidosulfonamide (66%). Rr 0.55 
(eluent: MeOH/37% NH3 in H20/CHC13 45:20:60, v/v). 
1H-NMR (D20) 8 1.30 (t, 3H, C!!3CH20), 1.38 (s, 9H, C(CH3\), 1.50-2.10 (m, 8H, C!!2C!!2CH2N, 
Pro-C3H2, Pro-c4H2), 3.00 (m, 2H, Phe-C3H2), 3.10 (m, lH, Pro-C5H"), 3.25 (t, 2H, CH2CH2C!1N), 
3.45 (d, 2H, CH2S02), 3.68 (bs, lH, Pro-C5Hb), 4.00 (s, Gly-C2H2), 4.25 (q, 2H, CH3C!!i0), 4.40 
(m, 2H, C!!CH2S02, Pro-C2H), 4.63 (m, lH, Phe-C2H), 7.25-7.45 (m, 5H, ArH). 
13C-NMR (D20) 8 12.6 (£H3CH20), 23.3 (Pro-C4), 23.5 (£H2CH2CH2N), 26.8, 26.9 (C(£H3) 3), 28.2 
(Pro-C3), 30.0 (£H2CH2N), 36.9 (Phe-C3), 39.8 (CH2CH2£H2N), 43.2 (Gly-C2), 44.3 
(S02CH2£HN), 46.8 (Pro-C5), 53.2 (Phe-C2), 55.1 (CH2SOz), 60.1 (Pro-C2), 61.7 (CH3£H20), 80.3 
(£(CH3) 3), 126.3, 127.9, 128.6, 135.3 (CA'), 155.8 (C(O)OtBu), 170.9 171.3, 171.5, 172.1 (Phe-
c1, Gly-c1, Pro-C1). 
Boc-D-Phe-Pro-Argw[CH2S07]-NH7-HC1 2 9. 
To a solution of 60 mg sulfonamide 23 (0.072 mmol) in 1 mL EtOH, 8 µL acetic acid and 20 mg 
Pd/C (10%) were added and the mixture was stirred for 5 hours under a hydrogen atmosphere. 
The catalyst was then removed by filtration and the solvent evaporated. The acetic acid salt was 
purified and converted to the hydrochloric acid salt 29 on a DOWEX er column. Lyophilization 
gave 40 mg of the peptidosulfonamide (92%). 
1H-NMR (D20) 8 1.38 (s, 9H, C(CH3) 3), 1.50-2.05 (m, 8H, C!!iC!!iCH2N, Pro-C3H2, Pro-C4H2), 
2.95 (d, 2H, Phe-C3H2), 3.05 (m, lH, Pro-C5H"), 3.20 (t, 2H, CH2CH2C!!2N), 3.40 (d, 2H, CH2S02), 
3.63 (bs, lH, Pro-C5Hb), 4.20, 4.35, 4.60 (three m, 3H, C!!CH2S02, Pro-C2H, Phe-C2H), 7 .20-7.40 
(m, 5H, ArH). 
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13C-NMR (D20) <> 21.0, 23.2, 23.4, 23.5 (£H2CH2CH2N, Pro-C4), 26.6, 28.7 (C(£H3) 3), 28.1, 30.0 
(Pro-C3), 29.9, 30.7 (£H2CH2N), 35.6, 36.5 (Phe-C3), 39.6 (CH2CH2£H2N), 44.3, 44.4 
(S02CHi£HN), 46.9, 49.1 (Pro-C5), 52.1, 53.2 (Phe-C2), 56.9 (CH2S02), 59.7, 60.0 (Pro-C2), 80.7 
(£(CH3) 3), 126.1, 126.5, 127.3, 127.8, 127.9, 128.1, 128.3, 128.5, 128.6, 135.2, 135.8 (C~, 
155.8, 156.3 (C(O)OtBu), 167.0 (C=N), 171.7, 172.0, 172.4, 172.8 (Phe-c1, Gly-C1, Pro-C1). 
FABMS mlz (M+W) 568.2. 
Boc-Gly-Arg'J'(CH2S02]-Pro-D-Phe-OMe'HCl 30. 
To a solution of 190 mg sulfonamide 24 (0.21 mmol) in 1 mL EtOH, 20 µL acetic acid and 20 
mg Pd/C (10%) were added and the mixture was stirred for 5 hours under a hydrogen 
atmosphere. The catalyst was removed by filtration and the solvent evaporated. The acetic acid 
salt was purified and converted to the hydrochloric acid salt 30 on a DOWEX ci- column. 
Lyophilization gave 135 mg of the peptidosulfonamide (92%). 
1H-NMR (D20) 3 1.43 (s, 9H, C(CH3) 3), 1.60-2.25 (m, 8H, C!!zC!!zCH2N, Pro-C3H2, Pro-C4H2), 
3.05-3.55 (d, 8H, Phe-C3H2, Pro-C5H2, CH2CH2C!!zN, CH2S02), 3.78 (s, 3H, CH30), 3.82 (s, 2H, 
Gly-C2H2), 4.35, 4.45, 4.75 (three m, 3H, C!!CH2S02, Pro-C2H, Phe-C2H), 7.22-7.42 (m, 5H, ArH). 
13C-NMR (CDC13) 3 24.8 (Pro-c4), 24.9 (£H2CH2CH2N), 28.4 (C(gf3) 3), 31.3 (Pro-C3, £H2CH2N), 
37.5 (Phe-C3), 41.2 (CH2CHi£H2N), 45.4 (S02CH2£HN), 48.0 (Pro-C5), 49.2 (Gly-C2), 52.4 
(CH30), 52.6 (CH2S02), 53.5 (Phe-C2), 61.6 (Pro-C2), 80.0 (£(CH3) 3), 127.1, 128.6, 129.3, 136.1 
(CAr), 156.5 (C(O)OtBu), 157.4 (C=N), 170.6, 172.1 , 172.2, (Phe-C1, Gly-C1, Pro-C1). 
FABMS m/z (M+H+) 640.3. 
Boc-Gly-Arg'J'(CH2S02J-D-Pro-Phe-OMe'HCl 31 
233 mg sulfonamide 25 (0.26 mmol) was dissolved in a mixture of 2 mL EtOH, 2 mL dioxane 
and 25 µL acetic acid. To this solution 20 mg Pd/C ( 10%) was added and the mixture was stirred 
overnight under a hydrogen atmosphere. The catalyst was removed by filtration and the solvent 
evaporated. The acetic acid salt was purified and converted to the hydrochloric acid salt 31 on a 
DOWEX ci- column. Lyophilization gave 155 mg of peptidosulfonamide 31 (88%). 
1H-NMR (D20) 3 1.43 (s, 9H, C(CH3) 3), 1.55-2.25 (m, 8H, C!!zC!!zCH2N, Pro-C3H2, Pro-C4H2), 
3.05-3.60 (d, 8H, Phe-C3H2, Pro-C5H2, CH2CH2C!:!2N, CH2S02), 3.75 (s, 2H, Gly-C2H2), 3.80 (s, 3H, 
CH30), 4.25, 4.40, 4.80 (three m, 3H, C!!CH2S02, Pro-C2H, Phe-C2H), 7.30-7.45 (m, 5H, ArH). 
FABMS mlz (M+W) 640.3. 
Dansyl-Arg'J'(CH2S02]-NH2'HCl 32. 
To a solution of 72 mg of sulfonamide 27 (0.099 mmol) in 1 mL EtOH, 0.1 mL lM HCl and 20 
mg Pd/C (10%) were added and the mixture was stirred for 2 hours under a hydrogen 
atmosphere. The catalyst was removed by filtration and the solvent evaporated. Lyophilization 
gave 155 mg of sulfonamide 32 (88%). 
1H-NMR (D20) 8 0.78, 0.99 ( two m, 2H, CH2C!:!2CH2N), 1.39 (m, 2H, C!:!2CH2CH2N), 2.41, 2.55 
(two m, CH2CH2C!!zN), 2.76 (s, 6H, NCH3), 3.41 (m, CHC!!zS), 3.57 (m, lH, CHN), 7.28 (d, lH, 
ArH), 7.55 (t, lH, ArH), 7.64 (t, lH, ArH), 8.25 (two d, 2H, ArH), 8.38 (d, lH, ArH). 
13C-NMR (D20) 3 24.0 (£H2CH2CH2N), 30.9 (£H2CH2N), 40.4 (CH2£H2N), 45.2 (NCH3), 50. l 
(CHN), 59.6 (CH2S02), 116.0, 119.3, 124.1, 129.07, 129.12, 129.2, 130.3, 130.5, 134.5, 151.2, 
156.4 (CAr). 
FABMS mlz (M+W) 457.2. 
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H-D-Phe-Pro-Arg\j/[CH2S07]-G1y-0Et2HC1 33. 
10 mg of 28 (14 µmol) was dissolved in 1 mL DCM and 1 mL ether, saturated with HCl, was 
added. After stirring for 45 minutes the solvent was removed in vacuo and the residue was 
dissolved in water. Lyophilization yielded 10 mg of peptidosulfonamide 33 (100%). 
1H-NMR (D20) o 1.30 (t, 3H, CJ1CH20), 1.50-2.15 (m, SH, C!bC!bCH2N, Pro-C3H2, Pro-C4H2), 
2.78 (q, lH, Pro-C5H"), 3.15-3.60 (m, 7H, Phe-C3H2, Pro-C5H\ CH2CH2C!bN, CH2S02), 4.01 (s, 
Gly-C2H2), 4.25 (q, 2H, CH3C!b0), 4.30, 4.44, 4.59 (three m, 3H, C!!CH2S02, Pro-C2H, Phe-C2H), 
7.30-7.50 (m, SH, ArH). 
FABMS mlz (M+H+) 554.2. 
H-D-Phe-Pro-Arg\j/[CH2S02]-G1y-OH2HC1 34. 
11 mg of sulfonamide 28 (15 µmol) was dissolved in 1 mL IM HCl and stirred for 24 hours at 
room temperature. Lyophilization gave 10 mg of peptidosulfonamide 34 (100%). 
'H-NMR (D20) o 1.50-2.15 (m, SH, C!!2C!bCH2N, Pro-C3H2, Pro-c4Hi), 2.78 (q, lH, Pro-C5H"), 
3.15-3.60 (m, 7H, Phe-C3H2, Pro-C5H\ CH2CH2C!!2N, CH2S02), 4.01 (s, Gly-C2H2), 4.32, 4.43, 
4.59 (three m, 3H, C!!CH2S02, Pro-C2H, Phe-C2H), 7.30-7.50 (m, SH, ArH). 
FABMS mlz (M+H+) 526.2. 
H-D-Phe-Pro-Arg\j/[CH2S02J-NH2·2HC135. 
9.9 mg of sulfonamide 29 (16 µmol) was dissolved in 1 mL DCM and 1 mL ether, saturated with 
HCl, was added. After stirring for 45 minutes the solvent was removed in vacuo The residue was 
dissolved in water and lyophilized, affording 9 .4 mg of peptidosulfonamide 35 (100% ). 
'H-NMR (D20) o 1.50-2.15 (m, SH, C!!2C!!zCH2N, Pro-C3H2, Pro-c4H2), 2.90 (d, lH, Pro-C5H"), 
3.10-3.65 (m, 7H, Pro-C5H\ CH2CH2C!!2N, CH2S02, Phe-C3H2), 4.32, 4.41, 4.59 (three m, 3H, 
C!!CH2S02, Pro-C2H, Phe-C2H), 7.30-7.50 (m, SH, ArH). 
FABMS mlz (M+H+) 468.2. 
H-Gly-Arg\j/[CH7S02]-Pro-D-Phe-0Me·2HC136. 
To a solution of 40 mg of 30 (59 µmol) in 2 mL DCM, 2 mL ether, saturated with HCl, was 
added. After stirring for 30 minutes the solvent was evaporated. Lyophilization from water gave 
36 mg of peptidosulfonamide 36 (100%). 
'H-NMR (D20) o 1.55-2.00 (m, 7H, C!!2C!!zCH2N, Pro-C3H", Pro-c4H2), 2.23 (m, lH, Pro-C3Hb), 
3.08 (dd, lH, Phe-C3H"), 3.25 (t, 2H, CH2CH2C!bN), 3.32 (dd, lH, Phe-C3Hb), 3.44 (m, 4H, Pro-
C5H2, CH2S02), 3.80 (s, 3H, CH30), 3.85 (s, 2H, Gly-C2H2), 4.30 (dd, lH, Pro-c2H), 4.44 (bs, lH, 
C!!CH2S02), 4.80 (m, lH, Phe-C2H), 7.30-7.47 (m, SH, ArH). 
13C-NMR (D20) o 24.5 (Pro-c4), 24.8 (£H2CH2CH2N), 31.1 (Pro-C3), 31.6 (£H2CH2N), 36.7 (Phe-
C3), 40.8 (CH2CH2£H2N, Gly-C2), 45.4 (S02CH£HN), 49.4 (Pro-C5), 52.0 (CH2S02), 53.3 (Phe-
C2), 54.1 (CHP), 62.0 (Pro-C2), 127.5, 129.1, 129.5, 136.7 (C~, 157.1 (C=N), 166.8, 173.5, 
174.4, (Phe-C', Gly-C', Pro-C'). 
FABMS mlz (M+H+) 540.3. 
H-Gly-Argw:[CH2S02]-D-Pro-Phe-0Me·2HC1 37. 
To a solution of 42 mg of sulfonamide 31 (62 µmol) in 2 mL DCM, 2 mL ether, saturated with 
HCl, was added. The solution was stirred for 30 minutes and then the solvent was removed in 
vacuo. The residue was dissolved in water and lyophilized, yielding 38 mg of peptidosulfonamide 
37 (100%). 
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1H-NMR (D20) 8 1.55-2.00 (m, 7H, C,!!2C,!!2CH2N, Pro-C3H", Pro-C4H2), 2.24 (m, lH, Pro-C3Hb), 
3.10 (dd, lH, Phe-C3H"), 3.25 (t, 2H, CH2CH2C_!!iN), 3.33 (dd, lH, Phe-C3Hb), 3.44 (m, 4H, Pro-
C5H2, CH2S02), 3.81 (s, 3H, CH30), 3.86 (s, 2H, Gly-C2H2), 4.31 (dd, lH, Pro-C2H), 4.46 (bs, lH, 
C!!CH2S02), 4.80 (m, lH, Phe-C2H), 7 .30-7 .50 (m, SH, ArH). 
13C-NMR (D20) 6 24.6 (Pro-C4), 24.7 (gH2CH2CH2N), 31.1 (Pro-C3), 31.6 (gH2CH2N), 36.7 (Phe-
C3), 40.8 (CH2CH2gH2N, Gly-C2), 45.4 (S02CH2gHN), 49.3 (Pro-C5), 51.8 (CH2S02), 53.3 (Phe-
C2), 54.1 (CHP), 62.0 (Pro-C2), 127.5, 129.1, 129.5, 136.6 (C~, 157.1 (C=N), 166.8, 173.5, 
174.4, (Phe-C1, Gly-C1, Pro-C1). 
FABMS m/z (M+W) 540.2. 
H-Gly-Argw[CH2SO,J-Pro-D-Phe-OHHCI 38. 
29 mg of sulfonamide 30 (50 µmol) was dissolved in 3 mL lM HCI and stirred for 72 hours at 
room temperature. Lyophilization gave 24 mg of peptidosulfonamide 38 (100% ). 
1H-NMR (D20) 8 1.55-2.00 (m, 7H, C_!!iC_!!iCH2N, Pro-C3H", Pro-c4H2), 2.22 (m, lH, Pro-C3Hb), 
3.08 (dd, lH, Phe-C3H•), 3.25 (t, 2H, CH2CH2C_!!iN), 3.34 (dd, lH, Phe-c3Hb), 3.41 (m, 4H, Pro-
C5H2, CH2S02), 3.85 (d, 2H, Gly-C2H2), 4.29 (dd, lH, Pro-C2H), 4.43 (bs, lH, C!!CH2S02), 4.80 (m, 
lH, Phe-C2H), 7 .25-7 .45 (m, 5H, ArH). 
13C-NMR (D20) 6 24.6 (Pro-c4), 24.8 (gH2CH2CH2N), 31.1 (Pro-C3), 31.6 (gH2CH2N), 36.9 (Phe-
C3), 40.9 (CH2CH&H2N, Gly-C2), 45.4 (S02CH2gHN), 49.4 (Pro-C5), 52.2 (CH2S02) , 54.0 (Phe-
C2), 62.0 (Pro-c2), 127.5, 129.1, 129.6, 136.8 (CAr), 157 .1 (C=N), 166.8, 174.3, 174.8 (Phe-C1, 
Gly-C 1, Pro-C1). 
FABMS m/z (M+W) 526.2. 
H-Gly-Argw[CH2SO,J-D-Pro-Phe-OH2HCI 39. 
32 mg of sulfonamide 31 (50 µmol) was dissolved in 3 mL IM HCI and stirred for 72 hours at 
room temperature. Lyophilization afforded 27 mg of peptidosulfonamide 39 (100%). 
1H-NMR (D20) 8 1.55-1.98 (m, 7H, C!!2C_!!iCH2N, Pro-C3H", Pro-c4H2), 2.21 (m, lH, Pro-C3Hh), 
3.09 (dd, lH, Phe-C3H"), 3.23 (bs, 2H, CH2CH2Cg2N), 3.33 (dd, lH, Phe-C3Hh), 3.42 (m, 4H, Pro-
C5H2, CH2S02), 3.84 (d, 2H, Gly-C2H2) , 4.28 (dd, lH, Pro-c2H), 4.44 (bs, lH, C!!CH2S02), 4.80 (m, 
lH, Phe-c2H), 7.25-7.45 (m, 5H, ArH). 
13C-NMR (D20) 6 24.6 (Pro-c4), 24.8 (gH2CH2CH2N), 31.0 (Pro-C3), 31.6 (gH2CH2N), 36.8 (Phe-
C3), 40.8 (CH2CH&H2N, Gly-C2), 45.4 (S02CH2gHN), 49.3 (Pro-C5), 51.8 (CH2S02), 54.0 (Phe-
C2), 62.0 (Pro-C2), 127.4, 129.1, 129.6, 136.7 (CA'), 157.1 (C=N), 166.8, 174.3, 174.7 (Phe-c1 , 
Gly-c1, Pro-C1). 
FABMS m/z (M+H+) 526.1. 
Alcohol 41. 
To a solution of 1.75 g of protected arginine 40 (2.87 mmol) and 401 µL triethylamine (2.87 
mmol) in 10 mL THF was added 275 µL ethyl chloroformate dropwise at -10° C. The mixture 
was stirred for 30 minutes at 0° C. Then 327 mg NaBH4 (8.64 mmol) and 8 mL MeOH were 
added subsequently at 0° C. Stirring was continued for one hour at room temperature before the 
solution was neutralized with IM HCl and concentrated in vacuo. The remaining aqueous 
solution was extracted with EtOAc three times. Then the combined organic layers were washed 
with IM KHS04, 5% NaHC03, brine and dried on Na2S04 • Evaporation of the solvent and flash 
chromatography ( eluent: 5 % Me OH in DCM, v/v) afforded 1.34 g of alcohol 41 (78 % ) . Rr O .1 7 
(eluent: 5% MeOH in DCM, v/v). 
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1H-NMR (CDC13) 8 1.50 (broad m, 4H, C!1C!!2CH2NH), 2.07 (s, 3H, CH3Ar), 2.59, 2.66 (two s, 
6H, CH3Ar), 3.05-3.65 (m, 6H, NC!!2CH2CH2C!!C!10!!), 3.74 (s, 3H, CHP), 4.09 (t, lH, 
C!!CH20C(O)), 4.30 (d, 2H, CHC!!iOC(O)), 5.68 (d, lH, NHFmoc), 6.32 (bs, 3H, C(NH)), 6.46 (s, 
lH, ArH), 7.21 (t, 2H, ArH), 7.33 (t, 2H, ArH), 7.52 (d, 2H, ArH), 7.70 (d, 2H, ArH). 
13C-NMR (CDC13) 8 11.9, 18.3, 24.0 (CH3Ar), 25.6 (£H2CH2CH2N), 28.5 (£H2CH2N), 41.0 
(CH2N), 47.2 (~HCH20C(O)), 52.7 (CHN), 55.3 (CH30), 64.6 (CH20H), 66.7 (CH£H20C(O)), 
111.8, 119.9, 124.9, 125.0, 127.0, 127.6, 133.4, 136.5, 138.4, 141.2, 143.8, 143.9, 156.5, 158.5 
(CA', C=O, C=N). 
Thioacetate 42. 
To an ice cold solution of 1.50 g Ph3P (5.70 mmol) in 30 mL THF under an argon cushion, 937 
µL DIAD (5.70 mmol) was added. The mixture was stirred at 0° C for 30 minutes, during which a 
precipitate formed. At -10° Ca solution of 405 µL HSAc (5.70 mmol) and 1.70 g alcohol 41 
(2.85 mmol) in 15 mL THF was added. Then the mixture was stirred for one hour at 0° C and 
overnight at room temperature. The solvent was evaporated followed by trituration with DCM and 
flash chromatography (eluent: EtOAc/hexanes 4:1, v/v) affording 1.3 g of thioacetate 42 (70%). 
Rr 0.51 (eluent: EtOAc). 
1H-NMR (CDC13) 8 1.48 (bs, 4H, C!!2C!!2CH2NH), 2.09 (s, 3H, CH3Ar), 2.29 (s, 3H, CH3C(O)), 
2.61, 2.69 (two s, 6H, CH3Ar), 2.90 (d, 2H, C!!2S), 3.20 (m, 2H, CH2N), 3.69 (bs, lH, C!!CH2S), 
3.76 (s, 3H, CH30), 4.13 (t, lH, C!!CH20C(O)), 4.31 (m, 2H, CHC!bOC(O)), 5.08 (d, lH, 
NHFmoc), 6.05 (bs, 3H, C(NH)), 6.48 (s, lH, ArH), 7.25 (t, 2H, ArH), 7.38 (t, 2H, ArH), 7.55 (d, 
2H, ArH), 7.77 (d, 2H, ArH). 
13C-NMR (CDC13) 8 11.8, 18.2, 23.9 (CH3Ar), 25.7 (~H2CH2CH2N), 30.4 (£H3C(O)), 31.7 (CH2S), 
33.7 (£H2CH2N), 40.8 (CH2N), 47.1 (~HCH20C(O)), 51.0 (CHN), 55.3 (CH30), 66.7 
(CH£H20C(O)), 111.7, 119.8, 124.7, 125.0, 126.9, 127.6, 133.6, 136.4, 138.3, 141.1, 143.7, 
143.8, 156.3, 158.4 (CA', C=O, C=N). 
Sulfonylchloride 44. 
500 mg thioacetate 42 (0.77 mmol) was dissolved in 3 mL cold HOAc. At 0° C, 6 mL HOAc and 
3 mL 30% hydrogen peroxide were added and the mixture was stirred for 15 minutes at that 
temperature. After stirring overnight at room temperature, the solvent was evaporated cautiously 
and the residue was coevaporated three times with water. The residue was dissolved in 50 mL 
water followed by the addition of 20 g of DOWEX-Na+. The mixture was shaken for 15 minutes, 
the resin was removed by filtration and the water was evaporated. The residue was coevaporated 
twice with EtOH and twice with benzene. The product was dried in vacuo over KOH, which 
afforded 478 mg of sodium salt 43 (91 %). FABMS m/z (M+W) 681.3. 
To a suspension of sodium salt 43 in 10 mL DCM, 138 mg triphosgene (0.46 mmol), 50 mg 
tetrabutylammonium chloride (0.18 mmol) and 200 µL DMF were added and the mixture was 
stirred for 2 hours. After evaporation of the volatiles the product was purified by elution of the 
reaction mixture over a silica plug (eluent: EtOAc), yielding 180 mg of sulfonylchloride 43 
(38%, Rr 0.98, eluent: EtOAc), which was used directly in the synthesis of hirutonin analog 45. 
H-D-Phe-Pro-Argw(CH2S02]-(GlykAsn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-OH 45. 
1.69 g Tentagel S PHB (0.24 mmol/g) and 429 mmol Fmoc-Leu-OH (1.20 mmol) were 
suspended in 8 mL NMP and shaken for 15 minutes under argon. Then 108 µL pyridine (1.32 
mmol) and 176 µL 2, 6-dichlorobenzoyl chloride (1.20 mmol) were added and the mixture was 
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shaken for 2 days, before the resin was washed with DMF, isopropanol, DMF and DCM 
subsequently. On 1.0 g of this resin (0.20 mmol) side chain protected Fmoc-(Gly)s-Asn-Gly-
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr was synthesized on an ABI 433A peptide synthesizer 
using the ABI FastMoc 1.0 mmol protocol. 0.65 g of the resin containing protected Fmoc-(Glyk 
Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu (0.085 mmol) was treated twice with 20% 
piperidine in NMP (v/v) for 5 and 15 minutes respectively, followed by washings with DMF and 
DCM. Then 2.5 mL DCM, 180 mg sulfonylchloride 44 (0.27 mmol) and 58 µL NMM were 
added and nitrogen was bubbled through the bead suspension overnight. After washings with 
DMF and DCM, the remaining free amines were capped with a solution of 94 µL acetic anhydride 
(1.0 mmol) and 139 µL triethylamine (1.0 mmol) in 2.5 mL DCM. After 30 minutes the resin 
was washed with DMF and DCM. Next Fmoc-Pro-OH and Boc-D-Phe-OH were attached by 
subsequent Fmoc removal as was described above and couplings using 188 mg BOP (0.43 
mmol), 148 µL DIPEA (0.86 mmol) and 143 mg Fmoc-Pro-OH (0.43 mmol) or 113 mg Boc-D-
Phe-OH (0.43 mmol) in 2.8 mL DCM/DMF (9:1, v/v). Between couplings the resin was washed 
with DMF and DCM subsequently. Finally, 5 mL TFA/EDT/water (95:2.5:2.5, v/v) was added to 
the resin and the mixture was shaken for 4.5 hours. The resin was removed by filtration and the 
filtrate was precipitated in cold ether. Purification of the precipitate by preparative HPLC 
afforded 3 mg of analog 45 (2%). 
FABMS m/z (M+H+) 2190.6. 
References and notes 
1) a) Liskamp, R.M.J. Angew. Chem. Int. Ed. Engl., 1994, 33, 305. b) Gante, J. Angew. Chem. 
Int. Ed. Engl., 1994, 33, 1699. c) Giannis, A.; Kolter, T. Angew. Chem. Int. Ed. Engl., 
1993, 32, 1244. 
2) e.g.: a) Simon, R.J.; Kania, R.S.; Zuckermann, R.N.; Huebner, V.D.; Jewell, D.A.; Banville, 
S.; Ng, S.; Wang, L.; Rosenberg, S.; Marlowe, C.K.; Spellmeyer, D.C.; Tan, R.; Frankel, 
AD.; Santi, D.V. ; Cohen, F.E.; Bartlet, P.A. Proc. Natl. Acad. Sci. USA, 1992, 89, 9367. b) 
Kruijtzer, J.A.W.; Liskamp, R.M.J. Tetrahedron Lett., 1995, 36, 6969. c) Burgess, K.; 
Linthicum, D.S.; Shin, H. Angew. Chem. Int. Ed. Engl., 1995, 34, 907. d) Cho, C.Y. ; Moran, 
E.J.; Cherry, S.R.; Stephans, J.C.; Fodor, S.P.A.; Adams, C.L.; Sundaram, A.; Jacobs, J.W.; 
Schultz, P.G. Science, 1993, 261. e) Bol, K.M.; Liskarnp R.M.J. Tetrahedron Lett., 1992, 48, 
6425. f) Sommerfield, T.; Seebach, D. Angew. Chem. Int. Ed. Engl., 1995, 34, 553 . g) Lin, 
P.; Ganesan, A. Bioorg. Med. Chem. Lett., 1998, 8, 511. 
3) a) Wolfenden, R. Acc. Chem. Res., 1972, 5, 10. b) Lienhard, G.E. Science, 1973, 180, 149. 
4) Ondetti, M.A.; Cushman, D.W. Biopolymers, 1981, 20, 2001. 
5) a) Choy, N.; Choi, H.; Won, H.J.; Kim, C.R.; Yoon, H.; Kim, S. C.; Lee, T.G.; Koh, J.S J. 
Med. Chem., 1997, 7, 2635. b) Decicco, C.P; Seng, J.L; Kennedy, K.E.; Covington, M.B.; 
Welch, P.K.; Amer, E.C.; Magolda, R.L.; Nelson, DJ. J. Med. Chem., 1997, 7, 2331. c) Paik, 
S.; White, E.H. Tetrahedron, 1996, 52, 5303. d) Benedetti, F.; Berti, F.; Colombatti, A.; 
Ebert, C.; Linda P.; Tonizzo, F. Chem. Commun., 1996, 1417. e) Mulliez, M.; Naudy, C. 
Tetrahedron, 1994, 50, 5401. f) Zecchini, G.P.; Paradisi, M.P.; Torrini, I.; Lucente, G.; 
Gavuzzo, E.; Mazza, F.; Pochetti, G. f) Gennari, C.; Salom, D.; Potenza, D.; Williams, A. 
Angew. Chem. Int. Ed. Engl., 1994, 33, 2067. h) see also ref 12. 
6) a) Davie, E.W.; Ratnoff, O.D. Science, 1964, 145, 1310. b) MacFarlane, R.G. Nature, 1964, 
202, 498. 
47 
Chapter 2 
7) Blomback, B. Br. J. Haematol., 1969, 17, 145. 
8) Recent examples: see e.g. a) Brady, S.F.; Staufer, K.J.; Lumma, W.C.; Smith, G.M.; Ramjit, 
H.G.; Lewis, S.D.; Lucas, B.J.; Gardell, S.J.; Lyle, E.A.; Appleby, S.D.; Cook, J.J.; Holahan, 
M.A.; Stranieri, M.T.; Lynch Jr., J.J.; Lin, J.H.; Chen, 1.-W.; Vastag, K.; Naylor-Olsen, A.M.; 
Vacca, J.P. J. Med. Chem., 1997, 41, 401. b) Semple, J.E.; Minami, N.K.; Tamura, S.Y.; 
Brunck, T.K.; Nutt, R.F.; Ripka, W.C. Bioorg. Med. Chem. Lett. , 1997, 7, 2421. c) 
Dominguez, C.; Carini, D.J.; Weber, P.C.; Knabb, R.M.; Alexander, R.S.; Kettner, A.; 
Wexler, R.R. Bioorg. Med. Chem. Lett., 1997, 7, 79. d) Saal, W. von der; Kucznierz, R.; 
Leinert, H.; Engh, A. Bioorg. Med. Chem. Lett., 1997, 7, 1283. e) Tamura, S.Y.; Shamblin, 
B.M.; Brunck, T.K.; Ripka, W.C. Bioorg. Med. Chem. Lett., 1997, 7, 1359. f) Akiyama, Y.; 
Tsutsumi, S.; Hatsushiba, E.; Ohuchi, S.; Okonogi, T. Bioorg. Med. Chem. Lett., 1997, 7, 
533. g)Semple, J.E.; Rowley, D.C.; Brunck, T.K.; Ripka, W.C. Bioorg. Med. Chem. Lett., 
1997, 7, 315. 
9) a) Wiley, M.R.; Chirgadze, N.Y.; Clawson, D.K.; Craft, T.J.; Gifford-Moore, D.S.; Jones, 
N.D.; Olkowski, J.L.; Schacht, A.L.; Weir, L.C.; Smith, G.F. Bioorg. Med. Chem. Lett., 1997, 
5, 2835. b) Collen, D.; Matsuo, 0. Stassen, J.M.; Kettner, C.; Shaw, E. J. Lab. Clin. Med., 
1982, 99, 76. c) Bajusz, S.; Barabas, E.; Szell, E.; Bagdy, D. Peptides: Chemistry, Structure, 
Biology, 1975, 603. d) Kettner, C.; Mersinger, L.M.; Knabb, R. J. Biol. Chem., 1990, 30, 
18289. e) Sherry, S.; Alkjaersig, N.; Fletcher, AP. Am. J. Physiol., 1965, 209, 577. f) 
Okamoto, S.; Kinjo, K.; Hijikata, A.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tonomura, S. 
J. Med. Chem., 1980, 23, 827. g) Bush, L.R. Cardiovasc. Drug Revs., 1991, 9, 247. 
10) a) Banner, D.W.; Hadvary, P. J. Biol. Chem., 1991, 266, 20085. b) Bode, W.; Mayr, I.; 
Baumann, U.; Huber, R.; Stone, S.R.; Hofsteenge, J EMBO J., 1989, 8, 3467. 
11) a) Jiang, H.; Chen, K.; Tang, Y.; Chen, J.; Li, Q.; Wang, Q.; Ji, R. J. Med. Chem., 1997, 40, 
3085. b) Kirn, S.; Hwang, S.Y.; Kim, Y.K.; Yun, M.; Oh, Y.S. Bioorg. Med. Chem. Lett., 
1997, 7, 769. c) Nienaber, V.L.; Mersinger, L.J.; Kettner, C.A. Biochemistry, 1996, 35, 
9690. d) Caflisch, A. J. Comp.-Aided Mol. Design, 1996, 10, 372. e) Grootenhuis, P.D.J.; 
Karplus, M. J. Comp.-Aided Mol. Design, 1996, 10, 1. f) Obst. U.; Gramlich, V.; Diederich, 
F.; Weber, L.; Banner, D.W. Angew. Chem. Int. Ed. Engl., 1995, 34, 1739. 
12) a) Moree, W.J.; Marel, G.A. van der; Liskamp, R.M.J. J. Org. Chem. 1995, 60, 5157. b) 
Bont, D.B.A. de; Moree, W.J.; Liskarnp, R.M.J. Bioorg. Med. Chem. 1996, 4, 667. 
13) In retro peptidomimetics the direction of the peptide chain is reversed compared with the 
original substrate, in this case going from the C-terminus to the N-terminus (see ref. le). 
For examples of retro-binding peptides to thrombin see: a) Lynas, J.F.; Walker, B. Bioorg. 
Med. Chem. Lett., 1997, 7, 1133. b) Nienaber, V.L.; Amparo, E.C. J. Am. Chem. Soc., 118, 
6807. c) Tabemero, L.; Chang, C.Y.; Obringer, S.L.; Lau, W.F.; Iwanowicz, E.J.; Han, W.-
C.; Wang, T.C.; Seiler, S.M.; Roberts, D.G.M.; Sack, J.S. J. Mal. Biol., 1995, 246, 14. 
14) Hilpert, K.; Ackermann, J.; Banner, D.W.; Gast, A.; Gubemator, K, Hadvary, P.; Labier, L; 
Muller, K,; Schmid, G; Tschopp, T.B.; Waterbeernd, H. van den J. Med. Chem., 1994, 37, 
3889. 
15) a) Qiu, X.; Padmanabhan, K.P.; Carperos, V.E.; Tulinsky, A.; Kline, T.; Maraganore, J.M.; 
Fenton, J.W. Biochemistry, 1992, 31, 11689. b) Kline, T.; Hammond, C.; Bourdon, P.; 
Maraganore, J.M. Biochem. Biophys. Res. Commun., 1991, 177, 1049. 
16) Fenton, J.W. II, Olson, T.A.; Zabinski, M.P.; Wilner, G.D. Biochemistry, 1988, 27, 7106. 
17) According to the nomenclature described in Schechter, I.; Berger, A. Biochem. Biophys. 
Res. Commun., 1967, 27, 157. Residue positions N-terminal to the scissile bond are 
48 
/3-substituted aminoethane sulfonamides 
designated as P1, P2, P3, ••• , Pn, and positions C-terminal to the scissile bond as Pi', P/, P3', ••• , 
Pn'· For an all L-amino acid peptide the corresponding binding subsites on the protein are 
S1, S2, S3, ••• , Sn and S1', S2', S3', ... Sn'· 
18) Skrzypczak-Jankun, E.; Carperos, V.E.; Ravichandran, K.G.; Tulinsky, A. J. Mol. Biol., 
1991, 221, 1379. b) Maraganore, J.M.; Bourdon, P.; Jablonski, J.; Ramachandran, K.L.; 
Fenton, J.W. II Biochemistry, 1990, 29, 7095. 
19) a) Moree, W.J.; Marel, G.A. van der; Liskamp, R.M.J.; Tetrahedron Lett. 1992, 33, 6389. b) 
Moree, W.J.; Schouten, A.; Kroon, J.; Liskamp, R.M.J. Int J. Pept. Prot. Res. 1995, 45, 501. 
20) a) Levallet, C.; Lerpiniere, J.; Ko, S.Y, Tetrahedron, 1997, 53, 5291. b) Yong, Y.F.; 
Kowalski, J.A.; Lipton, M.A. J. Org. Chem., 1997, 62, 1540. c) Kent, D.R.; Cody, W.L.; 
Doherty, A.M. Tetrahedron Lett., 1996, 37, 8711. d) Dodd, D.S.; Kozikowski, A.P. 
Tetrahedron Lett., 1994, 35, 977. e) Bernatowicz, M.S.; Wu, Y.; Matsueda, G.R. Tetrahedron 
Lett., 1993, 34, 3389. f) Wu, Y.; Matsueda, G.R.; Bernatowicz, M. J. Chem. Soc., Synth. 
Commun., 1993, 23, 3055. g) Bergeron, R.J.; McManis, J.S. J. Org. Chem., 1987, 52, 1700. 
21) a) See chapter 6. b) Lowik, D.W.P.M.; Mulders, S.J.E.; Cheng, Y.; Shao, Y.; Liskamp, 
R.M.J.; Tetrahedron Lett. 1996, 37, 8253. 
22) Bont, D.B.A. de; Moree, W.J.; Liskamp, R.M.J. Bioorg. Med. Chem., 1996, 4, 667. 
23) Kokotos, G. Synthesis, 1990, 299. 
24) Higashiura, K.; Ienaga, K. J. Org. Chem., 1992, 57, 764. 
25) H-Pro-D-Phe-OMe and H-D-Pro-Phe-OMe were prepared from H-Phe-OMe and H-D-Phe-
OMe respectively in two steps: coupling with Boc-D-Pro-OH or Boe-Pro-OH followed by 
removal of the Boe group. 
26) This was also found by Moree, W.J.; Marel, G.A. van der, Liskamp, R.M.J. Tetrahedron 
Lett., 1991, 32, 409. 
27) a) Bont, D.B.A. de; Dijkstra, G.H.; den Hartog, J.A.J.; Liskamp, R.M.J.; Bioorg. Med. Chem. 
Lett. 1996, 6, 3035. b) Gude, M.; Piarulli, U.; Potenza, D.; Salam, B.; Gennari, C. Tet. Lett., 
1996, 37, 8589. c) Reynolds, R.C.; Crooks, P.A.; Maddry, J.A.; Akhtar, M.S.; Montgomery, 
I.A.; Secrist, I.A. J. Org. Chem., 1992, 67, 2983. 
28) Fujino, M.; Wakimasu, M.; Kitada, C. Chem. Pharm. Bull., 1981, 29, 2825. 
29) Burgess, K., lbarzo, J.; Linthicum, D.S.; Russsell, D.H.; Shin, H.; Shintangkoon, A.; Totani, 
R.; Zhang, A.J. J. Am. Chem. Soc., 1997, 119, 1556. 
30) Volante, R.P.; Tetrahedron Lett., 1984, 22, 3119. 
31) TentaGel-PHB is a polyethyleneglycol based resin to which a p-hydroxybenzylalcohol 
linker is attached. 
32) Sieber, P. Tetrahedron Lett., 1987, 28, 6147. 
33) Strategies in Peptide Synthesis: Introduction to Cleavage techniques, Applied Biosystems, 
inc, 1990. 
34) Arx, E. von; Faupel, M; Bruggen, M. J. Chromatography 1976, 120, 224. 
49 

CHAPTER3 
Synthesis of a-substituted aminoethane sulfonamide 
Arg-Gly isosteres 
Introduction 
Peptide bond replacements are important in the development of peptidornimetics, as they are in 
many cases the first step from a biologically active peptide to analogs having improved 
properties 1• In the recent past numerous of these replacements have been reported2, including 
replacement by the sulfonamide moiety3. In the previous chapter the synthesis of ~-substituted 
aminoethane .sulfonamide arginine-glycine isosteres has been described, in which the 
sulfonamide moiety can be considered as a transition-state analog of the hydrolysis of a peptide 
bond between arginine and glycine. In these peptidomimetic structures the presence of an 
additional carbon atom between the arginine side chain and the sulfonamide moiety might have 
a negative effect on the binding to the biological target, viz. thrombin. Therefore, we decided to 
prepare sulfonamide analogs of arginine without the additional carbon atom between the side 
chain and the sulfonamide moiety, i.e. a-substituted aminoethane sulfonamides4 (figure 1). In 
this chapter the synthesis of these compounds will be described. 
0 0 
1 \\/; R,~l'R' 
NH 
HN~NH2 
Figure 1. An a-substituted aminoethane sulfonamide arginine analog. 
Three approaches were investigated of which the first two were based on previous work in our 
group4a. The first strategy should lead to homochiral isosteres while the second and third 
approach will lead to racemic mixtures. All three strategies feature the same key intermediate, 
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i.e. protected aminoalcohol 1 (scheme 1). This derivative can then be converted to the 
corresponding thioacetate 2, which, on its turn, can be transformed into sulfinylchloride 3. 
The latter is the actual precursor in the preparation of arginine-glycine derivatives containing the 
sulfonamide isostere. 
(p2 
-
( 
-
(p2 
p1N : 
~OH 
p1N : 
~SAc P
1N : Cl 
~s .... 
1 II 2 0 3 
Scheme 1. Synthetic intermediates in the preparation of a-substituted sulfonamide ornithine and 
arginine analogs. 
Results and discussion 
The first approach started with 8-Cbz protected omithine 4, as is depicted in scheme 2. The 
synthesis is analogous to the one previously described for the preparation of e.g. 
phenylalanine-praline sulfonamide isosteres4a. However, conversion of amino acid 4 into the 
aminoalcohol 5, could not be accomplished using Na2N02 and sulfuric acid5• This was 
probably due to the side chain functionality, of which the amine is not sufficiently protected by 
the Cbz group. Perhaps other protective groups would allow for this reaction to proceed, but 
this was not investigated. 
(HCbz 
~ 
(HCbz (HCbz 
- -
HO~NH2 HO~OH - H2N~OH 
1 
0 0 0 
4 5 6 
Scheme 2. Synthesis of 1 from 8-benzyloxycarbonyl ornithine. 
The second approach abandoned the goal of obtaining homochiral compounds for the time 
being and will lead to racemic mixtures instead. Key intermediate in this synthesis was the 
protected aminoaldehyde 10. This aldehyde might be converted to cyanohydrin 116, which can 
be converted to 1, analogous to the earlier described synthesis of a phenylalanine-praline 
sulfonamide analog4a (scheme 3). Three compounds, 7, 8 and 9, were considered as potential 
precursors for aldehyde 10. First, hydrolysis of acetal 7 should give Cbz-protected aldehyde 
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EtO~ NHCbz 
OEt 7 NHP 
or ~ N~:H HO~ * 1 NHBoc - -8 or 0 
HO~ 10 11 NHBoc P = Boe or Cbz 
0 9 
Scheme 3. Synthesis of 1 via N-protected aminobutyraldehyde 10. 
10. Several acids were used to catalyze this reaction, e.g. TFA, HCI, H2S04 or FeC13, but 
invariably a mixture of unidentifiable products was obtained. The only time that aldehyde 1 0 
seemed to have been formed, was as a byproduct during the work up of the starting material 7 ! 
Apparently the Cbz group was not a suitable protective group for the formation of this aldehyde 
from acetal 7, and in the literature only the conversion of an aminoacetal bearing a phthalimide 
group to the corresponding aminoaldehyde was reported7• Since the phthalimide group did not 
seem to be compatible with the remainder of the proposed synthetic approach, it was not used. 
Second, aminoalcohol 8 was oxidized using N-methyl morpholine-N-oxide and TPAP as a 
catalyst8. It appeared that Boe-protected aldehyde 10 was formed, but it was not very stable 
and could therefore not be isolated. Also using the crude aldehyde immediately in the next step 
did not give any of the desired cyanohydrin. Others in our lab had shown that the stability of 
aldehyde 10 was dependent on the employed method of oxidation and was probably influenced 
by the presence of certain impurities9• Because of these results and the lower cost of aminoacid 
9, compared to the previous two starting materials, it was decided to try to use aminoacid 9 to 
obtain aldehyde 10, as was reported in literature10• This involved the conversion of aminoacid 
9 into the corresponding N, 0-dimethyl hydroxamate for transformation to aldehyde 10. 
Unfortunately, our attempts to reduce this amide with LiAIH4 did not lead to the desired 
product, and therefore also this route was abandoned. 
The third route, started with 4-penten-1-ol 12 (scheme 4). The double bond was epoxidated, 
but due to the difficult work up of the epoxide of 12, it was decided to protect the alcohol first 
as a benzylether. This was accomplished in 77% yield by the reaction of alcohol 12 with 
benzylchloride in the presence of NaH. The thus obtained alkene 13 was epoxidated with 
mCPBA affording epoxide 14 in 74% yield. As a first attempt to open the epoxide ring the 
chiral a-methylbenzylamine was chosen11 , since it was anticipated that this would lead to a 
separable mixture of diastereoisomers and perhaps even to a substantial diastereomeric excess 
of amino alcohol 15. Unfortunately this was not the case, although the regioselectivity was 
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1) H2/Pd/C C 17 X = N3 17b 
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Ph3P1DIAD ~Ac 1) S02Cl2/Ac20 5 H O 
17 N3~NHB0c BocHN s ..... NJOEt 
HSAc 2) H-Gly-OEt I/\\ 
19 0 0 
Scheme 4. Synthesis of an ornithine-glycine mimic containing a sulfonamide isostere. 
correct. To increase the diastereoselectivity of the reaction, it was carried out at several 
temperatures, however, the diastereomeric ratio remained almost constant i.e. 1: 1. In addition, 
the diastereomers were hardly separable on TLC, thus hampering separation on a large scale. 
Because of these results it was decided not to use the more expensive chiral a-
methylbenzylamine but benzylamine instead (scheme 5). The ring opening reaction still showed 
the correct regioselectivity, i.e. affording lSb, but a considerable amount of byproduct 15 c 
was formed, resulting from di-alkylation of benzylamine12 • Therefore, ring opening with the 
earlier used a-methylbenzylamine was preferred. 
0 BnNH2 
Bno~-
14 
OH 
BnO~~ ............... Al + 
15b 
OH 
BnO~ Al 
N_/ 
BnO~ 15c 
OH 
Scheme 5. Opening of epoxide 14 with benzylamine. 
The synthesis was continued by the removal of the benzyl protective groups of 15 by 
hydrogenolysis and subsequent protection of the free amine with a Boe group. This was 
accomplished using Bocp in the presence of NaOH and afforded diol 16 in 93% yield. 
Remarkably, a considerable difference in reactivity of both diastereoisomers was observed 
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during the hydrogenation. Unfortunately, it was not possible to take advantage of this 
difference to separate the diastereomers. The next step was to convert the primary hydroxyl 
function in 16 to a group, that would eventually lead to the guanidine functionality of the 
arginine sulfonamide mimic. For this purpose the azido group was chosen, as a masked amine 
functionality 13, which can be converted to a guanidine group at a later stage. For introduction 
of the azide, it was attempted to convert the primary alcohol of diol 16 into the tosylate or the 
mesylate14• Tosylation did not give the desired product, and the mesylate was only obtained in 
a low yield. The mesylate was very unstable and decomposed slowly upon standing. To 
circumvent these problems, it was attempted to introduce the azido function directly via a 
Mitsunobu reaction15 • Fortunately, reaction of diol 16 with HN 3, Ph3P and t-butyl 
azodicarboxylate gave azide 17 in 60% yield and was converted to the Cbz protected 18 by 
catalytic reduction of the azide followed by reaction with Cbz-OSu. Choice of t-butyl 
azodicarboxylate, instead of e.g. the more common ethyl azodicarboxylate, was crucial. 
Otherwise it was not possible to separate the hydrazine derivative, formed in the reaction, from 
the product. In addition, a byproduct was formed, which was also observed in the tosylation 
reaction and seemed to have resulted from an intramolecular reaction. This product could not be 
isolated, having used the reaction conditions to obtain azide 17. However, it could be obtained 
in 67% yield by carrying out the Mitsunobu reaction, using ethyl azodicarboxylate and Ph3P 
without HN3, and turned out to be tetrahydrofuran derivative 17b. 
Having arrived at key synthon 18, corresponding to general structure 1, the remammg 
hydroxy function had to be converted to a thioacetate moiety. Unfortunately it was not possible 
to prepare the thioacetate of 18, probably because of interference by the Cbz protected amine. 
Consequently, it was decided to retain the azide as a masked amino function 13 in 17 and to 
convert the hydroxy function of this compound into a thioacetate. Again a Mitsunobu reaction 
was chosen to accomplish this. As was the case in the preceding Mitsunobu reaction, the 
choice of alkyl azodicarboxylate reagent proved to be crucial in order to be able to purify the 
product. The use of thiolacetic acid, Ph3P and isopropyl azodicarboxylate produced16 
thioacetate 19 in 69%. Subsequently, treatment with acetic anhydride and sulfurylchloride gave 
the corresponding sulfinylchloride, which was used directly for coupling with glycine 
ethylester. The thus obtained sulfinamides were oxidized immediately to the corresponding 
sulfonamide 20 in 52% using Nal04 and RuCl3 as a catalyst. Following the strategy outlined 
in chapter 2, the ornithine-glycine sulfonamide derivative 20 was converted into the arginine-
glycine analog by hydrogenation17 to hydrochloric acid salt 21 and subsequent introduction of 
the protected guanidine group (scheme 6), using pyrazole derivative 22 18 , to afford 23 in 
76%. 
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1) TFA 
2) BOP/DIPEA 
Boe-Pro-OH 
CbzHNYNCbz CbzH~NCbz 
HSN H H ?i :: ;;i~;~)H Al~ ~HSN H HJO 
N ,..N~ ~-N N ,...N 
B I 1s\ OEt BocHN S\ OEt oc '/\ //\ 
0 00 24 0 0 00 25 
1) H2/Pd/C 
2) DOWEXCt 
Scheme 6. Synthesis of protected ornithine-arginine analogs containing a sulfonamide isostere. 
In order to compare the data of the thrombin assay on the a-substituted sulfonamides with that 
obtained for the corresponding ~-substituted compounds, described in chapter 2, two N-
terminal groups were chosen to be introduced on the arginine-glycine mimic 23: D-
phenylalanylproline and a dansyl group. It should be noted, however, in order to obtain 
optimal compounds that might be used as thrombin ligands, other substituents may be 
suggested (from e.g. molecular modelling) that have a better fit for the S2-S3 subsites19 of the 
enzyme. The D-phenylalanine and praline residues were introduced via repetitive Boe removal 
with TFA and BOP mediated couplings with DIPEA as a base (scheme 6). This afforded 24 
and 25 as fully protected analogs in 68% and 62%, respectively. Arginine analog 23 was not 
used for the introduction of the dansyl group, because of the difficulties experienced earlier 
(see chapter 2) with the corresponding ~-substituted compounds. Instead azide 20, lacking the 
guanidine group, was preferred (scheme 7). After consecutive removal of the Boe group from 
azide 20 with TFA and reaction with dansylchloride in the presence of triethylamine, 
fluorescent 29 was formed in 80% yield. After hydrogenation of this azide 29, the protected 
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Scheme 7. Introduction of a dansyl group. 
guanidine group was introduced in a reaction using pyrazole derivative 22, leading to the 
protected analog 31 in 48%. The guanidine groups in peptidosulfonamides 25 and 31 were 
deprotected by hydrogenolysis yielding sulfonamides 26 and 32 in 75% and 100%, 
respectively. 
Finally, treatment with either HCl in ether or IM HCl in water afforded analogs 27, 28 and 33 
in quantitative yields (schemes 6 and 7). Compounds 26-28, 32 and 33 were all tested for 
their ability to inhibit thrombin. The results of these experiments will be discussed in chapter 5. 
Conclusion 
In this chapter the preparation of an a-substituted aminoethane sulfonamide arginine-glycine 
isostere was described. The successful approach started with 4-pentene-1-ol and ultimately led 
to the desired arginine-glycine analogs, containing a racemic sulfonamide arginine isostere. In 
order to obtain homochiral compounds, alternative chiral amines should be attempted for ring 
opening of the intermediate epoxide, since the chiral amine which was used in this study did 
not give rise to separable diastereomers. The strategy presented in this chapter, encompassing 
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the use of an alkene as a starting material, might also be applied to the synthesis of other a-
substituted aminoethane sulfonamides. In principle, a-substituted aminoethane sulfonamides 
corresponding to all proteinogenic amino acid analogs are accessible, starting from the 
appropriate alkene. 
Experimental 
General methods. 
DCM and DMF were dried on molecular sieve ( 4A). Triethylamine and DIPEA were distilled 
from ninhydrin and KOH. NMM was distilled from CaH2 and THF from LiAlH4 • 70% mCPBA 
was dried by treatment of a solution of mCPBA in DCM with MgS04• All other chemicals were 
used as purchased. Reactions were carried out at ambient temperature unless stated otherwise. 
TLC analysis was performed on Merck pre-coated silicagel 60 F-254 (0.25 mm) plates. Spots 
were visualized with UV light, ninhydrin or Cl2-TDM20 • Solvents were evaporated under reduced 
pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 ( 40-63 µm) 
and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 from Pharmacia 
was used for gel permeation chromatography. 
'H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 MHz) and chemical 
shift values are given in ppm relative to TMS. 13C-NMR spectra were recorded on a VARIAN 
G300-spectrometer (75.5 MHz) and chemical shift values are given in ppm relative to CDC13 
(77.0 ppm) or DMSO-d6 (39.7 ppm). 13C spectra were recorded using the attached proton test 
(APT) sequence. All compounds tested for thrombin inhibition were analyzed by HPLC and 
found to be over 95% pure. HPLC analysis was carried out on a Gilson automated HPLC system 
205 with a 233XL auto sampler and a 119 UV-Vis detector. Fast atom bombardment (F AB) mass 
spectrometry was carried out using a Jeol JMS SX/SX 102A four-sector mass spectrometer, 
coupled with a HP-9000 data system. 
4-benzyloxycarbonyl aminobutyraldehyde diethyl acetal 7. 
To a mixture of 864 µL of 4-aminobutyraldehyde diethyl acetal (5.0 mmol) and 767 µL 
triethylarnine (5.5 mmol) in 15 mL DCM, at 0° C, 749 µL benzylchloroformate in 5 mL DCM 
was added. After 1 hour the reaction mixture was washed with water (three times), 5% NaHC03, 
brine and dried on MgS04• Evaporation of the solvent and column chromatography (eluent: 
EtOAc/hexanes 1:1, v/v) gave 1.2 g of acetal 7 (85%). 
1H-NMR (CDCI3): o 1.18 (t, 6H, CJ:bCH20), 1.60 (m, 4H, C2H2, C3H2), 3.18 (q, 2H, C4HJ, 3.45, 
3.60 (two m, 4H, CH3C!b0), 4.45 (t, lH, c1H), 5.08 (bs, 3H, NH, OCH2Ph), 7.28 (m, 5H, ArH). 
13C-NMR (CDCl3): <> 15.2 (~H3CH20), 25.0 (C3), 30.8 (C2), 40.7 (c4), 61.2 (CH3£H20), 66.4 
(0£H2Ph), 102.5 (C'), 127.9, 128.3, 136.6 (CAr), 156.3 (C=O). 
4-t-butyloxycarbonyl aminobutanol 8. 
To 1.0 mL of 4-aminobutanol (10.8 mmol) in 20 mL DCM were added 1.58 mL triethylamine 
(11.3 mmol) and 2.36 g Boc20 (10.8 mmol). After stirring overnight the volatiles were removed 
in vacuo. The residue was dissolved in EtOAc and washed with lM KHS04, 5% NaHC03, water, 
brine and dried on Na2S04 • After evaporation of the solvent the product was purified by column 
chromatography (eluent: EtOAc/hexanes 3:2, v/v) yielding 1.8 g of alcohol 8 (88%). Rr 0.26 
(eluent: EtOAc/hexanes 3:2, v/v) . 
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1H-NMR (CDC13): 8 1.40 (s, 9H, C(CH3) 3), 1.55 (m, 4H, C2H2, C3H2), 2.63 (bs, lH, OH), 3.08 (q, 
2H, C4H2), 3.60 (bs, 2H, C1H2), 4.78 (bs, lH, NH). 
13C-NMR (CDC13): 8 26.5 (C3), 28.3 (C(gH3) 3), 29.6 (C2), 40.2 (C4), 62.1 (C1), 79.1 (f(CH3) 3), 
156.2 (C=O). 
4-t-butyloxycarbonyl aminobutyric acid 9. 
1.03 g of 4-aminobutyric acid (10.0 mmol) was dissolved in 22 rnL dioxane, 11 mL water and 21 
rnL 1 M NaOH. At o· C 2.29 g Boc20 (10.5 mmol), dissolved in 10 rnL dioxane, was added. The 
pH was kept at 9 until the reaction was complete according to TLC. The solvent was partially 
removed in vacuo and EtOAc and lM KHS04 were added. The aqueous layer was extracted three 
times with EtOAc. The combined organic layers were washed with lM KHS04 (twice), brine and 
dried on Na2S04• Evaporation of the solvent gave 2.0 g of protected amine 9 (100%). Re 
0.39(eluent: DCM/MeOH/HOAc 90: 10:0.5, v/v). 
1H-NMR (CDC13): 8 1.43 (s, 9H, C(CH3) 3), 1.80 (qu, 2H, C3H2), 2.38 (t, 2H, C2H2), 3.17 (m, 2H, 
C4H2), 4.77, 6.03 (two bs, lH, NH), 10.50 (bs, lH, COOH). 
13C-NMR (CDC13): 8 25.1 (C3), 28.3 (C(fH3) 3), 31.2 (C2), 39.5 (c4), 79.8 (f(CH3) 3), 178 .1 
(COOH). 
1-benzyloxy 4-pentene 13. 
At 0° C 1.32 g NaH (55 mmol) was added to a solution of 5.16 mL 4-penten-1-ol (50 mmol) in 
75 mL THF. After stirring for 10 minutes at room temperature, 5.75 rnL benzylchloride (50 
mmol) was added and the mixture was refluxed overnight. Neutralization with lM HCI followed 
by evaporation of the solvent and dissolving the residue in ether. This solution was washed with 
water (three times), brine and dried on MgS04• Evaporation of the solvent and column 
chromatography (eluent: hexanes to hexanes/ether 9:1, v/v), yielded 6.75 g of alkene 13 (77%). 
Re 0.51 (eluent: ether/hexanes 1:9, v/v). 
1H-NMR (CDCl3) : 8 1.78 (qu, 2H, C2H2), 2.21 (q, 2H, C3H2), 3.54 (t, 2H, c1H2) , 4.55 (s, 2H, 
CH2Ph), 5.00-5.12 (m, 2H, C5Hi), 5.81-5.94 (m, lH, c4H), 7.25-7.45 (m, 5H, ArH). 
13C-NMR (CDC13): 8 29.0 (C2), 30.3 (C3), 69.7 (C1), 72.8 (CH2Ph), 114.6 (C5), 127.4, 127.5, 128.3 , 
138.7 (CA'), 138.2 (C4) . 
1-benzyloxy 4, 5-pentaneoxide 14. 
1.15 g 1-benzyloxy 4-pentene (6.51 mmol) was dissolved in 15 rnL DCM. After addition of a 
solution of 1.95 g 70% mCPBA (dried) in 5 rnL DCM, the mixture was stirred overnight. The 
mixture was filtrated and an additional 80 mL DCM was added. The solution was washed with 
10% Na2S20 3, 5% NaHC03 brine and dried on MgS04• Evaporation of the solvent and 
purification by column chromatography (eluent: ether/hexanes 1 :3, v/v) gave 930 mg of epoxide 
14 (74%). Re 0.43 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13): 8 1.55-1.90 (m, 4H, C!!iC!!iCH), 2.47 (q, lH, C!fWCH), 2.74 (t, lH, 
CHa!tCH), 2.93 (m, lH, CH2C!!), 3.54 (m, 2H, CH2C!!iO), 4.52 (s, 2H, CH2Ph), 7.25-7.40 (m, SH, 
ArH). 
13C-NMR (CDC13): 8 26.1 (fH2CH2CH), 29.2 (CH2fH2CH), 46.8 (fH2CHCH2), 51.9 (CHifHCH2), 
69.7 (CH2fH 20), 72.8 (CH2Ph), 127.4, 127.5, 128.2, 138.4 (CA') . 
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1-benzyloxy 4-hydroxy 5-(S-a-methylbenzyl)amine 15. 
4.16 g epoxide 14 (21.6 mmol) and 2.78 mL S-a-methylbenzylamine (21.6 mmol), dissolved in 
30 mL MeOH, were stirred at 50° C overnight. The solvent was removed in vacuo and the product 
was purified by column chromatography (eluent: 10% MeOH in DCM, v/v). Yield: 4.98 g (74%). 
Re 0.46 (eluent: 10% MeOH in DCM, v/v), 0.71, 0.83 (eluent: 30% MeOH in DCM, v/v). 
1H-NMR (CDC13): o 1.39 (dd, 3H, CH3), 1.42-1.58 (m, 2H, C3H2), 1.58-1.81 (m, 2H, C2H2), 2.28-
2.65 (four dd, 2H, CH2N), 3.48 (two t, C1H2), 3.48-3.71 (two m, lH, CHO), 3.78 (two q, lH, 
CHN). 
13C-NMR (CDCl3): o 23.8, 24.l (CH3), 25 .9 (C2), 31.9, 32.0 (C3), 52.9, 53.5 (C5), 57.7, 58.5 
(CHN), 69.4, 69.9 (C4), 70.2 (C1), 72.8 (CH2Ph), 126.4, 127.5, 128.2, 128.4, 144.8, 145.l (CAr), 
126.9, 127.4, 138.3 (Car). 
1-benzyloxy 4-hydroxy 5-benzylamine 15b. 
385 mg epoxide 14 (2.0 mmol) and 2.2 mL benzylamine (2.0 mmol), dissolved in 3 mL MeOH, 
were stirred at reflux for 4 hours. The solvent was removed in vacuo and the product was purified 
by column chromatography (eluent: 10% MeOH in DCM, v/v). Yield: 289 mg (48%). Rr 0.27 
(eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDCl3): 0 1.54 (m, 2H, C3H2), 1.76 (m, 2H, C2H2), 2.52, 2.73 (two dd, 2H, C5H2), 2.98 
(bs, 2H, NH, OH), 3.52 (dt, 2H, NCH2Ph), 3.69 (m, lH, CHO), 3.80 (q, 2H, C1H2), 4.52 (s, 2H, 
OCH2Ph), 7.22-7.41 (m, lOH, ArH). 
13C-NMR (CDC13): o 25.9 (C2), 32.0 (C3), 53 .5 (C5), 54.7 (NCH2Ph), 69.3 (C4), 70.3 (C1), 72.8 
(OCH2Ph), 127.9, 127.4, 127.5, 128.1, 128.2, 128.4, 138.4, 139.7 (CAr). 
1-Boc amino 2, 5-dihydroxypentane 16. 
4.98 g of 15 (15.9 mmol) was dissolved in 100 mL dioxane, 37 mL water and 37 mL acetic acid. 
After addition of 750 mg 20% Pd(OH)2 on carbon, the mixture was shaken for 4 days under a 3 
Bar hydrogen atmosphere in a Parr apparatus. The catalyst was removed by filtration and the 
solvent evaporated. The residue was coevaporated with EtOH and then dissolved in 50 mL 
dioxane and 50 mL water. A solution of 3.47 g B0c20 (15.9 mmol) in 50 mL dioxane was added 
and the pH was adjusted to 9 with lM NaOH. During the reaction the pH was kept at 9 by the 
addition of IM NaOH. When the amine had disappeared, according to TLC, the volatiles were 
removed in vacuo and the residue was dissolved in a small amount of water. The resulting 
solution was extracted with EtOAc five times. The combined organic layers were dried on Na2S04 
after which the solvent was removed in vacuo. Column chromatography (eluent: 6% MeOH in 
DCM, v/v) gave 3.24 g of diol 16 (93%). Rr 0.28 (eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDC13) : o 1.38 (s, 9H, C(CH3) 3) , 1.32-1.67 (m, 4H, C3H2, C4Hz), 2.95, 3.18 (m, 2H, c1H2), 
3.60 (m, 4H, CHO, CH20), 4.03 (bs, lH, C50H), 4.46 (bs, lH, C20H), 5.38 (bs, lH, NH). 
13C-NMR (CDC13): o 28.3 (C(~H3) 3), 28.7 (C3), 31.6 (c4), 46.5 (C1), 62.3 (C5), 70.9 (C2), 79 .4 
(QCH3) 3), 156.7 (C=O). 
1-Boc amino 2-hydroxy 5-azido pentane 17. 
To a cooled (0° C) solution of 1.51 g triphenylphosphine (5.74 mmol) in 20 mL THF were 
added subsequently, 1.32 g di-tert-butyl azodicarboxylate (5.74 mmol), 5.22 mL of an 1.1 M 
HN3 solution in benzene21 and a solution of 1.26 g dial 16 (5.22 mmol) in 15 mL THF. The 
cooling was removed and the reaction mixture was stirred overnight at room temperature. The 
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solvent was evaporated and the residue was purified by column chromatography (eluent: 
EtOAc/hexanes 1:2, v/v). Yield: 775 mg (60%). Rf 0.40 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13): b 1.45 (s, 9H, C(CH3) 3), 1.47-1.85 (m, 4H, C3H2, c4H2), 2.67 (bs, lH, OH), 3.05 
(qu, lH, C1H), 3.27 (q, lH, C1H), 3.33 (t, 2H, C5H2), 3.72 (m, lH, C2H), 4.92 (bs, lH, NH). 
13C-NMR (CDC13): b 25.0 (C3) , 28.3 (C(£H3) 3), 31.6 (C4), 46.8 (C1), 51.4 (C5), 70.9 (C2), 79.7 
(£(CH3) 3), 156.8 (C=O). 
2-Boc aminomethyl tetrahydrofuran 17b. 
To a solution of 219 mg of diol 16 (1.0 mmol) and 262 mg triphenylphosphine (1.0 mmol) was 
added 164 µL DEAD (1.0 mmol). The mixture was stirred overnight and the solvent evaporated. 
135 mg of tetrahydrofuran derivative 17b (67%) was obtained by column chromatography 
(eluent: EtOAc/hexanes 1:2, v/v). Rf 0.50 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13): b 1.43 (s, 9H, C(CH3) 3), 1.50-1.60, 1.83-2.00 (m, 4H, C2H2, C3H2), 3.06, 3.38 
(two m, 2H, CH2N), 3.69-3.88 (m, 2H, c4H2), 3.93 (m, lH, CH), 4.88 (bs, lH, NH). 
13C-NMR (CDC13): b 25.8 (C2), 28.4 (C~H3) 3), 28.5 (C3), 44.5 (CH2N) , 68.0 (c4), 78.1 (C'), 79.2 
(£(CH3) 3), 156.1 (C=O). 
FABMS m/z (M+W) 202.16. 
I-Boe amino 2-hydroxy 5-(benzyloxycarbonyl)amino pentane 18. 
240 mg of azide 17 (0.98 mmol) and 50 mg Pd/C (10%) in 25 mL EtOH and 0.5 mL 
chloroform17 were shaken for one hour in a hydrogen atmosphere at a pressure of 3 Bar in a Parr 
apparatus. The catalyst was removed by filtration and the solvent evaporated. The residue was 
dissolved in 7 mL DCM followed by the addition of 139 µL triethylamine (1.0 mmol) and 244 
mg Cbz-0Su (0.98 mmol). After stirring overnight the solvent was removed in vacuo and the 
product purified by flash chromatography (eluent: 4% MeOH in DCM, v/v) yielding 220 mg of 
alcohol 18 (64%). Rr 0.25 (eluent: 4% MeOH in DCM, v/v). 
1H-NMR (CDC13): b 1.43 (s, 9H, C(CH3\), 1.50-1.70 (m, 4H, C3H2, c4H2), 3.00 (m, 2H, clH), 3.20 
(m, 4H, C1H2, C2H, C5H2) , 3.65 (bs, lH, OH), 5.05 (s, 2H, CH2Ph), 5.15 (m, 2H, NH), 7.30 (m, 5H, 
ArH). 
13C-NMR (CDC13): b 26.0 (C3), 28.2 (C(£H3) 3), 31.5 (c4), 40.8 (C5), 46.7 (C1), 66.6 (CH2Ph), 71.0 
(C2), 79.6 (£(CH3)3) , 128.0, 128.4, 136.6 (CA'), 156.6 (C=O). 
I-Boe amino 2-thioacetato 5-azido pentane 19. 
To a solution of 2.69 g triphenylphosphine (10.3 mmol) in 40 mL THF, 2.02 mL DIAD (10.3 
mmol) was added at 0° C. After stirring for 30 minutes at 0° C a precipitate had formed and the 
temperature was lowered to -10° C. Then a solution of 1.25 g of alcohol 17 (5.13 mmol) and 730 
µL thiolacetic acid (10.3 mmol), in 15 mL THF, was added. The mixture was allowed to warm up 
to room temperature and stirred overnight. After evaporation of the solvent the product was 
purified by column chromatography ( eluent: EtOAc/hexanes 1 :4, v/v) yielding 1.07 g of 
thioacetate 19 (69%). Rr 0.16 (eiuent: EtOAc/hexanes 1:5, v/v). 
1H-NMR (CDC13): b 1.43 (s, 9H, C(CH3) 3), 1.50-1.80 (m, 4H, C3H2, C4H2), 1.32 (s, 3H, CH3C(O)), 
3.15-3.40 (m, 4H, C1H2, C5H2), 3.55 (m, lH, C2H), 4.78 (bs, lH, NH). 
13C-NMR (CDC13): b 26.3 (C3), 28.3 (C(£H3) 3), 29.0 (C4), 30.7 (£H3C(0)), 44.3 (C1), 44.7 (C2), 
51.0 (C5), 79.5 (£(CH3) 3), 155.8 (C(O)NH), 195.1 ~(O)CH3). 
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Sulfonamide 20. 
1.023 g thioacetate 19 (3.38 mmol) was dissolved in 10 mL DCM and placed under an argon 
cushion. After cooling to -20° C, 319 µL Ac20 (3.38 mmol) and 549 µL sulfuryl chloride (6.76 
mmol) were added. The solution was stirred for 1 hour at -5° C and the volatiles were evaporated, 
followed by drying of the residue in vacuo. The crude sulfinylchloride (3.38 mmol) was used 
immediately for the next reaction and was dissolved in 10 rnL DCM, to which a suspension of 
944 mg of H-Gly-OEt.HCl (6.76 mmol) and 943 µL triethylamine (6.76 mmol) in 20 rnL DCM, 
was added under argon. The reaction mixture was stirred overnight and the solvent removed in 
vacuo. 770 mg of the sulfinamide (60%) was obtained by flash chromatography (eluent: 5% 
MeOH in DCM, v/v). Rr 0.26 (eluent: 5% MeOH in DCM, v/v). 
This sulfinamide (2.04 mmol) was dissolved in a mixture of 5 mL DCM, 5 mL acetonitrile and 
7.5 mL water. The mixture was cooled to 0° C and 567 mg NaI04 (2.67 mmol) and a catalytic 
amount of RuC13H 20 were added to the vigorously stirred solution. After warming up and stirring 
for 20 minutes at room temperature, the aqueous layer was extracted three times with DCM. The 
combined organic layers were dried on MgS04• Removal of the solvent in vacuo, gave after flash 
chromatography (eluent: 3% MeOH in DCM, v/v) 695 mg of sulfonamide 20 (87%). The overall 
yield was 52%. Rr 0.43 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDCl3): o 1.29 (t, 3H, C!!3CH2), 1.43 (s, 9H, C(CH3) 3), 1.60-2.10 (m, 4H, C!!2C!!2CH2), 
3.11 (m, lH, CH), 3.34 (t, 2H, CH2N3), 3.53, 3.75 (m, 2H, CHC!!zN), 3.94 (dd, 2H, Gly-C2H2), 
4.22 (q, 2H, CH20), 5.27 (t, lH, NHC(O)), 5.45 (NHS02). 
13C-NMR (CDC13): o 14.0 (~H3CH2), 24.0 ~H2CH2CH2N3), 26.0 (£H2CH2N3), 28.3 (C(£H3) 3), 39.0 
(N£H2CH), 44.4 (Gly-C2), 51.1 (CH2N3), 61.9 (CH20), 62.6 (CH), 80.0 (£(CH3) 3), 15 6 .1 
(C(O)NH), 169.8 (Gly-C1). 
a-Substituted aminoethane sulfonamide omithine-glycine analog 21. 
151 mg of azide 20 (0.38 mmol) was dissolved in 25 mL EtOH and 0.5 mL chloroform17 and 
shaken under a 3 Bar hydrogen atmosphere in a Parr apparatus for 2.5 hours. The catalyst was 
removed by filtration and the solvent evaporated, yielding hydrochloric acid salt 21 in a 
quantitative yield. The crude product was used directly for the preparation of sulfonamide 23. 
N, N' -bis-Cbz-1-guany lpyrazole 22. 
This compound was prepared as described by Wu et al. 18 Starting from 1.4 7 g l-H-pyrazole-1-
carboxamidine hydrochloride (10 mmol) afforded 2.0 g of the monoprotected intermediate 
(81 % ), which was crystallized from EtOH. The following reaction with this intermediate and Cbz-
OSu gave 2.1 g of bis-protected 22 (66%; pyrazole 22 was purified by column chromatography 
(eluent: EtOAc/hexanes 1 :2, v/v) before it was crystallized from ether/hexanes). 
a-Substituted aminoethane sulfonamide arginine-glycine analog 23. 
Sulfonamide 21 (0.38 mmol) was dissolved in 4 mL THF to which 145 mg of pyrazole 
compound 22 (0.38 mmol) and 53 µL triethylamine (0.38 mmol) were added. After stirring 
overnight, the solvent was removed in vacuo and the residue dissolved in EtOAc. The solution was 
washed with lM KHS04, 5% NaHC03, and dried on Na2S04 • After evaporation of the solvent and 
purification by flash chromatography (eluent: 2.5% MeOH in DCM, v/v) 168 mg of sulfonamide 
23 was obtained (76%). Rr 0.75 (eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDC13): o 1.25 (t, 3H, C!!3CH2), 1.43 (s, 9H, C(CH3) 3), 1.60-2.05 (m, 4H, 
C!!2C!!2CH2NH), 3.20 (m, lH, CH), 3.45 (CH2C!!2NH), 3.47, 3.72 (m, 2H, CHC!!2N), 3.85 (s, 2H, 
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Gly-C2H2), 4.18 (q, 2H, CH20), 5.10, 5.15 (twos, 4H, OCH2Ph), 5.35 (t, lH, NHBoc), 5.88 (bs, lH, 
NHS02), 7.20-7.45 (m, lOH, ArH), 8.38 (t, lH, CH2N!!C), 11.75 (s, lH, NHCbz). 
13C-NMR (CDCl3): 8 14.0 (£H1CH2), 24.0 (£H2CH2CH2N1), 26.0 (£H2CH2N1), 28.3 (C(£H3)3), 39.2 
(N£H2CH), 40.3 (CH2£H2N), 44.3 (Gly-C2), 61.7 (CH3£H20), 62.5 (CH), 67.1, 68.2 (OCH2Ph), 
79.8 (£(CH3)3), 128.0, 128.3, 128.4, 128.5, 128.6, 128.7, 134.6, 136.7 (CA'), 153.8 
(£(O)OCH2Ph), 156.1 (£(0)0C(CH3)), 163.5 (C=N), 169.8 (Gly-C1). 
Peptidosulfonamide 24. 
To a solution of 168 mg of sulfonamide 23 (0.29 mmol) in 1.5 mL DCM, 0.5 mL 1FA was 
added. After stirring the mixture for 30 minutes, the solvent was evaporated and the residue was 
coevaporated with DCM three times. To a solution of the residue in 2 mL DCM, 62 mg Boc-Pro-
OH (0.29 mmol), 128 mg BOP (0.29 mmol) and 151 µL DIPEA (0.87 mmol) were added. 
Stirring was continued overnight, the solvent was evaporated and the residue redissolved in 
EtOAc. This solution was washed with lM KHS04, 5% NaHC03, brine and dried on N~S04 • 
Evaporation of the solvent and purification of the product by column chromatography (eluent: 
EtOAc/hexanes 2:1, v/v) afforded 133 mg of peptidosulfonamide 24 (68%). Rr 0.23 (eluent: 
EtOAc/hexanes 2:1, v/v). 
1H-NMR (CDC13): 8 1.27 (t, 3H, C~CH2), 1.43 (s, 9H, C(CH3)3), 1.50-2.25 (m, 8H, 
C!!2C!!2CH2NH, Pro-C3H2, Pro
4H2), 3.20-3.75 (m, 4H, Pro-C5H2, C!!CH2N, CHC!!aN), 3.46 (q, 2H, 
CH2CH2C!!zNH), 3.92 (m, 3H, Gly-C2H2, CHC!!bN), 4.19 (m, 2H C!!zCH3, Pro-C2H), 5.12, 5.17 
(twos, 4H, OCH2Ph), 5.88, 6.17 (two bs, lH, NHS02), 7.27-7.41 (m, llH, ArH, CH2N!!C(O)), 
8.37 (t, lH, CH2CH2CH2N!!), 11.72 (NHCbz). 
13C-NMR (CDCl3): 8 14.1 (£H1CH2), 24.1 (£H2CH2CH2NH), 24.5 (broad, Pro-C4), 26.1 (Pro-C3, 
£H2CH2NH), 28.4 (C(£H3)3), 38.0 (N£H2CHS), 40.4, 40.5 (CH2CH2£H2NH), 44.3, 44.4 (Gly-C2), 
47.1 (Pro-C5), 60.7 (Pro-C2), 61.8 (CH3£H20), 62.0 (CHS), 67.1, 68.2 (OCH2Ph), 80.5, 80.6 
(£(CH3)3), 127.9, 128.1, 128.39, 128.44, 128.67, 128.75, 134.6, 136.7 (C~, 153.8, 156.16 
(£(O)OCH2Ph), 156.19 (£(0)0C(CH3) 3), 163.6 (C=N), 170.2 (Gly-C1), 173.2 (Pro-c1). 
Peptidosulfonamide 25. 
Peptidosulfonamide 25 was prepared according to the procedure described for 24. Starting with 
133 mg peptidosulfonamide 24 (0.196 mmol) afforded 100 mg of peptidosulfonamide 25 
(62%) after column chromatography (eluent: EtOAc/hexanes 7:3, v/v). Rr 0.32 (eluent: 
EtOAc/hexanes 3:1, v/v). 
I 
H-NMR (CDC13): 8 1.28 (dt, 3H, C!!3CH2), 1.39 (s, 9H, C(CH3) 3), 1.45-2.15 25 (m, 8H, 
C!!2C!!2CH2NH, Pro-C3H2, Pro4H2), 2.67 (m, lH, Pro-C5H"), 2.93 (m, Phe-C3H2), 3.23 (bs, lH, 
CHS), 3.45 (t, 2H, CH2CH2C!!2NH), 3.50-3.80 (m, 3H, NCffCHS, Pro-c5Hb), 3.94 (m, 3H, 
NC!!bCHS, Gly-c2H2), 4.19 (dq, 2H, CH3C!!20), 4.37 (two dd, lH, Pro-C2H), 4.48 (qu, lH, Phe-
C2H), 5.11, 5.16 (twos, 4H, OCH2Ph), 5.44 (d, lH, Phe-NH), 6.20, 6.32 (two t, lH, NHS02), 7.15-
7.48 (m, 16H, ArH, CHCH2N!!), 8.37 (t, lH, CH2CH2CH2N!!), 11.72 (NHCbz). 
13C-NMR (CDC13): 8 14.0 (£H3CH2), 24.0, 24.2, 24.5 (£H2CH2CH2NH, Pro-C4), 26.1, 26.2 
(£H2CH2N3), 28.3 (C(£H3)3), 28.5 (Pro-C3), 38.5, 38.8 (N£H2CHS, Phe-C3), 40.5 
(CH2CH2£H2NH), 44.2, 44.3 (Gly-C2), 46.8, 47.0 (Pro-C5), 54.0 (Phe-C2), 60.3, 60.5 (CHS), 61.6, 
61.8 (Pro-C2), 61.6, 61.7 (CH3£H20), 67.0, 68.0 (OCH2Ph), 80.1 (£(CH3) 3), 127.0, 127.1, 127.8, 
128.0, 128.3, 128.36, 128.45, 128.6, 128.7, 129.3, 134.6, 136.0, 136.1, 136.7 (CA,, 153.7 
(£(O)OCH2Ph), 155.5 (£(0)0C(CH3) 3), 156.0 (£(O)OCH2Ph), 163.6 (C=N), 170.4, 170.5 (Gly-
C1), 171.4, 171.7 (Pro-C1), 172.2 (Phe-C1). 
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Peptidosulfonamide 26. 
102 mg peptidosulfonamide 25 (0.124 mmol) was dissolved in 1 mL EtOH and 10 µL acetic 
acid. 20 mg Pd/C (10%) was added and the mixture was stirred overnight under a hydrogen 
atmosphere. The catalyst was removed by filtration and the solvent evaporated. The acetic acid 
salt was purified on a DOWEX ci- column. Lyophilization gave 55 mg of peptidosulfonamide 26 
(75 %). Rr 0.62 (eluent: MeOW37% NH3 in H20/CHC13 45:20:60, v/v). 
1H-NMR (Dz0): o 1.25 (t, 3H, C!!iCH20), 1.43 (s, 9H, C(CH3) 3), 1.60-2.10 (m, 8H, 
C!!iC!!2CH2NH, Pro-C3H2, Pro-C4Hi), 3.00 (d, 3H, Phe-C3H2, Pro-C5H"), 3.15 (t, 2H, 
CH2CH2C!!2NH), 3.40 (m, lH, CHS), 3.60-3.85 (m, 3H, NHC!!iCHS, Pro-C5Hb), 4.03 (s, 2H, Gly-
c2H2), 4.28 (q, 2H, CH3C!!i0), 4.32 (m, lH, Pro-C2H), 4.66 (m, lH, Phe-C2H), 7.20-7.50 (m, 5H, 
ArH). 
13C-NMR (D20): o 13.6 (£H3CH20), 23.7 (£H2CH2CH2NH), 24.2 (CH£H2CH2NH), 25.3 (Pro-c4), 
27.9 (C(£H3) 3), 29.4 (Pro-C3), 37.5 (Phe-C3), 38.0 (NH£82CHS), 41.0 (CH2CH£H2NH), 44.3 
(Gly-c2), 47.9 (Pro-C5), 54.4 (Phe-C2), 61.1 (CHS), 61.5 (Pro-C2), 63.0 (CH3£H20), 82.0 
(£(CH3) 3), 127.6, 129.0, 129.6, 136.2 (CA'), 157.1 (C=N, £(0)0C(CH3) 3), 172.2, 174.4 (C=O). 
FABMS m/z (M+H+) 654.3. 
Peptidosulfonamide 2 7. 
14 mg of peptidosulfonamide 26 (24 µmol) was dissolved in 1 mL DCM and 1 mL ether, 
saturated with hydrogen chloride, was added. After stirring for 45 minutes the volatiles were 
removed in vacuo and the residue dissolved in water and lyophilized, yielding 12 mg of 
peptidosulfonamide 27 (100%). 
1H-NMR (D20): o 1.31 (t, 3H, C!!3CH20), 1.60-2.10 (m, 8H, C!!iC!!iCH2NH, Pro-C3H2, Pro-C4H2), 
2.80 (q, lH, Pro-C5H"), 3.15-3.33 (m, 2H, Phe-C3H2), 3.27 (t, 2H, CH2CH2C!!iNH), 3.42 (m, lH, 
CHS), 3.55 (m, lH, Pro-C5Hh), 3.73 (m, 2H, NC!!2CHS), 4.04 (d, 2H, Gly-c2H2), 4.30 (q, 2H, 
C!!3CH20), 4.36 (dd, 2H, Pro-C2H), 4.60 (t, lH, Phe-C2H), 7.25-7.50 (m, 5H, ArH). 
13C-NMR (D20): o 13.6 (£H3CH20), 23.9 (£H2CH2CH2NH), 24.3 (CH2£H2CH2NH), 25.5, 25.6 
(Pro-c4), 29.7, 29.8 (Pro-C3), 36.8 (Phe-C3), 37.8, 37.9 (NH£H2CHS), 41.1 (CH2CH2£H2NH), 44.4 
(Gly-C2), 47.2 (Pro-C5), 52.6, 53.4 (Phe-C2), 61.0 (CHS), 61.5, 61.7 (Pro-C2), 63.1 (CH3£H20), 
128.7, 129.7, 130.0, 133.9 (CA'), 157.1 (C=N), 168.5 (Phe-C1), 172.2, 174.4 (Pro-C1, Gly-C1). 
FABMS m/z (M+H+) 554.2. 
Peptidosulfonamide 28. 
15 mg of peptidosulfonamide 26 (25 µmol) was dissolved in 3 mL lM HCl and stirred for 48 
hours at room temperature. Lyophilization gave 13 mg of peptidosulfonamide 28 (100%). 
1H-NMR (D20): o 1.60-2.10 (m, 8H, C!!2C!!2CH2NH, Pro-C3H2, Pro-c4H2), 2.80 (q, lH, Pro-C5H"), 
3.15-3.33 (m, 2H, Phe-C3H2), 3.27 (t, 2H, CH2CH2C!!2NH), 3.43 (m, lH, CHS), 3.56 (m, lH, Pro-
C5Hb), 3.72 (m, 2H, NC!!iCHS), 4.02 (d, 2H, Gly-C2Hi), 4.36 (dd, 2H, Pro-c2H), 4.60 (dd, lH, 
Phe-C2H), 7.25-7.50 (m, 5H, ArH). 
13C-NMR (DzD): o 23.8, 23.9 (£H2CH2CH2NH), 24.2 (CH2£H2CH2NH), 25.4, 25.5 (Pro-C4), 29.58, 
29.65 (Pro-C3), 36.7 (Phe-C3), 37.7, 37.9 (NH£H2CHS), 41.0 (CH2CH2£H2NH), 44.1 (Gly-C2), 
48.0 (Pro-C5), 53.2 (Phe-C2), 61.0 (Pro-C2), 61.3, 61.5 (CHS), 128.5, 129.4, 129.7, 133.7 (CAr), 
157.1 (C=N), 168.2, 174.40 (C=O). 
FABMS m/z (M+ff) 526.2. 
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a-Substituted aminoethane sulfonamide ornithine-glycine analog 29. 
To a solution of 201 mg sulfonamide 20 (0.51 mmol) in 1.5 mL DCM, 0.5 mL TFA was added. 
After stirring for 30 minutes, the solvent was evaporated and the residue was coevaporated with 
THF three times. The residue was dissolved in 3 mL DCM and 138 mg dansylchloride (0.51 
mmol) and 71 µL triethylamine (0.87 mmol) were added. The reaction mixture was stirred 
overnight. The solvent was evaporated and the product purified by column chromatography 
(eluent: 2% MeOH in DCM, v/v) yielding 215 mg of sulfonamide 29 (80%). ~ 0.20 (eluent: 2% 
MeOH in DCM, v/v). 
1H-NMR (CDC13): 6 1.28 (t, 3H, C!bCH20), 1.35-1.62, 1.75-1.94 (two m, 4H, C!1C!1N3), 2.89 (s, 
6H, CH3N), 3.01 (m, lH, CHS), 3.09 (t, CH2N3), 3.33 (m, CHC!!2N), 3.79 (q, Gly-C2H2), 4.20 (q, 
CH3C!!z0), 5.12 (bs, lH, Gly-NH), 6.01 (CHCH2N!!), 7.19 (d, lH, ArH), 7.55 (m, 2H, ArH), 8.25 
(dt, 2H, ArH), 8.56 (d, lH, ArH). 
13C-NMR (CDC13): 6 14.0 (£H3CHP), 23.9 (C!!2CH2CH2N3), 25.6 (C!!2CH2N3), 41.5 (CHC!1N), 
44.2 (Gly-C2), 45.3 (CH3N), 50.7 (CH2N3), 62.0 (CHS), 62.1 (CH3£H20), 115.4, 118.7, 123.1 , 
128.6, 129.5, 129.7, 129.9, 130.8, 134.3, 152.1 (CA'), 169.8 (Gly-C1). 
a-Substituted aminoethane sulfonamide arginine-glycine analog 31. 
To a solution of 215 mg of azide 29 (0.41 mmol) in 25 mL EtOH and 0.5 mL chloroform17 , 50 
mg Pd/C (10%) was added and the mixture was shaken overnight under a 3 Bar hydrogen 
atmosphere in a Parr apparatus. The catalyst was removed by filtration and the solvent evaporated, 
yielding 210 mg of hydrochloric acid salt 30 (0.39 mmol; 95%). Rr 0.13 (eluent: 
DCM/MeOH/E~N 90:10:1, v/v). The salt was dissolved in 3 mL THF and 154 mg of pyrazole 
derivative 22 (0.41 mmol) as well as 57 µL triethylamine (0.41 mmol) were added. The reaction 
mixture was stirred overnight, subsequently the THF was evaporated and the residue taken up in 
EtOAc. The resulting solution was washed with water, lM KHS04, 5% NaHC03, brine and dried 
on Na2S04• Evaporation of the solvent followed by flash chromatography (2.5 % MeOH in DCM, 
v/v) and gel permeation chromatography (LH-20, eluent: DCM/MeOH 1:1, v/v) afforded 160 mg 
of isostere 31 (48 % overall yield). Rr 0.27 (eluent: 2.5% MeOH in DCM, v/v). 
1
H-NMR (CDClJ 6 1.28 (t, 3H, C!bCH20), 1.35-1.62 (m, 3H, CffC!!2NH), 1.75-1.94 (m, lH, 
C!!bCH2NH), 2.89 (s, 6H, CH3N), 3.05 (m, lH, CHS), 3.25 (m, CH2NH, CHC!!2N), 3.73 (q, 2H, 
Gly-C2H2), 4.17 (q, 2H, CH3C!10), 5.10, 5.18 (twos, 2H, OCH2Ph), 5.22 (bs, lH, Gly-NH), 5.97 
(s, lH, CHCH2N!!), 7.19 (d, lH, ArH), 7.25 (m, IOH, ArH), 7.55 (m, 2H, ArH), 8.25 (m, 3H, ArH, 
CH2CH2N!!), 8.56 (d, lH, ArH), 11.75 (s, lH, NHCbz). 
13C-NMR (CDC13): 6 14.0 ~H3CH20), 23.8 (C!1CH2CH2N3), 25.6 (C!!2CH2N3), 40.0 (CH2N3), 41.7 
(CHC!!zN), 44.1 (Gly-c2), 45.3 (CH3N), 61.90 (CHS), 61.95 (CH3£Hz0), 67.1, 68.2 (OCH2Ph), 
115.3, 118.7, 123.1, 127.9, 128.1, 128.37, 128.40, 128.5, 128.6, 128.7, 129.5, 129.6, 129.9, 
130.7, 134.4, 134.6, 136.6, 1S2.0 (CAr), 153 .8, 156.1 (£(O)OCH2Ph), 163.5 (C=N), 169.8 (Gly-
C1). 
Arginine-glycine sulfonamide analog 32. 
151 mg sulfonamide 31 was dissolved in 1.5 mL EtOH and 15 µL acetic acid. 50 mg Pd/C (10%) 
was added and the mixture was stirred for 24 hours under a hydrogen atmosphere. The catalyst 
was removed by filtration and the solvent evaporated. The acetic acid salt was purified and 
converted to the hydrochloride acid salt on a DOWEX ci- column. Lyophilization gave 86 mg of 
sulfonamide 32 (80%). 
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1H-NMR (D20): o 1.19 (t, 3H, C!!3CH20), 1.34 (m, 2H, CH2Cg2CH2NH), 1.53 (m, lH, 
cg•cH2CH2NH), 1.74 (m, lH, C!!bCH2CH2NH), 2.88 (bs, 3H, CHS, CH2CH2C!!iNH), 2.95 (CH3N), 
3.33 (q, 2H, NC!!2CHS), 3.70 (s, 2H, Gly-C2H2), 4.13 (q, 2H, CH3C!!20), 7.45 (d, lH, ArH), 7.65 
(q, 2H, ArH), 8.25 (d, lH, ArH), 8.40 (d, 2H, ArH). 
13C-NMR (D20): o 13.6 (£H3CH20), 23.6 (£H2CH2CH2NH), 25.3 (CH2£H2CH2NH), 40 .8 
(CH2CH2£H2NH), 41.3 (N£H2CHS), 44.0 (Gly-C2), 45.7 (CH3N), 61.5 (CHS), 62.8 (CH3C!!P), 
117.3, 121.5, 125.1, 128.2, 128.96, 129.00, 129.3, 130.3, 134.3, 147.4 (CA'), 156.9 (C=N), 171.7 
(Gly-C1). 
FABMS m/z (M+H+) 543.2. 
Arginine-glycine sulfonamide analog 33. 
29 mg of sulfonamide 32 (50 µmol) was dissolved in 3 mL lM HCl and stirred for 7 hours at 40° 
C, overnight at room temperature and for 1.5 hours at 50° C. Evaporation of the solvent and 
lyophilization from water gave 28 mg of sulfonamide 33 (100%). 
1H-NMR (D20): o 1.40-1.70 (m, 3H, CH2Cg2CH2NH, CffCH2CH2NH), 1.82 (m, lH, 
C!!bCH2CH2NH), 3.00 (m, lH, CHS), 3.08 (t, 2H, CH2CH2Cg2NH), 3.43 (two dd, 2H, NC!!2CHS), 
3.56 (CH3N), 3.71 (d, 2H, Gly-c2H2), 7.96 (t, 2H, ArH), 8.16 (d, lH, ArH), 8.42 (d, lH, ArH), 
8.53 (d, lH, ArH), 8.80 (d, lH, ArH). 
13C-NMR (CDC13): o 23.7 (£H2CH2CH2NH), 25.3 (CH2£H2CH2NH), 40.8 (CH2CH2£H2NH), 41.2 
(N£H2CHS), 43.8 (Gly-C2), 47.1 (CH3N), 61.6 (CHS), 120.0, 125.9, 126.3, 126.8, 127.3, 128.6, 
128.9, 131.0, 135.3, 138.8 (CAr), 157.0 (C=N), 173.4 (Giy-C1). 
FABMS m/z (M+H+) 515.1. 
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CHAPTER4 
Synthesis of conformationally restricted aminoethane 
sulfonamide Arg-Gly isosteres 
Introduction 
Conformationally constrained amino acid derivatives have received considerable attention in the 
past1• These compounds have been used to study conformational requirements of a ligand 
binding to proteins or to increase the binding affinity of an unconstrained analog. The 
combination of the idea of increasing the rigidity together with the concept of replacing peptide 
bonds, led to the wish of developing conformationally restricted peptidomimetics2• 
O O HN~NH2 
a 's:N_R2 ~H n = 0 or 1 
R1-N H ~ ( )n 
0 0 p ,, ,, 2 
NH S ... __.R 
I N N 
HN?--NH2 / ~1 H 
.__ ______ ---.,. HQ,__ /.__ ______ ____, Q-iroH 
H O HQ, 
I ----- •. 00 -------... ,, ,, 2 S ... __.R N N 
0 0 1 1 H 
,, ,, 2 R 
:~SYR 
OH 
Figure 1. Hydroxyproline as a versatile precursor of various conformationally constrained 
sulfonamide amino acid derivatives. 
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Conformationally constrained arginine derivatives are particularly interesting in this respect, 
since it is known that arginine is often important as a binding determinant in protein-peptide 
interactions, as is the case e.g. in RGD peptide analogs3 and a number of protease inhibitors4. 
In view of our interest in sulfonamide based thrombin inhibitors, it was decided to design and 
synthesize conformationally restricted arginine-glycine mimics, as potential ligands for 
thrombin in addition to the unconstrained analogs, which were discussed in the previous two 
chapters. In order to synthesize the conformationally restricted peptidomimetics, naturally 
occurring 4-hydroxyproline was considered as a convenient starting material5• Not only does 
this amino acid contain a set of functional groups that may be independently functionallized, it 
might also serve as a versatile precursor for the synthesis of conformationally restrained 
mimetics of other amino acids, e.g. glutamic acid, glutamine or homoserine (figure 1). In this 
chapter the synthesis of conformationally restricted a- and ~-substituted arninoethane 
sulfonamide analogs of arginine-glycine will be described. The approach towards the synthesis 
of conformationally constrained a-substituted sulfonamide analogs, featured the use of a 
hydroxyproline derivative of which the carboxylic acid moiety was converted to a 
methylenearnine (figure 1, top left). For the synthesis of the ~-substituted isosteres, the 
approach described in chapter 2 was employed after conversion of the hydroxy group to a Cbz 
protected amine or a nitrile. This should give rise to two types of constrained P-substituted 
mimics, containing either two or three methylene groups between the guanidine group and the 
~-carbon atom (figure 1, top right). 
Results and discussion 
The synthesis of a conformationally restricted a-substituted aminoethane sulfonamide analog 
started with hydroxyproline 1, and is depicted in scheme I. Its functional groups were 
protected as a methylester 2 (100%), a carbamate 3 (88%) and as a TBDMS-ether 46 (100%), 
Hq_ HO HO 
S02Cl2 ~ B0c20 ~- TBDMS-Cl 
~OH - OMe- yYaMe MeOH N Et3N imidazole 
H O l HCI H O 2 Boe 0 3 
OTBDMS OTBDMS 1) NaBH4 OTBDMS ~ ~ ~ yYoMe NH3 Y'YNH2 HOAc ~NHCbz - 2) Cbz-Cl 
I 
Boe 0 Boe 0 Et3N Boe 
4 5 6 
Scheme 1. Synthesis of Cbz-protected amine 6 via an amide. 
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using standard procedures. Subsequently, methylester 4 was converted to amide 5 with a 
saturated solution of NH3 in MeOH. Attempts to reduce this amide to the corresponding amine, 
did not lead to any product, probably due to the instability of the amine. Direct protection with 
a Cbz group, after reduction with NaBH/HOAc7 was only partly successful, and the protected 
amine 6 was obtained in a low overall yield of 20%. To circumvent these problems, another 
strategy was followed in order to introduce an amino group at this position in the molecule. 
This new strategy featured the introduction of an already protected amine, starting from the 
corresponding alcohol 7, which was obtained in 93% by reduction of methylester 4 with 
LiBH4• In a Gabriel-like synthesis
8 the amine, protected as its phthalimide, was introduced by 
a Mitsunobu reaction to afford 8 in 95%. After cleavage of the silyl ether with 
tetrabutylammonium fluoride6, alcohol 9 was obtained in 74% and transformed into thioacetate 
10 in 62%, which is the key synthon of our sulfonamides. The yield of thioacetate 10 could 
not be improved, because it was always accompanied by 0-alkylation of thiolacetic acid. 
OTBDMS OTBDMS OTBDMS 
~- LiBH4 b_oH ~ 
~COOMe-
Pht-NH 
~NPht 
TBAF 
DEAD/Ph3P N N 
I I I 
Boe 4 Boe 7 Boe 8 
HQ_ AeS 
p 
~NPht 
S02CI2 
c1-s" 
~NPht 
HSAc 
~NPht D1AD/Ph3P Ac20 N N 
I I 
Boe 9 Boe 10 I 11 Boe 
~p ~p 
Boe,tlS, ~NHMe R,tls ... N~NHMe 
H-Gly-NHMe N N II 1) TFA H II 
------ H O -~-- 0 
2) R-Cl 
13a R = Ac 
NPht 12 NPht 13b R = Tos 
0 0 0 0 
~ij ~~ 
R,tls'N~NHMe R,tls'N~NHMe 
H O 1) H2/Pd/C H O 
2) CbzN...._ ............. NHCbz 2) DOWEX Ct 
l W NH NH 
N, A lSaR=Ac A 16aR=Ac 
~-~_l CbzHN NCbz 15b R = Tos H2N NH·HCI 16b R = Tos 
1) H2NNH2 
Scheme 2. Synthesis of conformationally restricted a-substituted sulfonamide arginine-glycine 
analogs. 
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Subsequently, thioacetate 10 was treated with acetic anhydride and sulfurylchloride to give the 
corresponding sulfinylchloride, which was used directly for the coupling with glycyl 
methylamide. The thus obtained inseparable mixture of sulfinamide diastereoisomers was 
oxidized immediately to the corresponding sulfonamide 12, using Nal04 and RuC13 as a 
catalyst, in an overall yield of 51 %. At this stage, it was not possible to remove the phthalimide 
group from the sulfonamide to introduce a guanidine group, because the resulting amine turned 
out to be unstable, as was described above in the preparation of 6. The cause of this instability 
was thought to be an intramolecular attack of the amine on the Boe group. To avoid this, the 
Boe group on the secondary amine was removed by treatment with TFA and the free amine 
was acetylated, affording peptidosulfonamide 13a in 62% yield, which was expected to be 
more stable once the phthalimide group was removed. Indeed this turned out to be true, since it 
was now possible to convert the primary amine to a guanidine group using pyrazole derivative 
14 9 , to give compound 15a in 62% yield. Still, a considerable amount of byproduct was 
formed by intramolecular attack of the intermediate amine, this time on the acetyl group. In 
order to try to reduce this side reaction even more, the corresponding tosyl compound was 
synthesized, by removal of the Boe group of pyrrolidine 12 and tosylation to give 
peptidosulfonamide 13b in 55%. The moderate yield of this reaction was due to a poor 
solubility of the product, making purification difficult. Nevertheless, tosyl compound 13b was 
more stable after the removal of the phthalimide protective group and the guanidino compound 
15b was obtained in 82%. Finally, both peptidosulfonamide 15a and 15b were deprotected 
by hydrogenolysis affording the desired conformationally constrained arginine-glycine 
sulfonamide derivatives 16a and 16b in 96% and 84% yield respectively. Both sulfonamides 
were tested for their ability to inhibit thrombin. 
The synthesis of conformationally restricted ~-substituted sulfonamides was started with a 
conversion of the earlier obtained alcohol 3 to mesylate 17 in 87% yield (scheme 3). To obtain 
an analog containing only two methylene groups between the ~-carbon atom and the guanidine 
group (figure 1, top right, n=O), azide 18 was prepared, with inversion of configuration at the 
carbon atom on the 4-position, in a reaction of mesylate 17 with sodium azide (89% ). 
Subsequent hydrogenation followed by a reaction with Cbz-OSu gave the Cbz-protected amine 
20 in 90%. Following a strategy analogous to the one described in chapter 2, methyl ester 2 0 
was reduced with LiBH4 to obtain ~-aminoalcohol 21 in 75% yield. After conversion of this 
alcohol to mesylate 22, the corresponding thioacetate 23 was obtained in 66% by a 
nucleophilic substitution with cesium thioacetate10• This thioacetate was then treated with acetic 
anhydride and sulfurylchloride to give the corresponding sulfinylchloride 24, which was used 
immediately for coupling with glycine methylamide to give the sulfinamide diastereoisomers in 
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Scheme 3. Synthesis of a conformationally restricted /3-substituted sulfonamide arginine-glycine 
analog. 
92% yield, which were oxidized to sulfonamide 25 in 64% yield. At this stage the protected 
primary amino group was converted to a protected guanidine group by hydrogenolysis of the 
Cbz group, followed by reaction with pyrazole 14 to give sulfonamide 26 in 76%. Finally, 
deprotection of 26 by hydrogenolysis and subsequent ion-exchange on DOWEX-CJ- column, 
resulted in sulfonamide 27, which was subjected to testing in a thrombin inhibition assay. 
The synthesis of the conformationally restricted analog containing a slightly elongated side-
chain (figure 1, top right, n= 1 ), involved substitution of the mesylate of 17 with cyanide 
instead of azide. Although, it was described in literature that displacement of such a mesylate 
with tetrabutylammonium cyanide gave the best yields 11 , the yield of nitrile 28 was quite low 
(15%). This yield could not be improved by changing reaction conditions. It was assumed that 
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the low yield of nitrile 28, was due to considerable hydrolysis of the methyl ester. However, 
experiments with the corresponding benzyl ester, which was expected to be more stable, did 
not lead to any improvement of the yield. Steric hindrance by the carboxyl function in 
combination with the poor nucleophilicity of the attacking cyanide might be responsible for 
these low yields, by leading to an elimination reaction instead of a nucleophilic substitution. 
Nevertheless, methyl ester 28 was reduced with LiBH4 to afford aminoalcohol 29 in 77%. 
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Scheme 4. Synthesis of a second conformationally restricted /3-substituted sulfonamide arginine-
glycine analog. 
After transformation to the corresponding thioacetate 30 (65% ), treatment with sulfurylchloride 
and acetic anhydride gave sulfiny !chloride 31, which was immediately converted to 
sulfonamide 32, via its sulfinamide in an overall yield of 46%. Unfortunately, a first attempt to 
reduce the nitrile functionality of sulfonamide 32 failed and due to lack of time it was not 
possible to prepare more of the required starting material. 
Conclusion 
The preparation of conformationally restricted a- and ~-substituted aminoethane sulfonamide 
arginine-glycine isosteres was described in this chapter. The approach to all analogs started 
with 4-hydroxyproline, a naturally occurring amino acid derivative. 
Since hydroxyproline is a P-aminoalcohol, it was transformed to the corresponding thioacetate, 
to be used as a precursor for the synthesis of a P-aminoethane sulfonamide. This led to the 
successful preparation of two conformationally restricted a-substituted P-aminoethane 
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sulfonamide arginine-glycine analogs, protected at the proline nitrogen with an acetyl and a 
tosyl group respectively. Boe protection of the proline nitrogen turned out not to be compatible 
with the synthetic strategy. 
Furthermore, the synthesis of rigid P-substituted P-aminoethane sulfonamide arginine-glycine 
isosteres has been described. Once the proper functional groups were introduced on the 4-
position of hydroxyproline, the approach for the synthesis of such sulfonamide arginine-
glycine mimics was analogous to the one described for the unconstrained analogs in chapter 2. 
Analogs containing only two methylene units between the guanidine group and the P-carbon 
atom were obtained by transformation of the alcohol function of hydroxyproline into a 
guanidine group and the carboxylic acid into a sulfonamide. In a similar way it was attempted 
to synthesize analogs containing three methylene groups between the guanidine group and the 
P-carbon atom. Unfortunately, this synthesis could not be finished. 
Thus, hydroxyproline is a versatile building block for the attachment of a variety of functional 
groups. In this case conformationally constrained a- and P-substituted aminoethane 
sulfonamide analogs of arginine were prepared. Further, other sulfonamide analogs might be 
synthesized from hydroxyproline, functioning as a scaffold for the synthesis of a range of 
conformationally restricted compounds. E.g. glutamic acid or homoserine analogs should be 
accessible from hydroxyproline. 
Experimental 
General methods. 
DCM and DMF were dried on molecular sieves (4A). Triethylamine and DIPEA were distilled 
subsequently from ninhydrin and KOH. THF was distilled from LiAIH4• All other chemicals were 
used as purchased. Reactions were carried out at ambient temperature unless stated otherwise. 
TLC analysis was performed on Merck pre-coated silicagel 60 F-254 (0.25 mm) plates. Spots 
were visualized with UV light, ninhydrin or Cl2-TDM12• Solvents were evaporated under reduced 
pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 (40-63 µm) 
and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 from Pharmacia 
was used for gel permeation chromatography. 
1H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 MHz) and chemical 
shift values are given in ppm relative to TMS or CHC13 (7.26 ppm). 13C-NMR spectra were 
recorded on a VARIAN G300-spectrometer (75.5 MHz) and chemical shift values are given in 
ppm relative to CDC13 (77.0 ppm) or DMSO-d6 (39.7 ppm) or CD30D (48.9 ppm). 13C spectra 
were recorded using the attached proton test (APT) sequence. IR spectra were recorded on a Bio-
Rad FTS-25 spectrometer. Fast atom bombardment (FAB) mass spectrometry was carried out 
using a Jeol JMS SX/SX 102A four-sector mass spectrometer, coupled with a HP-9000 data 
system. All compounds tested for thrombin inhibition were analyzed by HPLC and found to be 
over 95% pure. HPLC analysis was carried out on a Gilson automated HPLC system 205 with a 
233XL autosampler and a 119 UV-Vis detector. 
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4R-hydroxyproline methyl ester 2. 
At -10° C 12 mL of thionyl chloride was added to 190 mL MeOH. At that temperature 7.86 g 
hydroxyproline (60 mmol) was added and the mixture was stirred overnight at room temperature. 
The solvent was evaporated and repeated coevaporation with MeOH afforded 10.9 g methylester 
2 (100%). 
1H- NMR (D20) o 2.32, 2.51 (two m, 2H, Hyp-C3H2), 3.50 (m, 2H, Hyp-C5H2), 3.87 (s, 3H, CH30), 
4.72 (m, 2H, Hyp-c4H, Hyp-C2H). 
13C-NMR (D20) o 36.8 (Hyp-C3), 53.6 (Hyp-C5), 54.0 (CHP), 58.3 (Hyp-C2), 69.6 (Hyp-c4), 
170.4 (Hyp-c1). 
Boc-4R-hydroxyproline methyl ester 3. 
To a solution of 10.9 g methylester 2 (60 mmol) in 170 mL DCM, 9.2 mL triethylamine (66 
mmol) and a solution of 13.8 g Boc20 (63 mmol) in 30 mL DCM were added at 0° C. After 
stirring the mixture overnight at 40° C the solvent was evaporated and the residue redissolved in 
EtOAc. The solution was washed with lM KHS04 (twice), 5% NaHC03, water, brine and dried on 
Na2S04 • Evaporation of the solvent and crystallization of the residue from EtOAc/hexanes 
afforded 13.0 g of praline 3 (88%). Rr 0.52 (eluent: EtOAc). 
1H- NMR (CDC13) o 1.37, 1.42 (twos, 9H, C(CH3) 3), 2.01, 2.23 (two m, 2H, Hyp-C3H2), 3.38-3.62 
(m, 2H, Hyp-C5H2), 3.69 (s, 3H, CHP), 4.38 (m, 2H, Hyp-c4H, Hyp-C2H). 
13C-NMR (CDC13) o 28.1, 28.3 (C(£H3) 3), 38.3, 39.0 (Hyp-c3), 51.9, 52.1 (CHP), 54.5 (Hyp-C5), 
57.5, 57.9 (Hyp-C2), 69.1, 69.8 (Hyp-c4), 80.3, 80.4 (9CH3) 3), 154.0, 154.6 (C(O)N), 173.4, 
173.6 (Hyp-C1). 
Boc-4R-(t-butyl dimethyl silyloxy)-proline methyl ester 4. 
To a solution of 7 .36 g of alcohol 3 (30 mmol) in 30 mL DMF, 5.1 g imidazole (75 mmol) and 
5.4 g TBDMSCl (36 mmol) were added. The mixture was stirred overnight, concentrated in vacuo 
and the residue was dissolved in DCM. This solution was washed with lM KHS04, 5% NaHC03, 
water, brine and dried on MgS04 • Evaporation of the solvent followed by column 
chromatography (eluent: ether/hexanes 1:1, v/v) yielded 10.8 g of silyl ether 4 (100%). Rf 0.70 
(eluent: EtOAc/hexanes 1:1, v/v). 
1H- NMR (CDCl3) o 0.04 (s, 6H, CH3Si), 0.85 (s, 9H, SiC(CH3) 3) , 1.39, 1.44 (two s, 9H, C(CH3) 3), 
2.00, 2.14 (two m, 2H, Hyp-C3H2), 3.25-3.62 (two m, 2H, Hyp-C5H2), 3.71, 3.72 (two s, 3H, 
CH30), 4.29-4.42 (m, 2H, Hyp-C4H, Hyp-C2H). 
13C-NMR (CDCI) o -4.9 (CH3Si), 17 .9 (Si£(CH3) 3), 25.6 (SiC(£H3) 3), 28.2, 28.3 (C(£H3) 3), 38.9, 
39.7 (Hyp-c3), 51.9, 52.1 (CHp), 54.5, 54.8 (Hyp-C5), 57.6, 58.0 (Hyp-C2), 69.7, 70.4 (Hyp-c4), 
80.0 (£(CH3) 3), 153.8, 154.6 (C(O)N), 173.5, 173.7 (Hyp-C1). 
Boc-4R-(t-butyl dimethyl silyloxy)-proline amide 5. 
A solution of 870 mg of methylester 4 (2.41 mmol) in 25 mL MeOH, saturated with ammonia. , 
was stirred for 96 hours. Evaporation of the solvent afforded 830 mg of amide 5 (100%). Rr 0 .20 
(eluent: EtOAc/hexanes 1 :1, v/v). 
1H- NMR (CDC13) 8 0.04 (s, 6H, CH3Si), 0.84 (s, 9H, SiC(CH3) 3), 1.44 (s, 9H, C(CH3) 3), 1.90-2.40 
(m, 2H, Hyp-C3H2), 3.28-3.62 (m, 2H, Hyp-C5H2), 4.21-4.48 (m, 2H, Hyp-c4H, Hyp-C2H) 5.75 , 
6.05, 6.15, 6.83 (four bs, 2H, NH2) . 
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13C-NMR (CDC13) 6 -4.89, -4.82 (CH3Si), 17.9 (Sif(CH3) 3), 25.7, 25.9 (SiC(fH3) 3), 28.3 (C(£H3) 3), 
37.4, 40.3 (Hyp-C3), 55.0 (Hyp-C5), 58.5, 60.0 (Hyp-C2), 69.9, 70.4 (Hyp-C4), 80.6 (f(CH3) 3), 
155.0, 156.1 (C(O)N), 174.7, 176.0 (Hyp-c1). 
Pyrrolidine 6. 
To a suspension of 345 mg amide 5 (1.0 mmol) and 189 mg NaBH4 (5.0 mmol) in 6 mL 
dioxane, a solution of 286 µL HOAc (5.0 mmol) in 1.5 rnL dioxane was added slowly at 10° C. 
This mixture was stirred for one hour at 50° C under an argon cushion. After addition of water 
and DCM, the organic layer was separated, washed with 5% NaHC03 (twice) and subsequently 
dried on MgS04• The solvent was evaporated and the residue redissolved in 5 rnL DCM. At 0° C 
153 µL triethylamine (1.1 mmol) and 157 µL benzylchloroformate (1.1 mmol) were added and 
the mixture was stirred for 1.5 hours. After the addition of 50 rnL DCM, the solution was washed 
with lM KHS04 (twice), brine and dried on MgS04 • Evaporation of the solvent and column 
chromatography (eluent: ether/hexanes 35:65, v/v) gave 107 mg of pyrrolidine 6 (20%). Rr 0.42 
( eluent: ether/hexanes 1: 1, v/v). 
1H- NMR (CDC13) <> 0.04 (s, 6H, CH3Si), 0.84 (s, 9H, SiC(CH3)J, 1.44 (s, 9H, C(CH3) 3), 1.70-2.03 
(two m, 2H, C3H2), 3.15-3.60 (m, 4H, C1H2, C5H2), 4.03 (bs, lH, C4H), 4.28 (m, lH, C2H) 5.08 (s, 
2H, OCH2), 5.10, 6.03 (two bs, lH, NH), 7.35 (m, 5H, ArH). 
13C-NMR (CDC13) 6 -4.88, -4.78 (CH3Si), 17.9 (Sif(CH3)J, 25.7 (SiC(£H3) 3), 28.4 (C(£H3) 3), 38.9 
(C3), 45.7 (C 1), 55.5 (C5), 56.2 (C2), 66.5 (OCH2), 70.0 (C4), 80.0 (£(CH3) 3), 127.0, 128.0, 128.5, 
136.8 (CA,), 156.3, 156.8 (C(O)N). 
Alcohol 7. 
To a suspension of 10.4 g NaBH4 (275 mmol) in 200 mL DME, 36.7 g Lil (275 mmol) was 
added. The mixture was stirred for 5 minutes before a solution of 24.7 g of methylester 4 (68.6 
mmol) in 50 rnL DME was added dropwise. Stirring was continued overnight followed by 
quenching of the reaction mixture with lM KHS04 • The solution was concentrated in vacuo and 
the resulting aqueous solution was extracted with DCM four times. The combined organic layers 
were washed with brine, dried on MgS04 and evaporated subsequently. Column chromatography 
(eluent: ether) gave 22.0 g of alcohol 7 (93%). Rr 0.57 (eluent: ether). 
1H- NMR (CDCI3) 6 0.01 (s, 6H, CH3Si), 0.82 (s, 9H, SiC(CH3) 3), 1.42 (s, 9H, C(CH3\), 1.56, 1.90 
(two m, 2H, C3H2), 3.27-3.66 (m, 4H, C1H2 , C5H2), 3.84-4.39 (m, 2H, c4H, C2H), 4.90 (d, lH, OH). 
13C-NMR (CDC13) 6 -4.9, -4.8 (CH3Si), 17.9 (Sif(CH3\), 25.6 (SiC(£H3) 3), 28.4 (C(£H3) 3), 38.0 
(C3), 56.0 (C5), 59.0 (C2), 67.2 (C1), 69.8 (c4), 80.3 (£(CH3) 3), 157.3 (C(O)N). 
Phthalimide 8. 
To a solution of 10.4 g of alcohol 7 (30 mmol) and 8.66 g Ph3P (33 mmol) in 100 rnL THF, 
6.50 mL DEAD (33 mmol) and 4.86 g phthalimide (33 mmol) were added subsequently at 0° C. 
The mixture was stirred at 0° C for two hours and overnight at room temperature. Then the 
solvent was evaporated and the residue triturated with ether/hexanes. Column chromatography 
(eluent: EtOAc/hexanes 1:4, v/v) afforded 12.1 g of phthalimide 8 (95%). Rr 0.57 (eluent: 
EtOAc/hexanes 1:2, v/v). 
1H- NMR (CDCl3) 6 -0.01 (s, 6H, CH3Si), 0.80 (s, 9H, SiC(CH3) 3), 1.26, 1.37 (two s, 9H, C(CH3) 3), 
1.90 (m, 2H, C3Hi), 3.20-3.45 (m, 2H, C5H2), 3.58-3.91 (m, 2H, c1H2), 4.21, 4.38 (rn, 2H, C2H, 
C4H), 7 .68, 7 .81 (broad m and s, 4H, ArH). 
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13C-NMR (CDC13) <> -5.0 (CH3Si), 17.8 (Si£(CH3) 3), 25.6 (SiC(£H3\), 28.2 (C(£H3) 3), 38.1, 38.8 
(C3), 41.1 (C'), 54.0 (C5), 54.8 (C2), 69.6, 70.2 (c4), 79.2, 79.7 (£(CH3\), 123.0, 123.2, 132.0, 
132.3, 133.5, 133.9 (CA'), 154.7, 155.0 (C(O)O), 170.9 (C(O)Ar). 
Alcohol 9. 
9.66 g of silyl ether 8 (22.8 mmol) was dissolved in 100 mL THF. At 0° C 28.5 mL lM TBAF in 
THF was added and stirred for 5 minutes. After stirring for another 1.5 hours at room 
temperature the solvent was evaporated. The residue was dissolved in EtOAc and the resulting 
solution was washed with lM KHS04, 5% NaHC03, water, brine and dried on Na2S04 • Evaporation 
of the solvent and column chromatography (eluent: EtOAc/hexanes 2:1, v/v) afforded 5.2 g of 
alcohol 9 (74%). Rr 0.30 (eluent: EtOAc/hexanes 2:1, v/v). 
'H- NMR (CDC13) <> 1.45, 1.50 (twos, 9H, C(CH3) 3), 1.97 (m, 2H, C3H2), 3.30-3.50 (m, 2H, C5H2), 
3.50-3.95 (m, 2H, C1H2), 4.25, 4.43 (two bs, 2H, C2H, C4H), 7.68, 7.81 (two bs, 4H, ArH). 
13C-NMR (CDC13) <> 28.2 (C(£H3) 3), 38.1 (C3), 41.0 (C1), 54.0 (C5), 54.8 (C2), 69.0 (C4), 80.1 
(£(CH3) 3), 123.2, 131.9, 134.0 (CA'), 154.8 (C(O)O), 168.3 (C(O)Ar). 
Thioacetate 10. 
To a solution of 8.70 g Ph3P (33.2 mmol) in 100 mL THF, 5.22 mL DIAD (33.2 mmol) was 
added at 0° C under an argon cushion. The mixture was stirred for 30 minutes at 0° C, during 
which a precipitate formed. At -10° Ca solution of 2.36 mL HSAc (33.2 mmol) and 5.13 g 18 
(16.6 mmol) in 50 mL THF were added. The solution was stirred for one hour at 0° C and 
overnight at room temperature before the solvent was evaporated. Trituration with DCM, 
evaporation of the solvent and subsequent flash chromatography ( eluent: EtOAc/hexanes 1 :4, v/v) 
gave 1.4 g ofthioacetate 10 (62%). Rr0.54 (eluent: EtOAc/hexanes 1:1, v/v). 
'H- NMR (CDC13) <> 1.26, 1.35 (two s, 9H, C(CH3) 3), 1.75 (m, lH, C3H"), 2.31 (s, 3H, CH3C(O)), 
2.50 (m, lH, C3Hb), 3.18 (dd, lH, C5H"), 3.73 (dd, lH, c1H"), 3.80-4.10 (two dd and m, 3H, C5H\ 
c1H\ c4H), 4.21, 4.35 (two bs, lH, C2H), 7.69, 7.81 (two bs, 4H, ArH). 
13C-NMR (CDC13) 8 28.1 (C(£H3) 3), 30.4 (£H3C(O)), 34.7, 35.6 (C3), 38.7, 38.9 (C4), 41.2 (C'), 
51.4, 53.3 (C5), 52.3, 55.2 (C2), 80.2 (f(CH3) 3), 123.1 , 132.1, 133.8 (CAr), 154.0 (C(O)O), 168.2 
(C(O)Ar) 194.9 (C(O)S). 
Sulfinyl chloride 11. 
800 mg thioacetate 10 (2.18 mmol) was dissolved in 5 mL DCM and placed under an argon 
cushion. After cooling to -20° C, 205 µL Ac20 (2.18 mmol) and 353 µL S02Cl2 (4.35 mmol) 
were added. The solution was stirred for 1 hour at -5° C before the solvent was evaporated, 
followed by drying of the residue in vacuo. The crude sulfinylchloride, kept under argon, was 
used immediately for the preparation of sulfonamide 12. 
Sulfonamide 12. 
820 mg Boc-Gly-NHMe (4.35 mmol) was dissolved in 5 mL DCM and at 0° C 5 mL TFA was 
added. After stirring for 30 minutes the solvent was evaporated and the residue coevaporated with 
dioxane three times. To a solution of the residue in 10 mL DMF/DCM (3:1, v/v) 606 µL 
triethylamine (4.35 mmol) was added. At 0° C, this solution was added to 2.18 mmol 
sulfinylchloride 11, dissolved in 5 mL DCM under an argon cushion and then the mixture was 
stirred overnight. Evaporation of the solvent and flash chromatography (eluent: 10% MeOH in 
DCM, v/v) yielded 0.80 g of sulfinamide (92%). 
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This sulfinamide (2.0 mmol) was dissolved in a mixture of 6 mL DCM, 6 mL acetonitrile and 10 
mL water. At 0° C, 556 mg Na104 (32.6 mmol) and a catalytic amount of RuC13·H20 were added 
to the vigorously stirred solution. The mixture was stirred for 20 minutes at room temperature 
before the aqueous layer was extracted three times with DCM. The combined organic layers were 
dried on MgS04 and removed in vacuo. The product was purified by column chromatography 
(eluent: 5% MeOH in DCM, v/v), yielding 460 mg of sulfonamide 12 (55% ). The overall yield 
was 51 %. Rr 0.15 (eluent: EtOAc), 0.23 (eluent 5% MeOH in DCM, v/v). 
1H- NMR (CDC13) <> 1.22 (twos, 9H, C(CH3) 3), 2.22 (bs, lH, C3H"), 2.53 (m, lH, C3Hb), 2.82 (d, 
3H, CH3N), 3.58 (dd, lH, c5H"), 3.75, 3.85 (dd and m, 4H, c1H2, Gly-C2H2), 3.95-4.20 (m, 3H, 
C5H\ C4H), 4.36 (bs, lH, C2H), 6.33 (bs, lH, Gly-NH), 6.75 (bs, lH, N(!!)CH3), 7.70, 7.81 (two bs, 
4H, ArH). 
13C-NMR (CDC13) <> 26.3 (CH3N), 28.0 (C(fH3) 3), 30.4 (C3), 40.5 (C1), 45.8, 46.0 (Gly-c2, C5), 
55.2 (C2), 58.8 (C4), 80.6 (f(CH3) 3), 123.3, 132.0, 134.0 (CA'), 153.6 (C(O)O), 168.4 (C(O)Ar), 
169.2 (Gly-C1). 
N-acetyl pyrrolidine 13a. 
To a solution of 208 mg Boc-pyrrolidine 12 (0.50 mmol) in 2 mL DCM, 2 mL TFA was added at 
0° C. After stirring for 30 minutes the solvent was evaporated and the residue coevaporated with 
THF three times. This residue was dissolved in 4 mL THF after which 146 µL triethylamine (1.05 
mmol) and 38 µL acetylchloride (0.55 mmol) were added. After stirring for 5 minutes, the 
volatiles were removed in vacuo. Then 5 mL lM KHS04 was added and the resulting aqueous 
solution was extracted five times with EtOAc. The combined organic layers were dried on Na2S04 
and evaporated. Flash chromatography (eluent: 7% MeOH in DCM, v/v) afforded 174 mg of 
pyrrolidine 13a (97%). Rr 0.40 (eluent: 10% MeOH in DCM, v/v). 
1H- NMR (CDC13) <> 1.97, 2.08 (twos, 3H, CH3C(O)), 2.12-2.68 (m, 2H, C3H2), 2.79 (d, 3H, CH3N), 
3.56-4.20 (m, 6.7H, C5H2, C1H2, Gly-C2H2, C2H, C4H), 4.37 (m, 0.7H, C2H), 4.78 (m, 0.7H, C4H), 
6.37, 6.55 (two bs, lH, Gly-NH), 6.79, 6.87 (two q, lH, N(!!)CH3), 7.65-7.87 (m, 4H, ArH). 
13C-NMR (CDC13) <> 21.3, 22.6 (fH3C(O)), 26.3 (CH3N), 29.3, 30.9 (C3), 40.1, 41.2 (C1), 45.8 
(Gly-C2), 47.7 (C5), 54.8, 56.6 (C2), 58.3, 59.5 (C4), 123.2, 123.6, 131.5 131.9, 134.0, 134.5 (CAr), 
168.4, 168.8, 169.1, 169.3, 169.5, 169.7 (C=O). 
N-tosyl pyrrolidine 13b. 
To a solution of 249 mg Boc-pyrrolidine 12 (0.60 mmol) in 3 mL DCM, 3 mL TFA was added at 
0° C. After stirring for 30 minutes the solvent was evaporated and the residue coevaporated with 
THF three times. This residue was dissolved in 6 mL THF, after which 176 µL triethylamine ( 1. 26 
mmol) and 120 mg tosylchloride (0.55 mmol) were added. The mixture was stirred overnight 
before the solvent was removed in vacuo. The residue was dissolved in EtOAc and the resulting 
solution was washed with IM KHS04, 5% NaHC03, brine and dried on Na2S04 • Evaporation of the 
solvent and crystallization of the residue afforded 154 mg of pyrrolidine 13b (55%). Rr 0.29 
(eluent: 5% MeOH in DCM, v/v). 
1H- NMR (CD30D) <> 2.00, 2.18 (two m, 2H, C3H2), 2.37 (s, 3H, CH3Ar), 2.74 (s, 3H, CH3N), 3.37 
(m, lH, C5H"), 3.58-3.75 (two dd and s, 4H, C1H2, Gly-C2H2), 4.05-4.25 (m, 3H, C5H\ C4H, C2H), 
7.31 (d, 2H, ArH), 7.67 (d, 2H, ArH), 7.85 (m, 5H, ArH). 
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N, N' -bis-Cbz-1-guanylpyrazole 14. 
This compound was prepared as described by Wu et al.9 Starting from 1.4 7 g 1-H-pyrazole-1-
carboxamidine hydrochloride (10 mmol) afforded 2.0 g of the monoprotected intermediate 
(81 % ), which was crystallized from EtOH. The following reaction with this intermediate and Cbz-
OSu gave 2.1 g of bis-protected 14 (66%; pyrazole 14 was purified by column chromatography 
(eluent: EtOAc/hexanes 1:2, v/v) before it was crystallized from ether/hexanes). 
N-acetyl pyrrolidine 15a. 
To a solution of 54 mg of pyrrolidine 13a (0.15 mmol) in 2 rnL MeOH, 7.3 µL hydrazine 
hydrate (0.15 mmol) was added. After stirring overnight, the solvent was evaporated and the 
residue coevaporated with THF three times. To this residue 1 rnL THF and 57 mg of pyrazole 
derivative 14 (0.15 mmol) were added. The mixture was shaken for 48 hours before the solvent 
was removed in vacuo. The residue was redissolved in EtOAc and the resulting solution was 
washed with a small volume of 5% NaHC03 and brine followed by drying on Na2S04 • 
Evaporation of the solvent and flash chromatography of the residue (eluent: 7% MeOH in DCM) 
gave 50 mg of pyrrolidine 15a (62%). Rr 0.37 (eluent: 10% MeOH in DCM, v/v). 
1H- NMR (CDC13) <> 2.08, 2.18 (twos, 3H, CH3C(O)), 2.45 (m, 2H, C3H2), 2.65, 2.75 (two d, 3H, 
CH3N), 3.56-4.02 (m, 6.7H, C5H2, C1H2, Gly-C2H2, C2H, C4H), 4.18-4.40 (m, 1.3H, C2H, C4H), 5.08, 
5.19 (s and d, 4H, OCH2Ph) 6.15, 6.30 (two q, lH, N(!!)CH3), 6.63 (bs, lH, Gly-NH), 7.38 (m, 
lOH, ArH), 8.55, 8.93 (two t, lH, NHC=N), 11.63, 11.75 (two s, lH, NHCbz). 
13C-NMR (CDC13) <> 21.2, 22.5 (£H3C(O)), 25.8, 26.0 (CH3N), 30.0, 30.3 (C3), 43.1, 43.3 (C1), 
44.7, 44.9 (C5), 45.3, 45.5 (Gly-C2), 56.1, 57.0 (C2), 58.2, 59.4 (c4), 67.0, 67.1, 68.2, 68.3 
(OCH2Ph), 127.6, 127.88, 127.95, 128.3, 128.5, 128.6, 128.7, 134.4, 136.2 (C"'), 153.2, 156.4 
(C(O)O), 163.2 (C=N), 169.46, 169.52, 170.5 (C=O). 
N-tosyl pyrrolidine 15b. 
To a solution of 60 mg of pyrrolidine 13b (0.13 mmol) in 3 rnL MeOH, 6.2 µL hydrazine 
hydrate (0.13 mmol) was added. After stirring overnight at 60° C, the solvent was evaporated and 
the residue coevaporated with THF three times. To this residue 1 rnL THF and 53 mg of pyrazole 
compound 14 (0.14 mmol) were added. The mixture was shaken overnight and subsequently 
concentrated in vacuo and the residue was triturated with EtOAc. Evaporation of the solvent and 
flash chromatography (eluent: EtOAc/hexanes 6:1, v/v) yielded 68 mg of pyrrolidine 15b (82%). 
Rr 0.37 (eluent: EtOAc), 0.48 (eiuent: 10% MeOH in DCM, v/v). 
1H- NMR (CDC13) <> 2.21 (t, 2H, C3H2), 2.38 (s, 3H, CH3Ar), 2.69 (d, 3H, CH3N), 3.38 (qu, lH, 
C5H•), 3.62-3.99 (m, 7H, c5H\ c4H, C2H, c1H2, Gly-C2H2), 5.12, 5.19, 5.20 (sand d, 4H, OCH2Ph), 
6.20 (m, 2H, Gly-NH, N(!!)CH3), 7.22 (d, 2H, ArH), 7.30-7.43 (m, lOH, ArH), 7.73 (d, 2H, ArH), 
8.68 (t, lH, NHC=N), 11.68 (s, lH, NHCbz). 
13C-NMR (CDC13) <> 21.5 (£H3Ar), 26.2 (CH3N), 30.5 (C3), 44.1 (C1), 45.7 (Gly-C2), 49.3 (C5), 
58.6 (C2), 59.7 (C4), 67.3, 68.4 (OCH2Ph), 127.7, 128.17, 128.20, 128.48, 128.54, 128.6, 128.8, 
130.0, 133.3, 134.5, 136.4, 144.5 (Car), 153.5, 156.8 (C(O)O), 163.3 (C=N), 168.8 (Gly-C1). 
Restricted arginine-glycine analog 16a. 
To a solution of 77 mg sulfonamide 15a (0.14 mmol) in 2 rnL ethanol, 25 µL acetic acid and 20 
mg Pd/C (10%) were added and the mixture was stirred overnight under a hydrogen atmosphere. 
The catalyst was removed by filtration and the solvent evaporated. The thus obtained acetic acid 
salt was purified and converted to hydrochloric acid salt 16a on a DOWEX er column. 
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Lyophilization gave 42 mg of analog 16a (96%). Re 0.55 (acetic acid salt, eluent: MeOH/37% 
NH3 in H20/CHC13 45:20:60, v/v). 
1H- NMR (D20) o 2.17 (s, 3H, CH3C(O)), 2.21(m, lH, C3H•), 2.75 (m, lH, C3Hb), 2.81 (s, 3H, 
CH3N), 3.54 (bs, 2H, C5H2), 3.86 (bs, lH, C'H•), 3.90 (s, 2H, Gly-C2H2), 4.18 (m, 2H, C2H, C'Hb), 
4.39 (m, lH, C4H), 
13C-NMR (D20) o 20.7, 22.2 (fH3C(O)), 26.1 (CH3N), 29.7 (C3), 43.4, 44.0 (C'), 45.1, 45.6 (C5), 
48.6 (Gly-C2), 56.2, 57.5 (C2), 57.9, 58.9 (c4), 157.4, 157.5 (C=N), 171.8 (Gly-C1), 173.0, 173.7 
(f:(O)CH3). 
FABMS m/z (M+H+) 335.1. 
Restricted arginine-glycine analog 16b. 
To a solution of 68 mg of sulfonamide 15b (0.11 mmol) in 2 mL ethanol, 15 µL acetic acid and 
30 mg Pd/C (10%) were added and the mixture was stirred overnight under a hydrogen 
atmosphere. The catalyst was removed by filtration and the solvent evaporated. The resulting 
acetic acid salt was purified and converted to hydrochloric acid salt 16b on a DOWEX ci-
column. Lyophilization gave 37 mg of analog 16b (84%). Re 0.76 (eluent: MeOH/37% NH3 in 
H20/CHC13 45:20:60, v/v). 
'H- NMR (Dz0) o 1.99 (m, lH, C3H•), 2.37 (m, lH, C3Hb), 2.50 (s, 3H, CH3Ar), 2.78 (d, 3H, 
CH3N), 3.30 (qu, lH, c4H•), 3.46, 3.56 (two dd, 2H, C1H2), 3.68 (dd, lH, c5H•), 3.75 (s, 2H, Gly-
C2H2), 4.03 (dd, lH, C5Hb), 4.13 (m, lH, C2H), 7.57 (d, 2H, ArH), 7.86 (d, 2H, ArH). 
13C-NMR (CDC13 + CD30D) o 20.7 (fH3Ar), 25.3 (CH3N), 30.0 (C3), 43.9 (C1), 44.7 (Gly-c2), 
49.0 (C5), 58.5 (C2), 58.6 (C4), 127.2, 129.9, 132.5, 144.6 (CA'), 157.2 169.6 (Gly-C 1). 
Boc-4R-mesyloxyproline 17. 
To a solution of 6.14 g of alcohol 3 (25.0 mmol) in 100 mL DCM, 3.83 mL triethylamine (27.5 
mmol) and 2.03 mL mesylchloride (26.3 mmol) were added at 0° C, after which the mixture was 
stirred for 15 minutes at that temperature. Then the solvent was removed in vacuo and the residue 
redissolved in EtOAc. The resulting solution was washed with 5% NaHC03, brine and dried on 
Na2S04 • Evaporation of the solvent and crystallization of the residue from EtOAc/hexanes/ether 
afforded 7.00 g of mesylate 17 (87%). Rf 0.31 (eluent: EtOAc/hexanes 1:1, v/v). 
'H-NMR (CDC13): o 1.38, 1.43 (two s, 9H, C(CH3) 3), 2.20, 2.58 (two m, 2H, Pro-C3H2), 3.02 (s, 3H, 
CH3S02), 3.65-3.84 (m, 2H, Pro-C5H), 3.71 (s, 3H, OCH3), 4.39 (qu, lH, Pro-C2H), 5.22 (lH, m, 
Pro-c4H). 
13C-NMR (CDC13): o 28.1 (C(fH3) 3), 36.2, 37.3 (Pro-C3), 38.6 (CH3S02), 52.07, 52.25 (Pro-C5), 
52.13, 53.34 (CH30), 57.0, 57.3 (Pro-C2), 77.8, 78.1 (Pro-c4), 80.7 (f(CH3) 3), 153.2, 153.8 
(C(O)N), 174.4, 172.5 (Pro-C1). 
Boc-4S-azidoproline 18. 
To a solution of 6.92 g mesylate 17 (21.3 mmol) in 25 mL DMF, 6.95 g NaN3 (107 mmol) was 
added and the resulting mixture was stirred overnight at 50° C. The solvent was removed in vacuo 
and the residue was redissolved in EtOAc. The solution was washed with water (until the resulting 
water layer was no longer basic), lM KHS04, 5% NaHC03, brine and dried on Na2S04• 
Evaporation of the solvent and column chromatography (eluent: EtOAc/hexanes 1:3, v/v) gave 
5.43 g of azide 18 (89%). Rf 0.59 (eluent: EtOAc/hexanes 1:1, v/v). 
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1H-NMR (CDC13) o 1.38, 1.43 (twos, 9H, C(CH3) 3), 2.10, 2.15, 2.44 (two t and m, 2H, Pro-C3H2), 
3.44, 3.68 (two m, 2H, Pro-C5H), 3.71 (s, 3H, OCH3), 4.11 (lH, m, Pro-C4H), 4.29, 4.37 (two dd, 
lH, Pro-C2H). 
13C-NMR (CDC13) o 28.1, 28 .2 (C(£H3) 3), 35.0, 35.9 (Pro-C3), 50.7, 51.1 (Pro-C5), 52.1, 52.2 
(CH30), 57.2, 57.6 (Pro-C2), 58.1, 59.1 (Pro-c4), 80.4 (£(CH3) 3), 153.3, 153.8 (C(O)N), 171.8, 
172.1 (Pro-C 1). 
IR (film) 2106 (N3), 1806, 1756 (C=O). 
Boc-4S-aminoprolineHCl 19. 
2.86 g azide (10 mmol) was dissolved in 250 mL EtOH and 5 mL CHC13• After the addition of 
500 mg Pd/C (10%), the mixture was shaken for 5 hours under a 3 Bar hydrogen atmosphere in a 
Parr apparatus . The catalyst was removed by filtration and evaporation of the solvent gave 2.91 g 
of amine 19 (98%). 
1H-NMR (CDC13 + CD30D) o 1.38, 1.43 (two s, 9H, C(CH3) 3), 2.40, 2.57 (t and bs, 2H, Pro-C3H2), 
3.65-3.91 (two m, 2H, Pro-C5H), 3.71 (s, 3H, OCH3), 4.09 (lH, bs, Pro-c4H), 4.28, 4.37 (two d, 
1 H, Pro-C2H) . 
Boc-4S-(Cbz-amino)-proline 20. 
To a solution of 2.91 g amine 19 (9.73 mmol) in 50 mL DCM, 1.36 mL triethylamine (9.73 
mmol) and 2.43 g Z-0Su (9.73 mmol) were added. The mixture was stirred overnight before the 
solvent was evaporated and the residue redissolved in EtOAc. The resulting solution was washed 
with water, lM KHS04 (twice), 5% NaHC03 (twice), brine and dried on Na2S04 • Evaporation of 
the solvent and flash chromatography (eluent: EtOAc/hexanes 1 :2, v/v) afforded 3.48 g of proline 
20 (91 %). 
1H-NMR (CDC13) <> 1.38, 1.43 (two s, 9H, C(CH3) 3), 1.94, 2.44 (two m, 2H, Pro-C3H2), 3.40-3.67 
(two dd, 2H, Pro-C5H), 3.72 (s, 3H, OCH3), 4.21-4.33 (2H, m, Pro-c4H, Pro-C2H). 
13C-NMR (CDC13) o 28.0, 28 .1 (C(£H3) 3), 35.5, 36.5 (Pro-C3) , 49.4, 50.3 (Pro-C4), 52.0, 52.1 
(CH30), 52.3, 52.9 (Pro-C5), 57.3, 57.6 (Pro-C2), 66.5 (OCH2Ph), 80.2 (£(CH3) 3), 127.8, 128.2, 
136.3 (CA'), 153.1, 153.9 (C(O)N), 155.6 (C(O)NH), 174.0 (Pro-C1). 
Boc-4S-(Cbz-amino )-prolinol 21. 
Alcohol 21 was prepared from 3.45 g methylester 20 (8.74 mmol) according to the procedure 
described for alcohol 7. After the extraction, column chromatography (eluent: EtOAc/hexanes 
2:1, v/v) yielded 2.40 g of prolinol 21 (75%) Rr 0.34 (eluent: EtOAc/hexanes 2:1). 
1H-NMR (CDC13) o 1.43 (s, 9H, C(CH3) 3), 1.50-1.85, 2.35 (two broad m, 2H, C3H2), 3.18 (bs, lH, 
C5H'), 3.52, 3.68 (two dd, 2H, c1H2), 3.75-3.95 (3H, broad m, C2H, C5H\ OH), 4.17 (bs, lH, C4H), 
5.05 (s, 2H, OCH2Ph), 6.05, 6.45 (two bs, lH, NH), 7.28 (m, 5H, ArH). 
13C-NMR (CDC13) o 28.3 (C(£H3) 3), 34.5 (C3), 49.0 (c4), 53.9 (C5), 58.6 (C2), 64.8 (c1) 66.5 
(OCH2Ph), 80.3 (£(CH3) 3), 128.0, 128.4, 136.4 (CA') , 155.8 (C=O). 
Mesylate 22. 
To a solution of 2.38 g of alcohol 21 (7.47 mmol) in 50 mL DCM at 0° C, 1.15 mL triethylamine 
(8.22 mmol) and 607 µL mesylchloride (7.84 mmol) were added. The mixture was stirred for 
one hour at that temperature. Then the solvent was removed in vacuo and the residue redissolved 
in EtOAc. The resulting solution was washed with lM KHS04 (twice), water, 5% NaHC03, brine 
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and dried on Na2S04 • Evaporation of the solvent gave 3.34 g of mesylate 22 (100%). Re 0.52 
(eluent: EtOAc/hexanes 1:1, v/v). 
'H-NMR (CDC13) 8 1.43 (s, 9H, C(CH3) 3), 1.87, 2.45 (two m, 2H, C3H2), 2.98 (s, 3H, CH3S02), 3.16, 
(dd, lH, C5Ha), 3.83 (lH, bs, C5Hb), 4.00-4.33 (m, 3H, C4H, c1H2), 4.35-4.70 (broad m, lH, C2H), 
5.08 (s, 2H, OCH2Ph), 5.20 (bs, lH, NH), 7.37 (m, 5H, ArH). 
13C-NMR (CDC13) 8 28.1 (C(£H3) 3), 33.2 (broad, C3), 36.9 (CH3S02), 48.9 (C4), 52.3 (C5), 54.7 
(C2), 66.5 (OCH2Ph), 69.4 (C'), 80.2 (£(CH3) 3), 127.8, 128.3, 136.2 (C"'), 154.1 (C(O)N), 155 .7 
(C(O)NH). 
Thioacetate 23. 
To a solution of 316 mg Cs2C03 (0.97 mmol) in 8 mL DMF under an argon cushion, 138 mL 
thiolacetic acid (1.94 mmol) was added followed by the addition of a solution of 632 mg 
mesylate 22 (1.47 mmol) in 2 mL DMF. The mixture was stirred overnight after which it was 
poured into 50 mL water. The aqueous suspension was extracted with EtOAc four times. The 
combined organic layers were washed with water, 5% NaHC03 (twice), brine and dried on Na2S04• 
Evaporation of the solvent and flash chromatography (eluent: EtOAc/hexanes 1:2, v/v) gave 403 
mg of thioacetate 23 (66%). Re 0.59 (eluent: EtOAc/hexanes 1:1, v/v). 
'H-NMR (CDC13) 8 1.43 (s, 9H, C(CH3) 3), 1.58, 2.25 (two m, 2H, C3H2), 2.37 (s, 3H, CH3C(O)), 
3.05-3.35 (m, 3H, C1H2, C5H"), 3.65-4.00 (2H, two bs, C2H, C5Hb), 4.12 (q, lH, C4H), 5.08 (s, 2H, 
OCH2Ph), 5.58, 6.03 (two bs, lH, NH), 7.35 (m, 5H, ArH). 
13C-NMR (CDC13) o 28 .3 (C(£H3) 3) , 30.4 (CH3C(O)), 49.5 (C4), 56.2 (C2), 66.6 (OCH2Ph), 80.0 
(£(CH3) 3), 128.0, 128.4, 136.5 (Car), 154.1 (C(O)N), 155.9 (C(O)NH). The resonances of the 
remaining carbon atoms were not observed, due to their low signal to noise ratio. 
Sulfinyl chloride 24. 
Sulfinyl chloride 24 was prepared from 956 mg thioacetate 23 (8.74 mmol) according to the 
procedure described for sulfinyl chloride 11. The crude product was kept under argon and used 
directly for the preparation of sulfonamide 25. 
Sulfonamide 25. 
To a solution of 847 mg Boc-Gly-NHMe (4. 50 mmol) in 9 mL DCM, 9 mL ether, saturated with 
HCl, was added. After stirring for 30 minutes the solvent was evaporated and the residue 
coevaporated with DCM twice. The residue was dissolved in 10 mL DCM and then 628 µL 
triethylamine (4.50 mmol) was added. At 0° C this solution was added to 2.25 mmol of 
sulfinylchloride 24 dissolved in 9 mL DCM under argon. The mixture was stirred overnight 
before the solution was filtrated and the solvent evaporated. The product was purified by flash 
chromatography (eiuent: 6.5% MeOH in DCM, v/v), yielding 448 mg of the sulfinamide 
diastereoisomers (92%) . Rr 0.35, 0.37 (eluent: 10% MeOH in DCM, v/v). 
The sulfinamides (0.92 mmol) were dissolved in a mixture of 5 mL DCM, 5 mL CH3CN and 7 .5 
mL water. At 0° C, 257 mg NaI04 (1.20 mmol) and a catalytic amount of RuC13H 20 were added 
to the vigorously stirred solution. After stirring for 15 minutes at room temperature, the aqueous 
layer was extracted three times with DCM. The combined organic layers were dried on MgS04 
and after removal of the solvent in vacuo, the product was purified by column chromatography 
(eluent: 5% MeOH in DCM, v/v), yielding 695 mg of sulfonamide 25 (64% ). The overall yield 
was 59%. Re 0.48 (eluent 10% MeOH in DCM, v/v). 
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1H-NMR (CDCl3) 3 1.44 (s, 9H, C(CH3) 3), 2.03, 2.51 (bs and m, 2H, C3H2), 2.79 (d, 3H, N(H)C!b), 
3.19 (m, 2H, C1H", C5H•), 3.68-3.86 (2H, m, c1Hb, C5Hb), 3.75 (d, 2H, Gly-C2H2), 4.15 (q, IH, C4H), 
4.26 (m, IH, C2H), 5.09 (s, 2H, OCH2Ph), 5.44 (bs, IH, NHCbz), 6.03 (bs, IH, Gly-NH), 6.71 (bs, 
IH, N(!:!)CH3), 7.34 (m, 5H, ArH). 
13C-NMR (CDC13) 3 26.6 (N(H)C!:!3) 28.4 (C(~H3) 3), 36.9 (C3), 45.9 (Gly-C2), 49.9 (C4), 52.0 (C5), 
52.2 (c2), 56.0 (C1), 67.0 (OCH2Ph), 81.0 (f(CH3) 3), 128.1, 128.2, 128.6, 136.2 (C.,), 1~6.0 
(OC(O)), 168.9 (Gly-C1). 
Pyrrolidine 26. 
To a solution of 248 mg sulfonamide 25 (0.50 mmol) in 5 mL EtOH, 50 mg Pd/C (10%) was 
added and the mixture was stirred overnight. The catalyst was removed by filtration and the 
solvent evaporated, affording 156 mg amine (86%). To a solution of this amine in 4 mL THF, 
161 mg of pyrazole compound 14 (0.43 mmol) was added. After stirring overnight, the solvent 
was evaporated and flash chromatography (eluent: 4% MeOH in DCM, v/v) gave 254 mg of 
pyrrolidine 26 (88%). Rf 0.21 (eluent 4% MeOH in DCM, v/v). The overall yield was 76%. 
1H-NMR (CDC13) 3 1.44 (s, 9H, C(CH3) 3), 2.07, 2.59 (bs and m, 2H, C3H2), 2.81 (d, 3H, N(H)C!:!3), 
3.19 (m, 2H, C1H•, C5H•), 3.70-3.85 (2H, m, c1H\ C5Hb), 3.79 (d, 2H, Gly-c2H2), 4.25 (m, IH, 
C2H), 4.60 (q, IH, C4H), 5.12, 5.19 (twos, 4H, OCH2Ph), 5.44 (bs, lH, NHCbz), 6.03 (bs, IH, Gly-
NH), 6.83 (bs, lH, N(!:!)CH3), 7.37 (m, 5H, ArH), 8.44 (d, lH, NHC=N), 11.68 (s, lH, NHCbz). 
13C-NMR (CDC13) 3 26.2 (N(H)C!:!3) 28.3 (C(~H3) 3), 37.0 (C3), 45.9 (Gly-C2), 49.3 (C4), 51.7 (C5), 
52.3 (C2), 56.0 (C1), 67.3, 68.5 (OCH2Ph), 81.1 (9CH3) 3), 128.0, 128.1, 128.40, 128.43, 128.7, 
128.8, 134.4, 136.5 (Car), 153.9, 155.6 (OC(O)), 163.4 (C=N), 168.8 (Gly-c1) . 
Restricted arginine-glycine analog 27. 
To a solution of 254 mg sulfonamide 26 (0.38 mmol) in 3 mL ethanol, 25 µL acetic acid and 50 
mg Pd/C (10%) were added and the mixture was stirred overnight under a hydrogen atmosphere. 
The catalyst was removed by filtration and the solvent evaporated. The thus obtained acetic acid 
salt was purified and converted to the hydrochloric acid salt 27 on a DOWEX er column. 
Lyophilization gave 145 mg of analog 27 (87%). Rf 0.57 (eluent: MeOH/37% NH3 in H20/CHC13 
45:20:60, v/v). 
1H- NMR (D20) 3 1.52 (s, 9H, C(CH3\), 2.29, 2.65 (bs and m, 2H, C3H2), 2.82 (d, 3H, N(H)C!:!3), 
3.33 (bs, IH, c1H•), 3.47 (dd, lH, C5H•), 3.77-4.00 (2H, m, C1H\ C5Hb), 3.87 (d, 2H, Gly-C2H2), 
4.16 (qu, IH, C2H), 4.33 (bs, lH, C4H). 
13C-NMR (DP) 3 26.1 (N(H)C!:!3) 27.9 (C(fH3) 3), 35.8 (C3), 45.0, 45.1 (Gly-C2), 49.2, 49.8 (c4), 
49.4, 53.0 (C1), 50.5 (C\ 52.1, 54.0 (C2), 81.1 (f(CH3) 3), 155.8 (C=N), 156.7 (C=O), 171.9 
(Gly-C1). 
FABMS rn/z (M+H+) 393.2. 
Boc-4S-cyanoproline 28. 
To a solution of 3.14 g mesylate 17 (9.70 mmol) in 30 mL DMF, 4.82 g tetrabutylammonium 
cyanide (17 .9 mmol) was added and the resulting mixture was stirred for 20 hours at 55° C. Then 
the reaction mixture was cooled to room temperature and poured into crushed ice, which was 
subsequently extracted with EtOAc three times. The combined organic layers were washed with 
water (three times), brine and dried on Na2S04 • Evaporation of the solvent followed by flash 
chromatography ( eluent: ether/hexanes 2: 1, v/v) and crystallization from ether/hexanes, afforded 
340 mg of cyanide 28 (14%). Rf 0.54 (eluent: ether). 
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1H-NMR (CDCl3) 8 1.38, 1.43 (twos, 9H, C(CH3) 3), 2.28, 2.65 (two m, 2H, Pro-C3H2), 3.10 (m, lH, 
Pro-c4H), 3.65 (m, lH, Pro-C5H"), 3.72, 3.75 (s, 3H, OCH3), 3.91 (m, lH, Pro-C5Hb), 4.29, 4.38 
(two t, lH, Pro-C2H). 
13C-NMR (CDCl3) 8 26.4, 27.4 (Pro-c4), 28.1 (C(£H3) 3), 34.3 (Pro-C3), 49.0 (Pro-C5), 52.3 
(CHP), 57.8, 58.1 (Pro-C2), 81.1 (£(CH3) 3), 118.8 (CN), 152.8 (C(O)N), 171.7 (Pro-C1). 
IR (film) cm-' 2247 (N3), 1734, 1701 (C=O). 
Boc-4S-cyanoprolinol 29. 
To a suspension of 240 mg NaBH4 (6.3 mmol) in 25 mL DME, 804 mg Lil (6.0 mmol) was 
added. After stirring for 5 minutes, 340 mg of methylester 28 (1.34 mmol), dissolved in 5 mL 
DME, was added. The reaction mixture was stirred for 1 hour at 50° C and then cautiously 
quenched with lM KHS04 at 0° C. The resulting aqueous solution was extracted with DCM three 
times. The combined organic layers were washed with lM KHS04, 5% NaHC03, brine and dried 
on MgS04• Evaporation of the solvent and subsequent column chromatography (eluent: 3% 
MeOH in DCM/ v/v) gave 234 mg of alcohol 29 (77%). Rr 0.42 (eluent: DCM in MeOH, v/v) . 
1H-NMR (CDCl3) 8 1.42 (s, 9H, C(CH3) 3), 1.98, 2.42 (bs and qu, 2H, C3H2), 2.97 (m, lH, C4H), 
3.44 (m, lH, C5H"), 3.68 (bs, 2H, C1H2), 3.90 (bs, 2H, C5H\ C2H), 4.35 (bs, lH, OH). 
13C-NMR (CDCl3) 8 26.3 (C4), 28.2 (C(fH3) 3), 32.3 (C3), 49.8 (C5), 59.4 (C2), 65.3 (C1), 81.1 
(£(CH3) 3), 119.5 (CN), 155.8 (C(O)N). 
Thioacetate 30. 
To a solution of 234 mg alcohol 29 (1.03 mmol) and 298 mg Ph3P (1.14 mmol) in 3.5 mL THF 
at 0° C, 224 µL DIAD and 81 µL HSAc were added subsequently. After stirring for 2 hours at 0° 
C, the mixture was stirred overnight at room temperature. Evaporation of the solvent and 
purification of the residue by flash chromatography (eluent of first column: ether/hexanes 1:1, 
v/v; eluent of second column: 3% acetone in DCM, v/v), afforded 190 mg of thioacetate 30 
(65%). Rr 0.44 (eluent: 3% acetone in DCM). 
1H-NMR (CDC13) 8 1.44 (s, 9H, C(CH3) 3), 1.97, 2.43 (bs and qu, 2H, C3H2), 2.93 (qu, lH, C4H), 
3.03-3.45 (broad m, lH, C5H"), 3.41 (m, 2H, C1H2), 3.99 (bs, 2H, C5H\ c2H). 
13C-NMR (CDC13) 8 26.2 (C4), 28.2 (C(£H3) 3), 30.5 (CH3C(O)), 31.8 (C3), 34.2 (C1), 49.6 (C5), 
56.1 (C2), 80.8 (f(CH3) 3), 119.4 (CN), 153.4 (C(O)N) 194.4 (CH3£(0)). 
Sulfiny lchloride 31. 
Sulfinyl chloride 31 was prepared from 190 mg thioacetate 30 (0.67 mmol) according to the 
procedure described for sulfinyl chloride 11. The crude product was kept under argon and used 
immediately for the preparation of sulfonamide 32. 
Sulfonamide 32. 
251 mg Boc-Gly-NHMe (1.34 mmol) was dissolved in 2 mL DCM and 2 mL TFA was added. 
After stirring for 30 minutes the solvent was evaporated and the residue coevaporated with THF 
twice. To a solution of the residue in 2 mL DCM/DMF (3:1, v/v), 186 µL triethylamine (1.34 
mmol) was added and at 0° C this solution was added to 0.67 mmol sulfinylchloride 31, dissolved 
in 1 mL DCM under an argon cushion. The mixture was stirred overnight before the solvent was 
evaporated. Flash chromatography (eluent: 10% MeOH in DCM, v/v) yielded 138 mg of 
sulfinamide (60%). Rr 0.31 (eluent: 10% MeOH in DCM, v/v), 0.13 (eluent: EtOAc) . 
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This sulfinamide (0.40 mmol) was dissolved in a mixture of 1 mL DCM , 1 mL CH3CN and 1.5 
mL water. At 0° C, 112 mg NaI04 (0.52 mmol) and a catalytic amount of RuCl3H 20 were added 
to the vigorously stirred solution. After stirring for 20 minutes at room temperature, the aqueous 
layer was extracted three times with DCM. The combined organic layers were dried on MgS04 
and the solvent removed in vacuo. The product was purified by column chromatography (eluent: 
EtOAc) affording 100 mg of sulfonamide 32 (77%). The overall yield was 46%. Rr 0.31 (eluent 
10% MeOH in DCM, v/v), 0.36 (eluent: EtOAc). 
1H-NMR (CDC13) i> 1.44 (s, 9H, C(CH3) 3), 2.46, 2.57 (bs and qu, 2H, C3H2), 2.80 (d, 3H, N(H)C!fi), 
3.12 (qu, lH, C4H), 3.29 (t, lH, c1Ha), 3.55 (dd, lH, C5H"), 3.78 (bs, 4H, C1H\ C5H\ Gly-C2H2), 
4.30 (m, lH, C2H), 6.20 (Gly-NH), 6.85 (N(!!)CH3). 
13C-NMR (CDC13) l> 26.2 (N(H)CH3), 26.8 (c4), 28.2 (C(£H3) 3), 34.5 (C3), 45.7 (Gly-C2), 49.2 (C5), 
52.7 (C2), 55.0 (C1), 81.5 (f(CH3) 3), 120.3 (CN), 153.7 (C(O)N) 169.0 (Gly-C 1) . 
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Evaluation of aminoethane sulfonamide Arg-Gly 
isosteres as thrombin inhibitors 
Introduction 
Thrombin plays a central role in the blood coagulation cascade1• Since many cardiovascular 
diseases are caused by processes in which thrombin is involved, a large number of inhibitors 
of thrombin have been developed in the past2• Still a lot of research is devoted to the 
development of new thrombin inhibitors because of the limitations of the existing inhibitors 
with respect to stability, specificity or oral bioavailability3. In view of our interest in 
peptidosulfonamides, the structures of some existing inhibitors, shown in figure 1, inspired us 
to synthesize aminoethane sulfonamide derivatives: ~-substituted sulfonamides (chapter 2), a.-
substituted analogs (chapter 3) and conformationally restricted derivatives (chapter 4), of which 
the general structures are shown in figure 2. 
Rl= Ki Reference 
H2NyNH .JV'H 181 nM 9a 
l('c1 37 nM 9b ~ 0 yH 7.5 nM 9c 0 H-D-Phe-Pro-N R 1 pH 
H =B <0.004 nM 9d 
OH 
106 nM 9e 
103 nM 9f 
19 nM 9g 
Figure 1. Examples of existing thrombin inhibitors. 
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fibrinogen 
Scissile 
bond 
qv? 
"'NJ5'N"' 
H c... H 
NH 
H~NH2 a 
Figure 2. General structures of the aminoethane sulfonamides of which the preparation was 
described in chapters 2 (b), 3 (a) and 4 (c and d) and were evaluated for their 
inhibition of thrombin. 
These sulfonamides should act as transition-state analogs of the hydrolysis of an arginine-
glycine peptide bond, which is cleaved by thrombin resulting in formation of fibrin. Transition-
state analogs mimic the geometry and electronic structure of a transition-state of a reaction. 
Their resemblance allows them to act as enzyme inhibitors since Pauling has proposed that an 
enzyme has an complementary (active) site to the transition-state of a reaction which it 
catalyzes. This should give rise to a higher affinity of the enzyme for structures mimicking this 
transition-state than e.g. the substrate. Since these analogs are not processed by the enzyme 
they might act as inhibitors competing with the substrate. 
In this chapter the results of these aminoethane sulfonamides in an assay for thrombin 
inhibitory activity will be discussed. Furthermore, it will be attempted to rationalize some of 
these results using molecular modelling. The crystal structure of thrombin containing PP ACK 
(4.2), determined by Bode et al.4, will be used as a starting point for this purpose. 
Results and discussion 
First, the inhibitory activity of each of the ~-substituted aminoethane sulfonamide containing 
isosteres 2.23-2.34 (figure 3), was determined in a thrombin assay. This was performed by 
determining the concentration (IC50) of inhibitor, which resulted in a 50% decrease of the 
normal thrombin activity on the chromogenic substrate S-2238, as was monitored by the 
release of p-nitroaniline. It should be noted, however, that any observed inhibition, using 
substrate S-2238, should be attributed to binding of the inhibitor in the active site. Inhibitors 
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which do not bind in the active site will not cause a reduction of the conversion of this low 
molecular weight substrate5• 
None of the compounds 2.23-2.34 showed any inhibitory activity up to concentrations of 
300 µM of inhibitor. This was a rather surprising result, because of the similarity of the 
sulfonamides 2.23, 2.24 and 2.28-2.30 to existing high affinity inhibitors (figure 1 and 3). 
Compound 
2.23 
2.24 
2.25 
2.26 
2.27 
2.28 
2.29 
2.30 
2.31 
2.32 
2.33 
2.34 
Boc-D-Phe-Pro 
B oc-D-Phe-Pro 
Boc-Gly 
Boc-Gly 
Dansyl 
HClH-D-Phe-Pro 
HClH-D-Phe-Pro 
HClH-D-Phe-Pro 
HClH-Gly 
HClH-Gly 
HClH-Gly 
HClH-Gly 
Gly-OEt 
NH2 
Pro-D-Phe-OMe 
D-Pro-Phe-OMe 
NH2 
Gly-OEt 
Gly-OH 
NH2 
Pro-D-Phe-OMe 
D-Pro-Phe-OMe 
Pro-D-Phe-OH 
D-Pro-Phe-OH 
Figure 3. Arginine-glycine analogs that were tested for their thrombin inhibition. 
Therefore, it was attempted to rationalize these results using molecular modelling. The X-ray 
structure of thrombin co-crystalized with H-D-Phe-Pro-Arg-CH2Cl (PPACK)4 was used as a 
starting point for this purpose because of its considerable similarity to compounds 2.23 and 
2.24, which were expected to display a comparable mode of binding with respect to the N-
terminal D-Phe-Pro-Arg moiety. After removal of the inhibitor and the water molecules by 
molecular modelling, H-D-Phe-Pro-Arg-CH3, as a PPACK analog6, as well as sulfonamides 
2.23 and 2.24 were docked into thrombin. The docking was performed using the program 
Autodock7• Autodock uses a grid based scoring protocol combined with simulated annealing 
for conformational search. This method does not require a binding site a priori and can 
therefore be considered as an unbiased approach to dock ligands in a receptor. To reduce the 
number of conformations that have to be taken into account, the torsion angles in the D-Phe-
Pro residues were fixed. Using Autodock, the inhibitor analog H-D-Phe-Pro-Arg-CH3 docked 
to a similar position in thrombin as the inhibitor in the original crystal structure. The result is 
shown in figure 7a (see page 95), in which the backbone atoms of thrombin are schematically 
represented by a ribbon, the PP ACK carbon atoms are colored gray and possible sites of 
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interaction with thrombin are depicted as sticks and balls9 • Sulfonamides 2.23 and 2.24 were 
positioned in a comparable way in thrombin, as is depicted in figure 7b for 2.24. However, 
the side chain of the arginine sulfonamide analog moieties did not enter the specificity pocket as 
deep as that of PPACK, as can be seen in figure 7c, in which the docked sulfonamide 2.24 
and PP ACK were superimposed. It seemed that the sulfonamide moiety was not 
accommodated well, probably because of the additional carbon atom between the sulfonamide 
group and the arginine-like side chain of the aminoethane sulfonamide. Steric and electronic 
repulsion of the sulfonamide functionality by residues of thrombin at the S 1-S 1' site10, caused 
the entire sulfonamide residue to be lifted out of the specificity pocket. Because of this, the 
sulfonamide group cannot interact with the oxyanion hole and part of the electrostatic 
interaction of the guanidinium group with the carboxylic acid containing side chain of aspartate 
18911 at the bottom of the pocket will be lost, which might account for the complete loss of 
affinity for the sulfonamide containing compounds. From these results, it was concluded that 
the sulfonamide moiety in the ~-substituted aminoethane sulfonamides does not have a perfect 
fit for the thrombin active site, leaving the compounds containing such an isostere inactive. To 
substantiate this hypothesis, high molecular weight hirutonin 2.40 was prepared (figure 4). 
The C-terminal hirudin part of 2.40 can be expected to have high affinity for the fibrin 
recognition exosite12, bringing the N-terminal part near the active site. It was expected that if 
the sulfonamide would indeed lead to unfavorable interactions, the affinity of thrombin for 
2.40 had to be lower than that for the corresponding all amide hirutonin 2.40b 13 , i.e. 7.4 nM. 
The IC50 value of peptidosulfonamide 2.40 turned out to be 131 µM. From this IC50 value an 
apparent Ki, i.e. the equilibrium dissociation constant, of 2 µM can be estimated14. As 
mentioned earlier, any inhibition found, using substrate S-2238, can be attributed to binding of 
the inhibitor in the active site. Binding of only the C-terminal hirudin moiety would not result 
in a reduction of the conversion of the low molecular weight substrate. Therefore, comparing 
the Ki of 2.40 with that of the corresponding 2.40b, it can be concluded that the presence of 
an aminoethane sulfonamide moiety at the P 1- P 1' position of a ligand, leads to unfavorable 
interactions resulting in a low affinity for the active site of thrombin. 
A B C 
---------- - ----------------------
H 
H-D-Phe-PrrrN~X-(Gly)5-Asn-Gly-Asp-Phe-Glu-Glu-lle-Pro-Glu-Glu-Tyr-Leu-OH 
-) s 2.40 X = IA (Ki ,::: 2 µM) 
0 0 
HN 
H2NANH 
C 2.40b X = 11 
0 
(Ki = 7.4 nM) 
Figure 4. A hirutonin and its sulfonamide analog. A) Active site directed moiety. B) Linker. 
C) Peptide capable of binding to the fibrinogen-recognition exosite. 
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The assumption that the shift of the sulfonamide functional group due to the presence of an 
additional carbon atom, was the cause of the absence of inhibitory activity, led to the 
preparation of a-substituted aminoethane sulfonamides, which were described in chapter 3 
(figure 5). It was expected that the sulfonamide group could now be accommodated in a better 
way, leading to more favorable side chain interactions with the specificity pocket. This was 
confirmed by docking of model compound 3.01 (figure 7d). Unfortunately, none of the 
assayed a-substituted compounds 3.34-3.38 showed any activity. This may be explained by 
a shift of the functional groups of the N-terminal D-Phe-Pro moiety causing non-optimal 
interactions with the S2-S3 subsites of thrombin. Therefore, to investigate whether a-
substituted sulfonamide arginine analogs are suitable as a scaffold for thrombin inhibitors, a 
search has to be performed for residues that lead to optimal interactions of this side of the 
inhibitor with the corresponding sites on the enzyme. Preliminary results of de novo ligand 
design, starting with an a-substituted aminoethane sulfonamide in the S I site of the enzyme, 
confirmed that indeed other fragments than a D-Phe-Pro or a dansyl group would lead to 
optimal interactions. The program LUDI17, which searches for fragments that may be 
connected to an initial scaffold and dock into the binding sites of the enzyme, suggested e.g. to 
incorporate the amine of the sulfonamide arginine analog in an cyclohexane ring. As no such 
compounds were prepared, this opportunity was not pursued. 
Compound 
3.01 
3.34 
3.35 
3.36 
3.37 
3.38 
Ac 
Boc-D-Phe-Pro 
HCIH-D-Phe-Pro 
HCIH-D-Phe-Pro 
Dansyl 
Dansyl 
NH2 
Gly-OEt 
Gly-OEt 
Gly-OH 
Gly-OEt 
Gly-OH 
Figure 5. a-substituted aminoethane sulfonamide containing arginine-glycine analogs which 
were tested for their thrombin inhibition 16• 
Finally, the conformationally restricted analogs described in chapter 4 were assayed in the 
thrombin inhibition assay (figure 6). Again, none of the sulfonamides 4.16a, 4.16b and 
4.27 were found to be active. However, this was not that surprising, as the modifications 
compared with the unconstrained analogs were not expected to immediately lead to compounds 
that would have an ideal geometry and were provided with optimal substituents. 
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q, /? 
R,N\~S,N~NHMe 
( H 0 
NH A 4.16aR=Ac 
H2N NH·HCI 4.16b R = Tos 
HNYNH2.HCI 
HNh Q 0 
(~,)y~i: ~NHMe N N 
I H 
Boe O 4.27 
Figure 6. Conformationally restricted arginine-glycine sulfonamide analogs that were tested for 
their thrombin inhibition. 
Conclusion 
In this chapter the inhibitory activity on thrombin was evaluated of the sulfonamide isostere 
containing compounds, which were described in the previous three chapters. Only the high 
molecular weight compound 2. 4 0 showed a modest inhibition of thrombin. Because of the 
absence of any activity of the low molecular weight ~-substituted aminoethane sulfonamide 
containing derivatives and the poor affinity of the sulfonamide containing hirutonin 2.40 (Ki z 
2 µM), compared with the all amide analog 2.40h 13 (7.4 nM), it was concluded that ~-
substituted aminoethane sulfonamide arginine analogs are not suitable as a structural 
component of thrombin inhibitors. In addition, no inhibitory activity was observed for the a-
substituted aminoethane sulfonamides nor any of the conformationally restricted compounds, 
which were described in chapters 3 and 4, respectively. However, no inhibitory activity on 
thrombin was anticipated, because it was expected that the substituents of these arginine-
glycine analogs would not lead to optimal interactions with the enzyme. Further studies are 
necessary to ascertain the value of the a-substituted and constrained analogs 18 • Finally, it might 
be interesting to investigate whether the sulfonamides, that were prepared, can be used in the 
design of ligands for other targets, in which an arginine is important as a binding determinant, 
as is the case e.g. in RGD peptide analogs19• 
Experimental 
Thrombin inhibition assay, determination of an IC50-value. 
The assay was performed at Organon N.V. in Oss. To a solution of S2238 (H-D-Phe-Pip-Arg-p-
nitroanilide"2HC1, 240 µM) and inhibitor (0 and 1.0 µM to 300 µM) in 0.1 M NaCl, 0.05 M Tris, 
pH 7.4 at 37° C, was added a solution of thrombin (0.2 IU/mL) in 0.1 M NaCl, 0.05 M Tris, pH 
7.4, 0.3% PEG (Mr= 6000). The mixture was stirred thoroughly and the increase in absorbance 
( 405 nm) was measured every minute for a period of 90 minutes. The IC50-value, i.e. the 
concentration at which the thrombin activity was reduced to 50%, was calculated from the 
absorbances measure at 90 minutes. The Ki, i.e. the dissociation constant, was estimated 14 from the 
IC50 using the formula Ki= IC5of{ l+([S]/Km)}, using a~ of 3.33 µM 15 for S-2238. 
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Docking of H-D-Phe-Pro-Arg-CH3 and peptidosulfonamides 2.23 and 2.24 into thrombin. 
From the crystal structure of the thrombin-PPACK complex (PDB 20 identification code lppb) the 
covalently attached inhibitor and all water molecules were removed, using the molecular 
modelling package Sybyl 6.221 . Subsequently, essential hydrogens and charges (CFF9l 22) were 
added. The ligands were built starting from the crystal structure of PPACK and hydrogens and 
charges were added using Insight II 2.3.5 23 • Then the ligands were docked into thrombin using 
Autodock 2.47• A typical procedure consisted of 25 runs of 50 cycles each with a maximum of 
either 15000 accepted or rejected steps, annealing from a temperature of 1000 K, using a 
temperature reduction factor of 0.95. The conformers with the lowest energy were evaluated as 
described in this chapter. 
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Figure 7. Results of the docking into thrombin of a) ?PACK; b) 2.24; c) PPACK superimposed 
on 2.24; and d) 3.01 . 
Figure 8. Results of the binding assay with receptor molecules a) 1; b) 2; c) 3; and d) 5 on the 
24,389 member tripeptide library on Tentagez®. 
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CHAPTER 6 
Synthetic receptors based on peptidosulf onamide 
peptidomimetics 
Introduction 
Combinatorial chemistry has offered many new methodologies for the generation of libraries 
consisting literally of several ten thousands of compounds which can be subjected to high-
throughput screening for lead-finding and lead-optimization1• Furthermore, combinatorial 
chemistry offers tremendous possibilities to move beyond the generation of compounds for 
pharmaceutical screening purposes, since it may also be of great significance for the 
preparation of new synthetic receptors2, and catalysts3• The area which is now emerging might 
be referred to as "combinatorial supramolecular chemistry". Employing combinatorial 
chemistry for this purpose is in fact a very "biomimetic" approach, since in nature for example 
many antibodies -biological receptors- are generated against a particular antigen, from which 
then antibodies with optimal binding properties are selected. 
It was reasoned that combinatorial chemistry methods might offer attractive tools to probe the 
structure and interactions of peptidomimetics with peptides and proteins. We are interested in 
peptidosulfonamide peptidomimetics4, because the sulfonamide moiety might act as a 
transition-state isostere of the hydrolysis of the amide bond, as was discussed in the previous 
chapters. It is more resistant to degradation by proteases, more flexible than the amide bond4\ 
and its more acidic hydrogen may give rise to stronger hydrogen bonds5• Following the 
successful concept of creating tweezer-like, two armed molecules6 (figure 1), in this chapter the 
construction is described of synthetic receptors based on earlier described ~-substituted 
aminoethane peptidosulfonamides4• 
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Results and discussion 
Using diamino acid derivative 17 as a "hinge" molecule, sulfinylchlorides were employed as 
building blocks to construct the arms of the tweezers. Repetitive coupling of these 
sulfinylchlorides and subsequent oxidation of the obtained sulfinamides afforded the 
sulfonamide moieties, analogous to the procedures earlier developed in our laboratory4 and 
those described in the previous chapters. A dye is attached to the hinge in order to visualize 
binding in an assay using a tripeptide library (vide infra). 
Tweezer 
~ 1~-j/~J 
--:~~~ 
Arm 
Figure 1. A schematic representation of the concept of a tweezer-like receptor molecule. 
Thus, saponification of methylester 1, which was synthesized according to Mulders et al.7, and 
coupling to Disperse Red 1 gave the colored derivative 3 in 90% yield(scheme 1). After 
removal of the Boe-groups, receptor 6 was obtained by treatment with sulfinylchloride 4 in the 
presence of triethylamine, followed by oxidation using NaIO/RuC13 (overall yield 11 %). It 
was then attempted to obtain receptor 10 by subsequent removal of the Boe groups of 6, 
coupling with sulfinylchloride 7 and oxidation using NaI0/RuC13• The last step, however, i.e. 
the oxidation, had a very poor yield of 7%. As it was thought that this was due to competing 
oxidation of the dye part8, it was decided to first attach the sulfonamide arms before 
introducing the dye part. Therefore, the above synthesis was repeated, now commencing with 
the compound without the dye part, i.e. 1. Repetitive removal of the Boe groups, coupling 
with sulfinylchlorides 4 and 7, respectively, followed by oxidation, afforded receptor 
molecules 5 and 8, in 33% and 63% respectively. The low yield of the oxidation step had 
indeed improved and was significantly better than that carried out on the dye containing 
compound. Finally, Disperse Red 1 was introduced by saponification of methylester 8, using 
DCC as a coupling agent. Due to the poor solubility of the product purification of ester 10 was 
difficult, but despite this, colored receptor 10 was obtained in 52% yield from methylester 8. 
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_rNBoc 
0 ~ 
a~ A 
RO~ 
0 H 
~~Boe 
Cl R=Me Tesser's base 
DIC/DMAP C 2 R = H 
Disperse Red 1 3 R = DispRed: 
l.HCI 
I. HCl 
2. Et3N ?, 4 
BocHN..-_ S, Cl 
3.Nal04, 
RuCI3.H20 
6 R = DispRed 
Scheme 1. Synthesis of a synthetic receptor molecule utilizing sulfinylchlorides. 
1. HCl 
2.~I Et3N 
::::,... 0 
" 6 
BocHN S. Cl 
1---------
3. NaI04, RuCl3.H20 
4. repetition of 1 - 3 
ell R=Me Tesser's base 
DCC/DMAP ( 12 R = H 
Disperse Red 1 13 R = DispRed 
Scheme 2. Synthesis of second tweezer molecule. 
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Once the desired receptor molecules were synthesized, they were assayed for their binding 
properties towards a 24,389 (=293) member encoded tripeptide library on TentaGel®. This was 
performed by the addition of a solution of receptor molecules to beads containing this library 
(figure 2). Beads containing tripeptides that have an affinity for the tweezers, will become 
colored. The stained beads are separated and decoded by photolytic release of the molecular 
tags, followed by EC-GC (electron capture gas chromatographic) analysis9• 
Red colored peptidosulfonamide receptors 6, 10 and 13 were screened for binding against this 
24,389 (=293) member encoded tripeptide library on TentaGel® i.e. AA3-AA2-AA1-N(H)-
TentaGel (AA1_3 are specified in figure 3, the letters correspond to the one letter symbols of the 
various amino acids; a prefix 'd' indicates that the particular amino acid in the tripeptide was a 
D-amino acid). 
peptide 
~ / "' 
""-.....______ AB~- COE ~ ~ v -o -D 
FGH 
-t> IJF'O-a + 
colored 
tweezer 
! 
~} . 
1 Equilibrate 
AB~ 
FGH'O-[EJ~ 
COE 
-~ 
IJF'O-a ' 
COE 
-D 
FGH t> 
~eparation 
~f :tained beads 
Release C, D, E Decoding AAc-AAo-AAE 
of tags F, G, H AAp-AAa-AAH 
Figure 2. Schematic representation of a binding assay using an encoded tripeptide Library. 
Synthetic receptor 6 did not show any binding whatsoever with either the deprotected (both 
side chains and amino terminus) or protected library at concentrations as high as 500 µM. In 
contradistinction, with peptidosulfonamide receptor 10, containing an additional aminoethane 
sulfonamide moiety at each arm, binding was observed with the deprotected library in 
chloroform. At a concentration of 100 µM approximately 1 % of the library beads bound. 
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However, no binding was observed with the protected library. Furthermore, the binding 
depended strongly on the charged state of the library in chloroform with the best selectivity 
around neutrality, since no binding was observed with added TFA, and addition of DBU or a 
weaker base (Et3N) decreased the selectivity of binding. In order to try to obtain the best 
selectivity the bead-supported tripeptide library was equilibrated in a chloroform solution of the 
receptor having a slightly lower concentration (-70 µM). After 24 hours equilibration, the 
colored beads were separated and decoded by photolytic release of the molecular tags, followed 
by EC-GC (electron capture gas chromatographic) analysis9• A total of 34 beads were 
decoded 1°. The frequencies of different amino acid residues in tripeptide library members, that 
bound to peptidosulfonamide receptor 10 are shown in Fig. 3. All decoded sequences contain 
an acidic amino acid residue, which is practically always (found in 32 out of 34 decoded beads: 
94%) accompanied by a second polar amino acid residue, especially Asn or His, sometimes 
Ser, and in six sequences an acidic amino acid residue. In almost all cases (found in 32 out of 
34 decoded beads: 94%) the site for the acidic residue is AA3 or M in which AA3 is strongly 
biased towards being a Glu residue (found in 8 out of 34 decoded beads: 24%) and M an 
Asp residue (23 out of 34 beads: 68%). For AA3 an Ala residue was found in 17 out of 34 
decoded beads (50%). Mis almost invariably a polar (His, Asn, Glu or Asp) amino acid 
residue (found in 33 out of 34 decoded beads: 97% ). Interestingly, most variability is found in 
the first amino acid residue AAi, which -for recognition by this receptor- might be designated 
as a'wobble' amino acid residue. It is also noteworthy that in a number of cases (D)Ala-(L)Asp 
Figure 3. Frequencies of the different residues in the tripeptide library members that were found 
to bind to receptor 10. The letters correspond to the one letter symbols of the various 
amino acids; a prefix 'd' indicates a D-amino acid. 
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or its enantiomeric sequence (L)Ala-(D)Asp is found (found in 17 out of 34 decoded beads: 
50%). None of the corresponding diastereomeric sequences (D)Ala-(D)Asp or (L)Ala-(L)Asp) 
are found, indicating some degree of stereoselectivity of this receptor. Most tripeptide 
sequences, which were recognized by this receptor, have consensus sequence (D)Ala-(L)Asp-
(D)Xxx ( or the enantiomeric sequence, found in 17 out of 34 decoded beads: 50%) or (L)Glu-
Asn/(D)His-Xxx (found in 7 out of 34 decoded beads: 20% ). Finally, it is worth mentioning 
that some full tripeptide sequences were found multiple times10, e.g. (D)Ala-(L)Asp-(D)Asn 
and (D)Ala-(L)Asp-(D)Ser were found four times each, i.e. in 8 of 34 decoded beads (24%) 
and interestingly, Asn and Ser are quite similar. 
Unfortunately, peptidosulfonamide receptor 13, which had been prepared to increase the 
selectivity of binding, did not show binding with any of the libraries. The additional 
sulfonamide residue derived from phenylalanine clearly suppressed binding since no binding 
was observed using concentrations as high as 500 µM! 
For a quantitative estimation of the binding constant one of the peptides was selected, that 
bound to the receptor viz. (D)Ala-(L)Asp-(D)Ser-N(H)-TentaGel and belongs to one of the 
consensus sequences. No binding was observed when the N-terminus was either acetylated or 
the TFA-salt was used. In chloroform a association constant (Ka) of 310 ± 20 M-1 (~.G = - 14 
kJ moi-1) was determined. This binding was very sensitive to traces of a protic solvent such as 
methanol. The presence of only 1 % methanol was sufficient to reduce the binding to almost 
zero in both chloroform and dichloromethane. The enantiomer of the tripeptide i.e. (L)Ala-
(D)Asp-(L)Ser-N(H)-TentaGel showed a comparable binding to the peptidosulfonamide 
receptor, which is in agreement with the aforementioned screening results . Interestingly, if a 
diastereomeric sequence of these peptides was prepared e.g., (D)Ala-(L)Asp-(L)Ser-N(H)-
TentaGel virtually no binding was observed by the same method, of the beads containing this 
sequence after equilibration with receptor 10. As expected an arbitrary sequence such as 
(L)Ala-(L)Lys-(L)Phe-N(H)-TentaGel did not show any detectable binding with receptor 10. 
Conclusion 
In this chapter the synthesis of a tweezer-like synthetic receptor based on peptidosulfonamide 
peptidomimetics was described, showing a remarkable binding selectivity for such a simple 
system. The preference of the synthetic receptor for interacting with acidic amino acid residues 
is interesting and probably points to strong hydrogen bond donor properties of the sulfonamide 
N -H 11 • The absence of any binding capability of the less flexible receptor 13 for tripeptides 
from the used libraries was somewhat surprising. This may be caused by hindrance of one of 
the sulfonamides and therefore 13 may have reduced binding properties. Alternatively, if the 
iptramolecular interactions of the arms are too favorable, binding with a tripeptide from the 
102 
Peptidosulfonamide based synthetic receptors 
library will be less likely to occur. Therefore, in the next chapter less flexible hinges are 
described to which the peptidosulfonamide arms can be attached, thus avoiding intramolecular 
interactions of the arms as might be present in receptor 13. 
Experimental 
General methods. 
DCM and DMF were dried on molecular sieve (4A). Triethylamine and DIPEA were distilled 
from ninhydrin and KOH. NMM was distilled from CaH2 and THF from LiAlH4• All other 
chemicals were used as purchased. Tentagel®S NH2 resin (130 µm) was purchased from Rapp 
Polymere, Ttibingen, Germany. Reactions were carried out at ambient temperature unless stated 
otherwise. TLC analysis was performed on Merck pre-coated silicagel 60 F-254 (0.25 mm) 
plates. Spots were visualized with UV light, ninhydrin or Cl2-TDM12• Solvents were evaporated 
under reduced pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 
(40-63 µm) and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 
from Pharmacia was used for gel permeation chromatography. 
1H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 MHz) and chemical 
shift values are given in ppm relative to TMS. 13C-NMR spectra were recorded on a VARIAN 
G300-spectrometer (75.5 MHz) and chemical shift values are given in ppm relative to CDC13 
(77.0 ppm). 13C spectra were recorded using the attached proton test (APT) sequence. Fast atom 
bombardment (F AB) mass spectrometry was carried out using a Jeol JMS SX/SX 102A four-
sector mass spectrometer, coupled with a HP-9000 data system. UV-Vis spectra were recorded on 
a Perkin Elmer Lambda 2 UV/Vis spectrophotometer. 
Methylester 1. 
This compound was prepared as described by Mulders et al.7 
Carboxylic acid 2. 
A solution of 454 mg methylester 1 (1.0 mmol) in 20 mL 0.25 M LiOH in water/MeOH (1:3, v/v) 
was stirred overnight. Then the pH was brought below 2 with 1 M KHS04 and the aqueous 
solution was extracted with EtOAc three times. The combined organic layers were dried with 
N~S04 and evaporated. The product was dried in vacuo over KOH affording 431 mg of 
carboxylic acid 2 (98 %). 
1H-NMR (CDC13): <> 1.45 (s, 18H, C(CH3) 3), 3.48 (dt, 4H, CH2NHC(O)), 4.04 (t, 4H, OCH2), 5.04 
(bs, 2H, NH), 6.82 (t, lH, ArH), 7.20 (d, 2H, ArH). 
13C- NMR (CDC13) : 8 28.1 (C(fH3) 3), 39.8 (£H2NHC(O)), 67.l (CH20Ar), 79.1 (f(CH3) 3) , 106.1, 
108.1, 132.8, 159.4 (CA'), 155.9 (NHC(O)O), 168.3 (ArC(O)O). 
Colored hinge 3. 
To a solution of 959 mg carboxylic acid 2 (2.18 mmol) in 8 mL DCM and 2 mL DMF, 341 µL 
DIC (2.18 mmol), 62 mg DMAP and 685 mg Disperse Red 1 (2.18 mmol) were added 
consecutively. The mixture was stirred overnight before 50 mL DCM was added. The solution 
was washed with water, brine an dried on MgS04• Evaporation of the solvent and column 
chromatography (eluent: 1.6% MeOH in DCM, v/v) afforded 1.47 g of colored 3 (92%). Rf 0.66 
(eluent: 5% MeOH in DCM, v/v) . 
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1H-NMR (CDC13): o 1.27 (q, 3H, CH,£H3), 1.42 (s, 18H, C(CH3) 3), 3.49 (broad m, 4H, 
£H2NHC(O)), 3.57 (t, 2H, NfH2CH3), 3.81 (t, 2H, NfH2CH2), 3.98 (t, 4H, ArOCH2), 4.51 (t, 2H, 
NCH,£Hi0), 5.01 (bs, 2H, NH), 6.62 (t, lH, ArH), 6.86 (d, 2H, ArH), 7.11 (d, 2H, ArH), 7.90, 
7.92, 8.31 (three d, 6H, ArH). 
Sulfinylchloride 4. 
353 mg N, N' -diBoc-cystamine4' (1.0 mmol) was dissolved in 3 mL DCM and placed under an 
argon cushion. After cooling to -20° C, 94 µL Ac20 (1.0 mmol) and 162 µL sulfuryl chloride 
(2.0 mmol) were added. The solution was stirred for 1 hour at -5° C before the solvent was 
evaporated, followed by drying of the residue in vacuo. The crude sulfinylchloride, kept under 
argon, was used immediately for the formation of a sulfinamide. 
Tweezer 5. 
To a solution of 1.14 g of hinge 1 (2.5 mmol) in 10 mL DCM, 10 mL ether, saturated with HCl, 
was added. The mixture was stirred for 1 hour and the solvent evaporated. The product was dried 
in vacuo over KOH overnight before it was dissolved in 20 mL DCM and 15 mL DMF. A 
solution of 2.85 mL triethylamine (20.0 mmol) and 7 .5 mmol of sulfinylchloride 4 in 10 mL 
DCM and 3 mL DMF was added and the mixture was stirred overnight. After evaporation to 
dryness, the product was purified by column chromatography (eluent: 10% MeOH in DCM, v/v). 
To a solution of the thus obtained sulfinamide in a mixture of 4 mL DCM, 4 mL CH3CN and 7 
mL water, at 0° C, 600 mg NaI04 (2.8 mmol) and a catalytic amount of RuCl3H 20 were added. 
The mixture was stirred for 60 minutes at room temperature after which the aqueous layer was 
extracted five times with DCM and the combined organic layers were dried on MgS04 and 
evaporated. The product was purified by column chromatography ( eluent: EtOAc/hexanes 2: 1, 
v/v) affording 525 mg of tweezer 5 (33% overall). 
1H-NMR (CDC13): o 1.41 (s, 18H, C(CH3) 3), 3.49 (q, 4H, £H2NHS02), 3.58 (m, 4H, CH2NHC(O)), 
3.89 (s, 3H, OCH3), 4.08 (t, 4H, ArOCH2), 5.36, 5.59 (two bs, 4H, NH), 6.66 (t, lH, ArH), 7.12 (d, 
2H, ArH). 
13C-NMR (CDC13): o 28 .2 (C(fH3) 3), 35.6 (£H2NHC(O), 42.4 (CH2NHS02), 52.3 (OCH3), 52.4 
(CH2S02), 67.5 (ArOCH2), 80.0 (f(CH3) 3), 106.9, 108.3, 132.2, 156.0 (CA'), 159.2 (NHC(O)), 
166.5 (ArC(O)O). 
Tweezer 6. 
To a solution of 126 mg of hinge 3 (0.17 mmol) in 2 mL DCM, 2 mL ether, saturated with HCl, 
was added. The mixture was stirred for 4 hours and the solvent evaporated. The product was dried 
in vacuo over KOH overnight before it was dissolved in 4 mL DCM. A solution of 72 µL 
triethylamine (0.52 mmol) and 0.51 mmol sulfinylchloride 4 dissolved in 4 mL DCM was added 
and the mixture was stirred overnight. After evaporation of the solvent, the product was purified 
by column chromatography (eluent: 5% MeOH in DCM, v/v). To a solution of the thus obtained 
sulfinamide in a mixture of 1 rnL DCM, 1 rnL CH3CN and 2 rnL water, 110 mg NaI04 (0.51 
mmol) and a catalytic amount of RuCl3·H20 were added at 0° C. After stirring for 90 minutes at 
room temperature, the aqueous layer was extracted five times with DCM and the combined 
organic layers were dried on MgS04 and evaporated. Column chromatography (eluent: 
EtOAc/hexanes 3: 1, v/v) gave 19 mg of tweezer 6 (11 % overall). 
1H-NMR (CDC13): o 1.27 (q, 3H, CH2C!1), 1.42 (s, 18H, C(CH3) 3), 3.48 (q, 4H, fH2CH2NHS02), 
3.59 (m, 6H, CH2NHC(O), 3.83 (t, 2H, CH2fH2NAr), 4.04 (t, 4H, ArOCH2), 4.53 (t, 2H, 
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CH20C(O)), 5.24, 5.30 (two bs, 4H, NH), 6.67 (t, lH, ArH), 6.89 (d, 2H, ArH), 7.12 (d, 2H, ArH), 
7.92 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.34 (d, 2H, ArH). 
13C-NMR (CDC13): 6 12.3 (£H3CH2), 28.4 (C(£H3) 3), 35.7 (£H2NHC(O)), 42.5 (CH2NHS02), 45 .5 
(£H2CH3), 48.6 (CH2NAr), 52.7 (CH2S02), 62.3 (£H20C(O)), 67 .6 (ArOCH2), 80.1 ( (£(CH3) 3), 
107.4, 108.4, 111.7, 122.7, 124.8, 126.4, 131.9, 143.9, 147.6, 151.5, 156.0, 156.7 (C~, 159.3 
(NHC(O)O), 165.9 (ArC(O)O). 
Sulfinylchloride 7. 
443 mg (S)-2-Bocamino-3-phenylpropyl thioacetate4 (1.0 mmol) was dissolved in 3 mL DCM 
and placed under an argon cushion. After cooling to -20° C, 94 µL Acp (1.0 mmol) and 162 µL 
sulfuryl chloride (2.0 mmol) were added. The solution was stirred for 1 hour at -5° C before the 
solvent was evaporated, followed by drying of the residue in vacuo. The crude sulfinylchloride, 
kept under argon, was used immediately for the formation of a sulfinamide. 
Tweezer 8. 
To a solution of 213 mg of tweezer 5 (0.33 mmol) in 7 mL DCM, 7 mL ether, saturated with HCl, 
was added. The mixture was stirred for 1 hour and the solvent evaporated. The product was dried 
in vacuo over KOH overnight before it was dissolved in 2 mL DMF. A solution of 0.23 mL 
triethylamine (0.99 mmol) and 0.99 mmol of sulfinylchloride 7 in 3 mL DCM was added and the 
mixture was stirred overnight. Evaporation of the solvent and column chromatography (eluent: 
5% MeOH in DCM, v/v) afforded the intermediate sulfinamide. To a solution of this sulfinamide 
in a mixture of 2 mL DCM, 2 mL CH3CN and 3 mL water, 145 mg NaI04 (0.67 mmol) and a 
catalytic amount of RuCI3H 20 were added at 0° C. The solution was stirred for 30 minutes at 
room temperature before the aqueous layer was extracted three times with DCM. The combined 
organic layers were dried on MgS04 and evaporated. The residue was purified by flash 
chromatography (eluent: 3-4% MeOH in DCM, v/v) affording 213 mg of tweezer 8 (63% 
overall). 
1H-NMR (CDCI/CDPD): 6 1.38 (s, 18H, C(CH3) 3), 2.95 (bs, 4H, S02£H2CHi), 3.20 (m, 4H, 
CH2Ph), 3.30 (m, 4H, S02C!bCH), 3.50 (m, 8H, C_!1NHS02), 3.90 (s, 3H, OCH3), 4.15 (t, 4H, 
ArOCH2), 4.25 (bs, 2H, C!!CH2), 5.00 (bs, 2H, NHC(O)), 5.70, 5.85 (two bs, 4H, NHS02) , 6.82 (s, 
lH, ArH), 7.10-7.40 (m, 12H, ArH). 
13C-NMR (CDC13): 6 28.0 (C(£H3) 3), 37.7 (S02CH2£H2), 40.3 (CH2Ph), 42.l (CH2NHS02), 48.7 
(£HCH2), 52.2 (OCH3), 52.5 (S02£H2CH2), 54.5 (S02£H2CH), 67 .3 (ArOCH2), 77 .2 (£(CH3\), 
107.0, 108.2, 126.7, 128.5, 129.2, 132.0, 136.7, 156.0 (CA'), 159.3 (NHC(O)O), 162.9 
(ArC(O)O). 
Carboxylic acid 9. 
Carboxylic acid 9 was prepared from 71 mg methyl ester 1 (69 µmol) according to the procedure 
described for 2, affording 70 mg of product (99%). Rr 0.10 (eluent: 10% MeOH in DCM, v/v). 
The crude carboxylic acid was used immediately for the formation of tweezer 10. 
Tweezer 10. 
From 6: Tweezer 10 was prepared from 177 mg of tweezer 6 (186 µmol) according to the 
procedure described for 6, affording 17 mg of product 10 (7% overall). The sulfinamide was 
purified by column chromatography (eluent: 7% MeOH in DCM, v/v) and tweezer 10 by 
subsequent column chromatography (eluent: EtOAc/hexanes 2:1, v/v), gel permeation 
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chromatography (LH-20, MeOH/DCM 1:1, v/v) and column chromatography (eluent: 5% MeOH 
in DCM, v/v). 
From 9: To a solution of 70 mg of carboxylic acid 9 (68 µmol) were added 16 mg DCC (78 
µmol), 26 mg Disperse Red 1 (83 µmol) and a catalytic amount of DMAP. After stirring for three 
days the solvent was evaporated and flash chromatography (eluent: 3% MeOH in DCM, v/v) 
afforded 47 of tweezer 10 (52%). Rr 0.22 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDC13): o 1.26 (t, 3H, CH2C!b), 1.38 (s, 18H, C(CH3) 3), 2.94 (bs, 4H, S02fH2CH2), 3.19 
(m, 4H, CH2Ph), 3.30 (m, 4H, S02C!:!zCH), 3.49 (m, 8H, C!:!zNHS02), 3.58 (q, 2H, C!:!zCH3), 3.82 
(t, 2H, CH2C!LNAr), 4.05 (t, 4H, ArOCH2), 4.25 (bs, 2H, C!!CH2), 4.52 (t, 2H, £H20C(O)), 4.98 
(bs, 2H, NHC(O)), 5.61, 5.85 (two bs, NHS02), 6.82 (lH, t, ArH), 6.89 (d, 2H, ArH), 7.12 (d, 2H, 
ArH), 7.18-7.34 (m, lOH, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH). 8.34 (d, 2H, ArH). 
13C-NMR (CDCl/CDi0D): o 12.3 (CH2£H3), 28.3 (C(£H3) 3), 38.0 (S02CHz£H2), 40.3 (CH2Ph), 
42.3 (CH2NHS02), 45.5 (fH2CH3), 48.4 (fHCH2), 48.6 ((CH2fH2NAr), 52.5 (S02£H2CH2), 62.2 
(£H20C(O)), 67.3 (ArOCH2), 80.4 (9CH3) 3), 108.4, 111.6, 122.7, 124.7, 126.3, 127.0, 128.8, 
129.3, 131.7, 136.6, 143.8, 147.5, 151.4, 155.9, 156.7 (CAr), 159.3 (NHC(Q)Q), 166.0 
(ArC(O)O). 
FAB-MS m/z (M+W) 1345.3. 
Tweezer 11. 
To a solution of 909 mg 1 (2.0 mmol) in 8 mL DCM, 8 mL ether, saturated with HCl, was added. 
The mixture was stirred for 1 hour and the solvent evaporated. The product was dried in vacuo 
over KOH overnight before it was dissolved in 15 mL DCM and 20 mL DMF. A solution of 1.39 
mL triethylamine (10.0 mmol) and 6 mmol of sulfinylchloride 7 in 10 mL DCM was added and 
the mixture was stirred overnight. After evaporation, the product was purified by column 
chromatography (eluent: 3% MeOH in DCM, v/v). To a solution of the thus obtained sulfinamide 
in a mixture of 4 mL DCM, 4 mL CH3CN and 6 mL water, 543 mg NaI04 (2.54 mmol) and a 
catalytic amount of RuCl3 H20 were added at 0° C. The solution was stirred for 60 minutes at 
room temperature followed by extraction of the aqueous layer with DCM (five times). The 
combined organic layers were dried on MgS04 and evaporated. Column chromatography (eluent: 
EtOAc/hexanes 1:1, v/v) gave 470 mg of product (21 % overall). 
1H-NMR (CDC13): 1.40 (18H, s, (C(CH3) 3), 2.90 (4H, m, CH2Ph), 3.20 (4H, m, CH2S02), 3.45 (4H, 
q, C!!zNHS02), 3.88 (3H, s, OCH3), 4.05 (4H, m, ArOCH2), 4.30 (2H, broad m, C!!NHCO), 5.00 
(2H, broad d, NHCO), 5.70 (2H, bs, NHS02), 6.65 (lH, t, ArH), 7.15 (2H, d, ArH), 7.18-7.35 
(lOH, m, ArH). 
13C-NMR (CDC13): o 28.3 (C(fH3) 3), 40.4 (CH2Ph), 42.4 (CH2NHS02), 48.5 (fHNHCO), 52.2 
(CH30), 55.2 (CH2S02), 67.5 (ArOCH2), 80.2 (9CH3) 3), 106.7, 108.4, 127.0, 128.7, 129.2, 132.2, 
136.5, 155.7, (CAr), 159.2 (NHCOO), o 166.4 (OCOAr). 
219 mg of the thus obtained tweezer (186 µmol) was used to prepare tweezer 11 according to the 
procedure described for 6, affording 146 mg of product (62% overall). The sulfinamide was 
purified by flash chromatography (eluent: going from 3% to 5% MeOH in DCM, v/v) and 
tweezer 11 was obtained by flash chromatography (eluent: 2.5% MeOH in DCM, v/v). 
1H-NMR (CDC13): 1.38 (18H, s, C(CH3) 3), 2.50-2.95 (broad m, 8H, CH2C!!NHC(O)), 3.00 (broad 
d, 8H, CH2Ph), 3.30 (broad m, 4H, CH2NHS02C!!z), 3.45 (bs, 4H, C!!zNHS02), 3.90 (s, 3H, OCH3), 
4.05 (bs, 4H, ArOCH2), 4.15 (bs, 2H, C!!NHS02), 4.25 (bs, 2H, C!!NHC(O)), 4.65-5.20 (broad m, 
2H, NHC(O)), 5.45-6.15 (broad m, 4H, NHS02), 6.88 (t, lH, ArH), 7.15 (d, 2H, ArH), 7.18-7.35 
(m, 20H, ArH). 
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13C-NMR (CDC13): 28.2 (C(£H3) 3), 29.5, 41.6 (CH2Ph), 42.2 (CH2NHS02), 39.9, 47.9 (CH2£HN), 
52.1 (OCH3), 56.1, 56.2 (S02£H2CH), 67.1 (ArOCH2), 79.9 (£(CH3) 3), 107.2, 108.4, 126.7, 127.1, 
128.4, 128.7, 129.3, 129.5, 132.1, 136.5, 155.4 (CA'), 159.1 (NHC(O)O), 166.3 (ArC(O)O). 
Carboxylic acid 12. 
Carboxylic acid 12 was prepared from 144 mg methyl ester 11 (91 µmol) according to the 
procedure described for 2, affording 141 mg of product (99%). The crude carboxylic acid was 
used immediately for the formation of tweezer 13. 
Compound 13.(DRArPhePhe) 
To a solution of 91 mg of carboxylic acid 12 (0.057 mmol) in 1 mL DCM, 120 µL 0.5 MDCC 
in DCM (0.060 mmol), 1 mg DMAP and 19 mg Disperse Red 1 (0.060 mmol) were added 
consecutively. After stirring overnight the mixture was filtrated and the filtrate washed with DCM. 
The combined organic layers were evaporated and the residue was purified by column 
chromatography (eluent: 2.5% MeOH in DCM, v/v) and gel permeation chromatography (LH-20, 
eluent: MeOH/DCM 1:1 , v/v) affording 60 mg of tweezer 13 (56%). 
1H-NMR (CDC13): 1.26 (CH2C!L), 1.38 (18H, s, C(CH3) 3), 2.45-2.95 (broad m, 8H, 
C~CHNHC(O)), 3.00 (broad d, 8H, CH2Ph), 3.30 (bs, 4H, CH2NHS02C~), 3.40 (bs, 4H, 
C~NHS02), 3.58 (q, 2H, £H2CH3) , 3.82 (t, 2H, CH2C~NAr), 3.98 (bs, 4H, ArOCH2), 4.15 (bs, 
2H, C!fNHS02), 4.25 (bs, 2H, C!:!NHC(O)), 4.52 (t, 2H, CH20C(O)), 4.80 (bs, 2H, NHC(O)), 5 .40-
6.15 (broad m, 4H, NHS02), 6.88 (t, 1H, ArH), 6.95 (d, 2H, ArH), 7.12 (d, 2H, ArH), 7.18-7.34 
(m, 20H, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.34 (d, 2H, ArH) . 
13C-NMR (CDC13) : 12.3 (CH2fH3) , 28.3 (C(fH3) 3), 40.0, 41.7 (CH2Ph), 42.3 (CH2NHS02), 45.5 
(£H2CH3), 48 .6 (CH2NAr), 47.9, 52.2 (CH2£HN), 56.3 (S02£H2CH), 62.1 (CH20C(O)), 67.3 
(ArOCH2), 80.1 (£(CH3) 3), 107.7, 108.6, 111.5, 122.7, 124.7, 126.3, 126.8, 127.3, 128.6, 128.9, 
129.4, 129.6, 131.7, 136.6, 143.8, 147.5, 151.3, 155.6, 156.7 (CA'), 159.3 (NHC(O)O), 165.9 
(ArC(O)O). 
Tripeptides on TentaGel NH2 resin. 
The amino acids were coupled on 1.0 g resin (0.30 mmol/g) by treatment with 0.90 mmol of the 
appropriate Fmoc-protected amino acid, 0.90 mmol BOP and 1.80 mmol DIPEA for two hours 
and after washing of the resin, repeating this step. Fmoc groups were removed by treatment with 
DMF/piperidine (1: 1, v/v) for 5 and 15 minutes subsequently. The resin was washed after a 
coupling with DMF (5*5 minutes), isopropanol (3*5 minutes) and DCM (5*5 minutes). The 
resin was washed after deprotection with DMF (3*5 minutes), dioxane/water (2:1, v/v, 2 *5 
minutes), DMF (3*5 minutes) and DCM (4*5 minutes). After the final Fmoc removal, side chain 
deprotection was performed by treatment with a solution of TFA/DCM (1 :2, v/v) and 1 mg/mL 
indole as a scavenger for 5 and 55 minutes subsequently. Finally, the resin was washed with DCM 
(5*5 minutes), triethylamine/DCM (1:9, v/v, 3*5 minutes), DCM (5*5 minutes) and dried in 
vacuo overnight. The thus obtained tripeptides were used immediately for the determination of 
their association constants for a tweezer. 
Determination of the binding constant of receptor 10 with H-(D)-Ala-Asp-(D)-Ser-NH-TentaGel. 
After determination of the molar absorbance (E = 2.77·104 cm-1M- 1) of 10 as well as the loading 
of the tripeptide resin (H-(D)-Ala-Asp-(D)-Ser-N(H)-TentaGel: 220 µmol/g), six chloroform 
solutions of different concentrations of 10 were prepared in small glass vials (24, 26, 33, 38, 46, 
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54 µM). To 1 mL of each solution 35.0 mg of tripeptide resin was added and the solutions were 
equilibrated for 24hours. As a negative control TentaGel-OH was used. From equations 
K. = [HG]eq I [H]eq [Gleq (1), 
[G]eq = [G]0 - [HG]eq (2) and 
[HG]eq = [H]o - [H]eq (3) 
it was derived that 
1/([H]o - [Hle) = 1/([H]eq K[G]o) + 1/[G]o ( 4) 
in which [H]eq is the equilibrium concentration of receptor 10, [H]0 is the initial concentration of 
10 and [G] 0 is the loading of the resin per volume. [H] 0 and [G] 0 have to be corrected for the 
volume decrease when TentaGel is added as was gauged using unloaded Tentagel-OH. 
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The sequences found by decoding the beads where: 
(D)Glu-(D)Phe-(D)Asn (lx); (D)Pro-(L)Asp-(L)His (3x); 
(D)Val-(L)Asp-(L)Asp (lx); (D)Ala-(L)Asp-(D)Asn (4x); 
(D)Ala-(L)Asp-(D)Ser (4x); (D)Ala-(L)Asp-(D)Thr (lx); 
(D)Val-(D)Asp-(D)Asp (lx); 
(D)Ala-(L)Asp-(D)His (2x); 
Gly-(D)His-(D)Asp (l x); 
Gly-(L)Asp-(L)Asp (lx); 
(L)Glu-(D)His-(D)Glu (lx); 
(L)Glu-(L)Asn-(L)Asn (lx); 
(L)Ala-(D)Asp-(L)Asp (2x); 
(L)Pro-(L)Glu-(L)Pro (lx). 
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Gly-(L)Asn-(L)Asp (lx); (L)Glu-(D)Asn-(L)Val (2x); 
(L)Glu-(D)His-(L)Asn (lx); (L)Glu-(D)His-(L)Val (lx); 
(L)Glu-(L)Asn-(L)Leu (lx); (L)Ala-(D)Asp-(L)Asn (2x); 
(L)Ala-(D)Asp-(L)Val (lx); (L)Ala-(D)Asp-(L)Ser (lx); 
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Trans. 2, 1995, 2213. 
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CHAPTER 7 
Tweezers with different bite: Increasing the affinity 
of synthetic receptors by varying the hinge part 
Introduction 
Despite the tremendous progress in the design and synthesis of receptor molecules with 
predicted binding properties, it remains a difficult task to design a molecule, capable of binding 
to a particular ligand. Therefore, recent efforts have turned to a more "biomimetic approach" 
using combinatorial chemistry for the generation of libraries of synthetic receptors capable of 
binding certain desired ligands. The approach is inspired by Nature's very own combinatorial 
approach so clearly demonstrated by the immune system. In the immune system, instead of 
designing and (bio )synthesizing a receptor molecule, which can bind to the protein of e.g. a 
virus, a very large number of potential binder molecules i.e. antibodies is already present from 
the very start. From this "library" of antibodies the best are selected by the protein, the 
antigen, for production in sufficient quantities in order to protect us against pathogens. 
Based on the successfoi concept of "tweezer-like", two armed synthetic receptors1, we have 
developed synthetic receptors consisting of peptidosulfonamide peptidomimetics2, We would 
like to prepare libraries of tweezer-like receptors, which can be screened for binding affinity to 
a variety of ligands, peptides, other biomolecules e.g. which are present on pathogenic 
organisms, drugs and signaling molecules. Although the synthetic receptor described in chapter 
6 showed a remarkable binding selectivity2, the binding affinity with ligands, in view of 
possible applications, had to be increased. In view of this, in this chapter the incorporation and 
results of using less flexible "hinges" in tweezer-like synthetic receptors has been described. 
Our present "tweezer-like" synthetic receptors consist of three different parts (figure 1): a hinge 
to which the tweezer arms are attached; a dye or a solid phase bead attached to this hinge and 
two binding arms, which so far consist of peptidosulfonamide peptidomimetics. 
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Figure 1. Structures of tweezer-like synthetic receptor. R = Disperse Red 1; the hinge parts are 
shown in the frames; AAJ.3: reference 12. 
The easy availability as well as a considerable diversity of the building blocks of which the 
tweezers are composed is essential for combinatorial strategies. Therefore approaches where 
one takes advantage of the "natural diversity" of e.g. amino acids and compounds which can be 
easily derived thereof are particularly attractive. The arms of our tweezer molecules possess in 
principle such a natural diversity. In order to increase the diversity of the hinge molecules with 
the aim to increase the binding affinity we looked for relatively easy accessible hinge molecules 
having two amino functions and a third functionality to which the dye part could be attached or 
could serve as a handle for attachment to a solid phase resin bead. 
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Based on the original hinge in tweezer 1 (chapter 6), hinges in tweezers 2 and 3 were selected 
to gradually decrease the flexibility. Since the decrease of flexibility is accompanied by a 
decrease in the distance between the nitrogens going from 1 to 3 and as a consequence 
between the tweezer arms, it was desired to include a rigid hinge with a relatively large distance 
between the amino nitrogens. For this purpose the carbazole hinge present in synthetic receptor 
4 was selected. The pyrrolidine hinge in compound 5 was chosen as an interesting hinge 
candidate in view of its chirality and its successful application in the synthetic receptors of Still 
et al.3 Finally, hinge compound 6 was selected as an extremely rigid hinge having a structure 
which seems to mimic the structure of a tweezer very closely. Since, the goal was to evaluate if 
the affinity of the synthetic receptor would increase upon introduction of these hinges, the same 
peptidosulfonamide arms were employed as were used in the earlier described receptor 12 . For 
the construction of these arms a new strategy was followed. Sulfonylchlorides, instead of 
sulfinylchlorides (cf. chapter 6), were used as building blocks, leading to improved yields of 
synthetic receptors based on peptidosulfonamides. 
Results and discussion 
The route for the preparation of the various synthetic receptor molecules proceeded by first 
synthesizing the required hinge, containing two Boe protected amines and a carboxylic acid 
functionality. This was followed by either attachment of the dye followed by the introduction 
of the sulfonamide arms or the reverse, i.e., coupling of the sulfonamide moieties and 
subsequent attachment of the dye. As was found earlier (see previous chapter) that introduction 
of the arms using sulfinylchlorides was difficult, due to problems with the oxidation of the 
intermediate sulfinamides, it was decided to employ the corresponding sulfonylchlorides 
instead. Using these sulfonylchlorides avoids the problematic oxidation step altogether. The 
necessary sulfonylchlorides 7 and 8 are easily synthesized according to de Bont et al.4 
0 0 ,, ,, 
B0cHN~8 'c1 
7 
~ 00 
,, ,, 
BocHN 8 'c1 
8 
Figure 2. The sulfonylchloride building blocks used in the synthesis of the receptor molecules. 
In order to find out whether the use of sulfonylchlorides would indeed be advantageous, 
receptor molecule 1 was resynthesized employing sulfonylchlorides. The synthesis was started 
by saponification of methylester 9, which was synthesized according to Mulders et al.5, and 
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Scheme 1. Synthesis of receptor molecule 1 using sulfonylchlorides. 
1 
coupling to Disperse Red 1 affording the colored derivative 11 in 90% yield, as is outlined in 
scheme 1. After removal of the Boe-groups, receptor 12 was obtained in 50% by treatment 
with sulfonylchloride 7 in the presence of NMM. Subsequently, after removing the Boe-
groups again, receptor 1 was obtained in 52% yield, now by treatment with sulfonylchloride 8 
and NMM as a base. This compares favorably with the yields of the sulfinylchloride approach, 
i.e. 11 % and 7% respectively. The absence of the oxidative step allowed for the presence of the 
dye from the start, which also increased the overall yield for tweezer 1, as it has been shown 
that it was difficult to attach the dye last (see chapter 6). 
The bis(aminomethyl) benzoic acid hinge present in receptor 2 was synthesized from 3,5-
dimethyl benzoic acid 136 . The carboxylic acid was converted to methyl ester 14, by treatment 
with thionylchloride in MeOH. The benzylic positions of 14 were then brominated using N-
bromosuccinimide and AIBN under irradiation with visible light and reflux. We took advantage 
from the fact that always some mono bromination of 14 occurred by using the thus formed 
mono brominated product 16 for preparation of the so-called amputated tweezer containing 
only one arm i.e. 2a (vide infra). The di- and monobrominated products 15 and 16 were 
obtained in a yield of 28% and 25% respectively. The amino groups were introduced in a 
reaction of 15 with sodium diformylamide followed by treatment with HCl to afford HCl salt 
17 in 65%. Of course diamine 17 could have been used immediately in a reaction with a 
sulfonylchloride. However, first the Boe-protected derivative 18 was prepared using Bocp, 
because also a synthon was needed for attachment to a solid phase. After removal of the Boe-
protective groups in 18, the peptidosulfonamide arms were introduced by the sulfonylchloride 
approach, as was described for receptor 1, to give first tweezer 19 (51 % ) and then tweezer 2 0 
in a 40% yield. Saponification of the methyl ester followed by coupling to Disperse Red 1 
(DispRed) completed the synthesis of the intensely blood red colored synthetic receptor 2. 
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Scheme 2. Synthesis of the bis( aminomethyl) benzaic acid hinge containing tweezer 2. 
For synthesis of amputated receptor 2a monobromo compound 16 was transformed into Boe-
protected amine 23 in an analogous manner to that described for the corresponding dibromo 
compound 15. At this stage, however, the dye was attached to the hinge before the 
sulfonamide moieties were introduced. Saponification of methylester 23 and coupling to 
Disperse Red 1 gave colored compound 25. Removal of the Boe group and coupling with 
sulfonylchloride 7 afforded compound 26 in 28% yield, which was followed by another 
removal of the Boe group and coupling with sulfonylchloride 8 to give 'one-armed tweezer' 2a 
in 13%. The low yields were due to the poor solubility of these sulfonamides, which hampered 
their purification. 
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Scheme 3. Synthesis of amputated tweezer 2a. 
The synthesis of the very rigid tweezer 3, started with the methylester of 3,5-diaminobenzoic 
acid, as is depicted in scheme 4. The amino groups were protected by treatment with Bocp 
and triethylamine to give 28 in only 22%, due to several byproducts that were formed, which 
hampered purification. Methylester 28 was then hydrolyzed, using Tesser' s base, to afford 
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Scheme 4. Synthesis of the diaminobenzoic acid hinge containing tweezer 3. 
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carboxylic acid 29 quantitatively. It was also attempted to prepare carboxylic acid 29 directly 
from 3,5-diamino benzoic acid in a reaction with Bocp. However, it turned out that 3,5-
diamino benzoic acid was completely imeactive in su,ch a reaction. The synthesis was 
continued by a coupling to Disperse Red 1 to afford colored hinge 30 in 83%. Deprotection of 
the Boe-groups and introduction of the sulfonamide arms employing sulfonylchlorides 7 and 
8, as has been described above, led to tweezers 31 and 3 in a yield of 35% and 27% 
respectively. The low yields were, again, due to a poor solubility of the products. 
For the synthesis of the carbazole containing tweezer 4, dinitrocarbazole derivative 35 was 
synthesized according to Pieters et al.7 Coupling of methyl 3-bromobenzoate and carbazole in a 
Goldberg-like reaction gave derivative 34, which was then nitrated to afford dinitrocarbazole 
35. This carbazole derivative 35 was reduced to the corresponding diamine protected with Boe 
groups 36 in 70%, by catalytic hydrogenation in the presence of BoczO and triethylamine. The 
methylester of carbazole derivative 36 was saponified and the thus obtained carboxylic acid 37 
MeOb-O 
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32 33 
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Scheme 5. Synthesis of the carbazole-derived hinge containing tweezer 4. 
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coupled with Disperse Red 1 to afford colored hinge 38 in 72%. Finally, tweezer 4 was 
prepared by repetitive removal of the Boe groups and coupling with sulfonylchlorides 7 and 8 . 
Receptor molecules 39 and 4 were obtained in 75% and 48% yield respectively. 
The pyrrolidine hinge in tweezer 5 was prepared starting form L-tartaric acid. The pyrrolidine 
·diol 42 was prepared according to Nagel et al. 8 by subsequent ring closure with benzylarnine 
and reduction by NaBH4 in the presence of BF3·Etp. After conversion of the diol to diazide 
439 in 95%, reduction and protection of the resulting amino groups afforded protected diamine 
44 in 73% yield. After hydrogenolysis of the benzyl group on the secondary amine of 44 to 
give free amine 45, the stage was set for introduction of the dye attached to a spacer3a. 
Reaction of amine 45 with succinic acid derivative 46 yielded colored hinge 4 7. 
Subsequently, the Boe-protecting groups in 47 were removed and introduction of the 
peptidosulfonamide arms by the sulfonylchloride approach completed the synthesis of synthetic 
receptor 5. 
HOO::c,OH BnNH2 
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Scheme 6. Synthesis of the pyrrolidine-derived hinge containing tweezer 5. 
The synthesis of pre-organized tweezer hinge present in receptor 6 commenced with a Mannich 
reaction of 1,3-diphenylacetone, benzylarnine and paraformaldehyde according to Diederich et 
al. 10 to afford diazabicyclononane 50 in 59%, as is shown in scheme 7. It was decided to 
reduce the keto function to an alcohol, as a handle to eventually attach the dye to. Therefore 
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~o'·. N 
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Scheme 7. Synthesis of the diazabicyclononane-derived hinge containing tweezer 6. 
ketone 50 was transformed to alcohol 51 in 90% yield, using LiAH4• Subsequently, the two 
benzyl groups were replaced for two Boe groups by consecutive hydrogenolysis and treatment 
with Bocp and NaOH to obtain alcohol 52. This Boe protected derivative 52 was much easier 
to handle than dibenzylamine 51, due to absence of the basic nitrogens present in 51, part of 
an urethane in 52. Surprisingly, it was also possible to obtain alcohol 51 directly by 
hydrogenolysis of ketone 50 followed by a reaction with Bocp (scheme 8). Because always 
some ketone 52b was formed as a byproduct in this reaction, which was had to be separated 
from alcohol 52, the two step procedure depicted in scheme 7 was preferred. 
0 '-- N,Bn _1)_P_d(_OH_)_21_c_1H_2 __ 
N, Bn 2) BoczO/NaOH 
0 ;,Boe+ 
'Boe 
/} 
50 
/} 
52 
8 
Scheme 8. Dual hydrogenolysis and reduction of ketone 50. 
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To attach the hinge to a dye (or resin) it was desired to introduce a carboxylic acid group in the 
molecule. However, it was very difficult to functionalize the hindered secondary hydroxy 
function in the diazabicyclononane part of alcohol 52 with a suitable anchor molecule to which 
the dye had to be attached. Many reagents and reaction condition have been tried, e.g., glutaric 
anhydride with DMAP as a catalyst, ethyl bromoacetate in the presence of NaH, bromoacetic 
acid with KOtBu or benzoyl chloride (as a model compound) in the presence of triethylamine11 . 
Ultimately, the use of p-bromomethyl benzoic acid methyl ester in the presence of potassium 
hydride and 18-crown-6 turned out to be a satisfactory approach and gave the desired 
benzylether 53 in 56% yield. Benzylether 53 was also stable to treatment with TFA/DCM (1:1, 
v/v), used to remove the Boe groups. The ester in hinge 53 was saponified and the resulting 
carboxylic acid 54 was coupled to Disperse Red 1 to give colored hinge 55 in 79%. Removal 
of the Boe groups and reaction with the appropriate sulfonylchlorides 7 and 8 afforded 
subsequently tweezers 56 (63%) and 6 (32%). 
The thus obtained receptors 1-6 were screened for binding against a 24,389 ( =293) member 
encoded sidechain-deprotected tripeptide library on TentaGel® i.e. AA3-M-AA1-N(H)-
TentaGel 12• To this end the bead-supported tripeptide library was equilibrated in a chloroform 
solution of the receptor, as has been described in chapter 6. It was attempted to reach a 
concentration of the receptor slightly lower than that was required for binding of approximately 
1 % of the library beads (see fig. 8, page 95). These concentrations are listed in Table 1. 
Immediately it can be seen that receptors 2, 3 and 4 showed an increased binding affinity, 
since the concentration for binding of these receptors to the beads was lower than the 
concentration for binding of the original receptor. Binding by the pyrrolidine receptor 5 is 
comparable to that of the original receptor 1 and clearly two tweezer arms are needed for a 
significant binding, since the "amputated" receptor 2a, having one arm, does not give rise to an 
appreciable binding even at a concentration of 425 µM. At first glance the absence of any 
binding whatsoever by receptor 6 was surprising. However we reasoned that repulsion 
between the oxygen lone pairs of the sulfonamide moieties attached to the diazabicyclononane 
system might disfavor the chair-chair shape and as a consequence favor the formation of a 
boat-chair conformation leading to opening of the tweezer-like structure 13. Further, the absence 
of binding might be influenced by the fact that receptor 6 lacks two hydrogen bond donors in 
comparison with receptors 1-5. 
After 72 h equilibration, the colored beads were separated and decoded by photolytic release of 
the molecular tags, followed by EC-GC (electron capture gas chromatographic) analysis 14 • The 
number of beads which were decoded for each synthetic receptor are shown in Table 1. This 
table also shows the consensus sequences bound by each receptor, the frequencies with which 
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they were found among the decoded beads and frequency of their occurrence in the bead-
supported tripeptide library. 
Practically all consensus sequences of all tweezers show the presence of an acidic amino acid 
residue mostly occurring at position AA3• ~ is almost invariably a polar amino acid residue 
e.g. Asn and very often His. Like the earlier described synthetic receptor 1, both the diamino 
receptor 3 and the pyrrolidine receptor 5 show some degree of stereoselectivity since (L)Glu-
(D)His or (D)Glu-(L)His are found, but not the corresponding diastereomeric 
sequences(L)Glu-(L)His or (D)Glu-(D)His. This stereo selectivity is also shown, albeit less 
clear, by the other two receptors i.e. 2 and 4 capable of recognizing the Glu-His sequence. As 
was the case with the original receptor 1, most variability is found in the amino acid residue 
receptor 
r 
2· 
4 
s · 
6 
equilibrium 
cone. 
(µM) 
70 
40 
425 
20 
40 
80 
500 
decoded 
beads 
number 
34 
28 
3 
33 
16 
19 
none 
consensus sequence 
AA3-AA2-AA1 
(L/D)Ala-(D/L)Asp-(L/D)Xxxct 
(L)Glu-(D)His/ Asn-Xxxd 
Glu-Xxx-Xxxc 
(L/D)Glu-(D/L)His-Xxxct 
(L/D)Glu-Xxx-(L/D)Valct 
Gly-Asn/His-Asp/Glu 
Glu/Asp-Xxx-Xxx 
Glu-Xxx-Xxx 
Xxx-His-Xxx 
Xxx-Xxx-Asp 
(L/D)Glu-(D/L)His-Xxxct 
Glu-Xxx-Xxx 
Xxx-His-Xxx 
(L/D)Glu-(D/L)His-Xxxct 
(L/D)Glu-(D/L )His-Xxxct 
(L/D)Glu-(D/L)His-Phect 
none 
found 
frequency 
(%)" 
50 
20 
61 
32 
21 
21 
100 
64 
70 
27 
61 
63 
56 
38 
95 
26 
library 
member 
frequency 
(%)b 
0.1 
0.3 
6.9 
0.2 
0.2 
0.07 
14 
6.9 
6.9 
6.9 
0.2 
6.9 
6.9 
0.2 
0.2 
0.02 
Table 1. Binding selectivity of receptors 1-6 for tripeptides in a 24,389 (=293 ) member encoded 
sidechain-deprotected tripeptide library on TentaGel® i.e. AA3-AA2-AA1-N(H)-
TentaGel12. a) only consensus sequences found in 2 20% of the beads are listed here; b) 
frequency with which these are actually present in the tripeptide library; c) no prefix L 
or D indicates no preference for either enantiomer by the synthetic receptor; d) the 
prefixes L and D placed in this manner indicate that e.g. (L)Glu-(D)His-Xxx and 
(D)Glu-(L)His-Xxx are found, but not (L)Glu-(L)His-Xxx or (D)Glu-(D)His-Xxx. e) see 
figure 8, page 95. 
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AA1 that is nearest to the polymer support. However, in the original receptor 1 this is 
predominantly a polar amino acid residue, in the receptors i.e. 2 and 3 containing the less 
flexible hinges based on the hinge of the original receptor as well as in the carbazole receptor 4 
the distribution of polar vs. nonpolar amino acids in AA1 is about equal, whereas in the 
pyrrolidine based receptor 5 there is a shift to an apolar amino acid for AA1• 
Although the trends are clear and we seem to be on our way towards realizing our main aim i.e. 
increase of the binding affinity, binding of the peptide sequences found by decoding the beads 
had to be verified by binding experiments with these peptides obtained by independent 
synthesis and determination of some representative binding constants. Based on the sequences 
found from the decoding experiments we selected the indicated sequences for resynthesis 
(Table 2). 
Receptor Resynthesized peptide 
1 (D)Ala-(L)Asp-(D)Ser 
(L)Glu-(D)Asn-(L) Val 
2 (D)Ala-(L)Asp-(D)Ser 
(L)Glu-(D)Asn-(L) Val 
3 (D)Ala-(L)Asp-(D)Ser 
(L)Glu-(D)Asn-(L)Val 
(L)Glu-(D)His-(L)Val 
Gly-(L)His-(L)Asp 
4 Gly-(L)His-(L)Asp 
5 (D)Ala-(L)Asp-(D)Ser 
(L)Glu-(D)His-(L)Val 
screening 
affinity• 
+ 
+ 
[f] 
+++ 
[e] 
[e] 
++ 
++ 
+ 
[e] 
+++ 
binding K. (M-1)' L\G(kJ mor1) 
affinitl 
++ 320 -14.2 
+ 95 -11.2 
+++ 4100 -20.5 
+++ 1680 -18.3 
++ 760 -16.4 
+ [d] [d] 
+++ 210 -13.2 
+++ [d] [d] 
+ [d] [d] 
++ -40 - -9 
++ 80 -10.8 
Table 2. Binding affinity of receptors 1-5 for peptides, which were synthesized based on the 
sequences found by decoding. aas determined from incubation with the bead-supported 
tripeptide library: +++: red colored beads; ++: dark orange to red colored beads; +: 
dark orange beads; has determined from incubation with the indicated resynthesized 
peptide on the bead; cthe error is ±10%, with the exception of 4100 M-1: ±5% and 210 
and 40 M-1, each ±15%; dnot determined; 'not found; 1not found however the related 
sequence (D )Ala-( L)Asp-( D )Thr was found. 
Several binding constants were determined. Indeed it was found that the binding affinity of the 
sequence that bound with high selectivity to the original receptor 1 i.e. (D)Ala-(L)Asp-(D)Ser 
could be increased more than 10-fold (from 330 to 4100 M-1) in synthetic receptor 2. An 
increasing affinity was also observed with the sequence (L)Glu-(D)Asn-(L)Val that bound with 
low affinity to the original receptor (70 M-1) and now bound to tweezer 2 with a respectable 
affinity, i.e. a Ka of 1690 M- 1. A two-fold increase in binding affinity of (D)Ala-(L)Asp-(D)Ser 
was observed using the more rigid tweezer 3, having less space between the 
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peptidosulfonamide arms, however. This tweezer, like the previous tweezer 2, also improved 
the binding affinity of similar tripeptides e.g. (L)Glu-(D)His-(L)Val, which bound to the 
original tweezer (1). Although coloring of the tripeptide containing beads took place upon 
incubation with a concentration of the carbazole tweezer ( 4), comparable to that of benzyl 
tweezer 2, none of beads were colored dark orange or red. Therefore, the binding affinity as 
compared to the original receptor (1) was considered not be significantly enhanced. 
Apparently, despite the rigid character of the carbazole hinge the distance between the arms is 
too large for a clear increase of the binding affinity. The pyrrolidine hinge seemed a very 
attractive one with respect to rigidity and chirality and the selectivity of binding of the tweezer 
containing this hinge (5) was very high (see fig. 8d, page 95). In 95% of the decoded beads 
the sequence (L/D)Glu-(D/L)His-Xxx was found and moreover (L)Glu-(D)His-Xxx and 
(D)Glu-(L)His-Xxx are found, but not the corresponding diastereomeric sequences i.e. 
(L)Glu-(L)His-Xxx or (D)Glu-(D)His-Xxx (Table 1). However, the binding affinity was a 
little disappointing. Apparently, the tweezer arms point too much away from each other for a 
significant increase of binding to occur. 
Conclusion 
In this chapter the synthesis of several tweezer-like synthetic receptors has been described. 
Using sulfonylchlorides instead of sulfinylchlorides as building blocks for the tweezer arms, 
resulted in improved yields for the preparation of receptor molecule 1 (see chapter 6). Further it 
has been shown that by varying the hinge part of tweezer-like synthetic receptor molecules it is 
possible to significantly increase the binding affinity of tripeptides. Varying the hinge part 
inevitably leads to different distances between the receptor arms, thereby leading to receptors 
with different bite. Interestingly, this does not comprise the selectivity of binding of 
tripeptides. However, receptors with different bite might also be interesting for binding other 
compounds than peptides and even be capable of binding selectively certain compounds from a 
mixture of even more diverse compounds than those present in a tripeptide library. The 
availability of a variety of hinges or scaffolds and "natural diversity" inspired building blocks 
will provide the access to all sorts of required libraries. 
Experimental 
General methods. 
DCM and DMF were dried on molecular sieve (4A). Triethylamine and DIPEA were distilled 
from ninhydrin and KOH. NMM was distilled from CaH2 and THF from LiAIH4 • All other 
chemicals were used as purchased. Tentagel®S NH2 resin (130 µm) was purchased from Rapp 
Polymere, Tiibingen, Germany. Reactions were carried out at ambient temperature unless stated 
otherwise. TLC analysis was performed on Merck pre-coated silicagel 60 F-254 (0.25 mm) 
plates. Spots were visualized with UV light, ninhydrin or Cl2-TDM 15 • Solvents were evaporated 
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under reduced pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 
(40-63 µm) and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 
from Pharmacia was used for gel permeation chromatography. 
1H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 MHz) and chemical 
shift values are given in ppm relative to TMS. 13C-NMR spectra were recorded on a VARIAN 
G300-spectrometer (75.5 MHz) and chemical shift values are given in ppm relative to CDC13 
(77.0 ppm) or DMSO-d6 (39.7 ppm). 13C spectra were recorded using the attached proton test 
(APT) sequence. Fast atom bombardment (FAB) mass spectrometry was carried out using a Jeol 
JMS SXJSX 102A four-sector mass spectrometer, coupled with a HP-9000 data system. 
Boc-taurylchloride 7. 
This compound was prepared as described by de Bont et al.4 1.0 g of the tetrabutylammonium 
salt of Boc-taurine afforded 309 mg of sulfonylchloride 7 (59%). Rf 0.73 (eluent: EtOH/EtOAc 
40:60, v/v). The product was stored under argon and directly used for synthesis of sulfonamides. 
Boc-benzyltaurylchloride 8. 
This compound was prepared as described by de Bont et al.4 1.4 g of the tetrabutylammonium 
salt of Boc-benzyltaurine afforded 572 mg of sulfonylchloride 8 (67%) . The product was stored 
under argon and directly used for synthesis of sulfonamides. 
Methylester 9. 
This compound was prepared as described by Mulders et al. 5 
Carboxylic acid 10. 
A solution of 454 mg methylester 9 (1.0 mmol) in 20 mL 0.25 M LiOH in water/MeOH (1 :3, v/v) 
was stirred overnight. Then the pH was brought below 2 with 1 M KHS04 and the aqueous 
solution was extracted with EtOAc three times. The combined organic layers were dried on 
Na2S04 and evaporated. The product was dried in vacuo over KOH affording 431 mg of 
carboxylic acid 10 (98%). 
1H-NMR (CDC13): 6 1.45 (s, 18H, C(CH3) 3), 3.48 (dt, 4H, CH2NHC(O)), 4.04 (t, 4H, OCHz), 5.04 
(bs, 2H, NH), 6.82 (t, lH, ArH), 7.20 (d, 2H, ArH). 
13C- NMR (CDC13): 6 28.1 (C(fH3) 3), 39.8 (fH2NHC(O)), 67.1 (CH20Ar), 79.1 (f(CH3) 3), 106.1, 
108.1, 132.8, 159.4 (CAr), 155.9 (NHC(O)O), 168.3 (ArC(O)O). 
Dyed compound 11. 
To a solution of 959 mg carboxylic acid 10 (2.18 mmol) in 8 mL DCM and 2 mL DMF, 341 µL 
DIC (2.18 mmol), 62 mg DMAP (0.50 mmol) and 685 mg Disperse Red 1 (2.18 mmol) were 
added consecutively. The mixture was stirred overnight before 50 mL DCM was added. The 
solution was washed with water, brine and dried on MgS04 • Evaporation of the solvent and 
column chromatography (eluent: 1.6% MeOH in DCM, v/v) afforded 1.47 g of colored 11 
(92%) . Rr 0.66 (eluent: 5% MeOH in DCM, v/v). 
'H-NMR (CDC13) : 6 1.27 (q, 3H, CH£H3) , 1.42 (s, 18H, C(CH3) 3), 3.49 (broad m, 4H, 
fH2NHC(O)), 3.57 (t, 2H, NfH2CH3), 3.81 (t, 2H, NfH2CH2), 3.98 (t, 4H, ArOCHz), 4.51 (t, 2H, 
NCH2fHP), 5.01 (bs, 2H, NH), 6.62 (t, lH, ArH), 6.86 (d, 2H, ArH), 7.11 (d, 2H, ArH), 7.90, 
7.92, 8.31 (three d, 6H, ArH). 
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Tweezer 12. 
To a solution of 220 mg colored 11 (0.30 mmol) in 2 mL DCM, 2 mL ether, saturated with HCI, 
was added. The mixture was stirred for 1 hour before the solvent was evaporated. The residue was 
dried in vacuo over KOH overnight. Then the residue was dissolved in 2 mL DCM followed by 
the addition of 218 µL NMM (l.98 mmol) and 335 mg Boe-Tau-Cl 7 (1.38 mmol). The 
mixture was stirred overnight before 30 mL DCM was added. The solution was washed with 1 M 
KHS04, 5% NaHC03 and dried on MgS04 • Evaporation of the solvent and flash chromatography 
(eluent: EtOAc/hexanes 3:1, v/v) gave 142 mg of tweezer 12 (50%). Rr 0.33 (eluent: 
EtOAc/hexanes 3:1, v/v). 
3.59 (m, 6H, CH2NHC(O), 3.83 (t, 2H, CH£H2NAr), 4.04 (t, 4H, ArOCH2), 4.53 (t, 2H, 
CH20C(O)), 5.24, 5.30 (two bs, 4H, NH), 6.67 (t, lH, ArH), 6.89 (d, 2H, ArH), 7.12 (d, 2H, ArH), 
7.92 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.34 (d, 2H, ArH). 
13C-NMR (CDC13): o 12.3 ~H3CH2), 28.4 (C(£H3) 3), 35.7 (£H2NHC(O)), 42.5 (CH2NHS02), 45.5 
(£H2CH3), 48.6 (CH2NAr), 52.7 (CH2S02), 62.3 (£H20C(O)), 67.6 (ArOCH2), 80.1 ((£(CH3) 3), 
107.4, 108.4, 111.7, 122.7, 124.8, 126.4, 131.9, 143.9, 147.6, 151.5, 156.0, 156.7 (CAr), 159.3 
(NHC(O)O), 165.9 (ArC(O)O). 
Tweezer 1. 
To a solution of 275 mg of tweezer 12 (0.29 mmol) in 3 mL DCM, 3 mL ether, saturated with 
HCI, was added. The mixture was stirred for 1 hour before the solvent was evaporated. The 
residue was dried in vacuo over KOH overnight. Then the residue was dissolved in 2 mL DCM 
followed by the addition of 139 µL NMM (1.27 mmol) and 230 mg sulfonylchloride 8 (0.69 
mmol). The mixture was stirred for one hour before 50 mL DCM was added. The solution was 
washed with water, lM KHS04, 5% NaHC03, brine and dried on MgS04• Evaporation of the 
solvent and flash chromatography (eluent: 4% MeOH in DCM, v/v) afforded 179 mg of tweezer 1 
(52%). Rr 0.31 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDC13): o 1.26 (t, 3H, CH2C!!3), 1.38 (s, 18H, C(CH3) 3), 2.94 (bs, 4H, S02£H2CH2), 3.19 
(m, 4H, CH2Ph), 3.30 (m, 4H, S02C!!zCH), 3.49 (m, 8H, C!!2NHS0z), 3.58 (q, 2H, C!!zCH3), 3.82 
(t, 2H, CH2C!!2NAr), 4.05 (t, 4H, ArOCH2), 4.25 (bs, 2H, C!!CH2), 4.52 (t, 2H, £H20C(O)), 4.98 
(bs, 2H, NHC(O)), 5.61, 5.85 (two bs, NHS02), 6.82 (lH, t, ArH), 6.89 (d, 2H, ArH), 7.12 (d, 2H, 
ArH), 7.18-7.34 (m, lOH, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH). 8.34 (d, 2H, ArH). 
13C-NMR (CDCI/CD30D): o 12.3 (CH2£H3), 28.3 (C(£H3) 3), 38.0 (S02CH2£H2), 40.3 (CH2Ph), 
42.3 (CH2NHS02), 45.5 (£H2CH3), 48.4 (£HCH2), 48.6 ((CH2£H2NAr), 52.5 (S02£H2CH2), 62.2 
(£H20C(O)), 67.3 (ArOCHz), 80.4 (£(CH3) 3), 108.4, 111.6, 122.7, 124.7, 126.3, 127.0, 128.8, 
129.3, 131.7, 136.6, 143.8, 147.5, 151.4, 155.9, 156.7 (CAr), 159.3 (NHC(O)O), 166.0 
(ArC(O)O). 
FAB-MS m/z (M+H+) 1345.3. 
Methyl-3,5-dimethylbenzoate 14. 
At -10° C 14 mL thionyl chloride was added to 50 mL MeOH. At that temperature 7.5 g 3,5-
dimethylbenzoic acid (50 mmol) was added and the mixture was stirred overnight at room 
temperature. The solvent was evaporated and the residue dissolved in ether. The solution was 
washed with 5% NaHC03 (twice) and dried on MgS04 • Evaporation of the solvent yielded 8.2 g 
of methylester 14 (98%). Rr 0.89 (eluent: MeOH/DCM 1:9, v/v). 
1H-NMR (CDC13): o 2.36 (s, 6H, ArCH3), 3.90 (s, 3H, OCH3), 7.18 (s, lH, ArH), 7.66 (s, 2H, ArH). 
125 
Chapter 7 
13C-NMR (CDC13): o 21.0 (ArCH3), 51.8 (OCH3), 127.2, 130.0, 134.4, 137.9 (CA'), 167.3 
(ArC(O)O). 
Methyl-3, 5-bis (bromomethyl)benzoate 15 and methyl-3-(bromomethyl)-5-methylbenzoate 16. 
To a solution of 1.2 g methyl-3,5-dimethylbenzoate 14 (7 .3 mmol) in 30 mL methylformiate, 
3.2 g N-bromosuccinimide (18 mmol) and a catalytic amount of AIBN were added. This mixture 
was irradiated for three hours with a 250 W broadband lamp causing the solution to reflux. Then 
the solvent was evaporated and the residue triturated with ether. The oil that was obtained, after 
evaporation of the solvent, was subjected first to column chromatography (eluent: ether/hexanes 
1:16) and second to a 'dry' column (eluent: ether/hexanes 1:4, v/v), yielding 646 mg bis-bromo 
compound 15 (28%) and 432 mg mono-bromo 16 (25%). Rf 0.31, 0.39 (eluent: ether/hexane 
1:4, v/v) respectively. 
15: 1H-NMR (CDC13): o 3.93 (s, 3H, OCH3), 4.50 (s, 4H, CH2Br), 7.62 (t, lH, ArH), 8.00 (d, 2H, 
ArH). 
13C-NMR (CDC13): o 31.8 (CH2Br), 52.3 (OCH2), 130.0, 131.4, 133.8, 138.9 (CA'), 165.9 
(ArC(O)O). 
16: 1H-NMR (CDC13): o 2.40 (s, 3H, ArCH3), 3.92 (s, 3H, OCH3), 4.48 (s, 2H, CH2Br), 7.40 (s, lH, 
ArH), 7.79 (s, lH, ArH), 7.86 (s, lH, ArH). 
Methyl-3,5-bis(methylamino)benzoate·2 HCl 17. 
637 mg dibromide 15 (2.0 mmol) and 470 mg sodium diformylamide (5.0 mmol) were refluxed 
for three hours in 8 mL acetonitrile. After cooling the mixture to room temperature and filtration 
of the solution, the solvent was evaporated to afford an oil. To this oil 10 mL methanol and 1 mL 
37% hydrochloric acid were added after which the mixture was refluxed for 1.5 hours. 
Evaporation of the solvent and crystallization from MeOH/ether gave 346 mg of HCI salt 17 
(65%) which was immediately used for the synthesis of 18. Rf 0.80 (eluent: CHCl/MeOH/25% 
ammonia 60:45:20, v/v). 
Methyl-3,5-bis(N-Boc-methylamino)benzoate 18. 
The pH of a solution of 346 mg of salt 17 (1.3 mmol) in 10 mL dioxane and 2 mL of water was 
adjusted to ·8 by the addition of 4M NaOH. Then a solution of 594 mg Boc20 (2.7 mmol) in 5 
mL dioxane was added and the pH was kept above 8 by addition of IM NaOH. After two hours 
the mixture was concentrated and water was added. The solution was extracted with EtOAc twice. 
The combined organic layers were washed with lM KHS04, brine and dried on Na2S04• 
Evaporation of the solvent and column chromatography (eluent: EtOAc/hexanes 1:2, v/v) yielded 
414 mg of bis-Bocamino 18 (85%). Rf 0.46 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13): o 1.46 (s, 18H, C(CH3) 3)), 3.91 (s, 3H, OCH3), 4.33 (d, 4H, C!!iNH), 4.99 (bs, 
2H, NHC(O)O), 7.39 (s, lH, ArH), 7.84 (s, 2H, ArH). 
13C-NMR (CDC13): o 28.3 (C(~H3) 3)), 44.1 (ArCH2), 52.1 (OCH3), 79.6 (£(CH3) 3)), 127.2, 130.6, 
130.7, 139.9 (CA'), 155.8 (C(O)OtBu), 166.7 (ArC(O)O). 
Tweezer 19. 
To a solution of 162 mg bis-Bocamine 18 (0.41 mmol) in 1 mL DCM, 1 mL ether, saturated with 
HCl, was added. The mixture was stirred for one hour followed by the evaporation of the solvent 
and drying of the residue in vacuo. Then, to a solution of this residue in 3 mL DCM, 200 µL 
NMM (1.8 mmol) and 231 mg Boe-Tau-Cl (0.95 mmol) were added. After stirring the mixture 
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for two hours the solvent was evaporated and the product was purified by flash chromatography 
(eluent: 3% MeOH in DCM, v/v) affording 127 mg of tweezer 19 (0.21 mmol) (51 %). 
1H-NMR (CDC13): cS 1.40 (s, 18H, C(CH3) 3), 3.16 (t, 4H, S02C!!2CH2), 3.51 (q, 4H, S02CH2C!!i), 
3.89 (s, 3H, OCH3), 4.30 (d, 4H, ArC!!2NH), 5.42 (broad t, 2H, NHC(O)O), 6.19 (bs, 2H, NHS02), 
7.67 (s, lH, ArH), 7.88 (d, 2H, ArH). 
13C-NMR (CDC13): cS 28.3 (C(£H3) 3), 35.4 (S02CH2£H2), 46.3 (ArCH2NH), 52.3 (OCH3), 52.5 
(S02fH2CH2), 79.9 (£(CH3) 3), 128.3, 130.8, 131.6, 138.5 (C~, 156.0 (C(O)OtBu), 166.4 
(ArC(O)O). 
Tweezer 20. 
Tweezer 20 was prepared from 127 mg tweezer 19 (0.21 mmol) and 160 mg sulfonylchloride 8 
(0.48 mmol) according to the procedure described for 19. The product was purified by flash 
chromatography (eluent: 2.25% MeOH in DCM) affording 85 mg of tweezer 20 (40%). Rf 0.59 
(eluent: 10% MeOH in DCM, v/v). 
1H-NMR (CDC13): cS 1.36 (s, 18H, C(CH3) 3), 2.95 (m, 4H, CH2Ph), 3.16-3.31 (m, 8H, S02CH2), 
3.44 (m, 4H, S02CH2C!!2), 3.90 (s, 3H, OCH3), 4.25 (m, 2H, C!!CH2), 4.35 (d, 4H, ArC!!2NH), 
5.00 (bs, 2H, NHC(O)O), 5.90 (bs, 4H, NHS02), 7.18-7.34 (m, lOH, ArH), 7.71 (s, lH, ArH), 7 .92 
(d, 2H, ArH). 
Carboxylic acid 21. 
85 mg of methylester 20 (84 µmol) was dissolved in 5 mL Tesser's base (dioxane/MeOH/4M 
NaOH 14:5:1, v/v) and the resulting solution was stirred overnight. Then the solvent was 
evaporated and the residue redissolved in water. The mixture was acidified with lM KHS04 and 
subsequently extracted with EtOAc three times. The combined organic layers were washed with 
brine and dried on Na2S04• Evaporation of the solvent gave 79 mg of carboxylic acid 21 (95%), 
which was directly used for the synthesis of colored tweezer 2. Rr 0.27 (DCM/MeOH/HOAc 
90:10:0.5, v/v). 
Colored tweezer 2. 
To a solution of 28 mg of carboxylic acid 21 (29 µmol) in a mixture of 0.8 mL DCM and 0.1 
mL DMF, 15 µL DIC (96 µmol), 9 mg disperse red 1 (29 µmol) and a catalytic amount of DMAP 
were added. The mixture was stirred overnight after which subsequent evaporation of the solvent, 
flash chromatography (eluent: 2.5% MeOH in DCM, v/v), gel permeation chromatography (LH-
20, eluent: MeOH/DCM 1:1. v/v) and column chromatography (eluent: 2.75% MeOH in DCM) 
afforded 15 mg of tweezer 2 (41 %). Rr 0.41 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (DMS0-d6): cS 1.27 (t, 3H, CH2C!!3) 1.33 (s, 18H, C(CH3) 3), 2.95-3.05 (m, 4H, CH2Ph), 
3.22-3.43 (m, 8H, S02CH2), 3.51 (t, 4H, S02CH2C!!i), 3.70 (q, 2H, C!!2CH3), 3.97 (t, 2H, 
ArNC!!2CH2), 4.25 (m, 2H, C!!CH2), 4.38 (s, 4H, ArC!!2NH), 4.59 (t, 2H, ArNCH2C!!2), 6.16 
(broad d, 2H, NHC(O)O), 6.29 (bs, 2H, N!!S02CH2CH), 6.80 (broad t, 2H, ArCH2N!!), 7.03 (d, 
2H, ArH), 7.19-7.28 (m, lOH, ArH), 7.69 (s, lH, ArH), 7.92 (d, 2H, ArH), 7.98 (d, 2H, ArH), 8.00 
(d, 2H, ArH), 8.37(d, 2H, ArH). 
13C-NMR (DMS0-d6): 8 12.6 (CH2~ 3), 28.6 (C(£H3) 3), 38.7 (S02CH2fH2), 40.8 (CH2Ph), 46.4 
(ArNC!!2CH3), 46.9 (ArCH2NH), 49.5 (ArN£H2CH2), 49.6 (S02CH2£H), 53.3 (S02CH2£H2), 55.8 
(S02£H2CH), 63.2 (ArNCH2£H2), 79.5 (£(CH3) 3), 112.7, 123.5, 125.6, 127.0, 127.3, 128.9, 129.2, 
130.2, 131.6, 132.8, 139.0, 140.3, 144.6, 148.5, 152.8, 157.7 (CA'), 156.4 (C(O)OtBu), 166.5 
(ArC(O)O). 
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FAB-MS m/z 1285.5 (M+W). 
Methyl-3-(methylamino)-5-methylbenzoate"HCI 22. 
292 mg monobromide 16 (1.2 mmol) and 138 mg sodium diformylamide (1.4 mmol) were 
refluxed for three hours in 5 mL acetonitrile. After cooling the mixture to room temperature and 
filtration of the solution the solvent was evaporated to afford an oil. To this oil 10 mL methanol 
and 1 rnL 37% hydrochloric acid were added after which the mixture was refluxed for 1.5 hours. 
Evaporation of the solvent yielded 260 mg amine 22, which was used without further purification 
in the synthesis of 23. 
Methyl-3-(N-Boc-methy lamina )-5-methylbenzoate 23. 
The pH of a solution of 260 mg of salt 22 (1.2 mmol) in 10 rnL dioxane and 2 mL of water was 
adjusted to 8 by the addition of lM NaOH. Then a solution of 288 mg Boc20 (1.3 mmol) in 2 
rnL dioxane was added and the pH was kept above 8 by addition of lM NaOH. After 1.5 hours 
the mixture was concentrated and water was added. The solution was extracted with EtOAc 
(twice). The combined organic layers were washed with lM KHS04, brine and dried on Na2S04 • 
Evaporation of the solvent and column chromatography (eluent: EtOAc/hexanes 1:5, v/v) gave 
224 mg of Boe-amine 23 (67%). Rr 0.18 (eluent: EtOAc/hexanes 1:5, v/v). 
1H-NMR (CDCl3): <> 1.46 (s, 9H, C(CH3) 3), 2.37 (s, 3H, ArCH3), 3.89 (s, 3H, OCH3), 4.30 (d, 2H, 
C!!2NH), 5.09 (bs, lH, NHC(O)O), 7.28 (s, lH, ArH), 7.74 (s, 2H, ArH). 
13C-NMR (CDC13): <> 21.1 (ArCH3), 28.3 (C(£H3) 3), 44.2 (ArCH2), 51.9 (OCH3), 79.5 (£(CH3) 3), 
125.5, 129.0, 132.6, 130.3, 138.4, 139.3 (CAr), 155.8 (C(O)OtBu), 167.0 (ArC(O)O). 
Carboxylic acid 24. 
224 mg of methylester 23 (0.80 mmol) was dissolved in 10 mL Tesser's base 
(dioxane/MeOH/4M NaOH 14:5:1, v/v) and the resulting solution was stirred overnight. Then the 
solvent was evaporated and the residue redissolved in water. The mixture was acidified with 1 M 
KHS04 and subsequently extracted with EtOAc three times. The combined organic layers were 
dried on Na2S04• Evaporation of the solvent gave 192 mg of carboxylic acid 24 (91 %), which was 
directly used for the synthesis of colored 25. 
Colored ester 25. 
To a solution of 100 mg of carboxylic acid 24 (29 µmol) in a mixture of 3 mL DCM and 0.5 rnL 
DMF, 60 µL DIC (0.38 mmol), 118 mg disperse red 1 (0.38 mmol) and a catalytic amount of 
DMAP were added. The mixture was stirred overnight after which subsequent evaporation of the 
solvent and flash chromatography (eluent: EtOAc/hexanes 5: 11, v/v) gave 116 mg of colored 25 
(55%). Rr 0.58 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13): <> 1.28 (t, 3H, CH2C~), 1.46 (s, 9H, C(CH3) 3), 2.35 (s, 3H, ArCH3), 3.58 (q, 2H, 
ArNC!:!iCH3), 3.82 (t, 2H, ArNC!!2CH2), 4.29 (d, 4H, ArCH2), 4.53 (t, 2H, ArNCH2C!:!i), 4.96 (bs, 
lH, NHC(O)O), 6.87 (d, 2H, ArH), 7.29 (s, lH, ArH), 7.70 (s, 2H, ArH), 7.90 (s, 2H, ArH), 7 .93 
(s, 2H, ArH), 8.31 (s, 2H, ArH). 
13C-NMR (CDC13): <> 12.3 (CHz.£H3), 21.1 (ArCH3), 28.3 (C(QH3) 3), 45.6 (ArN£H2CH3), 48.8 
(ArN£H2CH2), 61.9 (ArNCH2£H2), 80.0 (Q(CH3) 3), 111.6, 122.6, 124.6, 125.6, 126.2, 129.2, 
129.9, 132.0, 138.6, 139.5, 143.9, 147.4, 151.3, 156.7 (CA'), 155.9 (C(O)OtBu), 166.5 
(ArC(O)O). 
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Amputated tweezer 26. 
Tweezer 26 was prepared from 115 mg of colored 25 (0.21 mmol) and 70 mg sulfonylchloride 7 
(0.29 mmol) according to the procedure described for 21. The product was purified by flash 
chromatography (eluent: EtOAc/hexanes, v/v) affording 38 mg of tweezer 26 (28%). Rr 0.46 
(eluent: EtOAc/hexanes 1:1, v/v) 
'H-NMR (CDC13): o 1.29 (t, 3H, CH2C!L), 1.42 (s, 9H, C(CH3) 3), 2.37 (s, 3H, ArCH3), 3.11 (t, 2H, 
S02C!1CH2), 3.50-3.63 (m, 4H, S02CH2C!1, ArNC!1CH3), 3.84 (t, 2H, ArNC!!2CH2), 4.26 (d, 2H, 
ArC!!2NH), 4.53 (t, 2H, ArNCH2C!!2), 5.16 (m, 2H, CH2N!!), 6.88 (d, 2H, ArH), 7.37 (s, lH, ArH), 
7.75 (d, 2H, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.33 (d, 2H, ArH). 
13C-NMR (CDC13): o 12.4 (ArNCH2£H3), 21.2 (ArCH3), 28.3 (C(£H3) 3), 45.6 (ArN£H2CH3), 46.6 
(S02CH2_£H2), 48.7 (ArN£H2CH2), 52.9 (S02£H2CH2), 62.1 (ArNCH2CH2), 111.7, 122.6, 124.7, 
126.1, 126.2, 130.0, 10.2, 133.5, 137.3, 139.2, 143.9, 147.5, 151.4, 156.7 (CAr), 155.9 
(C(O)OtBu), 166.2 (ArC(O)O). 
Amputated tweezer 2a. 
Tweezer 2a was prepared from 38 mg of colored 26 (56 µmol) and 28 mg sulfonylchloride 8 
(82 µmol) according to the procedure described for 21 . The product was purified by flash 
chromatography (eluent: 2% MeOH in DCM, v/v) and subsequent gel permeation 
chromatography (LH-20, DCM/MeOH 1:1, v/v) affording 6 mg of tweezer 2a (13%). Rr 0.49 
(eluent: 5% MeOH in DCM, v/v) 
1H-NMR (CDC13): o 1.26 (t, 3H, CH2C~), 1.32 (s, 9H, C(CH3) 3), 2.37 (s, 3H, ArCH3), 2.98 (d, 2H, 
CH2Ph), 3.18 (m, 4H, S02CH2), 3.47 (m, 2H, S02CH2C!!z), 3.59 (q, 2H, ArNC!1CH3), 3.84 (t, 2H, 
ArNC!!2CH2), 4.28 (m, 3H, C!!CH2, ArC!!zNH), 4.53 (t, 2H, ArNCH2C!!z), 4.77 (bs, lH, 
NHC(O)O), 5.80 (bs, 2H, NHS02), 6.88 (d, 2H, ArH), 7.20-7.36 (m, 5H, ArH), 7.38 (s, lH, ArH), 
7.75 (s, lH, ArH), 7.79 (s, lH, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.34 (d, 2H, ArH). 
FAE-MS mlz 866.4 (M+H+). 
Methyl 3,5-di-(Boc-amino) benzoate 28. 
To a solution of 997 mg of 3,5-diamino benzoic acid methyl ester (6.0 mmol) in 25 mL DCM, 
1.8 mL triethylamine (12.6 mmol), 2.75 g Boc20 (12.6 mmol) and a catalytic amount of DMAP 
were added. The mixture was stirred at 45° C overnight followed by the evaporation of the 
solvent. The residue was dissolved in EtOAc and the resulting solution was washed with water, 1 M 
KHS04 (twice), NaHC03 (twice), brine and dried on Na2S04• Evaporation of the solvent and 
column chromatography (eluent: EtOAc/hexanes 1:4, v/v) yielded 480 mg of diBoc-amine 28 
(22%). Rr 0.71 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (DMSO-d6) o 1.47 (s, 18H, C(CH3) 3), 3.82 (s, 3H, CH30), 7.73 (d, 2H, ArH), 7.85 (t, lH, 
ArH), 9.52 (s, 2H, NHBoc). 
3,5-di-(Boc-amino) benzoate 29. 
480 mg of methyl ester 28 (1.31 mmol) was saponified with 10 mL of Tesser's base (4M NaOH, 
methanol, dioxane 1 :4: 15, v/v) , stirring for 48 hours. Then the solvent was evaporated and the 
residue redissolved in water. The mixture was acidified with lM KHS04 and subsequently 
extracted with EtOAc three times. The combined organic layers were dried on Na2S04 • 
Evaporation of the solvent gave 461 mg of carboxylic acid 29 (100% ), which was directly used 
for the synthesis of colored 30. 
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Colored ester 30. 
To a solution of 176 mg of carboxylic acid 29 (0.5 mmol) in 3 mL DCM, 157 mg Disperse Red 
1 (0.5 mmol), 78 µL DIC (0.5 mmol) and a catalytic amount of DMAP were added. After stirring 
overnight, the solvent was evaporated and the residue redissolved in EtOAc. The solution was 
washed with water, lM KHS04, 5% NaHC03, brine and dried on Na2S04 • Evaporation of the 
solvent and column chromatography (eluent: 1 % MeOH in DCM, v/v) afforded 270 mg of ester 
30 (83%). Rr 0.25 (eluent: 1 % DCM in MeOH, v/v). 
'H-NMR (CDC13) o 1.25 (t, 3H, C!1CH2N), 1.47 (s, 18H, C(CH3) 3), 3.58 (q, 2H, CH3C!!zN), 3.78 (t, 
2H, OCH2C!!zN), 4.47 (t, 2H, OCH2C!!zN), 6.80 (m, 4H, ArH, NHBoc), 7.75 (d, 2H, ArH), 7.80 
(m, lH, ArH), 7.87 (d, 2H, ArH), 7.90 (d, 2H, ArH), 8.27 (d, 2H, ArH). 
13C-NMR (CDC13) o 12.2 (C!1CH2N), 28.2 (C(£H3) 3), 45.8 (CH3~H2N), 48.7 (OCH2£H2N), 62.0 
(OfH2CH2N), 80.8 (£(CH3) 3), 111.5, 112.8, 113.9, 122.5, 124.5, 126.2, 130.9, 139.4, 143.8, 
147.3, 151.2, 152.5 (CA'), 156.7 (C(O)NH), 166.0 (ArC(O)O). 
Tweezer 31. 
Tweezer 31 was prepared from 130 mg of colored 30 (0.20 mmol) and 100 mg sulfonylchloride 
7 (0.41 mmol) according to the procedure described for 21. After evaporation of the solvent the 
residue was dissolved in EtOAc and the resulting solution was washed with water, lM KHS04, 5% 
NaHC03, brine and dried on Na2S04 • Evaporation of the solvent and flash chromatography 
(eluent: 3% MeOH in DCM, v/v) followed by flash chromatography (eluent: EtOAc/hexanes 3:2, 
v/v) afforded 60 mg of tweezer 31 (35%). 
1H-NMR (CDCI/CDPD) o 1.30 (t, 3H, C!1CH2N), 1.39 (s, 18H, C(CH3) 3), 3.30 (t, 4H, CH2C!LS), 
3.53 (t, 4H, CH2C_!1S), 3.62 (q, 2H, CH3C!!2N), 3.84 (t, 2H, OCH2C_!1N), 4.57 (t, 2H, OC!!zCH2N), 
6.85 (d, 2H, ArH), 7.35 (bs, lH, ArH), 7.63 (s, 2H, ArH), 7.92, 7.93 (two d, 4H, ArH), 8.34 (d, 2H, 
ArH). 
13C-NMR (CDCl/CD3QD) o 11.9 (C!1CH2N), 27.9 (C(£H3) 3), 35.0 (fH2CH2S), 45.7 (CH3£H2N), 
48.4 (OCH£H2N), 51.0 (CH2fH2S), 62.3 (O£H2CH2N), 80.0 (£(CH3) 3), 111.3, 113.8, 115.9, 
122.4, 124.4, 126.1, 131.1, 131.9, 138.9, 143.6, 147.2, 151.1 (CA'), 156.6 (C(O)NH), 165.4 
(ArC(O)O). 
Tweezer 3. 
Tweezer 3 was prepared from 130 mg of tweezer 31 (70 µmol) and 70 mg sulfonylchloride 8 
(0.21 mmol) according to the procedure described for 21. After evaporation of the solvent the 
residue was dissolved in EtOAc and the resulting solution was washed with water, lM KHS04 
(twice), 5% NaHC03 brine and dried on Na2S04 • Evaporation of the solvent and column 
chromatography (eluent: EtOAc/hexanes 1:1, v/v) followed by flash chromatography (eluent: 
3.5% MeOH in DCM, v/v) afforded 24 mg of tweezer 3 (27%). 
'H-NMR (DMSO-d6) o 1.20 (t, 3H, C!!3CH2N), 1.28 (s, 18H, C(CH3) 3), 2.75, 2.83 (two dd, 4H, 
CH2Ph), 3.05-3.35 (m, 12H, C!!2C!!zS, CHC!!zS), 3.60 (q, 2H, CH3C!!2N), 3.84 (t, 2H, OCH2C!!2N), 
3.98 (m, 2H, C!!CH2S), 4.47 (t, 2H, OC!!zCH2N), 6.87 (d, 2H, NHBoc), 6.97 (d, 2H, ArH), 7.15-
7.30 (m, 12H, ArH, CH2N!!S02), 7.37 (s, lH, ArH), 7.58 (s, 2H, ArH), 7.85, 7.95 (two d, 4H, 
ArH), 8.38 (d, 2H, ArH), 10.25 (bs, 2H, ArNHSOz). 
13C-NMR (DMSO-d6) o 12.1 (C!!3CH2N), 28.1 (C(£H3) 3), 37.0 (£H2CH2S), 40.4 (CH2Ph), 47.0 
(CH3fH2N), 48.0 (OCH2fH2N), 49.0 (£HCH2S), 51.3 (CH2£H2S), 55.0 (CHfH2S), 62.3 
(OfH2CH2N), 77.9 (f(CH3) 3), 111.7, 122.5, 124.9, 126.2, 128.1, 129.1, 131.4, 138.1, 143.6, 
146.9, 151.4 (CA'), 156.6 (C(O)NH), 165.4 (ArC(O)O) . 
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N-(3-methoxycarbony lpheny 1)-carbazole 3 4. 
Carbazole 34 was prepared from 2.67 g methyl 3-bromobenzoate (12.4 mmol), 2.08 g carbazole 
(12.4 mmol) and 4.44 g thoroughly dried Cu20 (31.0 mmol) according to the procedure 
described by Pieters et al.7 Crystallization from hexanes yielded 2.98 g of carbazole 34 (80%). Rr 
0.78 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDC13) o 1.50 (s, 18H, C(CH3) 3), 3.89 (s, 3H, OCH3), 6.86 (hr, 2H, NH), 7.22 (m, 2H, 
ArH), 7.32 (m, 2H, ArH), 7.61 (m, lH, ArH), 7.65 (m, lH, ArH), 8.11 (m, 2H, ArH), 8.16 (m, lH, 
ArH) 
13C-NMR (CDC13) o 28.4 (C(£H3) 3), 52.3 (OCH3), 80.2 (£(CH3\), 109.7, 111.3, 119.1, 123.7, 
127.7, 128.1, 130.0, 131.0, 131.4, 132.1, 137.6, 138.2 (CA'), 153.4 (NHCO), 166.3 (£(0)0CH3) 
N-(3-methoxycarhonylphenyl)-3,6-dinitrocarhazole 35. 
To a solution of 1.5 g N-(3-methoxycarbonylphenyl)-carbazole in 21 rnL acetic acid, 10.5 mL 
concentrated nitric acid was added dropwise. The mixture was then stirred at exactly 60° C for 
three hours. "The product was precipitated in water and removed by filtration, after which it was 
dried in vacuo over P20 5, affording 1.95 g of product containing dinitrocarhazole 35. The 
product, a mixture of isomers, was used without any further purification directly in the synthesis 
of 36. Rf 0.59 (eluent: EtOAc/hexanes 1:1, v/v). 
N-(3-methoxycarbony lpheny 1)-3 ,6-di-(Boc-amino )-carbazole 3 6. 
To a suspension of 1.95 g of stereoisomers of N-(3-methoxycarbonylphenyl)-dinitrocarhazole 
35 (4.98 mmol) and 300 mg palladium on carbon (10%) in 100 rnL EtOH, 2.73 g B0c20 (12.5 
mmol) and 2.09 rnL triethylamine (15 mmol) were added. The mixture was stirred overnight 
under a hydrogen atmosphere. Then the catalyst was removed by filtration and the solvent 
evaporated. The product was purified by column chromatography (eluent: EtOAc/hexanes 4:13, 
v/v) yielding 1.86 g of diBoc-amine 36 (70%). Rf 0.64 (eluent: EtOAc/hexanes 1:1, v/v). 
1H-NMR (CDCl3) o 1.50 (s, 18H, C(CH3) 3), 3.89 (s, 3H, OCH3), 6.86 (hr, 2H, NH), 7.22 (m, 2H, 
ArH), 7.32 (m, 2H, ArH), 7.61 (m, lH, ArH), 7.65 (m, lH, ArH), 8.11 (m, 2H, ArH), 8.16 (m, lH, 
ArH). 
13C-NMR (CDCl3) o 28.4 (C(£H3) 3), 52.3 (OCH3), 80.2 (£(CH3) 3), 109.7, 111.3, 119.1, 123.7, 
127.7, 128.1, 130.0, 131.0, 131.4, 132.1, 137.6, 138,2 (CAr), 153,4 (NHC(O)O), 166,3 
(C(O)OCH3) 
N-(3-hydroxycarbonylphenyl)-3,6-di-(Boc-amino)-carbazole 37. 
56 mg (0.11 mmol) N-(3-methoxycarbonylphenyl)-3,6-di-(Boc-amino)-carbazole was stirred 
overnight in 2.6 rnL Tesser's base (dioxane/methanol/4M NaOH 14:5:1, v/v). Then the mixture 
was concentrated in vacuo and subsequently acidified with lM KHS04 • The aqueous solution was 
extracted with EtOAc two times. The combined organic layers were dried on Na2S04 and 
evaporation of the solvent gave 54 mg of carb?xylic acid 37 (99% ). Rf 0.52 (eluent: 
DCM/MeOH/HOAc 90:10:0.5, v/v). 
1H-NMR (DMSO-d6) o 1.52 (s, 18H, C(CH3) 3), 5.00 (bs, lH, OH), 7.31 (m, 2H, ArH), 7.45 (m, 
2H, ArH), 7.72 (m, 2_H, ArH), 8.11 (m, 2H, ArH), 8.34 (m, 2H, ArH), 9.37 (s, 2H, NH). 
13C-NMR (DMSO-d6) o 28.4 (C(£H3) 3), 78.9 (£(CH3) 3), 109.7, 118.74, 123.03, 126.96, 128.07, 
129.31, 130.07, 132.94, 136.57, 137.37 (CA'), 153.4 (C(O)OtBu). 
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Colored ester 38. 
To a solution of 54 mg of carboxylic acid 37 (0.1 mmol) in 1 mL DCM/DMF (8:2, v/v), 33 mg 
Disperse Red 1 (0.1 mmol), 16 µL DIC (0.1 mmol) and a catalytic amount of DMAP were added. 
After stirring overnight and evaporation of the solvent, flash chromatography (eluent: 
EtOAc/hexanes 2:3, v/v) afforded 60 mg of ester 38 (73%). Rr 0.33 (eluent: EtOAc/hexanes 2:3, 
v/v). 
1H-NMR (CDCI3) o 1.26 (t, 3H, CJ1CH2N), 1.58 (s, 18H, C(CH3) 3), 3.57 (q, 2H, CH3C!1N), 3.81 (t, 
2H, OCH2C!1N), 4.56 (t, 2H, OC!1CH2N), 6.67 (s, 2H, NHBoc), 6.83 (d, 2H, ArH), 7.22 (d, 2H, 
ArH), 7.31 (dd, 2H, ArH), 7.65 (m, 2H, ArH), 7.82 (d, 2H, ArH), 7.89 (d, 2H, ArH), 8.10 (m, 4H, 
ArH), 8.32 (d, 2H, ArH). 
13C-NMR (CDC13) o 12.3 (£H3CH2N), 28.4 (C~H3) 3), 45.6 (CH3£H2N), 48.7 (OCH2£H2N), 62.2 
(O£H2CH2N), 80.2 (£(CH3) 3), 102.9, 109.6, 111.4, 122.6, 123.7, 124.6, 126.2, 127.6, 128.1, 
130.1, 131.2, 131.4, 131.5, 137.4, 138.2, 143.8, 147.4, 151.2, 153.3 (CA'), 156.6 (C(O)NH), 
165.7 (ArC(O)O). 
Tweezer 39. 
Tweezer 39 was prepared from 60 mg of colored 38 (74 µmol) and 37 mg sulfonylchloride 7 
(0.15 mmol) according to the procedure described for 21. The product was purified by column 
chromatography ( eluent: EtOAc/hexanes going from 1: 1 to 2: 1, v/v) affording 57 mg of tweezer 
39 (75%). Rr 0.53 (eluent: EtOAc/hexanes 2:1, v/v). 
1H-NMR (CDC13) o 1.26 (t, 3H, C!LCH2N), 1.38 (s, 18H, C(CH3) 3), 3.31 (t, 4H, CH2C!1S), 3.58 (q, 
2H, CH3C!!2N), 3.66 (t, 4H, C!1C!!2S), 3.84 (t, 2H, OCH2C!1N), 4.59 (t, 2H, OC!1CH2N), 5 .36 
(bs, 2H, NHBoc), 6.84 (d, 2H, ArH), 7.26 (d, 2H, ArH), 7.40 (dd, 2H, ArH), 7.68 (m, 4H, ArH, 
NHS02), 7.84 (d, 2H, ArH), 7.89 (d, 2H, ArH), 8.10 (m, 4H, ArH), 8.30 (d, 2H, ArH). 
13C-NMR (CDC13) o 12.3 (£H3CH2N), 28.3 (C(£H3) 3), 35.8 (£H2CH2S), 45.6 (CH3£H2N), 48.7 
(OCH2£H2N), 50.9 (CH2£H2S), 62.4 (O£H2CH2N), 80.2 (£(CH3\), 110.5, 111.5, 115.7 122.6, 
123.7, 124.7, 126.2, 127.9, 129.4, 130.4, 131.4, 131.9, 137.5, 139.3, 143.9, 147.5, 151.2, 156.2 
(CA'), 156.6 (C(O)NH), 165.6 (ArC(O)O). 
Tweezer 4. 
Tweezer 4 was prepared from 57 mg of colored 39 (55 µmol) and 38 mg sulfonylchloride 8 
(0.11 mmol) according to the procedure described for 21. The product was purified by column 
chromatography (eluent: 3.5% MeOH in DCM, v/v) affording 38 mg of tweezer 4 (48%). Rr 0.21 
(eluent: 3.5% MeOH in DCM, v/v). 
1H-NMR (CDC13) o 1.26 (t, 3H, C~CH2N), 1.33 (s, 18H, C(CH3) 3), 2.95 (bs, 4H, CH2Ph), 3.33 
(broad m, 8H, CH2C!!iS), 3.59 (q, 2H, CH3C!1N), 3.65 (t, 4H, C!1CH2S), 3.83 (t, 2H, 
OCH2C!!2N), 4.31 (bs, 2H, C!!CH2S), 4.58 (t, 2H, OC!!2CH2N), 5.11 (bs, 2H, NHBoc), 6.10 (bs, 
2H, CH2N!!S02), 6.84 (d, 2H, ArH), 7.00-7.35 (m, 14H, ArH, ArNH), 7.42 (d, 2H, ArH), 7.66 (d, 
2H, ArH), 7.88 (m, 4H, ArH), 8.12 (m, 4H, ArH), 8.31 (d, 2H, ArH). 
13C-NMR (CDCI3) o 12.3 (£H3CH2N), 28.3 (C(£H3) 3), 38.0 (CH2Ph), 39.9 (£H2CH2S), 45.6 
(CH3£H2N), 48.2 (£HCH2S), 48.7 (OCH2£H2N), 50.2 (CH&H2S), 54.5 (CHC!!2S), 62.4 
(O£H2CH2N), 80.2 (£(CH3) 3), 110.5, 111.5, 116.6 122.6, 123.6, 124.1 , 124.7, 126.2, 127.0, 
127.8, 128.8, 129.1, 129.3, 130.4, 131.4, 131.9, 136.4, 137.4, 139.5, 143.9, 147 .5, 151.2, 156.0 
(CA'), 156.7 (C(O)NH), 165.5 (ArC(O)O). 
FABMS m/z (M+W) 1422.8. 
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N-benzyl 3R, 4R-dihydroxy-succinimide 41. 
This compound was prepared as described by Nagel et al. 8 Starting from 45.3 g L-tartaric acid 
(300 mmol) and 33 mL benzylamine (300 mmol) afforded 49.8 g of succinimide 41 (75%). 
1H-NMR (DMS0-d6) 6 4.40 (d, 2H, CH2Ph), 4.60 (d, 2H, CH), 6.30 (d, 2H, OH), 7.30 (m, 5H, 
ArH). 
13C-NMR (CDC13) 6 41.2 (CH2Ph), 74.5 (CH), 127.4, 127.5, 128.5, 135.9 (CA'), 174.5 (C=O). 
N-benzyl 3S, 4S-dihydroxypyrrolidine 42. 
This compound was prepared as described by Nagel et al. 8 Starting from 27 .4 g succinimide 41 
(124 mmol) afforded 16.1 g of pyrrolidine 42 (67%). 
'H-NMR (DMSO-d6) 6 2.32, 2.77 (two dd, 4H, CHC!L), 3.52 (q, 2H, CH2Ph), 3. 88 (d, 2H, 
C!!CH2), 4.86 (d, 2H, OH), 7.30 (m, 5H, ArH). 
13C-NMR (DMSO-d6) 6 60.1 (CH2Ph), 60.9 (CH£H2), 77.8 (£HCH2), 126.8, 128.2, 128.6, 139.2 
(C.,). 
N-benzyl 3R, 4R-diazidopyrrolidine 43. 
This compound was prepared as described by Skarzewski et al.9 Starting from 1.0 g pyrrolidine 
42 (5.2 mmol) afforded 1.16 g of diazidopyrrolidine 43 (95%). Rr 0.36 (eluent: 
hexanes/diisopropylether/CHC13 4: 1:1, v/v). 
1H-NMR (CDC13) 6 2.63, 3.00 (two dd, 4H, CHC!L), 3.67 (q, 2H, CH2Ph), 3. 89 (d, 2H, C!!CH2), 
7.34 (m, 5H, ArH). 
13C-NMR (CDC13) 6 57.5 (CH£H2), 59.2 (CH2Ph), 65.6 (£HCH2), 127.3, 128.3, 128.5, 137.7 (ca'). 
N-benzyl 3R, 4R-di(Boc-amino)pyrrolidine 44. 
To a suspension of 173 mg LiA1H4 ( 4.6 mmol) in 2 mL THF, a solution of 420 mg diazide 43 
(l.73 mmol) in 2 mL THF was added. The mixture was refluxed for 30 minutes. After cooling 
the solution to 0° C 1.1 mL IM NaOH and 1.1 mL water were added dropwise consecutively. The 
precipitate was removed by filtration and washed with THF. The filtrate was concentrated in vacuo 
and the residue was dissolved in 3 mL water and 3 mL dioxane. To this mixture a solution of 
0.76 g Boc20 (3.5 mmol) in 3 mL dioxane was added at 0° C. Stirring was continued for 3 hours 
and the pH was kept above 8 by the addition of lM NaOH. Then the solvent was evaporated and 
the residue redissolved in EtOAc. The solution was washed with water (twice), brine and dried on 
Na2S04 • Evaporation of the solvent, column chromatography (eluent: 2% MeOH in DCM, v/v) 
and crystallization from EtOAc/hexanes afforded 497 mg of diBoc-amine 44 (73%). 
'H-NMR (CDC13) 6 1.43 (s, 18H, C(CH3) 3), 2.40, 2.99 (bs and t, 4H, CHC!:!2), 3.58 (s, 2H, CH2Ph), 
3. 83 (bs, 2H, C!!CH2), 4.87 (bs, 2H, NHBoc), 7.24 (m, 5H, ArH). 
13C-NMR (CDC13) 6 28.4 (C(£H3)), 57.2 (£HCH2), 59.0 (CH£H2), 59.8 (CH2Ph), 79.6 (£(CH3)), 
127.2, 128.3, 128.7, 138.0 (CA'), 155.5 (C=O). 
3R, 4R-di(Boc-amino)pyrrolidine 45. 
To a solution of 1.5 g benzyl compound 44 (3.83 mmol) in 100 mL tBuOH/water (4:1, v/v), 500 
mg Pd/C (10%) was added. The mixture was shaken overnight under a 3 Bar hydrogen 
atmosphere in a Parr apparatus. The catalyst was removed by filtration and evaporation of the 
solvent gave, after coevaporating the residue three times with benzene, 1.14 g of amine 45 (99% ). 
1H-NMR (CDC13) 6 1.41 (s, 18H, C(CH3) 3), 2.73, 3.25 (two dd, 4H, CHC!!2), 3.78 (bs, 2H, C!!CH2), 
5.20 (bs, 2H, NHBoc). 
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Carboxylic acid 46. 
This compound was prepared as described by Yoon et al.3" Starting from 0.8 g Disperse Red 1 
(2.55 mmol) and 0.30 g succinic anhydride (3.0 mmol) afforded 960 mg of carboxylic acid 46 
(91 %). Rr 0.31 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDC13) 6 1.25 (t, 3H, C!bCH2N), 2.65 (m, 4H, C!!iC!!2C(O)), 3.55 (q, 2H, CH3C!bN), 
3.67 (t, 2H, OCH2C!!2N), 4.35 (t, 2H, OC!!2CH2N), 6.80 (d, 2H, ArH), 7.89, 7.91 (two d, 4H, ArH), 
8.35 (d, 2H, ArH). 
Colored di-(Boc-amino)pyrrolidine 47. 
To a solution of 90 mg amine 45 (0.30 mmol) and 110 mg carboxylic acid 46 (0.27 mmol) in 
40 mL DCM, 40 mg HOBt (0.30 mmol) and 47 µL DIC (0.30 mmol) were added. The mixture 
was stirred overnight and then the solvent was evaporated. The residue was dissolved in EtOAc 
and the resulting solution was washed with lM KHS04 (twice), NaHC03 (twice), brine and dried 
on Na2S04• Evaporation of the solvent and flash chromatography (eluent: 5% MeOH in DCM, 
v/v) gave 68 mg of colored 47 (37%). 
1H-NMR (CDC13) 6 1.25 (t, 3H, C!bCH2N), 1.43 (s, 18H, C(CH3) 3), 2.49, 2.64 (two t, 4H, 
C!!2C!bC(O)), 3.17 (m, 2H, C!!.CH), 3.52 (q, 2H, CH3C!!2N), 3.68 (t, 2H, OCH2C!!2N), 3.94 (m, 
4H, C!!bCH, CH2C!!), 4.30 (t, 2H, OC!!iCH2N), 4.89, 5.34 (d and bs, 2H, NHBoc), 6.78 (d, 2H, 
ArH), 7.87, 7.89 (two d, 4H, ArH), 8.30 (d, 2H, ArH). 
13C-NMR (CDC13) 6 12.2 (£H3CH2N), 28.2 (C(£H3) 3), 28.5, 28.8 (£H2£H2C(O)), 45.6 (CH3£H2N), 
46.5, 50.3 (CH£H2), 48.7 (OCH2£H2N), 53.5, 56.1 (£HCH2), 61.4 (O£H2CH2N), 80.3 (£(CH3) 3), 
111.4, 122.6, 124.6, 126.6, 143.8, 147.4, 151.8, 156.7 (C~, 155.8 (C(O)NH), 170.0 (C(O)N), 
172.8 (C(O)O). 
Tweezer 48. 
Tweezer 48 was prepared from 65 mg of colored 47 (93 µmol) and 60 mg sulfonylchloride 7 
(0.25 mmol) according to the procedure described for 21. The product was purified by column 
chromatography (eluent: 5% MeOH in DCM, v/v) affording 55 mg of tweezer 48 (65%). Re 0.20 
(eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDC13) 6 1.23 (t, 3H, C!bCH2N), 1.43 (s, 18H, C(CH3) 3), 2.49, 2.62 (two t, 4H, 
C!!2C!bC(O)), 3.20-3.40 (m, 6H, C!fCH, CH2C!!2S), 3.55 (m, 6H, CH3C!!iN, C!!2CH2S), 3.68 (t, 
2H, OCH2C!!2N), 3.80-4.05 (m, 4H, C!!bCH, CH2C!!), 4.27 (t, 2H, OC!!iCH2N), 5.40 (bs, 2H, 
NHBoc), 6.35, 6.50 (two bs, 2H, NHS02), 6.78 (d, 2H, ArH), 7.87, 7.89 (two d, 4H, ArH), 8.30 (d, 
2H, ArH). 
13C-NMR (CDC13) 6 12.3 (£H3CH2N), 28.4 (C(£H3) 3), 28.8 (£H2£H2C(O)), 36.0 (£H2CH2S) 45.7 
(CH3£H2N), 48.8 (OCH2£H2N), 50.3 (CH£H2), 52.6 (CH2£H2S), 55.5 (£HCH2), 61.7 
(O£H2CH2N), 80.4 (£(CH3) 3), 111.5, 122.7, 124.7, 126.3, 143.8, 147.5, 151.3, 156.2 (CAr), 156.8 
(C(O)NH), 170.4 (C(O)N), 173.0 (C(O)O). 
Tweezer 5. 
Tweezer 5 was prepared from 54 mg of colored 48 (49 µmol) and 49 mg sulfonylchloride 8 
(0.15 mmol) according to the procedure described for 21. The product was purified by column 
chromatography (eluent: 4% MeOH in DCM, v/v) affording 56 mg of tweezer 5 (73%). Rr 0.20 
(eluent: 4% MeOH in DCM, v/v). 
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'H-NMR (CDC13) 6 1.23 (t, 3H, C!bCH2N), 1.38 (s, 18H, C(CH3) 3), 2.45, 2.60 (two bs, 4H, 
C!:1C!!2C(O)), 2.75-3.00 (bs, 4H, CH2Ph), 3.10-3.40 (m, 12H, C!:bCH, C!!2C!:1S), 3.55 (m, 6H, 
CH3C!:1N, C!:1CH2S), 3.64 (t, 2H, OCH2C!!2N), 3.95 (bs, 4H, C!!bCH, CH2C!!), 4.23 (broad t, 2H, 
OC!:1CH2N), 5.15, 5.65, 6.05, 6.38 (four bs, 4H, NHS02, NHBoc), 6.78 (d, 2H, ArH), 7.20 (m, 
lOH, ArH), 7.87, 7.89 (two d, 4H, ArH), 8.25 (d, 2H, ArH). 
13C-NMR (CDC13) 6 12.2 (£H3CH2N), 28.3 (C(£H3) 3), 28.5, 28.7 (£H2.£H2C(O)), 38.0 (_£H2CH2S), 
40.0 (CH2Ph), 45.6 (CH3£H2N), 48.7 (OCH2£H2N), 50.1 (CH£H2), 53.3 (CH2£H2S), 54.8 
(CHCH2S), 55.6 (£HCH2), 57 .0 (C!!CH2S), 61.7 (O£H2CH2N), 80.2 (£(CH3) 3), 111.5, 122.6, 
124.6, 126.2, 127.0, 128.7, 129.4, 136.6 143.8, 147.5, 151.3, 156.7 (CA'), 155.7 (C(O)NH), 
170.6 (C(O)N), 173.0 (C(O)O). 
FABMS mlz (M+H+) 1306.4 
1, 5-diphenyl-3, 7-dibenzyldiazabicyclo[3 .3. l ]nonane-9-one 5 0. 
A mixture of 5.3 g 1,3-diphenylacetone 49 (25 mmol), 8.2 mL benzylamine (75 mmol), 6.0 g 
paraformaldehyde (200 mmol) and 8.4 mL acetic acid (147 mmol) in 60 mL ethanol was 
refluxed for 6 hours. After cooling to room temperature the precipitate was removed by filtration 
and washed with ethanol and hexanes subsequently and dried in vacuo yielding 6.9 g 
cyclononane 50 (59%). Re 0.37 (eluent: EtOAc/hexanes 1 :4). 
'H-NMR (CDCI3) 6 3.53, 3.11 (dd, 8H, CCH2N, J = 10.5 Hz), 3.72 (s, 4H, CH2Ph), 7.14-7.41 (m, 
20H, ArH). 
13C-NMR (CDC13) 6 54.4 (£(C=0)); 61.9 (CH2Ph), 64.9 (CCH2N), 126.5, 126.9, 127.4, 127.8, 
128.4, 129.0, 138.0, 142.6 (CA'), 210.9 (C=O). 
FAB-MS m/z 473.4 (M+W). 
1, 5-diphenyl-3, 7-dibenzyldiazabicyclo[3 .3. l]nonane-9-ol 51. 
To a solution of 1.0 g (2.1 mmol) of diazabicyclo[3.3.l]nonane-9-one 50 in 10 mL THF, a 
suspension of 161 mg LiAIH4 (4.2 mmol) in 15 mL THF was added, over a period of 20 minutes. 
After the addition stirring was continued for 10 minutes before, cautiously, 2.1 mL 1 M N aOH 
and 2.1 mL of water were added subsequently. The precipitate was removed by filtration and the 
filtrate was concentrated in vacuo. Water was added to the residual oil and the resulting solution 
was extracted with EtOAc four times. The combined organic layers were dried on MgS04 and 
evaporated affording 888 mg of alcohol 51 (90%). 
'H-NMR (CDC13) 6 2.20, 2.77 (dd, 4H, CCH2N, J = 11.6 Hz), 3.33, 3.22 (dd, 4H, CCH2N, J = 10.8 
Hz), 3.48, 3.67 (twos, 4H, CH2Ph), 4.41 (s, lH, C!!OH), 4.00-5.00 (bs, lH, OH), 7.19-7.40 (m, 
20H, ArH). 
FAB-MS mlz 475.4 (M+H+). 
1,5-diphenyl-3, 7-di(t-butyloxycarbonyl)diazabicyclo[3 .3 .1 ]nonane-9-ol 52. 
From ketone 50: A mixture of 1.5 g of diazabicyclo[3.3.l]nonane-9-one 50 (3.2 mmol), 20 mL 
dioxane, 7.5 mL acetic acid, 7.5 mL water and a catalytic amount of Pd(OH)2 on carbon were 
shaken for 20 hours under a 3 Bar hydrogen atmosphere in a Parr apparatus. EtOH was added, 
the catalyst removed by filtration and the solvent evaporated. The residue was dissolved in 10 mL 
dioxane and the pH of the solution was adjusted to 8 with 4M NaOH. Then a solution of 1.5 g 
Boc20 (6.6 mmol) in 5 mL dioxane, was added. During the reaction the pH was kept above 8 with 
lM NaOH. After 1.5 hours the solvent was evaporated and the residue was dissolved in water. The 
aqueous solution was extracted with EtOAc twice and the combined organic layers were washed 
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with lM KHS04, 5% NaHC03, brine and dried on Na2S04 • Evaporation of the solvent and flash 
chromatography (eluent: EtOAc/hexanes 1:4) yielded 1.1 g of alcohol 52 (70%) and 133 mg of 
ketone 52b (8%). Rf 0.20 and 0.36 (eluent: ethyl acetate/hexanes 1:4) respectively. 
From 51: Compound 52 was obtained using the procedure described to obtain alcohol 52 from 
ketone 50. 1.5 g of ketone 51 (3.2 mmol) afforded 1.49 g of alcohol 52 (95%). 
52: 1H-NMR (CDC13) 8 1.41, 1.51 (s, 18H, C(CH3) 3), 1.65 (d, lH, OH), 3.14, 4.18 (dd, 2H, CCH2N, 
J = 13.5 Hz), 3.05, 4.36 (dd, 2H, CCH2N, J = 13.5 Hz), 3.59, 4.45 (dd, 2H, CCH2N, J = 12.3 Hz), 
3.54, 4.60 (dd, 2H, CCH2N, J = 12.9 Hz), 4.74 (s, lH, C!!OH), 7.26-7.52 (m, lOH, ArH). 
13C-NMR (CDC13) 8 28.4, 28.5 (C(fH3) 3), 41.8 (f(COH)), 45.1, 46.0 (CCH2N), 73.0 (COH), 79.8, 
79.9 (f(CH3) 3), 125.9, 127.4, 128.9, 140.8 (CA'), 154.2, 154.4 (C(O)OtBu). 
52b: 1H-NMR (CDC13) 8 1.49 (s, 18H, C(CH3\), 3.74, 4.71 (dd, 4H, CCH2N, J = 12.0 Hz), 3.74, 
4.95 (dd, 4H, CCH2N, J = 12.0 Hz), 7.25-7.41 (m, lOH, ArH). 
t3C-NMR (CDC13) 8 28.4 (C(fH3) 3), 53.1 (f(C=O)), 55.1, 56.6 (CCH2N), 80.9 (f(CH3) 3), 127.4, 
127.6, 128.2, 136.7 (CA'), 154.4 (C(O)OtBu), 208.7 (C=O). 
9-{ [ 4-(methyloxycarbony l)benzyl]oxy }-1,5-dipheny 1-3, 7-di(t-butyloxy carbonyl)diazabicyclo-
[3.3. l ]nonane 53. 
To a solution of 350 mg (0.71 mmol) alcohol 52 in 4 rnL THF under an argon cushion, 374 mg 
18-crown-6 ( 1.4 mmol), 173 mg KH (35 wt% dispersion in mineral oil; 1.5 mmol) and 487 mg 
methyl (4-bromomethyl)benzoate (2.1 mmol) were added. The mixture was stirred for three 
hours and then the mixture was acidified by adding carefully lM KHS04• The aqueous solution 
was extracted with EtOAc twice. The combined organic layers were washed with lM KHS04, 5% 
NaHC03, brine and dried on Na2S04. Evaporation of the solvent, flash chromatography (eluent: 
EtOAc/hexanes 1:4) and precipitation in hexanes yielded 255 mg of ether 53 (56%). Rf 0.21 
( eluent: EtO Ac/hexanes 1 : 4). 
1H-NMR (CDC13) 8 1.43, 1.49 (s, 18H, C(CH3) 3), 3.44-3.59 (two d, 2H, CCH"N), 3.62 (s, 2H, 
CH2Ph), 3.74-3.83 (two d, 2H, C!!HN), 3.83 (s, 3H, OCH3), 4.15 (d, lH, C!!HN, J = 14.3 Hz), 4.34 
(m, 3H, C(H)O, CC!!HN), 4.53 (d, lH, C!!HN, J = 12.5 Hz), 6.46 (d, 2H, ArH), 7.22-7.53 (m, 
lOH, ArH), 7.68 (d, 2H, ArH). 
9-{ [ 4-(hydroxycarbonyl)benzyl]oxy }-1,5-diphenyl-3,7-dibocdiazabicyclo-[3.3. l]nonane 54. 
255 mg of methylester 53 (0.40 mmol) was dissolved in 10 rnL Tesser's base 
(dioxane/MeOH/4M NaOH 14:5:1, v/v) and the resulting solution was stirred overnight. Then the 
solvent was evaporated and the residue redissolved in water. The mixture was acidified with 1 M 
KHS04 and subsequently extracted with EtOAc three times. The combined organic layers were 
dried on Na2S04 • Evaporation of the solvent gave 236 mg of carboxylic acid 54 (95%), which was 
directly used for the synthesis of colored ester 55. 
Colored ester 55. 
To a solution of 236 mg carboxylic acid 54 (0.38 mmol) in a mixture of 3 rnL DCM and 0.5 mL 
DMF, 60 µL DIC (0.38 mmol), 118 mg Disperse Red 1 (0.38 mmol) and a catalytic amount of 
DMAP were added. The mixture was stirred for 36 hours after which the solvent was evaporated. 
The product was purified by flash chromatography (eluent: EtOAc/hexanes 10:19, v/v) affording 
287 mg of ester 55 (83%). Rr 0.34 (eluent: EtOAc/hexanes 10:18). 
tH-NMR (CDC13) 8 1.25 (t, 3H, ArNCH2C!!3), 1.42, 1.49 (s, 18H, C(CH3) 3), 3.41-3.62 (m, 6H, 
ArNC!!zCH3, OCH2Ar, CC!!HN), 3.78 (m, 4H, C!!HN, ArNC!!zCH2), 4.14 (m, lH, C!!HN) 4.28-
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4.38 (m, 3H, C(H)O, CC!!HN), 4,45-4.54 (m, 3H, CH2Cg20C(O), CC!!HN), 6.46 (d, 2H, ArH), 
6.83 (d, 2H, ArH), 7.2907.52 (m, lOH, ArH), 7.66 (d, 2H, ArH), 7.90 (d, 2H, ArH), 7.93 (d, 2H, 
ArH), 8.34 (d, 2H, ArH). 
13C-NMR (CDC13) o 12.3 (ArNCH2£H3), 28.4, 28.5 (C(£H3) 3), 41.7 (fC(H)O), 45.7 (ArNfH2CH3), 
48.9 (ArNfH2CH2), 61.8 (ArNCH2CH2), 74.6 (ArCH20), 79.9, 80.0 (£(CH3) 3), 85.1, (C(H)O), 
111.5, 122.6, 124.7, 126.0, 126.3, 127.0, 127.2, 128.4, 128.6, 129.2, 143.5 143.9, 147.5, 151.2, 
156.7 (CA'), 154.2, 155.6 (C(O)OtBu), 166.2 (ArC(O)O). 
Tweezer 56. 
Tweezer 56 was prepared from 44 mg of colored 55 (48 µmol) and 27 mg sulfonylchloride 7 
(0.11 mmol) according to the procedure described for 21. The product was purified by flash 
chromatography (eluent: EtOAc/hexanes 10:11, v/v) affording 34 mg of tweezer 56 (63%). Rf 
0.24 (eluent: EtOAc/hexanes 10:11, v/v). 
'H-NMR (CDC13) o 1.26 (t, 3H, ArNCH2C~), 1.42, 1.44 (s, 18H, C(CH3) 3), 3.20, 3.27 (two t, 4H, 
S02C!!zCH2), 3.52-3.61 (m, 6H, S02CH2C!!z, ArNC!!zCH3, ArCH20), 3.69 (m, 2H, S02CH2Cg2), 
3.75-3.90 (m, 8H, CCH2N, ArNC!!zCH2), 4.03 (d, 2H, CCH2N), 4.40 (s, lH, C(H)O). 4.48 (t, 2H, 
ArNCH2Cg2), 5.19, 5.25 (two bs, 2H, NHC(O)O), 6.37 (d, 2H, ArH), 6.84 (d, 2H, ArH), 7.32-7.48 
(m, lOH, ArH), 7.66 (d, 2H, ArH), 7.91 (d, 2H, ArH), 7.94 (d, 2H, ArH), 8.33 (d, 2H, ArH). 
13C-NMR (CDC13) o 12.3 (ArNCH2£H3), 28.3 (C(£H3) 3), 35.1 (C£H2N), 42.2 (fC(H)O), 45.7 
(ArNfH2CH3), 47.4 (S02CHz£H2), 48.8 (ArN£H2CH2), 49.8, 50.7 (CfH2N), 55.8 (S02fH2CH2), 
61.9 (ArNCH2£H2), 75.2 (ArCH20), 79.8, 79.9 (£(CH3) 3), 83.8 (C(H)O), 111.5, 122.6, 124.7, 
125.8,126.2, 127.4, 127.8, 128.7, 128.9, 129.3, 141.3, 142.6, 143.9, 147.5, 151.2, 156.7 (CAr), 
155.7 (C(O)OtBu), 166.2 (ArC(O)O). 
Tweezer 6. 
Tweezer 6 was prepared from 34 mg of tweezer 56 (30 µmol) and 22 mg sulfonylchloride 8 (67 
µmol) according to the procedure described for 21. The product was purified by flash 
chromatography (eluent: 2% MeOH in DCM, v/v) followed by gel permeation chromatography 
(LH-20, eluent: DCM/MeOH 1:1, v/v) affording 15 mg of tweezer 6 (32%). Rr 0.38 (eluent: 4% 
MeOH in DCM, v/v). 
'H-NMR (CDC13) o 1.25 (t, 3H, ArNCH2C~), 1.36, 1.39 (s, 18H, C(CH3) 3), 2.96 (m, 4H, CH2Ph), 
3.18-3.36 (m, 8H, S02CH2), 3.52-3.62 (m, 8H, S02CH2C!!z, ArNC!:!2CH2, ArCH20, CCH2N), 3.77 
(m, 6H, ArNC!!zCH2, S02CH2C!!z, CCH2N), 3.86, 4.03 (dd, 4H, CCH2N), 4.27 (m, 2H, C!!CH2), 
4.41 (s, lH, C(H)O), 4.47 (t, 2H, ArNCH2Cg2), 4.97 (bs, 2H, NHC(O)O), 5.66, 5.76 (two bs, 2H, 
NHS02), 6.39 (d, 2H, ArH), 6.84 (d, 2H, ArH), 7.20-7.48 (m, lOH, ArH), 7.66 (d, 2H, ArH), 7.91 
(d, 2H, ArH), 7.94 (d, 2H, ArH), 8.33 (d, 2H, ArH). 
FAB-MS m/z 1533.9 (M+H+). 
Tripeptides on TentaGel NH2 resin. 
The amino acids were coupled on 1.0 g resin (0.30 mmol/g) by treatment with 0.90 mmol of the 
appropriate Fmoc-protected amino acid, 0.90 mmol BOP and 1.80 mmol DIPEA for two hours 
and after washing of the resin, repeating this step. Fmoc groups were removed by treatment with 
DMF/piperidine (1:1, v/v) for 5 and 15 minutes subsequently. The resin was washed after a 
coupling with DMF (5*5 minutes), isopropanol (3*5 minutes) and DCM (5*5 minutes). The 
resin was washed after deprotection with DMF (3*5 minutes), dioxane/water (2:1, v/v, 2 * 5 
minutes), DMF (3*5 minutes) and DCM (4*5 minutes). After the final Fmoc removal, side chain 
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deprotection was performed by treatment with a solution of TFA/DCM (1:2, v/v) and 1 mg/mL 
indole as a scavenger for 5 and 55 minutes subsequently. Finally, the resin was washed with DCM 
(5*5 minutes), triethylamine/DCM (1:9, v/v, 3*5 minutes), DCM (5*5 minutes) and dried in 
vacuo overnight. The thus obtained tripeptides were used immediately for the determination of 
their association constants for a tweezer. 
Determination of the association constant of a receptor and a resin bound tripeptide. 
The association constants were determined as described in chapter 6. 
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Binding of alanine carboxylic acid to pyrrolidine 
based receptor molecules: 
a biased combinatorial approach 
Introduction 
In the past many receptor molecules have been synthesized, which were designed to bind a 
particular ligand1•2. It has turned out that de novo design is a difficult task. And once a 
particular receptor molecule is constructed, optimization of the binding of a ligand means 
synthesis of new derivatives, which is a time consuming process. Therefore, the possibility of 
a combinatorial approach by synthesizing a small biased library was investigated. 
Hamilton et al. 3 have shown that diaminocyclohexane derivatives 1 are good receptors for the 
tetrabutylammonium salt of acetic acid. Their results are summarized in figure 1. 
la X = NH, Y = H, Z = NHCbz 
lb X = NH, Y = CH3, Z = NHCbz 
le X = NH, Y = CH20H, Z = NHCbz 
ld X = NH, Y = CH20H, Z = NPht 
le X = 0, Y = CH20H, Z = NHCbz 
Receptor 
la 
lb 
le 
le 
ld 
le 
solvent K. (M-1) 
CD3CN 2.1 X 102 
CD3CN 3.4 X 102 
CD3CN 2.7 X 105 
DMS0-d6 89 
CD3CN 1.4 X 103 
CD3CN 1.0 X 104 
Figure 1. Diaminocyclohexane based receptor molecules and their association constants for 
tetrabutylammonium acetate. 
It was proposed by the authors that the acetate ion forms a complex with receptors 1, held 
together by hydrogen bonds. The high affinity of receptor le was explained by the fact that 
primary hydrogen bonding contacts to the acetate carboxylate were made by both the hydroxyl 
and urethane-NH groups (figure 2, left). This result seemed to be a good starting point to 
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create a library of receptors with an affinity for a carboxylic acid. In order to be able to create 
such a library on a solid phase an additional functional group was needed for attachment to the 
resin. As there is none in the cyclohexane ring to do so, the corresponding diaminopyrrolidine 
ring was chosen. It was assumed that receptors created from this ring would have a comparable 
affinity for tetrabuty !ammonium acetate and that the nitrogen in the pyrrolidine ring could serve 
as a handle for attachment to a resin (figure 2). 
Figure 2. Proposed mechanism of binding of le and a pyrrolidine based analogon. 
By increasing the acidity of the serine-NH's and as a consequence their hydrogen bonding 
ability, it was expected that the binding affinity could be improved. In order to achieve this, the 
benzyloxycarbonyl group was replaced with various sulfonamides. The sulfonamides were 
chosen to provide for receptor molecules with a range of pK values for the serine-NH's (-14-
17 in DMS0)4, all lower than that of a urethane-NH (> 17)4. 
As a ligand compound 2 was chosen (figure 3). This compound resembles 
tetrabutylammonium acetate in having a tetrabutylammonium carboxylic acid moiety. Alanine 
was chosen to introduce the carboxylic acid part as a first step towards an investigation of 
binding to D-Ala-D-Ala containing compounds. This sequence is of great interest2 because it is 
part of the peptidoglycan precursor in gram-positive bacteria and the target of antibiotics as e.g. 
vancomycin5• A dye moiety was introduced as part of the ligand for visualization of its binding 
to receptor molecules, which are attached to a resin. The dye was linked to alanine via p-
hydroxybenzoic acid. 
Figure 3. A colored ligand. 
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Ligand 2 was used in a similar assay as that described in chapters 6 and 7, the difference being 
that the receptor molecules are now attached to the resin and the ligand is in solution. Visual 
inspection of the beads gave an indication of the affinity of the different receptors for the 
ligand, i.e. the more intense the (red) color of the beads the higher the affinity of the receptor 
for the ligand. A few of these receptor molecules were resynthesized in solution to determine 
their association constants for tetrabutylammonium acetate, in order to quantify the qualitative 
results that were obtained by the assay. For NMR titrations tetrabutylammonium acetate was 
chosen as a simple analog of ligand 2. 
Results and discussion 
The synthesis of the receptor library is outlined in scheme 1 and started with the earlier 
prepared di-Bocamino pyrrolidine 3 (see chapter 7). The secondary amine of 3 was reacted 
with succinic anhydride to give carboxylic acid 4 in 97% yield. Succinic acid was introduced 
as a spacer between the pyrrolidine ring and a solid phase resin. Loading of the resin with 4 
was carried out using BOP as a coupling agent, followed by removal of the Boe groups using 
aNHBoc O~O 
o NHBoc 
Hyv-NJ,NHBoc 
0 
Tentagel NH2 
H .,,'NH Boe BOP/DIPEA 
3 4 
H 
o N-Ser(tBu)-Fmoc H_ A jL r--(NHBoc 1) 1FA 
NY v NV··,'NHBoc 2) BOP 
HyJ- ;--( 
""N NV·,, 
·,'N-Ser(tBu)-Fmoc 
0 DIPEA 
1jg:~Ser 
5 
0 H 
piperidine 
R2-Cl/NMM 
Fmoc-Ser(tBu) 
BOP/DIPEA 
0 NH-R2 
H o (XNKoR' 
N. A JlN 
'l( v .,'NH ,-OR1 
0 \_.:' 
C 7a-i R1 = tBu 1FA Sa-i R1 = H 
Ofr~NH-R2 
Scheme 1. Synthesis of a nine-membered pyrrolidine based library. 
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TFA/DCM. Another BOP-mediated coupling with Fmoc-Ser(tBu)-OH or Cbz-Ser-OH as the 
carboxylic acid afforded 6 and Sj respectively. In case of the introduction of the Fmoc 
protected serine, it was possible to determine the efficiency of the couplings, which was found 
to be >95%, by determining the Fmoc content of the resin. Subsequently, the Fmoc group was 
removed with 20% piperidine in NMP. The resin was now divided into 9 portions and reacted 
with different sulfonylchlorides, to afford t-butyl protected compounds 7a-i. Finally, the 
tertiary butyl groups were removed with TFA in DCM, giving a library consisting of receptor 
molecules Sa-i. The Cbz protected 8j should function as a positive control in view of its 
resemblance with diaminocyclohexane derivative le of Hamilton et al.3 (see figure 2). 
Ligand 2, needed in the binding assay, was synthesized as is outlined in scheme 2. The 
mesylate of Disperse Red 110 was reacted with methyl p-hydroxybenzoate 9, using K2C03 as 
a base, to give ether 11 in a quantitative yield. Saponification with Tesser' s base produced 
carboxylic acid 12 (99% yield), which could be coupled to H-Ala-OtBu with BOP as a 
coupling agent, producing 13 in 97%. Cleavage of the t-butylester was carried out by HCl, 
affording carboxylic acid 14 in 70%, which was transformed to tetrabutylammonium salt 2. 
~ DispRedOMs 10 ~ 
H~OMe DispRed~OR 
9 
DispRed~N~OR 
H 0 
HCI ( 13 R = tBu 
C 14 R= H Bu4NOH 2 R = NBu4 
Tesser's ( 11 R = Me 
base 12 R = H 
Scheme 2. Synthesis of a colored ligand. 
BOP/DIPEA 
Ala-OtBu 
Now the stage was set for screening of this small library of receptor molecules on their ability 
to bind ligand 2. To this end a 15 µM solution of 2 in acetonitrile was added to resin 
containing receptor molecules 8a-j. After 24 hours of equilibration the beads were visually 
inspected. The results are shown schematically in figure 4. On the left the substituents are 
depicted belonging to receptors that resulted in an intense red color of the beads and while 
going to the right the coloration decreased. The beads, to which the "reference" 8j was 
attached, were colored red indicating that this receptor molecule is indeed capable of binding 
carboxylate 2. Resins containing receptor molecules 8a,b or g had a more intense red color, 
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-s-
11 
0 
''-0-.,..,.~ ~ 8 N02 
0 d 
Carboxylic acid binding receptors 
¢=.i;;;;;;;;;;;.F----------'!0----~()==J 
Stained Colorless 
Figure 4. Results of the binding assay. 
which implied they have a higher affinity for ligand 2. On the other hand, resins with receptors 
8c,d,f,h or i showed less or no staining at all, and thus a low affinity was expected for these 
receptors. The receptor with the dinitrophenylsulfonyl group Se had to be omitted because it 
was colored by itself, making an estimation of the binding by eye impossible. At first these 
results do not seem to be in agreement with the original assumption that N-terminal substituents 
capable of increasing the acidity of the serine NH' s will lead to an increase of the binding 
affinity. Following this reasoning, the receptor with the p-nitrophenylsulfonyl group 8d 
should then have a higher affinity than the receptor containing p-methoxyphenylsulfonyl 
groups Sa. Thus, the mechanism of binding is probably more complicated than originally 
assumed or it changes drastically going from a benzyloxycarbonyl group to the sulfonamide 
substituents. Another explanation might be that the results from this assay cannot be directly 
translated into affinities of the corresponding compounds in solution 6. In order to reach a better 
understanding of these qualitative results, the five receptor molecules showing the highest 
affinity, Sa, b ,d , g and j , were resynthesized in solution and their binding constants 
determined. 
Two routes were used to synthesize the receptor molecules. As shown in scheme 3, pyrrolidine 
3 (see scheme 1) was mesylated to give 15 in 87%. The secondary amine was mesylated 
instead of acetylated because acetylation gave rise to complicated 1H-NMR spectra7, which 
would hamper the determination of the binding constants using proton NMR. After removal of 
the Boe groups with HCl in ether, Cbz-protected serine was introduced via a BOP coupling, 
yielding receptor 16j (68%). Removal of the Cbz groups folJowed by attempts to introduce 
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0 NH-R 
NHBoc 
HaNHBoc 
3 
MsCl 
- (XNHBoc l)HCl C(NKOH Ms Ms-N 
'NH Boe 2) BOP/DIPEA .. ,,NH _o H 
15 
R-Ser-OH }--< 
O NH-R 
Scheme 3. Route I towards pyrrolidine based receptor molecules. 
sulfonyl groups using sulfonylchlorides failed, however. Direct incorporation of N-
sulfonylated serines, led to receptors 16a (25%) and 16b (62%). The low yield of the p-
methoxyphenylsulfonyl receptor 16a was caused by a poor solubility of the compound making 
purification very tedious. An attempt to synthesize 16d in this way failed completely . 
Fortunately, receptors 16a, d and g could be obtained using an indirect, but more versatile 
route (scheme 4) . This involved the coupling of a fully protected serine residue followed by 
introduction of the sulfonyl groups. The synthesis started with compound 15 from which the 
Boe groups were removed by HCl in ether, followed by a coupling to Cbz-Ser(tBu)-OH 
leading to the protected receptor 17 in 62%. After hydrogenolysis of the Cbz groups, the 
desired sulfonyl group was introduced by a reaction with the appropriate sulfonylchloride and 
triethylamine as a base affording 19a (57%), 19d (68%) and 19g (61 %). These products 
were easily purified, in comparison with the side chain deprotected analog 16a. Treatment with 
TFA converted 19a, d and g into 16a, d and gin yields of 55%, 86% and 97%, respectively. 
H H (XNHBoc l) HCl aN-Ser(tBu)Cbz Ms Ms H2/Pd/C . ;--(N-Ser(tBu)OH Msv .. ,, 
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, 2) BOP .. ,, S ( B )C 
NHBoc Z-Ser(tBu)-OH W er t u bz .. ,'NSer(tBu)OH H 
15 DIPEA 17 
TFA ( 19 RI == tBu 
16 RI = H 
R2 == 
0 0 
-~-Q-oMe -~-Q-No2 
O a O d 
Scheme 4. Route II towards pyrrolidine based receptor molecules. 
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Having synthesized the receptor molecules in solution, 1H-NMR spectroscopy was used to 
determine the association constants8• The shift of protons, supposedly involved in binding, 
was monitored as a function of the ligand concentration. These observed resonances are an 
average of the complexed and uncomplexed species, which are in rapid equilibrium at room 
temperature on the 300 MHz NMR time-scale. The NMR titrations were carried out in DMS0-
d6, as in other solvents the solubility of the receptor molecules was too low. The signal that 
was examined was that of the pyrrolidine amide-NH's, because the sulfonamide and hydroxyl 
proton resonances broadened or even completely disappeared upon addition of Bu4NOAc. 
Only for receptor 16j both the amide and urethane resonances could be followed through the 
whole concentration range of the ligand. It turned out that either signal could be used in 
calculating the association constant, leading to only small differences, well within the range of 
the experimental error. The details of these calculations are given in the appendix of this 
chapter. 
Titration of compound 16j, being a pyrrolidine analog of le, showed downfield shifts for 
both the amide and urethane resonances. This was consistent with the formation of a hydrogen 
bonded complex. The shape of the titration curve (figure 5) was in agreement with the 
formation of a 1:1 complex (equation l; H = receptor, G = ligand). 
Ku 
H + G ~ HG (1) 
1.2 
0.8 
--m-- 16a 
0.6 • 16b 
<.1 0.4 • 16d 
0.2 ... 16g 
0 16j 
25 
-0.2 
-0.4 • 
GO/HO 
Figure 5. The relative shift of amide protons of receptors 16 at various ligand/receptor ratios. 
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Non-linear regression analysis9 of the binding curve afforded an association constant of 101 M· 
1 for 16j, which is comparable to the value of 89 M·1 found for compound le as reported by 
Hamilton et al. 3 The other receptor molecules 16a, b, d and g showed a similar downfield 
shift for the amide resonances, however, at higher ligand concentrations the signals were found 
to go upfield again, as can be seen in figure 5. This effect can be accounted for by assuming 
the formation of a 1 :2 receptor-ligand complex in addition to the 1: 1 complex 10 ( equation 2; H 
= receptor, G = ligand). 
H + 2G --
--
HG+ G 
--
(2) 
The titration curves of receptor molecules 16a, b, d and g were described well in this way, 
and non-linear regression gave the K 11 and K 12 that describe the two equilibria involved. 
Compound 16d seemed to have other binding properties though, because at low ligand 
concentrations as compared to the receptor concentration (ratio ligand/receptor ::; 0.5) the 
resonances did not shift. Also the solutions of this receptor in DMSO-d6 turned yellow upon 
addition of tetrabutylammonium acetate. This suggests that the sulfonamide proton of the serine 
was abstracted in an acid-base reaction with the ligand, because the acidity of the proton was 
increased by the electron withdrawing properties of the p-nitrophenylsulfonyl group. 
However, the titration curve could still be adequately described by assuming the formation of a 
1: 1 and a 1 :2 complex. It should be noted, however, that when proton transfer is indeed 
involved, another mathematical model should be used in the non-linear regression analysis of 
the curve. An attempt in this direction did not show an improvement, so further experiments 
should be performed to give a definite answer. The association constants (K11 and K12) and the 
calculated amide-NH resonances for the 1: 1 (~11 ) and 1 :2 (~12)11 complexes are summarized in 
table 1. 
Receptor relative K 11 (M·1t K12 (M.1) A1/ A1z° 
affinity• 
16a ++++ 150 12 0.87 0.53 
16b +++ 117 6 0.95 0.20 
16d + 271 41 0.27 -0.45 
16g +++++ 389 8 0.35 -0.77 
16j ++ 101 1.23 
Table 1. Association constants of receptors 16a,b,d and g with Bu4NOAc in DMSO-d6. a) as 
estimated from the qualitative assay using 2 as a ligand ( see figure 4); +++++ 
representing the highest affinity. b) The error is 10%. c) see reference 11. 
The association constants were in agreement with the qualitative results that were obtained with 
the solid phase binding assay using colored ligand 2, except for the p-nitro compound 16d. 
For this receptor a low K-value was expected as it was found to bind less to ligand 2 than the 
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other receptor molecules 16a, b, g and j. This fact might be explained by assuming an acid-
base equilibrium for receptor 16d with Bu4NOAc, and consequently the calculated association 
constant is not reliable. Another explanation could be that this receptor has a low affinity for 
ligand 2, and that Bu4NOAc is not a good model for the carboxylate moiety of 2. Also the 
relative binding constants might be affected by the change of solvent from acetonitrile used in 
the qualitative binding assay to DMSO, which was used in the NMR experiments. 
Conclusions 
We have described a method to improve binding properties of a known receptor molecule. 
First, on a solid phase resin pyrrolidine based receptors were synthesized. These receptors 
were varied in a way that an improvement of the binding properties was to be expected. It was 
assumed that by introducing a sulfonamide instead of an urethane, better hydrogen bonds could 
be formed and consequently binding would be improved. The choice of a colored ligand 
allowed for a simple visual inspection of the beads to obtain a qualitative assessment of the 
relative association constants of the synthesized receptor molecules. The results were not in 
agreement with the concept that increasing acidity of the sulfonamide proton would lead to an 
increased affinity. Five receptor molecules, having the highest affinity, were resynthesized in 
solution to reach a better understanding of these results. It turned out that these receptors were 
synthesized in solution most easily via the same route that was employed for the solid phase 
synthesis of the receptors, instead of a direct coupling of the diaminopyrrolidine with 
sulfonamide protected serine derivatives. The latter approach was even impossible for some 
receptor molecules due to their insolubility. Once the receptors were synthesized, their 
association constants for tetrabutylarnrnonium acetate were evaluated with 1H-NMR. This 
ligand was chosen as a simple analog of the ligand used in the solid phase binding assay. 
Except for the host containing the p-nitrophenylsulfonyl group, the association constants that 
were found, were in agreement with was expected from the qualitative solid phase results. It 
should be noted, however, that to calculate the association constants of the sulfonamide 
containing receptors, in addition to a 1: 1 complex a 1 :2 complex had to be assumed. This may 
point out that these molecules show a somewhat different mechanism of binding than the 
urethane type receptors. More experiments should be performed to have a complete 
understanding of the different association values. But it has been shown, that it is possible to 
obtain new receptor molecules with a higher affinity than the original by screening of a small 
biased library of analogs. 
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Experimental 
General methods. 
DCM and DMF were dried on molecular sieve (4A). Triethylamine and DIPEA were distilled 
subsequently from ninhydrin and KOH. NMM was distilled from CaH2 and THF from LiAlH4• 
All other chemicals were used as purchased. Tentagel®S NH2 resin (130 µm) was purchased from 
Rapp Polymere, Tu bingen, Germany. Reactions were caried out at ambient temperature unless 
stated otherwise. TLC analysis was performed on Merck pre-coated silcagel 60 F-254 (0.25 mm) 
plates. Spots were visualized with UV light, ninhydrin or Cl2-TDM. Solvents were evaporated 
under reduced pressure at 40° C. Column chromatography was performed on Merck kieselgel 60 
(40-63 µm) and flash chromatography on Merck kieselgel 60H (5-40 µm). Sephadex LH-20 
from Pharmacia was used for gel permeation chromatography. 
1H-NMR spectra were recorded on a VARIAN G-300 spectrometer (300.1 Mhz) and chemical 
shift values are given in ppm relative to TMS. 13C-NMR spectra were recorded -on a VARIAN 
G300-spectrometer (75.5 MHz) and chemical shift values are given in ppm relative to CDC13 
(77.0 ppm) or DMSO-d6 (39.7 ppm). 13C spectra were recorded using the attached proton test 
(APT) sequence. 
3R,4R-di-(Boc-amino)-pYrrolidine 3. 
This compound was synthesized as described in chapter 7. 
N-succinyl-3,4-di-(Boc-amino )-pyrrolidine 4. 
530 mg pyrrolidine 3 (1.76 mmol), 176 mg succinic anhydride (1.76 mmol) and 293 µL 
triethylamine (2.10 mmol) were dissolved in 20 mL DCM. The mixture was stirred for 40 
minutes before the solvent was evaporated. The residue was dissolved in EtOAc and the resulting 
solution washed with lM KHS04, water and brine and dried on Na2S04• Evaporation of the 
solvent yielded 692 mg pyrrolidine 4 in 97%. Rr 0.18 (eluent: 5% MeOH in DCM, v/v). 
1H-NMR (CDC13) <> 1.45 (s, 18H, C(CH3\), 2.54 (bs, 2H, NC(O)CH2), 2.65 (bs, 2H, NCH"CH), 3.28 
(bs, 2H, C!.!zC02H), 3.86 (bs, 2H, NCHbCH), 4.03 (bs, 2H, NCH2C!!), 5.61 (bs, 2H, NH), 8.75 (b, 
lH, C02H). 
13C-NMR (CDC13) <> 28.3 (C(fH3) 3), 28.6 (£H2C02H), 28.9 (NCO£H2), 50.3 (N£H2CH), 55.8 
(NCHz£H), 69.8 (£(CH3) 3), 156.2 (f02CCH3), 171.1 (N£OCH2), 175.8 (C02H). 
Tentagel® containing 4. 
500 mg Tentagel®-NH2 (0.30 mmol/g) was loaded with 180 mg pyrrolidine 4 (0.45 mmol) using 
200 mg BOP (0.45 mmol), 2.5 mL DCM and 160 µL DIPEA (1.80 mmol). This coupling was 
repeated, followed by capping of the resin (twice) using 2.5 mL DCM, 140 µL acetic anhydride, 
420 µL triethylamine and a catalytic amount of DMAP. 
Resin containing receptor Si or pyrrolidine 6. 
Resin containing pyrrolidine 4 was deprotected using TF A/DCM 1: 1 for 20 minutes. After 
repeating this, the resulting resin was washed with 10% triethylamine in DCM until it was no 
longer acidic. Then the resin was washed with DMF and DCM followed by a double coupling, 
carried out with 71 mg Cbz-Ser-OH or 345 mg Fmoc-Ser(tBu) (0.90 mmol) using 400 mg BOP 
(0.90 mmol), 2.5 mL DCM and 200 µL NMM (1.80 mmol) affording resin containing receptor 
Si or pyrrolidine 6. 
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Preparation of protected sulfonamide library 7 a-i. 
Resin containing pyrrolidine 6 was deprotected with 20% piperidine in NMP for 15 minutes. 
After repeating the deprotection and washing of the resin, portions of 35 mg (0.01 mmol) were 
treated with either 31 mg p-methoxyphenylsulfonylchloride (0.15 mmol), 29 mg tosylchloride 
(0.15 mmol), 32 mg p-chlorophenylsulfonylchloride (0.15 mmol), 33 mg p-
nitrophenylsulfonylchloride (0.15 mmol), 40 mg 2,4-dinitrophenylsulfonylchloride (0.15 
mmol), 38 mg (lS)-(+)-10-camphorsulfonylchloride (0.15 mmol), 41 mg dansylchloride (0.15 
mmol), 34 mg 8-quinolinesulfonylchloride (0.15 mmol) or 11 µL mesylchloride (0.15 mmol) in 
1 mL DCM and 35 µL NMM (0.32 mmol) for 3 hours after which the coupling was repeated and 
the resin washed with DMF and DCM. This gave resins containing pyrrolidine 7a-i. 
Preparation of deprotected sulfonamide library 8a-i. 
Resins containing receptors 7a-i were deprotected by treatment with 2 mL TFA/DCM 1:1 and 100 
µL anisole for 1 hour. After repeating this deprotection the resin was thoroughly washed with 
DCM, DMF and DCM to give resins containing receptors 8a-i. 
Assay of receptor library 8 with ligand 2. 
1.2 mg ligand 2 (1.4 µmol) was dissolved in 100 mL acetonitrile. Of this solution 0.5 mL was 
added to 2 mg of resin containing one of the receptor molecules Sa-j. The vials containing the 
resin and the ligand solution were shaken for 24 hours. 
DispRedOMs 10. 
To a solution of 314 mg Disperse Red 1 ( 1.0 mmol), purified by flash chromatography ( eluent: 
2% MeOH in DCM, v/v), in 5 mL DCM, 208 µ1 triethylamine (1.5 mmol) and 107 µl 
mesylchloride were added at 0° C. After stirring for 1 hour at 0° C the solvent was evaporated and 
EtOAc was added. The solution was washed with IM KHS04 , 5% NaHC03, water, brine and dried 
on N~S04• Evaporation of the solvent gave 390 mg of mesylate 10 (99%). Rr 0.64 (eluent: 
EtOAc). 
1H-NMR (CDC13) 8 1.27 (t, 3H, NCH2C!!3), 3.00 (s, 3H, CH3S02), 3.57 (q, 2H, NC!!iCH3), 3.82 (t, 
2H, NC!!2CH20), 4.41 (t, 2H, NCH2C!!20), 6.80 (m, ArH) 7.93 (m, 4H, ArH), 8.33 (m, 2H, ArH). 
13C-NMR (CDC13) 8 12.3 (NCH2£H3), 37.6 (CH3S02), 46.0 (N£H2CH3), 49.4 (N£H2CH20), 65 .9 
(NCH~H2Q), 111.6, 122.7, 124.7, 126.2, 144.0, 147.7, 151.2, 157.0 (CAr) . 
Ether 11. 
390 mg of mesylate 10 (0.99 mmol), 159 mg methyl-p-hydroxybenzoate (1.05 mmol) and 145 
mg K2C03 (1.05 mmol) were dissolved in 20 mL DMF. The mixture was stirred for 72 hours at 
50° C after which the solvent was evaporated. The residue was dissolved in DCM, washed with 5% 
NaHC03, water, brine and dried on MgS04• Removal of the solvent in vacuo yielded 443 mg ether 
11 (100%). Rr 0.83 (eluent: 2% MeOH in DCM, v/v). 
1H-NMR (CDC13) 8 1.29 (t, 3H, NCH2C!!3), 3.62 (q, 2H, NC!!2CH3), 3.88 (t, 2H, NC!!2CH20), 3.90 
(s, 3H, C02CH3), 4.25 (t, 2H, NCH2C!!iO), 6.82 (m, 2H, ArH), 6.91 (m, 2H, ArH), 7.91 (m, 4H, 
ArH), 7.97 (m, 2H, ArH), 8.32 (m, 2H, ArH). 
13C-NMR (CDC13) 8 12.3 (NCH2£H3), 46.2 (N£H2CH3), 49.7 (N£H2CH20), 51.9 (C02£H3), 65.6 
(NCH2_£H20), 111.48, 114.0, 122.7, 124.7, 126.3, 127.0, 131.7, 143.9, 147.5, 156.8, 161.2, 162.1 
(CAr), 156.6 (£02CHJ. 
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Carboxylic acid 12. 
A solution of 515 mg of methylester 11 (1.15 mmol) in 20 mL Tesser's base (14 mL dioxane, 5 
mL MeOH and lM 4M NaOH) was stirred overnight at 70° C. After cooling to room temperature 
the mixture was concentrated in vacuo and acidified with 1 M HCl. The aqueous solution was 
extracted with EtOAc three times. After drying on N~S04, the combined organic layers were 
evaporated giving 491 mg of carboxylic acid 12 (99%). The crude product was used directly for 
the synthesis of protected ligand 13. Rr 0.10 (eluent: DCM/MeOH/HOAc 90:10:0.5, v/v). 
Protected ligand 13. 
43 mg of carboxylic acid 12 (0.10 mmol), 44 mg BOP (0.10 mmol), 18 mg HClAlaOtBu (0.10 
mmol) and 52 µL DIPEA (0.30 mmol) were dissolved in 4 mL DCM. After stirring for three 
hours DCM was added and the mixture was washed with lM KHS04, 5% NaHC03, water, brine 
and dried on MgS04• Evaporation of the solvent and column chromatography (eluent: 
EtOAc/hexanes 2:3, v/v) afforded 55 mg of dye 13 (97%). Rr 0.60 (eluent: EtOAc/hexanes 1:1, 
v/v). 
1H-NMR (CDC13) <> 1.27 (t, 3H, NCH2C!!3), 1.46 (d, 3H, NHCHC!!3), 1.49 (s, 9H, C(CH3\), 3.61 
(q, 2H, NC!!2CH3), 3.87 (t, 2H, NC!!zCH20), 4.23 (t, 2H, NCH2C!!P), 4.66 (p, lH, NHC!!CH3), 
6.73 (d, lH, N!!CHCH3), 6.81 (m, 2H, ArH), 6.91 (m, 2H, ArH), 7.77 (m, 2H, ArH), 7.91 (m, 4H, 
ArH), 8.30 (m, 2H, ArH). 
13C-NMR (CDC13) o 12.3 (NCH2£H3), 18.9 (NHCH£H3), 28.0 (C(£H3) 3), 46.1 (N£H2CH3), 49.0 
(NH£HCH3), 49.7 (NfH2CH20), 65.5 (NCH2£H20), 82.1 (gCH3) 3), 111.5, 114.2, 122.6, 124.6, 
126.2, 127.1, 128.9, 143.9, 147.5, 151.2, 156.8, 161.1 (CAr), 157.0 (CONH), 172.6 (£02C(CH3)). 
Carboxylic acid 14. 
To a solution of 55 mg of t-butylester 13 (0.10 mmol) in 2 mL DCM, 200 µL anisole and 2 mL 
ether, saturated with HCl, were added. After stirring for 1 hour the solvent was evaporated. The 
product was purified by column chromatography (eluent: 4% MeOH in DCM, v/v) yielding 34 
mg of carboxylic acid 14 (70%). Rr 0.50 (eluent: 10% DCM in MeOH, v/v). 
1H-NMR (CDC13) o 1.30 (t, 3H, NCH2C!!3,), 1.51 (d, 3H, NHCHC~), 3.16 (d, lH, N!!CHCH3), 
3.63 (q, NC!!2CH3), 3.78 (m, lH, OH), 3.89 (t, 2H, NC!!zCH20), 4.25 (t, 2H, NCH2C!!zO), 4.75 (q, 
lH, NHC!!CH3), 6.84 (m, 2H, ArH), 6.93 (m, 2H, ArH), 7.79 (m, 2H, ArH), 7.92 (m, 4H, ArH), 
8.33 (m, 2H, ArH). 
13C-NMR (CDC13) o 12.1 (NCH2£H3), 18.0 (NHCH£H3), 46.0 (N£H2CH3), 48.3 (NH£HCH3), 49.6 
(N£H2CH20), 65.5 (NCH2£H20), 111.4, 114.1, 122.5, 124.5, 126.1 , 126.4, 129.0, 143.7, 147.1 , 
151.2, 156.7, 161.2 (CAr), 166.7 (C(Q)NH), 173.8 (C02H). 
Carboxylic acid tetrabutylammonium salt 2. 
34 mg of carboxylic acid 14 (0.070 mmol) was dissolved in 1.55 mL 0.0426 M 
tetrabutylammonium hydroxide. The solution was stirred for 1 hour before the solvent was 
removed in vacuo and the residue was coevaporated three times with benzene, giving 59 mg of 
ligand 2 (100%). 
1H-NMR (CDC13) o 0.98 (t, 3H, NCH2CH2CH2C~). 1.28 (t, 3H, NCH2C!!3), 1.42 (m, 2H, 
NCH2CH2C!!2CH3), 1.53 (d, 3H, NHCHC~), 1.64 (m, 2H, NCH2C!!2CH2CH3), 3.30 (t, 2H, 
NC!!2CH2CH2CH3), 3.61 (q, 2H, NC!!zCH3), 3.85 (t, 2H, NC!!2CH20), 4.21 (t, 2H, NCH2C!!zO), 
4.27 (q, lH, NHC!!CH3), 6.80 (m, 2H, ArH), 6.89 (m, 2H, ArH), 7.29 (m, lH, N!!CHCH3), 7.82 
(m, 2H, ArH), 7.92 (m, 4H, ArH), 8.31 (m, 2H, ArH). 
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13C-NMR (CDC13) b 12.2 (NCH2£H3), 13.6 (NCH2CH2CH£H3), 19.7 (NCH2CH£H2CH3), 19.8 
(NHCH£H3), 24.0 (NCH2£H2CH2CH3), 46.1 (N£H2CH3), 49.7 (N£H2CH20), 51.3 (NH£HCH3), 
58.8 (N£H2CH2CH2CH3) , 65.4 (NCH2£H20), 111.4, 113.7, 122.6, 124.6, 126.2, 128.79, 128.81, 
143.8, 147.3, 151.2, 156.8, 160.3 (CA'), 165.1 (C(O)NH), 176.1 (£02NBu4) 
N-mesyl-3,4-di-(Boc-amino )-pyrrolidine 15. 
To a solution of 603 mg (2.0 mmol) 3,4-di-(Boc-amino)-pyrrolidine and 307 µ1 (2.2 mmol) 
triethylamine in 20 mL DCM, 163 µI (2.1 mmol) mesylchloride was added dropwise at 0° C. 
After stirring for 30 minutes at 0° C the solvent was evaporated and the residue redissolved in 
EtOAc. This solution was washed with lM KHS04, 5% NaHC03, water, brine and dried on Na2S04• 
The EtOAc was removed in vacuo and the product was purified by flash chromatography (eluent: 
EtOAc/hexanes 2:3 v/v) yielding 660 mg of pyrrolidine 15 (87%). Rr 0.50 (eluent: 10% DCM in 
MeOH, v/v). 
1H-NMR (CDC13) b 1.44 (s, 18H, C(CH3) 3), 2.87 (s, 3H, CH3S02), 3.17 (q, 2H, NC!:!"CH), 3.78 (q, 
2H, NC!:!bCH), 4.03 (m, NCH2C!:!), 5.15 (bs, lH, NH). 
13C-NMR (CDC13) b 28.3 (C~H3) 3), 35.5 (CH3S02), 50.7 (N£H2CH), 55.4 (NCH2£H), 80.4 
(£(CH3) 3), 155.7 (NHCO). 
p-Methoxyp hen y lsulfon y I-serine. 
To a solution of 311 mg H-Ser-OMe·HCl (2.0 mmol) in a mixture of 10 mL DCM and 1 mL 
DMF, 279 µL triethylarnine (2.0 mmol) and 191 mg tosylchloride (2.0 mmol) dissolved in 5 mL 
DCM were added. After stirring overnight the mixture was concentrated and redissolved in 
EtOAc. This solution was washed with lM KHS04, 5% NaHC03,and brine and dried on Na2S04 • 
After evaporation of the solvent the product was purified by column chromatography (eluent: 
EtOAc/hexanes 2:1, v/v), yielding 230 mg of tosyl-serine methylester (84%). This methylester 
was dissolved in 10.4 mL Tesser's base (MeOH/dioxane/4 M NaOH, 5:14:1, v/v) and stirred for 30 
minutes. After the addition of 1 M KHS04 the mixture concentrated and the residual water was 
extracted with EtOAc four times. The combined organic layers were dried on Na2S04 and 
evaporated affording 215 mg p-methoxyphenylsulfonyl-serine (100%) which was used as such. 
Synthesis of N-mesyl-3,4-di-(Tos-Ser-amino )-pyrrolidine 16b. 
To a solution of 137 mg of pyrrolidine 15 (0.36 mmol) in 3 mL DCM, 3 mL ether, saturated with 
HCl, was added. After stirring for 1 hour the solvent was removed in vacuo. The residue, 319 mg 
BOP (0.72 mmol), 187 mg Tos-Ser-OH (0.72 mmol) and 252 µL DIPEA (1.44 mmol) were 
dissolved in a mixture of 4 mL DCM and 10 mL DMF and stirred overnight. After evaporation of 
the solvent the residue was dissolved in EtOAc and washed with lM KHS04, 5% NaHC03, brine 
and dried on Na2S04• The solvent was evaporated and the product triturated with 10 mL 
MeOH/DCM 1:1 and filtered off, yielding 150 mg of receptor 16b (62%) . 
1H-NMR (DMSO-d6) b 2.37 (s, 6H, CH3Ar), 2.80 (s, 3H, CH3S02), 2.95 (d, 2H, NC!:!"CH), 3.30-
3.50 (m, 8H, NC!:!bCH, Ser-C3£!i) , 3.70 (t, 2H, NCH2C!:!), 3.80 (bs, 2H, Ser-C2H), 4.90 (bs, 2H, Ser-
OH), 7.37 (d, 4H, ArH), 7.65 (d, 4H, ArH), 7.74 (bs, 2H, NHC(O)), 8.18 (d, 2H, NHSOi). 
13C-NMR (DMSO-d6) b 34.8 (CH3S02), 52.4 (N£H2CH), 54.4 (NCH2£H), 56.8 (CH30), 59.3 (Ser-
C2), 63.2 (Ser-C3) , 115.3, 130.0, 134.1, 163.5 (CA'), 171.0 (Ser-C1). 
13C-NMR (DMS0-d6) b 21.7 (CH3Ar), 34.5 (CH3S02), 51.8 (£HCH2NS02), 54.0 (CH£H2NS02), 
58.4 (Ser-C3), 58.9 (Ser-C3), 127.5, 130.5, 138.5, 144.3 (CA'), 170.8 (Ser-C1). 
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Synthesis of N-mesyl-3,4-di-(Z-Ser-amino)-pyrrolidine 16j. 
Receptor 16j was prepared from 215 mg pyrrolidine 15 (0.57 mmol) and 271 mg Z-Ser-OH 
(1.14 mmol) in 5 mL DCM according to the procedure decribed for 16b. After the extraction 
flash chromatography (eluent: 6% MeOH in DCM, v/v) yielded 240 mg ofreceptor 16j (68%). Rr 
0.40 (eluent: 10% MeOH in DCM, v/v). 
'H-NMR (DMS0-d6) 8 2.87 (s, 3H, CH3S02), 3.08 (dd, 2H, NC!fCH), 3.57 (m, 6H, NqtcH, Ser-
C3Hz), 4.03 (m, 2H, NCH2C!!), 4.20 (bs, 2H, Ser-C2H), 4.85 (t, 2H, Sere.OH), 5.03 (d, 4H, OCH2Ph), 
7.16 (d, 2H, Ser-NH), 8.30 (d, 2H, NCH2CHN!!). 
13C-NMR (DMSO-d6) 8 34.4 (CH3S02), 51.8 (N£H2CH), 53.9 (NCH£H), 57.8 (Ser-C2), 58.4 
(Ser-C3), 66.6 (OCH2Ph), 128.7, 128.9, 129.4, 137.7 (CAr), 157.0 (£OOCH2Ph), 166.9 (Ser-C'). 
Synthesis of N-mesyl-3,4-di-(Z-Ser(tBu)-amino)-pyrrolidine 17. 
Protected receptor 17 was prepared from 380 mg pyrrolidine 15 (1.0 mmol) and 591 mg Z-
Ser(tBu)-OH (2.0 mmol) in 4 mL DCM according to the procedure decribed for 16b. After the 
extraction column chromatography (eluent: EtOAc/hexanes 2:1, v/v) yielded 456 mg of 
pyrrolidine 17 (62%). 
'H-NMR (CDC13) 8 1.16 (s, 18H, (C(CH3)3), 2.86 (s, 3H, CH3S02), 3.16 (m, 2H, S02NCH"), 3.37 
(m, 2H, Ser-C3H"), 3.77 (m, 4H, S02NCH\ Ser-C3W), 4.19 (m, 2H, C!!CH2NS02), 4.27 (m, 2H, 
Ser-C2H), 5.11 (s, 4H, C!!zPh), 5.64 (m, 2H, Ser-NH), 7.05 (m, 2H, N!!C(O)CH), 7.32 (m, lOH, 
ArH). Rf 0.20 (eluent: EtOAc/hexanes 2:1, v/v). 
13C-NMR (CDC13) 8 27.5 (C(£H3) 3), 37.3 (CH3S02), 50.3 (CH2NS02), 54.2 (Ser-C2), 54.8 
(£HCH2NS02), 61.6 (Ser-C3), 67.0 (£H2Ph), 74.0 (£CH3)3), 128.0, 128.1, 128.4, 136.1 (CAr), 
154.9 (Ser-C'), 171.2 (NH£(0)CH). 
N-mesyl-3,4-di-(Ser(tBu)-amino)-pyrrolidine 18. 
To a solution of 410 mg 17 (0.56 mmol) in 5 mL EtOH, 50 mg Pd/C (10%) was added and the 
mixture was stirred overnight under a hydrogen atmosphere. The catalyst was removed by 
filtration and the filtrate evaporated, yielding 260 mg of pyrrolidine 18 (100%), which was used 
as such. 
N-mesyl-3,4-di-(p-methoxyphenylsulfonyl-Ser(tBu)-amino)-pyrrolidine 19a. 
145 mg of pyrrolidine 18 (0.30 mmol), 128 mg (0.60 mmol) p-methoxyphenylsulfonylchloride 
and 84 µL triethylamine (0.60 mmol) were dissolved in 3 mL DCM. After stirring for 5 hours the 
mixture was concentrated and redissolved in EtOAc. This solution was washed with lM KHS04, 
5% NaHC03, water and brine and dried on Na2S04• After evaporation of the solvent the product 
was purified by column chromatography (eluent: EtOAc/hexanes 2:1, v/v). Yield: 133 mg (57%). 
Rf 0.20 (eluent: 3% MeOH in DCM, v/v). 
'H-NMR (CDC13).8.l.06 (s, 18H, C(CH3) 3), 2.90 (s, 3H, CH3S02), 3.22 (q, 2H, Ser-C3H"), 3.27 (q, 
2H, CHC!fNS02), 3.61 (q, 2H, Ser-C3Hb), 3.73 (m, 4H, C!!CH2NS02, CHC!!bNSOz), 3.87 (s, 6H, 
OCH3), 4.23 (m, 2H, Ser-C2H), 5.85 (d, 2H, NHC(O)), 6.98 (m, 4H, ArH), 7.34 (d, 2H, NHS02), 
7.80 (m, 4H, ArH). 
13C-NMR (CDC13) 8 27.2 (C(£H3) 3), 35.4 (CH3S02), 50.6 (CH2NS02), 54.2 (Ser-C2), 55.6 (OCH3), 
56.5 (£HCH2NS02), 61.3 (Ser-C3), 74.1 (£(CH3) 3), 114.3, 129.4, 130.7, 163.2 (CAr), 170.1 (Ser-
C1). 
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N-mesy 1-3 ,4-di-(p-nitropheny lsulfony l-Ser( tB u)-amino )-pyrrolidine 19d. 
130 mg of pyrrolidine 18 (0.28 mmol), 124 mg (0.56 mmol) p-nitrophenylsulfonylchloride and 
78 µL triethylamine (0.56 mmol) were dissolved in 3 mL DCM. After stirring overnight the 
mixture was concentrated and the product was purified by column chromatography ( eluent: 3 % 
MeOH in DCM, v/v). Yield: 160 mg (68%). Rr 0.20 (eluent: 3% MeOH in DCM, v/v). 
1H-NMR (CDCI3) S 1.08 (s, 18H, C(CH3) 3), 2.91 (s, 3H, CH3S02), 3.25 (q, 2H, Ser-C3H"), 3.36 (q, 
2H, CHqfNS02), 3.63 (q, Ser-C3Hb), 3.78 (m, 4H, C!!CH2NS02, CHC!!bNS02), 4.26 (m, 2H, Ser-
c2H), 7.31 (d, 2H, N!!C(O)), 8.08 (m, 2H, ArH), 8.36 (m, 2H, ArH). 
13C-NMR (CDC13) S 27.2 (C(Q13) 3), 36.4 (CH3S02), 50.6 (CH2NS0z), 54.5 (Ser-C2), 56.7 
(~HCH2NS0z), 61.7 (Ser-C3), 74.6 (~(CH3) 3), 124.5, 128.6, 145.3, 150.4 (CA'), 169.8 (Ser-C1). 
N-mesyl-3,4-di-(dansyl-Ser(tBu)-amino)-pyrrolidine 19g. 
140 mg of pyrrolidine 18 (0.30 mmol), 162 mg (0.60 mmol) dansylchloride and 84 µL 
triethylamine (0.60 mmol) were dissolved in 5 mL DCM. After stirring overnight the mixture was 
concentrated and the product was purified by column chromatography (eluent: 3.5% MeOH in 
DCM, v/v). Yield: 170 mg (61 %). Rr 0.30 (eluent: 4% MeOH in DCM, v/v). 
1H-NMR (CDC13) S 0.86 (s, 18H, C(CH3) 3), 2.81 (s, 3H, CH3S02), 2.87 (s, 6H, CH3N), 2.92, 3.00 
(two dd, 4H, Ser-C3H•, CHCffNSOz), 3.53 (m, 4H, Ser-C3H\ CHC!!bNSOz), 3.67 (bs, 2H, 
C!!CH2NS02), 3.98 (q, 2H, Ser-C2H), 5.89 (bs, 2H, Ser-NH), 7.10 (d, 2H, NHC(O)), 7.18 (d, 2H, 
ArH), 7.54 (m, 4H, ArH), 8.21 (dd, 2H, ArH), 8.29 (d, 2H, ArH), 8.55 (d, 2H, ArH). 
13C-NMR (CDC13) S 27.0 (C~H3) 3), 35.5 (CH3S02), 45.3 (CH3N), 50.3 (CH2NS02), 54.1 
(~HCH2NS02), 56.9 (Ser-c2), 60.8 (Ser-C3), 74.0 (9CH3) 3), 115.5, 118.4, 123.1, 128.9, 129.5, 
129.88, 129.93, 131.1, 133.8, 152.3 (CA'), 170.0 (Ser-C 1). 
p-Methoxyphenylsulfonyl-serine. 
p-Methoxyphenylsulfonyl-serine was prepared from 622 mg H-Ser-OMeHCl (4.0 mmol) and 
413 mg p-methoxyphenylsulfonylchloride (2.0 mmol) according to the procedure decribed for 
tosyl-serine. After the extraction, column chromatography (eluent: 5% MeOH in DCM, v/v) 
yielded 461 mg p-methoxyphenylsulfonyl-serine (25%) which was used as such. 
N-mesy 1-3 ,4-di-(p-methoxypheny lsulfony I-Ser-amino )-pyrrolidine 16a. 
Route I: Receptor 16a 
1
was prepared from 150 mg pyrrolidine 15 (0.40 mmol) and 218 mg p-
methoxyphenylsulfonyl~Ser-OH (0.80 mmol) in 2 mL DCM and 5 mL DMF according to the 
procedure decribed for 16b. After the extraction, flash chromatography (eluent: 6% MeOH in 
DCM, v/v) and recrystallization from DCM/MeOH yielded 65 mg 16a (25%). 
Route II: To a solution of 144 mg of protected pyrrolidine 19a (0.17 mmol) in 3 mL DCM, 1 
mL TFA was added at 0° C and the mixture was stirred for 6 hours at that temperature. The 
solvent was evaporated and the residue was coevaporated with THF three times and twice with 
DCM. The product was crystallized from DCM/MeOH, yielding 65 mg 16a (55%). Rr 0.38 
(eluent: 10% MeOH in DCM, v/v). 
'H-NMR (DMSO-d6) S 2.83 (s, 3H, CH3S02), 2.97 (d, 2H, CHCWNS02), 3.37 (m, 6H, 
CHCHbNS02, Ser-C3H2), 3.69 (m, 2H, C!!CH2NS02), 3.83 (s, 8H, OCH3, Ser-C2H), 4.91 (t, 2H, OH), 
7.06 (m, 4H, ArH), 7.64 (d, 2H, Ser-NH), 7.71 (m, 4H, ArH), 8.18 (d, 2H, N!!CHCH2N). 
13C-NMR (DMS0-d6) S 34.5 (CH3SQ2), 52.1 (CH~H2NS02), 54.1 (~HCH2NS02), 56.5 (CH30), 
59.0 (Ser-C2), 62.9 (Ser-C3), 115.0, 129.7, 133.8, 163.2 (CA'), 170.7 (Ser-C 1). 
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N-mesyl-3.4-di-(p-nitrophenylsulfonyl-Ser-amino)-pyrrolidine 16d. 
To a solution of 144 mg of protected pyrrolidine 19d (0.17 mmol) in 3 mL DCM, 1 mL TFA 
was added. After stirring overnight the solvent was evaporated and the residue was coevaporated 
twice with DCM/MeOH. The product was purified by gel permeation chromatography (LH-20; 
eluent: DCM/MeOH 1:1, v/v) yielding 107 mg 16d (86%). Rr 0.38 (eluent: 10% MeOH in DCM, 
v/v). 
1H-NMR (DMSO-d6) o 2.81 (s, 3H, Cl:£3S02), 2.93 (d, 2H, CHCffNS02), 3.40 (rn, 6H, 
CHqtNS02, Ser-C3H2), 3.79 (m, 4H, C!!CH2NS02, Ser-c2H), 4.96 (bs, 2H, OH), 8.03 (d, 4H, 
ArH), 8.24 (d, 2H, N!!CHCH2N), 8.30 (bs, 2H, Ser-NH), 8.35 (d, 4H, ArH). 
13C-NMR (DMSO-d6) B 33.9 (CH3S02), 51.1 (fHCH2NS02), 53.2 (CHfH2NS02), 58.4 (Ser-C2), 
62.0 (Ser-C3), 124.2, 128.1, 146.8, 149.5 (CA'), 169.1 (Ser-C1). 
N-mesyl-3.4-di-(p-dansyl-Ser-amino)-pyrrolidine 16g. 
170 mg of protected pyrrolidine 19g (0.18 mmol) was dissolved in 3 mL DCM and 1 mL TF A. 
After stirring overnight the solvent was evaporated and the residue was coevaporated twice with 
DCM/MeOH. The product was purified by gel permeation chromatography (LH-20; eluent: 
DCM/MeOH 1:1, v/v) yielding 145 mg 16g (97%). Rr 0.38 (eluent: 10% MeOH in DCM, v/v). 
1H-NMR (DMSO-d6) o 2.74 (s, 3H, CH3S02), 2.80 (s, 6H, CH3N), 2.80-2.85 (m, 2H, 
CHC!!aNS02), 3.25-3.45 (m, 8H, OH, Ser-C3H2, CHC!!bNS02), 3.76 (4H, C!!CH2NS02, Ser-C2H), 
4.90 (Ser-NH), 7.22 (d, 2H, ArH), 7.57 (m, 4H, ArH), 8.12 (d, 2H, NHC(O)), 8.14 (dd, 2H, ArH), 
8.30 (d, 2H, ArH), 8.42 (d, 2H, ArH). 
13C-NMR (DMSO-d6) B 33.7 (CH3SOJ, 45 .0 (CH3N), 51.3 (CHfH2NS02), 53.3 (fHCH2NS02) , 
58.0 (Ser-C2), 62.0 (Ser-C3), 115.0, 119.3, 123.4, 127.7, 128.1, 129.0, 129.1, 129.5, 136.5, 151.2 
(CA'), 169.5 (Ser-c1). 
NMR titrations. 
Three stock solutions were prepared of the following composition: 1) 10 mM receptor in DMSO-
d6; 2) 10 mM receptor and -20 mM Bu4NOAC in DMSO-d6; 3) 10 mM receptor and 200 mM 
Bu4NOAc. To solution 1 an amount of solution 2 or 3 was added to afford 1 mL with the 
appropriate ratio 12of receptor to ligand, . ~hus keeping the receptor concentration constant. To 
obtain higher ratios than 20 for [ligand]/[receptor] additional Bu4NOAc was added to solution 3. 
The sample without ligand was used to obtain the B value for the unbound receptor NH 
resonance. The 88 values were then determined relative to this shift value. Non-linear regression 
of the titration curves (of [ligand] vs. 8 -value) gave the association constant(s). 
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Determination of association constants by NMR 
One of many methods used to study the nature of complex formation is 1H-NMR8. It is based 
on the fact that the complexed and the uncomplexed species can give resonances at different 
chemical shift values. In most cases there will be a rapid equilibrium between the the two states 
on the NMR time-scale, as will be assumed for the complexes studied here. This means that the 
observed signal (8) for a specific nucleus on e.g. the host will be the average of the chemical 
shifts of the nucleus in the uncomplexed (H) and the complexed state (HG) or more general the 
average of all the possible states: 
8 = I1;Aj (1) 
i,j 
Where 8ij represents the chemical shift value for the observed nucleus in the complex of the 
form Hpj and J;j the fractional occupancy of this state. In the following we will only consider 
two types of complex formation, a 1: 1 complex: 
K11 
H + G ~ HG (2) 
and a 1:2 complex in addition to a 1:1 complex10: 
K11 K12 
H + 2G ~ HG + G ~ HG2 (3) 
Where His the receptor (host) and G the ligand (guest). The involved association constants are 
defined as 
K = [HG] 
11 [H][G] 
K = [HGz] 
12 [HG][GJ 
(4) 
(5) 
Higher order complex formation is normally not considered because of the rapid increase in 
parameters involved. 
For a 1: 1 complex formation the chemical shift of the observed nuclues can thus be written as 
8 = !10810 + ii 1811 (6) 
Defining the chemical shift difference as 
~ = 8-810 (7) 
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and 
di) = 811 - 810 
allows eq (6) to be expresed as d = fi/:::. 11 • When the fractions are defined as 
[HG] 
hi =[HG]+ [H] 
[H] 
ho= [HG]+ [H] 
the combination of eq. (4) and (9) will give us 
K11[G] 
fi1 = K11[G] + 1 
Since d = fi 1d 11 it will follow from eq. (11) that 
d = d11K1JG] 
K11 [G]+ 1 
(8) 
(9) 
(10) 
(11) 
(12) 
[G] the actual ligand concentration is not be be confused with [G]0 the total ligand 
concentration, but these are related to each other just like [H] and [H]0: 
[H] = [H]0 - [HG] (13) 
[G] = [G]0 -[HG] (14) 
Combining eq. (13) and (14) with (4) leads to [G] expressed in terms of the known 
concentrations [H]0 and [G]0 : 
([G]0 K11 -[H]0 K11 -1) + -)([H]0 K 11 -[G]0 K11 + 1)2 + 4K11 [G]0 [G]=~~~~~~~---'-~~~~~~~~~~
2K11 
Eq. (15) and (12) will give an expression for the chemical shift difference~: 
Ji {([G]oK11 - [H]oK11 -1) + ~([H]oK11 -[G]oK11 + 1)2 + 4K11 [G]o} 
~ = { } ~11 Ji ([G]oK11 -[H]oK11 -l)+~([H]0 K11 -[G]oK11 +1)2 +4K11 [G]o +1 
(15) 
(16) 
The association constant K 11 and the complexation induced shift ~ 11 are unknown and can be 
obtained by non-linear regression using eq. (16) in the fitting procedure. 
For the assumption that there are a 1:1 and a 1:2 complex described by eq. (3) and (5) the 
weighted average expression of the observed chemical shift is 
8 = fio810 + !11811 + /12812 
which can be written as 
~ = li1~11 + li2~12 
(17) 
(18) 
Where~= 8 - <>io, ~11 = 811 - 810 and ~ 12 = 812 - 8w Now in the line of the derivation for the 
1: 1 complex follows 
~ = d11K11[G] + ~12K11K12[G]2 
Kl I [ G] + K11 K12 [ G]2 + 1 
[G] = [G]o _ K11fH]o[G] + K11K12[HJo[G]2 
K 11 [G] + K11 K12 [G]2 + 1 
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Or expressing [G]0 in terms of [G] 
[G]o = [G] + K11[H]o[G] + K11K12[H]o[G]2 
K11[G] + K11K12[G]2 + 1 
and defining the following function g: 
K11 [H][G]+ K11 Kn[H][G]2 
g([G]) = [G] + K
11
[G] + K
11
Kn[G]2 + 1 
(22) 
(23) 
An expression for [G] can be found in terms of [G]0 by expanding funtion g in a Taylor's 
series and truncating at the linear term: 
[G] = [G] + [G]o - g([G]o) 
o g' ([G]o) (24) 
where g' is dg/d[G]0, the first derivative of g. Substituting eq. (24) into (20) gives an 
expression for the chemical shift difference Ll. Again non-linear regression gives the unknown 
association constants K 11 and K12 and the complexation induced shifts Ll11 and Ll12. 
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M 
Ac 
Acp 
AIBN 
Bn 
Boe 
Boc20 
BOP 
bs 
Bu 
Cbz 
amino acid 
acetyl 
acetic anhydride 
List of abbreviations 
2, 2'-azobis(2-methylpropionitrile) 
benzyl 
tert-butyloxycarbonyl 
di-tert-butyl dicarbonate 
benzotriazol-y loxytris( dime thy lamino )phosphonium hexafluorophosphate 
broad singlet 
butyl 
benzyloxycarbonyl 
Cbz-OSu benzyloxycarbonyl-N-oxysuccinimide 
d doublet 
DCC N, N'-dicyclohexylcarbodiimide 
DCM dichloromethane 
dd double doublet 
DEAD diethyl azodicarboxylate 
DIAD diisopropy 1 azodicarboxy late 
DIC N, N' -diisopropy lcarbodiimide 
DIPEA diisopropy lethy lamine 
DispRed Disperse Red 1 
DMAP 4-dimethy laminopyridine 
DMF N, N-dimethylformamide 
DMSO dimethylsulfoxide 
dq double quartet 
dt double triplet 
DtBAD di-tert-butyl azodicarboxylate 
ECF ethyl chloroformate 
EDT 1,2-ethanedithiol 
Et3N triethy lamine 
EtOAc ethy !acetate 
EtOH ethanol 
FAB fast atom bombardment 
Fmoc 9-fluorenylmethyloxycarbonyl 
HOBt 1-hydroxybenzotriazole 
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Abbreviations 
HPLC high performance liquid chromatography 
HSAc thiolacetic acid 
HYP hydroxyproline 
IC50 dose that inhibits 50% of the activity of e.g an enzyme 
IR infrared 
Ki dissociation constant of enzyme-inhibitor complex 
m multiplet 
mCPBA 3-chloroperoxybenzoic acid 
Me methyl 
MeOH 
MsCl 
NMM 
NMP 
methanol 
mesylchloride 
N-methyl morpholine 
1-methy 1-2-pyrrolidinone 
NMR nuclear magnetic resonance 
Ph phenyl 
Pht phthaloyl 
PP ACK phenylalanylprolylarginyl chloromethylketone 
q quartet 
qu quintet 
Re retardation factor 
s singlet 
triplet 
Tau taurine 
TBACN tetrabutylammonium cyanide 
TBDMS tert-butyldimethylsilyl 
TFA trifluoroacetic acid 
THF 
TLC 
TMS 
TPAP 
Trt 
Xxx 
tetrahydrofuran 
thin layer chromatography 
tetramethylsilane 
tetrapropylammonium perruthenate 
trityl 
any amino acid 
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SUMMARY 
It has been proven in the past that it is very difficult to predict the exact behavior for a set of 
interacting molecules. Therefore, designing new molecules with certain properties towards 
other molecules is not an easy task. From this pursuit supramolecular chemistry has evolved, 
which studies the properties of assemblies of molecules as a result from their non-covalent 
interactions. Simple systems involve two molecules capable of complexing one another. The 
fundamental insights that are acquired by these uncomplicated studies may well be used, in e.g. 
drug research, on more complex systems, such as nature offers. Drug research studies the 
influence of certain compounds (ligands) on a biological system or a target in particular 
(receptor). 
Since peptides are involved in the regulation of virtually all biological processes they seem to be 
interesting starting points for the development of new drugs. However, they suffer from some 
undesired properties, e.g. poor bioavailability and instability, which causes them to be 
unattractive therapeutic agents. This has led to the development of peptidomimetics. These are 
molecules which imitate the action of a peptide by displaying structural and functional features 
that mimic those of the native peptide, leading to certain (improved) biological properties of 
these mimetics. A first step from peptides to mimics with improved properties are peptide bond 
isosteres in which a peptide bond has been replaced with another functional group. Many of 
these replacements have been reported, but the sulfonamide moiety in P-aminoethane 
sulfonamides (peptidosulfonamides) did not receive much attention. Therefore, on the one hand 
the aim of this thesis was to investigate the use of these sulfonamides as peptidomimetics for 
the purpose to develop thrombin inhibitors, on the other to construct sulfonamide containing 
tweezer-like receptor molecules as a first step in obtaining a better understanding of the nature 
of interactions between sulfonamides and peptides. Consequently, this thesis consists of two 
parts. 
In the first part of this thesis the synthesis of P-aminoethane sulfonamide arginine analogs is 
described. It was attempted to design and synthesize sulfonamide based thrombin inhibitors by 
exploiting their resemblance with the transition-state of the hydrolysis of an amide bond 
between an arginine and a glycine residue, the primary target of the serine protease thrombin. 
Chapter 2 deals with the synthesis of P-substituted aminoethane sulfonamide arginine-glycine 
analogs. Structures of presently existing thrombin inhibitors were used as a basis for these 
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compounds. Low molecular weight structures were synthesized by the sulfinylchloride 
approach, available by using a thioacetate as a crucial synthon. The thus obtained sulfinamides 
were converted to the corresponding sulfonamides. It was decided to synthesize first omithine-
glycine analogs, which were converted to twelve different ~-substituted aminoethane 
sulfonamide analogs of an arginine-glycine moiety, that might act as thrombin inhibitors. In 
addition, a ~-substituted aminoethane sulfonamide arginine-glycine analog was incorporated 
into a longer peptide. For this purpose a novel method was developed for the synthesis of the 
required arginine sulfonamide analog building block, which was included in the solid-phase 
Fmoc-strategy employed for peptide synthesis. Although the yield for the synthesis of the 
sulfony lchloride building block, was only moderate using this novel method, optimization 
should certainly lead to improved yields and it can be considered as an additional method for 
the preparation of Fmoc-protected sulfonylchloride building blocks. 
The synthesis of a-substituted aminoethane sulfonamide arginine-glycine analogs is described 
in chapter 3. Since it was not possible to prepare these compounds using the earlier developed 
routes, an entirely different strategy was devised starting from an alkene, 4-pentene-1-ol. This 
strategy led to racemic mixtures of the desired a-substituted sulfonamide arginine-glycine 
analogs. Unfortunately, attempts to produce homochiral compounds or to effect separation of 
enantiomers faileµ. Nevertheless, the present strategy, starting from an alkene, may well be 
used in the synthesis of a variety of (functionalized) a-substituted aminoethane sulfonamides. 
In principle, analogs of all proteinogenic amino acids are accessible starting from an appropriate 
alkene. 
In chapter 4 the synthesis of conformationally restricted a-and ~-substituted aminoethane 
sulfonamide arginine-glycine analogs is described, employing 4-hydroxyproline as a 
convenient starting material. The a-substituted analogs were prepared by using hydroxyproline 
as a B-aminoalcohol, which could be transformed to the corresponding thioacetate. The B-
substituted compounds were obtained, after conversion of the 4-hydroxy group into the proper 
functional group, via a route comparable to that described in chapter 2. Hydroxyproline can be 
considered as a versatile building block from which not only the above mentioned compounds, 
but also other conformationally restrained sulfonamide mimetics can be prepared, e.g. the 
sulfonamide mimetics of glutamic acid or homoserine. 
Finally, all aminoethane sulfonamide arginine-glycine analogs were tested for their inhibitory 
activity on thrombin, as is described in chapter 5. Unfortunately, only the peptide containing 
the ~-substituted arginine analog, showed a modest activity. When the affinity of this 
compound (~ :::: 2 µM) was compared to that of the corresponding all amide analog (7.4 nM), 
it was concluded that B-substituted aminoethane sulfonamides are unsuitable as components of 
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thrombin inhibitors. In addition, an attempt was undertaken to rationalize these results, using 
molecular modelling. Further, the a-substituted and conformationally constrained analogs did 
not show any inhibitory activity towards thrombin either, which was explained by the fact that 
these compounds do not posses substituents that would lead to optimal interactions with the 
enzyme. 
In order to obtain a more thorough understanding of the interactions between sulfonamides and 
peptides, it was decided to synthesize and study sulfonamide containing tweezer-like 
molecules. In chapter 6 the synthesis is described of such a molecule, consisting of three parts: 
1) a dye moiety for visualization in a binding assay, 2) two arms, consisting of aminoethane 
sulfonamides and 3) a hinge part, i.e. a scaffold to which the arms and the dye were attached. 
The binding properties were evaluated using a -25,000 membered resin bound tripeptide 
library. It was found that such a simple artificial receptor was able to specifically bind twenty to 
thirty tripeptides out of these 25,000. The affinity for these peptides was only moderate, which 
was apparent from a binding constant of around 300 M-1• 
In chapter 7 the consequences of using less flexible hinges have been illustrated. These hinges 
were synthesized in order to improve the affinity of the above mentioned rather selective 
receptor molecule. Five new hinges were synthesized, varying in rigidity and distance between 
the points of attachment for the peptidosulfonamide arms. For the attachment of the 
sulfonamide arms sulfonylchlorides were used instead of sulfinylchlorides, which resulted in 
improved yields for the synthesis of the receptor described in chapter 6. Furthermore, it has 
been shown that by varying the hinge part of the receptor molecule it was possible to increase 
its binding affinity for tripeptides. Interestingly, the selectivity of the new receptor molecules 
was not affected, while the affinity ranged over two orders in magnitude ( 40-4000 M-1). These 
hinge molecules may provide for a diversity of scaffolds that might be used in the preparation 
of all sorts of libraries of compounds using a variety of building blocks. 
Finally, in chapter 8 a preliminary study is described on the synthesis and binding properties of 
a small biased library of carboxylic acid binding receptor molecules. First, qualitative results 
were obtained on a solid-phase. These results were quantified by resynthesizing some of the 
receptor molecules in solution and their association constants were determined by NMR. 
Except for one receptor molecule, the quantitative results were in agreement with the earlier 
obtained qualitative solid-phase results. More experiments should be carried out, however, in 
order to determine the different association constants. Nevertheless, it was shown that it is 
feasible to obtain molecules with a particular improved property by screening a small but biased 
library. 
163 

SAMENV ATTING 
In het verleden is al veelvuldig aangetoond dat het heel moeilijk is om van het exacte gedrag van 
moleculen, die elkaar be'invloeden, een beschrijving te geven. Hierdoor is het ontwerpen van 
nieuwe moleculen met een bepaalde eigenschap ten opzichte van andere geen eenvoudige 
opgave. Zo'n streven, echter, heeft geleid tot de ontwikkeling van de supramoleculaire chemie, 
die zich ten doel stelt de eigenschappen van complexen van moleculen te bestuderen, die het 
resultaat zijn van hun onderlinge niet-covalente interacties. Eenvoudige systemen hierbij 
bestaan uit twee moleculen die in staat zijn met elkaar te associeren. Fundamentele inzichten die 
uit zulke studies voortvloeien zouden kunnen worden gebruikt voor een studie aan 
ingewikkeldere . systemen, zoals die in de natuur voorkomen en in o.a. het 
geneesmiddelenonderzoek warden bestudeerd. In het geneesmiddelenonderzoek warden 
namelijk biologische effecten van bepaalde verbindingen (liganden) onderzocht door 
bestudering van de interactie met hun aangrijpingspunt (receptor). 
Peptiden lijken, door de rol die ze spelen in vrijwel alle biologische processen, een interessant 
uitgangspunt te zijn voor de ontwikkeling van nieuwe geneesmiddelen. Nadelen zoals hun 
slechte biobeschikbaarheid en instabiliteit, maken peptiden echter niet erg geschikt voor 
therapeutische doeleinden, wat heeft geleid tot de ontwikkeling van peptidomimetica. Dit zijn 
verbindingen die de werking van een peptide imiteren door hun overeenkomstige structurele en 
functionele kenmerken, met bepaalde (betere) biologische eigenschappen van deze mimetica als 
doel. Een eerste stap van een peptide naar een mimeticum met verbeterde eigenschappen, zijn 
peptidebinding isosteren, waarbij de plaats van de peptidebinding is ingenomen door een 
andere functionele groep. Alhoewel een groat aantal van dit soort vervangingen zijn 
beschreven, heeft de sulfonamide functie zoals die aanwezig is in ~-aminoethaan sulfonamiden 
(peptidosulfonamiden) nooit veel aandacht gekregen. Het doel van het in dit proefschrift 
beschreven onderzoek is dan ook, het bestuderen van het gebruik van deze 
peptidosulfonamiden enerzijds als protease remmende peptidomimitica, in het bijzonder van 
trombine, en anderzijds als bouwstenen voor pincet-achtige receptorrnoleculen, om uiteindelijk 
een beter beeld te krijgen van de aard van interacties tussen sulfonamiden en peptiden. Dit 
proefschrift bestaat dan ook uit twee delen. 
In het eerste deel is de synthese beschreven van ~-aminoethaan sulfonamide arginine analoga. 
Er is gepoogd sulfonamide bevattende trombine remmers te ontwerpen gebaseerd op bestaande 
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remmers, gebruikmakend van de overeenkomst van deze sulfonamiden met de 
overgangstoestand van de hydrolyse van een arginine-glycine peptide binding, die door 
trombine gesplits wordt. In hoofdstuk twee wordt de synthese beschreven van ~-
gesubstitueerde aminoethaan sulfonamide arginine-glycine analoga. De synthese van deze 
verbindingen verliep via een sulfinylchloride bouwsteen, die verkregen werd uit een thioacetaat 
synthon. Dit leverde in de eerste plaats sulfinamiden op, die vervolgens konden warden 
omgezet in de gewenste sulfonamiden. Vervolgens werden de aldus verkregen omithine 
analoga omgezet in twaalf arginine-glycine analoga, die als trombine remmer getest werden. 
Verder werd ook een ~-gesubstitueerde aminoethaan sulfonamide arginine-glycine eenheid 
ingebouwd in een peptideketen bestaande uit twintig aminozuren. Hiervoor werd een nieuwe 
synthesemethode ontwikkeld voor het vervaardigen van de arginine-achtige bouwsteen, die 
nodig was in de Fmoc-strategie aan de vaste fase, gebruikt bij het maken van het sulfonamide 
bevattende peptide. Hoewel de opbrengsten nog niet optimaal waren, lijkt deze methode een 
prima aanvulling te zijn op al bestaande manieren, die elk hun eigen nadelen hebben, om 
sulfonamide bouwstenen te synthetiseren. 
In hoof dstuk 3 wordt de syn these van a-gesubstitueerde aminoethaan sulfonamide arginine-
glycine analoga beschreven. Daar het niet mogelijk bleek deze verbindingen te bereiden via 
bestaande routes, werd een nieuwe strategie ontwikkeld, waarbij werd uitgegaan van een 
alkeen. Zo leidde 4-penteen-1-ol tot racemische mengsels van de gewenste a-gesubstitueerde 
sulfonamide arginine-glycine analoga. Helaas was het niet mogelijk homochirale verbindingen 
te maken of de verkregen enantiomeren van elkaar te scheiden. Desalniettemin lijkt deze nieuwe 
aanpak een prima manier om ook andere (gefunctionaliseerde) a-gesubstitueerde sulfonamide 
analoga te synthetiseren. In principe zullen, wanneer men uitgaat van een geschikt alkeen, alle 
analoga van protdnogene aminozuren toegankelijk zijn. 
In hoofdstuk 4 wordt de synthese beschreven van a- en ~-gesubstitueerde aminoethaan 
sulfonamide arginine-glycine analoga, die over een beperkte conformationele vrijheid 
beschikken. 4-hydroxyproline bleek hiervoor een geschikt uitgangsstof te zijn. De a-
gesubstitueerde verbindingen werden bereid, door 4-hydroxyproline te gebruiken als een ~-
aminoalcohol, die in het overeenkomstige thioacetaat kon warden omgezet. De ~-
gesubstitueerde verbindingen werden verkregen, na omzetting van de 4-hydroxy groep van 
hydroxyproline in een geschikte functionaliteit, via een route die vergelijkbaar is met de in 
hoofdstuk 2 beschreven methode. Hydroxyproline kan dus gezien warden als een veelzijdige 
bouwsteen, die niet alleen geschikt is om de bovengenoemde verbindingen te maken maar ook 
voor de synthese van andere starre sulfonamide rnimetica bijvoorbeeld afgeleid van 
glutaminezuur of homoserine. 
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Tot slot zijn alle aminoethane sulfonamide arginine-glycine analoga getest op hun remmende 
werking op trombine, zoals beschreven is in hoofdstuk 5. Helaas bl eek slechts de ~-
gesubstitueerde analogon bevattende peptideketen een bescheiden activiteit te vertonen. Na 
vergelijking van deze activiteit (~ ~ 2 µM) met die van het overeenkomstige peptide (Ki ~ 7 .4 
nM), dat enkel en alleen uit amide bindingen is opgebouwd, werd geconcludeerd dat ~-
gesubstitueerde aminoethaan sulfonamiden niet geschikt zijn om ingebouwd te worden in 
trombineremmers. Met behulp van molecular modelling is een poging gedaan dit resultaat 
enigszins te verklaren. Verder bleek dat ook de a-gesubstitueerde en rigide analoga trombine 
niet kunnen remmen. Dit werd verklaard door te veronderstellen dat deze verbindingen niet die 
substituenten bevatten, die zouden leiden tot optimale interacties met het enzym. 
Om de interacties tussen sulfonamiden en peptiden aan een meer fundamentele studie te 
onderwerpen, werd besloten sulfonamide bevattende pincet-achtige moleculen te maken en te 
bestuderen. In hoof dstuk 6 staat de syn these beschreven van een dergelijk molecuul, dat is 
opgebouwd uit drie verschillende onderdelen: 1) een kleurstof-deel, voor visualisatie 
doeleinden in een bindingsassay, 2) twee armen, bestaande uit aminoethaan sulfonamiden en 3) 
een scharnier gedeelte waaraan de armen en de kleurstof konden worden bevestigd. De 
bindingseigenschappen werden bestudeerd met behulp van een peptidebiblioteek aan een hars, 
bestaande uit - 25.000 verschillende tripeptiden. Het bleek dat de eenvoudige kunstmatige 
receptor in staat was twintig tot dertig tripeptiden specifiek te herkennen met een affiniteit van 
om en nabij de 300 M· 1. 
In hoofdstuk 7 is het gevolg beschreven van het gebruik van minder flexibele schamieren, met 
als doel de affiniteit van het hierbovengenoemde behoorlijk selectieve receptor-molecuul te 
vergroten. Vijf nieuwe schamiermoleculen, die varieren in starheid en in afstand tussen 
aanhechtingspunten voor de armen, werden gesynthetiseerd. Voor het aanbrengen van de 
sulfonamide armen werden nu sulfonylchlorides gebruikt in plaats van sulfinylchlorides, wat 
leidde tot hogere opbrengsten voor de in hoofdstuk 6 beschreven receptor. Uit bindingsstudies 
bleek dat het mogelijk was de affiniteit van de pincet-achtige moleculen voor tripeptiden te 
verhogen door variatie in het scharnier gedeelte. De nieuw bereide receptormoleculen 
vertoonden een selectiviteit die vergelijkbaar was met de eerstgenoemde, terwijl de affiniteit 
varieerde van 40 to 4000 M·1• Verder onderzoek zal moeten aantonen of deze verzameling 
schamieren gebruikt kan worden bij het ontwerpen van een varieteit aan nieuwe bibliotheken 
van verbindingen en zo verbindingen kan opleveren met interessante eigenschappen. 
Tot slot werd in hoofdstuk 8 een aanzet gegeven voor een studie naar carbonzuur 
complexerende verbindingen, door de synthese en bindingseigenschappen te beschrijven van 
een kleine bibliotheek van dit soort moleculen. De kwalitatieve resultaten, verkregen door 
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middel van synthese aan een vaste drager, werden gekwantificeerd door enkele verbindingen 
opnieuw, maar nu in oplossing te synthetiseren en associatieconstanten met behulp van NMR te 
bepalen. Op een receptor na waren deze resulten in overeenstemming met de eerder genoemde 
resultaten aan de bars. Er zullen echter meer experimenten moeten worden uitgevoerd, om alle 
verschillen in bindingsconstanten volledig te kunnen begrijpen. Desalniettemin werd 
aangetoond dat het mogelijk is een molecuul te vinden met bepaalde (betere) eigenschappen 
door middel van screening van een kleine bibliotheek van verbindingen. 
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De auteur van dit proefschrift werd geboren op 30 november 1969 te 's Hertogenbosch. Na het 
behalen van het diploma gymnasium ~ aan het Titus Brandsmalyceum in Oss, begon de 
schrijver in 1988 met de studie scheikunde aan de Katholieke Universteit Nijmegen. Het 
propaedeutisch examen werd in 1989 behaald. Het doctoraal programma bestond onder andere 
uit een uitgebreide hoofdvakstage Organische Chemie onder leiding van Prof. Dr. R.J.M Nolte 
en een bijvakstage Polymeer Chemie aan de Technische Universiteit Eindhoven onder leiding 
van Prof. Dr. E.W. Meijer (vakgroep Organische Chemie) en Prof. Dr. P.J. Lemstra 
(vakgroep Polymeer Chemie). In februari 1994 werd het doctoraal examen (cum laude) 
af gelegd. V anaf april van dat jaar tot april 1998 was de schrijver werkzaam als Onderzoeker in 
Opleiding bij de vakgroep/discipline Medicinal Chemistry van de Faculteit Farmacie aan de 
Universiteit Utrecht onder begeleiding van Prof. Dr. R.M.J. Liskamp. Gedurende deze periode 
werd het onderzoek verricht dat in dit proefschrift staat beschreven. Momenteel is de auteur 
werk:zaam als post-doc bij het Instituut voor Biotechnologie aan de Universiteit van Cambridge 
(Engeland) onder leiding van Prof. Dr. C.R. Lowe. 
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Tot slot, of moet ik zeggen om te beginnen, als dit het eerste is dat je leest: dit werk was niet tot 
stand gekomen zonder de hulp of steun van anderen, waarvan ik een aantal mensen hieronder 
in het bijzonder wil bedanken. 
Als eerste natuurlijk Rob Liskamp, die me de mogelijkheid . heeft geboden het 
promotieonderzoek te doen. Ik heb de afgelopen vier jaar met veel plezier gewerkt onder jouw 
begeleiding. Het waren altijd je leuke nieuwe ideeen voor nieuwe moleculen die me 
inspireerden om verder te gaan. Ook wist je je begeleiding prima te doseren, zodat ik het idee 
had dat ik een grote vrijheid genoot om het onderzoek te doen zonder bang te hoeven zijn om 
het spoor kwijt te raken. Verder was dit proefschrift nooit zo snel klaar geweest zonder jouw 
snelle correctiewerk en com.111entaar op mijn schrijfk.unsten. 
Dan zijn er natuurlijk de mensen die het dagelijks lief en leed deelden op de labvloer. In het 
begin waren er maar twee: Karen Sliedregt, een bondgenoot in het roken en John Kruijtzer, 
soms onverstaanbaar, maar onmisbaar als het praktische syntheseproblemen aangaat en altijd 
bereid nog even wat mee te gaan drinken. Al snel volgde Suzanne Mulders, de eerste uit een rij 
van Nijmegenaren die nog komen zou. Zonder jouw hulp was het receptorproject nooit van de 
grond gekomen. Met haar kwam ook Arwin (Ortwin!) Brouwer. Natuurlijk ben ik jou zeer 
dankbaar voor je bereidheid om iedere keer weer wat monomeer af te staan voor mijn proefjes. 
Vooral ook voor het diaminopyrrolidine, dat nogal wat bloed, zweet en tranen heeft gekost. 
Maar ik zou het wel even bijmaken. Verder waren ook onze fitnessavondjes met het 
bijbehorende aftrainen (zeer belangrijk) en andere stapavonden en concerten altijd zeer gezellig. 
Je lach en enthousiasme zullen me altijd bijblijven. Vervolgens kwam Dries de Bont, de eerste 
post-doc op het lab. Jouw Leids-Nijmeegse inbreng op het lab wordt niet snel vergeten, al was 
het maar vanwege je lengte. Het onderzoek aan sulfonamiden van jouw kant, heeft het mijne 
enorm geholpen. Met de komst van Lovina Hofmeijer werd eindelijk voetbal een gesprek in de 
koffiehoek op maandag, al heb je helaas niet zoveel verstand van het spel (=Feyenoordfan). 
Achteraf vraag ik me af hoe het lab kon bestaan zonder jou. Je bereidheid om iedereen te helpen 
en je grote organisatietalent heeft van ons een echte groep gemaakt, voor wie je onmisbaar bent 
geworden. Ik zal je hulp en gezelligheid missen. Zo halverwege mijn onderzoek begon de 
groep groter te worden door de komst van drie nieuwe mensen: Rob Ruijtenbeek (reine 
Ossenaar), Astrid Boeijen en John Reichwein, waarvan Astrid nu eens niet uit Nijmegen 
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kwam, maar in plaats daarvan wel weer een connectie had met Oss. Je was altijd prima op de 
kast de jagen, waar ik veelvuldig gebruik van heb gemaakt. Na jullie kwamen nog Steven van 
Leeuwen (drijvende kracht achter een uiterst geslaagd Ardennen weekend) en Dirk Rijkers. De 
laatste ben ik zeer dankbaar voor het zeer zorgvuldig doomemen van de conceptversie van dit 
proefschrift. Je fotografische geheugen heeft je vast geholpen bij het vinden van 
inconsequenties die meer dan 50 bladzijden uit elkaar staan. 
In de koffiehoek kreeg het lab nog eens versterking van Marco Steehouwer, Ronald 
Schoenmakers, Jean van de Elsen en Jan Hollebeek. Na bet werk werd de gezelligheid vaak 
voortgezet in Jan Primus. Jan Hollebeek wil ik bier in bet bijzonder bedanken omdat je me 
enthousiast hebt weten te maken voor bet klimmen. 
Het duurde even, maar na een tijdje bleken ook studenten bun weg te vinden naar ons lab. 
Twee daarvan durfden bet aan onder mijn begeleiding te werken. De eerste was Matthias 
Broekema. Door je HBO achtergrond hoefde ik je op bet praktische vlak niet veel te leren. Het 
moeilijkste was je wat langzamer te leren spreken en wat duidelijker te schrijven, maar ik 
betwijfel of er iets veranderd is, getuige je route beschrijving "vinyl de Uilhol" naar Lunetten. 
Daama kwam Jeroen van Ameijde, die aan een half woord genoeg had. Je hebt hetzelfde met 
(wiskundige) problemen als ik, je moet ze oplossen. Het was een plezier om met jullie beide 
samen te werken. 
Al was het niet gemakkelijk om mezelf uit bet lab los te rukken, ik heb enkele pogingen 
ondemomen mezelf achter de computers op de zevende verdieping te zetten om te modellen. Ik 
ben Ed Moret dan ook zeer dankbaar voor de hulp die hij heeft geboden zodat o.a. de lading 
van thrombine een geheel getal werd. Verder wil ik ook Hans Hilbers en Gertjan Boks niet 
vergeten die me opvingen bij allerlei computerproblemen. Tot slot wat betreft de "droge" 
chemie wil ik Jan Tollenaere noemen, die altijd met een groot enthousiasme openstond voor 
vraagstukken rond sulfonamiden en na kort overleg op vrijdag, 's zaterdags de computers bij 
Janssen al op volle toeren liet draaien. Daamaast heb ik enorm genoten van onze discussies 
over van alles en nog wat (meestal onder bet genot van wat bier) en in het bijzonder de 
discussie in Maastricht die leidde tot het (onoplosbare?) drie-deeltjes probleem. 
Een andere groep die belangrijk is geweest voor mij, en ik denk voor onze hele groep nog 
steeds is, is de afdeling massaspectrometrie met Cees Versluis en Wik Heerma, die altijd 
klaarstonden om nog even wat metingen te doen. 
I will tum to English to thank Prof. Clarke Still en his coworkers Y. Cheng, Y. Shao and 
David Weingarten. Without your collaboration, the second half of my thesis would not exist. I 
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am very glad you were willing to put a lot of effort in screening my receptor molecules on their 
binding properties. I hope everyone realizes how much work the decoding has been, which I 
merely summarized in a graph and a table. 
Ben lab kan natuurlijk niet draaien zonder allerlei ondersteuning daaromheen zoals bijvoorbeeld 
het secretariaat met eerst Pien van de Minnen en later N atatia Lemmert. Verder wil ik de 
mensen van de financiele administratie bedanken, het magazijn (Jan bedankt voor je concert en 
muziektips), de glasblazerij, de computerondersteuning (Hans Reijn en Leo van der Hark) en 
tot slot de grafische dienst bestaande uit Pieter van Dorp van Vliet, Catholijn Luteijn en Martijn 
Pieck. De laatste was een enorme hulp bij het fabriceren van de kleurenplaatjes en de kaft, die 
toch prachtig is geworden ondanks het feit dat het allemaal al gisteren af moest zijn van mij. 
Gelukkig bes ton den de af gel open vier jaar niet alleen uit werk. Ik kon hierbij altijd terugvallen 
op mijn vrienden waarmee ik lief en leed gedeeld heb. Ik denk hierbij vooral aan de club uit 
Nijmegen die altijd achter mij heeft gestaan. Van deze groep wil ik twee vrienden in het 
bijzonder noemen. Als eerste Rob Heijmans: vooral jij stond altijd klaar om me ergens mee te 
helpen of gewoon, om feest mee te vieren. Je toonde ook altijd interesse in mijn onderzoek en 
was in staat door op het oog eenvoudige vragen te stellen, me nog eens na te laten denken waar 
ik nu eigenlijk mee bezig was. Maar ook Xander de Haan: we zijn al vrienden sinds de 
middelbare school en na onze studietijd in Nijmegen was ik dan ook blij te horen dat je besloot 
je promotieonderzoek ook in Utrecht te gaan doen, wat ons opnieuw bij elkaar bracht. 
Gelukkig heb ik je enthousiast weten te maken voor het klimmen, zodat we aardig wat 
avondjes even alles konden vergeten als we aan de muur bingen. Ik ben blij dat jullie beide 
mijn paranimfen willen zijn. 
Naast vrienden kon ik ook nog altijd terugvallen op mijn broers Gerard en Clemens en mijn zus 
Sylvia. Jullie beschouw ik als een soort vervangende ouders op wie ik kan bouwen en die ik 
als voorbeeld kan nemen. Zonder jullie was ik nooit zover gekomen. 
Jeannette, voor jou zou ik eigenlijk minstens een hele bladzijde vol moeten schrijven om aan te 
geven wat je voor me betekent en wat voor steun je bent geweest, maar ik denk dat je dat wel 
weet. Ik hoop dat we nog lang en gelukkig samen zullen zijn ... 
173 



